{"status":"ok","message-type":"work-list","message-version":"1.0.0","message":{"facets":{},"total-results":183010,"items":[{"indexed":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T15:48:38Z","timestamp":1726069718772},"edition-number":"0","reference-count":1,"publisher":"CRC Press","isbn-type":[{"type":"electronic","value":"9780429151866"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2004,1,28]]},"DOI":"10.1201\/9781439834404-18","type":"book-chapter","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T19:34:02Z","timestamp":1594323242000},"page":"253-290","source":"Crossref","is-referenced-by-count":0,"title":["Developing Safe Vaccines"],"prefix":"10.1201","member":"301","reference":[{"key":"ref12","unstructured":"1. Centers for Disease Control and Prevention. Achievements in Public Health 1900\u20131999: Control of Infectious Diseases. MMWR Morb Mort Wkly Rep 1999; 48:621\u2013628."}],"container-title":["New Generation Vaccines"],"language":"en","deposited":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T19:34:28Z","timestamp":1594323268000},"score":23.348667,"resource":{"primary":{"URL":"https:\/\/www.taylorfrancis.com\/books\/9781439834404\/chapters\/10.1201\/9781439834404-18"}},"issued":{"date-parts":[[2004,1,28]]},"ISBN":["9780429151866"],"references-count":1,"URL":"https:\/\/doi.org\/10.1201\/9781439834404-18","published":{"date-parts":[[2004,1,28]]}},{"indexed":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T05:22:37Z","timestamp":1715577757814},"reference-count":0,"publisher":"American Academy of Pediatrics","isbn-type":[{"value":"9781581104899","type":"electronic"},{"value":"9781581103748","type":"print"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2010,4,1]]},"DOI":"10.1542\/9781581104899-part02-safe","type":"book-chapter","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T20:12:45Z","timestamp":1636402365000},"page":"42-42","source":"Crossref","is-referenced-by-count":0,"title":["Safe Storage of Vaccines"],"prefix":"10.1542","member":"417","container-title":["Practice Management Consultant"],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/aapbooks\/book\/chapter-pdf\/769215\/aap_9781581104899-part02-safe.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T20:13:15Z","timestamp":1636402395000},"score":20.31799,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/aapbooks\/book\/377\/chapter\/5793041\/Safe-Storage-of-Vaccines"}},"issued":{"date-parts":[[2010,4,1]]},"ISBN":["9781581104899","9781581103748"],"references-count":0,"URL":"https:\/\/doi.org\/10.1542\/9781581104899-part02-safe","published":{"date-parts":[[2010,4,1]]}},{"indexed":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T12:10:17Z","timestamp":1721045417705},"reference-count":9,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>In 2019, an outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease (COVID-19), caused an ongoing public health crisis [...]<\/jats:p>","DOI":"10.3390\/vaccines9070722","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T07:19:32Z","timestamp":1625210372000},"page":"722","source":"Crossref","is-referenced-by-count":1,"title":["Vectored-Vaccine Platforms Enabled Rapid Development of Safe and Effective Vaccines in Response to COVID-19 Pandemic Situation"],"prefix":"10.3390","volume":"9","author":[{"given":"Amine A.","family":"Kamen","sequence":"first","affiliation":[{"name":"Department of Bioengineering, McGill University, Montreal, QC H3A 0E9, Canada"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Farn\u00f3s, O., Venereo-S\u00e1nchez, A., Xu, X., Chan, C., Dash, S., Chaabane, H., Sauvageau, J., Brahimi, F., Saragovi, U., and Leclerc, D. (2020). Rapid High-Yield Production of Functional SARS-CoV-2 Receptor Binding Domain by Viral and Non-Viral Transient Expression for Pre-Clinical Evaluation. Vaccines, 8.","DOI":"10.3390\/vaccines8040654"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Benest, J., Rhodes, S., Quaife, M., Evans, T.G., and White, R.G. (2021). Optimising Vaccine Dose in Inoculation against SARS-CoV-2, a Multi-Factor Optimisation Modelling Study to Maximise Vaccine Safety and Efficacy. Vaccines, 9.","DOI":"10.3390\/vaccines9020078"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Baldo, A., Leunda, A., Willemarck, N., and Pauwels, K. (2021). Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2. Vaccines, 9.","DOI":"10.3390\/vaccines9050453"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Folegatti, P.M., Flaxman, A., Jenkin, D., Makinson, R., Kingham-Page, L., Bellamy, D., Ramos Lopez, F., Sheridan, J., Poulton, I., and Aboagye, J. (2021). Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies. Vaccines, 9.","DOI":"10.3390\/vaccines9030262"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sun, W., McCroskery, S., Liu, W.-C., Leist, S.R., Liu, Y., Albrecht, R.A., Slamanig, S., Oliva, J., Amanat, F., and Sch\u00e4fer, A. (2020). A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines, 8.","DOI":"10.1101\/2020.07.30.229120"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Rohaim, M.A., and Munir, M. (2020). A Scalable Topical Vectored Vaccine Candidate against SARS-CoV-2. Vaccines, 8.","DOI":"10.1101\/2020.05.31.126524"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Choi, H., Chun, J., Park, M., Kim, S., Kim, N., Lee, H.-J., Kim, M., Shin, H.Y., Oh, Y.-K., and Kim, Y.B. (2021). The Safe Baculovirus-Based PrM\/E DNA Vaccine Protected Fetuses against Zika Virus in A129 Mice. Vaccines, 9.","DOI":"10.3390\/vaccines9050438"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Sawada, A., Ito, T., Yamaji, Y., and Nakayama, T. (2021). Chimeric Measles Virus (MV\/RSV), Having Ectodomains of Respiratory Syncytial Virus (RSV) F and G Proteins Instead of Measles Envelope Proteins, Induced Protective Antibodies against RSV. Vaccines, 9.","DOI":"10.3390\/vaccines9020156"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Chowdhury, S.I., Pannhorst, K., Sangewar, N., Pavulraj, S., Wen, X., Stout, R.W., Mwangi, W., and Paulsen, D.B. (2021). BoHV-1-Vectored BVDV-2 Subunit Vaccine Induces BVDV Cross-Reactive Cellular Immune Responses and Protects against BVDV-2 Challenge. Vaccines, 9.","DOI":"10.3390\/vaccines9010046"}],"container-title":["Vaccines"],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/7\/722\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T11:51:55Z","timestamp":1721044315000},"score":20.126373,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/7\/722"}},"issued":{"date-parts":[[2021,7,2]]},"references-count":9,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["vaccines9070722"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9070722","ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"published":{"date-parts":[[2021,7,2]]}},{"indexed":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T23:08:37Z","timestamp":1720048117243},"reference-count":23,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2015,1,2]]},"DOI":"10.1586\/14760584.2015.965691","type":"journal-article","created":{"date-parts":[[2014,9,30]],"date-time":"2014-09-30T11:33:39Z","timestamp":1412076819000},"page":"1-4","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":18,"title":["Prospects for safe and effective vaccines against prion diseases"],"prefix":"10.1586","volume":"14","author":[{"given":"Neil Andrew","family":"Mabbott","sequence":"first","affiliation":[]}],"member":"301","published-online":{"date-parts":[[2014,9,30]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nature01457","volume":"422","author":"White AR","year":"2003","journal-title":"Nature"},{"key":"CIT0002","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0002-9440(10)64151-X","volume":"161","author":"Sigurdsson EM","year":"2002","journal-title":"Am J Pathol"},{"key":"CIT0003","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.cellimm.2010.03.018","volume":"263","author":"Sassa Y","year":"2010","journal-title":"Cell Immunol"},{"key":"CIT0004","doi-asserted-by":"crossref","first-page":"6619","DOI":"10.4049\/jimmunol.0804385","volume":"183","author":"Gourdain P","year":"2009","journal-title":"J Immunol"},{"issue":"9","key":"CIT0005","doi-asserted-by":"crossref","first-page":"e1002216","DOI":"10.1371\/journal.ppat.1002216","volume":"7","author":"Iken S","year":"2011","journal-title":"PLoS Pathog"},{"key":"CIT0006","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1099\/vir.0.013417-0","volume":"91","author":"Bachy V","year":"2010","journal-title":"J Gen Virol"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.005041-0"},{"key":"CIT0008","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/dna.2009.0940","volume":"29","author":"Alexandrenne C","year":"2010","journal-title":"DNA Cell Biol"},{"key":"CIT0009","first-page":"523","volume":"24","author":"Han Y","year":"2011","journal-title":"Biomed Environ Sci"},{"key":"CIT0010","doi-asserted-by":"crossref","first-page":"9321","DOI":"10.1016\/j.vaccine.2011.10.017","volume":"29","author":"Ishibashi D","year":"2011","journal-title":"Vaccine"},{"key":"CIT0011","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.vaccine.2014.01.027","volume":"32","author":"Maricinuik K","year":"2014","journal-title":"Vaccine"},{"key":"CIT0012","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jneuroim.2014.05.001","volume":"272","author":"David MA","year":"2014","journal-title":"J Neuroimmunol"},{"key":"CIT0013","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s10571-011-9696-z","volume":"31","author":"Fujita K","year":"2011","journal-title":"Cell Mol Neurobiol"},{"key":"CIT0014","doi-asserted-by":"crossref","first-page":"e7160","DOI":"10.1371\/journal.pone.0007160","volume":"4","author":"Bremer J","year":"2009","journal-title":"PLoS One"},{"key":"CIT0015","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1126\/science.1094273","volume":"303","author":"Solforosi L","year":"2004","journal-title":"Science"},{"key":"CIT0016","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1126\/science.1215579","volume":"335","author":"Kl\u00f6hn P-C","year":"2012","journal-title":"Science"},{"key":"CIT0017","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1099\/vir.0.023838-0","volume":"91","author":"Tayebi M","year":"2010","journal-title":"J Gen Virol"},{"key":"CIT0018","doi-asserted-by":"crossref","first-page":"e59143","DOI":"10.1371\/journal.pone.0059143","volume":"8","author":"Xanthopoulos K","year":"2013","journal-title":"PLoS One"},{"key":"CIT0019","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature12402","volume":"501","author":"Sonati T","year":"2013","journal-title":"Nature"},{"key":"CIT0020","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.neuroscience.2008.02.051","volume":"153","author":"Go\u00f1i F","year":"2008","journal-title":"Neuroscience"},{"key":"CIT0021","doi-asserted-by":"crossref","first-page":"694","DOI":"10.7589\/2012-07-200","volume":"49","author":"Pilon JL","year":"2013","journal-title":"J Wildlife Dis"},{"key":"CIT0022","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1128\/JVI.03469-12","volume":"87","author":"Dobie K","year":"2013","journal-title":"J Virol"},{"key":"CIT0023","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1523\/JNEUROSCI.3526-13.2014","volume":"34","author":"Klyubin I","year":"2014","journal-title":"J Neurosci"}],"container-title":["Expert Review of Vaccines"],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/14760584.2015.965691","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T21:28:18Z","timestamp":1498166898000},"score":19.743303,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1586\/14760584.2015.965691"}},"issued":{"date-parts":[[2014,9,30]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,9,30]]},"published-print":{"date-parts":[[2015,1,2]]}},"alternative-id":["10.1586\/14760584.2015.965691"],"URL":"https:\/\/doi.org\/10.1586\/14760584.2015.965691","ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"published":{"date-parts":[[2014,9,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"}]},{"institution":[{"name":"American Psychological Association","acronym":["APA"]}],"indexed":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:30:06Z","timestamp":1707870606405},"reference-count":0,"publisher":"American Psychological Association (APA)","content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2004]]},"DOI":"10.1037\/e716682007-003","type":"dataset","created":{"date-parts":[[2013,2,23]],"date-time":"2013-02-23T16:32:01Z","timestamp":1361637121000},"source":"Crossref","is-referenced-by-count":0,"title":["FDA Ensures Vaccines are Safe and Effective"],"prefix":"10.1037","member":"15","container-title":["PsycEXTRA Dataset"],"deposited":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T16:40:54Z","timestamp":1707842454000},"score":19.69291,"resource":{"primary":{"URL":"https:\/\/doi.apa.org\/doi\/10.1037\/e716682007-003"}},"subtitle":["(716682007-003)"],"issued":{"date-parts":[[2004]]},"references-count":0,"alternative-id":["716682007-003"],"URL":"https:\/\/doi.org\/10.1037\/e716682007-003","published":{"date-parts":[[2004]]}},{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T03:37:31Z","timestamp":1648784251628},"reference-count":0,"publisher":"OMICS Publishing Group","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Vaccines Vaccin"],"DOI":"10.4172\/2157-7560.1000e130","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T03:41:48Z","timestamp":1487216508000},"source":"Crossref","is-referenced-by-count":1,"title":["Fractional Delivery: Toward a Painless, Safe and Effective Cutaneous Vaccination"],"prefix":"10.4172","volume":"08","author":[{"given":"Ji","family":"Wang","sequence":"first","affiliation":[]}],"member":"2674","published-online":{"date-parts":[[2017]]},"container-title":["Journal of Vaccines &amp; Vaccination"],"deposited":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T15:00:20Z","timestamp":1492095620000},"score":19.6283,"resource":{"primary":{"URL":"https:\/\/www.omicsonline.org\/open-access\/fractional-delivery-toward-a-painless-safe-and-effective-cutaneous-vaccination-2157-7560-1000e130.php?aid=84889"}},"issued":{"date-parts":[[2017]]},"references-count":0,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.4172\/2157-7560.1000e130","ISSN":["2157-7560"],"issn-type":[{"value":"2157-7560","type":"electronic"}],"published":{"date-parts":[[2017]]}},{"indexed":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T12:12:55Z","timestamp":1657023175807},"reference-count":0,"publisher":"Gavin Publishers","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Vaccines Immunol"],"DOI":"10.29011\/2575-789x.000173","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T10:42:14Z","timestamp":1656931334000},"source":"Crossref","is-referenced-by-count":0,"title":["LubecaVax: The Safe way out of the Anti-Corona Vaccination Chaos"],"prefix":"10.29011","volume":"7","member":"11549","published-online":{"date-parts":[[2022,7,1]]},"container-title":["Journal of Vaccines, Immunology and Immunopathology"],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T10:42:14Z","timestamp":1656931334000},"score":19.6283,"resource":{"primary":{"URL":"https:\/\/www.gavinpublishers.com\/article\/view\/lubecavax-the-safe-way-out-of-the-anti-corona-vaccination-chaos"}},"issued":{"date-parts":[[2022,7,1]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.29011\/2575-789x.000173","ISSN":["2575-789X"],"issn-type":[{"value":"2575-789X","type":"electronic"}],"published":{"date-parts":[[2022,7,1]]}},{"indexed":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T23:36:20Z","timestamp":1725752180121},"publisher-location":"Vienna","reference-count":121,"publisher":"Springer Vienna","isbn-type":[{"type":"print","value":"9783709114186"},{"type":"electronic","value":"9783709114193"}],"license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"published-print":{"date-parts":[[2013]]},"DOI":"10.1007\/978-3-7091-1419-3_18","type":"book-chapter","created":{"date-parts":[[2013,10,15]],"date-time":"2013-10-15T15:56:26Z","timestamp":1381852586000},"page":"313-327","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of Safe and Efficacious Bluetongue Virus Vaccines"],"prefix":"10.1007","author":[{"given":"Polly","family":"Roy","sequence":"first","affiliation":[]},{"given":"Meredith","family":"Stewart","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,8,16]]},"reference":[{"key":"18_CR00181","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0368-1742(49)80018-X","volume":"59","author":"RM Gambles","year":"1949","unstructured":"Gambles, R.M.: Bluetongue of sheep in Cyprus. J. Comp. Pathol. 59, 176\u2013190 (1949)","journal-title":"J. Comp. Pathol."},{"key":"18_CR00182","first-page":"350","volume":"48","author":"J Manso-Ribeiro","year":"1957","unstructured":"Manso-Ribeiro, J., et al.: Fievre catarrhale du mouton (blue-tongue). Bull. Off. Int. Epizoot. 48, 350\u2013367 (1957)","journal-title":"Bull. Off. Int. Epizoot."},{"key":"18_CR00183","first-page":"109","volume":"61","author":"PG Howell","year":"1963","unstructured":"Howell, P.G.: Emerging diseases of animals: Bluetongue. FAO Agric. Stud. 61, 109 (1963)","journal-title":"FAO Agric. Stud."},{"key":"18_CR00184","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrmicro1090","volume":"3","author":"BV Purse","year":"2005","unstructured":"Purse, B.V., et al.: Climate change and the recent emergence of bluetongue in Europe. Nat. Rev. Microbiol. 3, 171\u2013181 (2005)","journal-title":"Nat. Rev. Microbiol."},{"key":"18_CR00185","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jviromet.2007.05.014","volume":"145","author":"AE Shaw","year":"2007","unstructured":"Shaw, A.E., et al.: Development and initial evaluation of a real-time RT-PCR assay to detect bluetongue virus genome segment 1. J. Virol. Methods 145, 115\u2013\u200a126 (2007)","journal-title":"J. Virol. Methods"},{"key":"18_CR00186","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.prevetmed.2009.08.007","volume":"92","author":"AR Elbers","year":"2009","unstructured":"Elbers, A.R., van der Spek, A.N., van Rijn, P.A.: Epidemiologic characteristics of bluetongue virus serotype 8 laboratory-confirmed outbreaks in The Netherlands in 2007 and a comparison with the situation in 2006. Prev. Vet. Med. 92, 1\u20138 (2009)","journal-title":"Prev. Vet. Med."},{"key":"18_CR00187","unstructured":"OIE: Notifiable diseases list. http:\/\/www.oie.int\/eng\/maladies\/en_classification2009.htm?e1d7 (2009)"},{"key":"18_CR00188","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0147-9571(94)90043-4","volume":"17","author":"NJ MacLachlan","year":"1994","unstructured":"MacLachlan, N.J.: The pathogenesis and immunology of bluetongue virus infection of ruminants. Comp. Immunol. Microbiol. Infect. Dis. 17, 197\u2013206 (1994)","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"18_CR00189","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1751-0813.1975.tb00049.x","volume":"51","author":"JL Hourrigan","year":"1975","unstructured":"Hourrigan, J.L., Klingsporn, A.L.: Bluetongue: the disease in cattle. Aust. Vet. J. 51, 170\u2013174 (1975)","journal-title":"Aust. Vet. J."},{"key":"18_CR001810","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1865-1682.2008.01063.x","volume":"56","author":"E Meroc","year":"2009","unstructured":"Meroc, E., et al.: Bluetongue in Belgium: episode II. Transbound. Emerg. Dis. 56, 39\u201348 (2009)","journal-title":"Transbound. Emerg. Dis."},{"key":"18_CR001811","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0368-1742(05)80073-6","volume":"18","author":"J Spreull","year":"1905","unstructured":"Spreull, J.: Malarial catarrhal fever (bluetongue) of sheep in South Africa. J. Comp. Pathol. Therap. 18, 321\u2013337 (1905)","journal-title":"J. Comp. Pathol. Therap."},{"key":"18_CR001812","first-page":"65","volume":"51","author":"BJ Erasmus","year":"1975","unstructured":"Erasmus, B.J.: Bluetongue in sheep and goats. Aust. Vet. J. 51, 65\u2013170 (1975)","journal-title":"Aust. Vet. J."},{"key":"18_CR001813","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/030098589202900615","volume":"29","author":"WW Laegreid","year":"1992","unstructured":"Laegreid, W.W., Burrage, T.G., Stone-Marschat, M., Skowronek, A.: Electron microscopic evidence for endothelial infection by African horsesickness virus. Vet. Pathol. 29, 554\u2013556 (1992)","journal-title":"Vet. Pathol."},{"key":"18_CR001814","first-page":"1198","volume":"47","author":"CR Mahrt","year":"1986","unstructured":"Mahrt, C.R., Osburn, B.I.: Experimental bluetongue virus infection of sheep; effect of vaccination: pathologic, immunofluorescent, and ultrastructural studies. Am. J. Vet. Res. 47, 1198\u20131203 (1986)","journal-title":"Am. J. Vet. Res."},{"key":"18_CR001815","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1139\/m70-073","volume":"16","author":"KS Tsai","year":"1970","unstructured":"Tsai, K.S., Karstad, L.: Epizootic hemorrhagic disease virus of deer: an electron microscopic study. Can. J. Microbiol. 16, 427\u2013432 (1970)","journal-title":"Can. J. Microbiol."},{"key":"18_CR001816","first-page":"159","volume":"43","author":"A Pini","year":"1976","unstructured":"Pini, A.: Study on the pathogenesis of bluetongue: replication of the virus in the organs of infected sheep. Onderstepoort J. Vet. Res. 43, 159\u2013164 (1976)","journal-title":"Onderstepoort J. Vet. Res."},{"key":"18_CR001817","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1006\/viro.2002.1476","volume":"296","author":"CD DeMaula","year":"2002","unstructured":"DeMaula, C.D., Leutenegger, C.M., Bonneau, K.R., MacLachlan, N.J.: The role of endothelial cell-derived inflammatory and vasoactive mediators in the pathogenesis of bluetongue. Virology 296, 330\u2013337 (2002)","journal-title":"Virology"},{"key":"18_CR001818","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0165-2427(02)00012-0","volume":"86","author":"CD DeMaula","year":"2002","unstructured":"DeMaula, C.D., Leutenegger, C.M., Jutila, M.A., MacLachlan, N.J.: Bluetongue virus-induced activation of primary bovine lung microvascular endothelial cells. Vet. Immunol. Immunopathol. 86, 147\u2013157 (2002)","journal-title":"Vet. Immunol. Immunopathol."},{"key":"18_CR001819","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/vr.162.17.564","volume":"162","author":"K De Clercq","year":"2008","unstructured":"De Clercq, K., et al.: Transplacental bluetongue infection in cattle. Vet. Rec. 162, 564 (2008)","journal-title":"Vet. Rec."},{"key":"18_CR001820","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0034-5288(18)32870-4","volume":"27","author":"EP Gibbs","year":"1979","unstructured":"Gibbs, E.P., Lawman, M.J.P., Herniman, K.A.J.: Preliminary observations on transplacentar infection of bluetongue virus in sheep \u2013 a possible overwintering mechanism. Res. Vet. Sci. 27, 118\u2013120 (1979)","journal-title":"Res. Vet. Sci."},{"key":"18_CR001821","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3201\/eid1512.090788","volume":"15","author":"KE Darpel","year":"2009","unstructured":"Darpel, K.E., et al.: Transplacental transmission of bluetongue virus 8 in cattle, UK. Emerg. Infect. Dis. 15, 2025\u20132028 (2009)","journal-title":"Emerg. Infect. Dis."},{"key":"18_CR001822","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1865-1682.2008.01044.x","volume":"55","author":"K De Clercq","year":"2008","unstructured":"De Clercq, K., et al.: Transplacental infection and apparently immunotolerance induced by a wild-type bluetongue virus serotype 8 natural infection. Transbound. Emerg. Dis. 55, 352\u2013359 (2008)","journal-title":"Transbound. Emerg. Dis."},{"key":"18_CR001823","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01538812","volume":"136","author":"NJ MacLachlan","year":"1994","unstructured":"MacLachlan, N.J., et al.: Detection of bluetongue virus in the blood of inoculated calves: comparison of virus isolation, PCR assay, and in vitro feeding of Culicoides variipennis. Arch. Virol. 136, 1\u20138 (1994)","journal-title":"Arch. Virol."},{"key":"18_CR001824","doi-asserted-by":"crossref","first-page":"8789","DOI":"10.1128\/JVI.00626-09","volume":"83","author":"B Hemati","year":"2009","unstructured":"Hemati, B., et al.: Bluetongue virus targets conventional dendritic cells in skin lymph. J. Virol. 83, 8789\u2013\u200a8799 (2009)","journal-title":"J. Virol."},{"key":"18_CR001825","doi-asserted-by":"crossref","first-page":"860","DOI":"10.2460\/ajvr.2003.64.860","volume":"64","author":"BE McLaughlin","year":"2003","unstructured":"McLaughlin, B.E., DeMaula, C.D., Wilson, W.C., Boyce, W.M., MacLachlan, N.J.: Replication of bluetongue virus and epizootic hemorrhagic disease virus in pulmonary artery endothelial cells obtained from cattle, sheep, and deer. Am. J. Vet. Res. 64, 860\u2013865 (2003)","journal-title":"Am. J. Vet. Res."},{"issue":"Pt 7","key":"18_CR001826","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1099\/0022-1317-70-7-1663","volume":"70","author":"LE Whetter","year":"1989","unstructured":"Whetter, L.E., Maclachlan, N.J., Gebhard, D.H., Heidner, H.W., Moore, P.F.: Bluetongue virus infection of bovine monocytes. J. Gen. Virol. 70(Pt 7), 1663\u20131676 (1989)","journal-title":"J. Gen. Virol."},{"key":"18_CR001827","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/1743-422X-7-362","volume":"7","author":"ME Stewart","year":"2010","unstructured":"Stewart, M.E., Roy, P.: Role of cellular caspases, nuclear factor-kappa B and interferon regulatory factors in Bluetongue virus infection and cell fate. Virol. J. 7, 362 (2010)","journal-title":"Virol. J."},{"key":"18_CR001828","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1128\/JVI.78.6.2875-2883.2004","volume":"78","author":"E Mortola","year":"2004","unstructured":"Mortola, E., Noad, R., Roy, P.: Bluetongue virus outer capsid proteins are sufficient to trigger apoptosis in mammalian cells. J. Virol. 78, 2875\u20132883 (2004)","journal-title":"J. Virol."},{"key":"18_CR001829","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1128\/jvi.10.4.783-794.1972","volume":"10","author":"DW Verwoerd","year":"1972","unstructured":"Verwoerd, D.W., Els, H.J., De Villiers, E.M., Huismans, H.: Structure of the bluetongue virus capsid. J. Virol. 10, 783\u2013794 (1972)","journal-title":"J. Virol."},{"key":"18_CR001830","unstructured":"Roy, P.: Orbiviruses and their replication. In: Fields\u2019 Virology - Fifth Edition, (Knipe, D.M. et al., eds.). Lippincott Williams & Wilkins, Philadelphia, USA. (2007)"},{"key":"18_CR001831","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/jvi.5.1.1-7.1970","volume":"5","author":"DW Verwoerd","year":"1970","unstructured":"Verwoerd, D.W., Louw, H., Oellermann, R.A.: Characterization of bluetongue virus ribonucleic acid. J. Virol. 5, 1\u20137 (1970)","journal-title":"J. Virol."},{"key":"18_CR001832","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1743-422X-5-48","volume":"5","author":"AE Firth","year":"2008","unstructured":"Firth, A.E.: Bioinformatic analysis suggests that the Orbivirus VP6 cistron encodes an overlapping gene. Virol. J. 5, 48 (2008)","journal-title":"Virol. J."},{"key":"18_CR001833","doi-asserted-by":"crossref","first-page":"e1002477","DOI":"10.1371\/journal.ppat.1002477","volume":"7","author":"M Ratinier","year":"2011","unstructured":"Ratinier, M., et al.: Identification and characterization of a novel non-structural protein of bluetongue virus. PLoS Pathog. 7, e1002477 (2011)","journal-title":"PLoS Pathog."},{"key":"18_CR001834","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1128\/JVI.02284-06","volume":"81","author":"M Forzan","year":"2007","unstructured":"Forzan, M., Marsh, M., Roy, P.: Bluetongue virus entry into cells. J. Virol. 81, 4819\u20134827 (2007)","journal-title":"J. Virol."},{"key":"18_CR001835","doi-asserted-by":"crossref","first-page":"8356","DOI":"10.1128\/JVI.75.18.8356-8367.2001","volume":"75","author":"SH Hassan","year":"2001","unstructured":"Hassan, S.H., Wirblich, C., Forzan, M., Roy, P.: Expression and functional characterization of bluetongue virus VP5 protein: role in cellular permeabilization. J. Virol. 75, 8356\u20138367 (2001)","journal-title":"J. Virol."},{"key":"18_CR001836","doi-asserted-by":"crossref","first-page":"9832","DOI":"10.1128\/JVI.73.12.9832-9842.1999","volume":"73","author":"SS Hassan","year":"1999","unstructured":"Hassan, S.S., Roy, P.: Expression and functional characterization of bluetongue virus VP2 protein: role in cell entry. J. Virol. 73, 9832\u20139842 (1999)","journal-title":"J. Virol."},{"key":"18_CR001837","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1128\/JVI.78.15.8059-8067.2004","volume":"78","author":"EL Nason","year":"2004","unstructured":"Nason, E.L., et al.: Interactions between the inner and outer capsids of bluetongue virus. J. Virol. 78, 8059\u2013\u200a8067 (2004)","journal-title":"J. Virol."},{"key":"18_CR001838","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1073\/pnas.0913403107","volume":"107","author":"X Zhang","year":"2010","unstructured":"Zhang, X., et al.: Bluetongue virus coat protein VP2 contains sialic acid-binding domains, and VP5 resembles enveloped virus fusion proteins. Proc. Natl. Acad. Sci. U.S.A. 107, 6292\u20136297 (2010)","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"18_CR001839","first-page":"51","volume":"48","author":"H Huismans","year":"1981","unstructured":"Huismans, H., Erasmus, B.J.: Identification of the serotype-specific and group-specific antigens of bluetongue virus. Onderstepoort J. Vet. Res. 48, 51\u201358 (1981)","journal-title":"Onderstepoort J. Vet. Res."},{"key":"18_CR001840","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0042-6822(87)90326-6","volume":"157","author":"H Huismans","year":"1987","unstructured":"Huismans, H., van der Walt, N.T., Cloete, M., Erasmus, B.J.: Isolation of a capsid protein of bluetongue virus that induces a protective immune response in sheep. Virology 157, 172\u2013179 (1987)","journal-title":"Virology"},{"key":"18_CR001841","first-page":"347","volume":"178","author":"H Huismans","year":"1985","unstructured":"Huismans, H., van der Walt, N.T., Erasmus, B.J.: Immune response against the purified serotype specific antigen of bluetongue virus and initial attempts to clone the gene that codes for the synthesis of this protein. Prog. Clin. Biol. Res. 178, 347\u2013353 (1985)","journal-title":"Prog. Clin. Biol. Res."},{"issue":"Pt 8","key":"18_CR001842","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1099\/0022-1317-73-8-1947","volume":"73","author":"PV Rossitto","year":"1992","unstructured":"Rossitto, P.V., MacLachlan, N.J.: Neutralizing epitopes of the serotypes of bluetongue virus present in the United States. J. Gen. Virol. 73(Pt 8), 1947\u2013\u200a1952 (1992)","journal-title":"J. Gen. Virol."},{"key":"18_CR001843","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1128\/jvi.64.5.1998-2003.1990","volume":"64","author":"P Roy","year":"1990","unstructured":"Roy, P., Urakawa, T., Van Dijk, A.A., Erasmus, B.J.: Recombinant virus vaccine for bluetongue disease in sheep. J. Virol. 64, 1998\u20132003 (1990)","journal-title":"J. Virol."},{"key":"18_CR001844","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0168-1702(90)90062-G","volume":"17","author":"AR Gould","year":"1990","unstructured":"Gould, A.R., Eaton, B.T.: The amino acid sequence of the outer coat protein VP2 of neutralizing monoclonal antibody-resistant, virulent and attenuated bluetongue viruses. Virus Res. 17, 161\u2013172 (1990)","journal-title":"Virus Res."},{"key":"18_CR001845","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/0042-6822(90)90041-O","volume":"176","author":"HW Heidner","year":"1990","unstructured":"Heidner, H.W., Rossitto, P.V., MacLachlan, N.J.: Identification of four distinct neutralizing epitopes on bluetongue virus serotype 10 using neutralizing monoclonal antibodies and neutralization-escape variants. Virology 176, 658\u2013661 (1990)","journal-title":"Virology"},{"issue":"Pt 6","key":"18_CR001846","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1099\/0022-1317-71-6-1325","volume":"71","author":"JR White","year":"1990","unstructured":"White, J.R., Eaton, B.T.: Conformation of the VP2 protein of bluetongue virus (BTV) determines the involvement in virus neutralization of highly conserved epitopes within the BTV serogroup. J. Gen. Virol. 71(Pt 6), 1325\u20131332 (1990)","journal-title":"J. Gen. Virol."},{"key":"18_CR001847","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1073\/pnas.0306448101","volume":"101","author":"M Forzan","year":"2004","unstructured":"Forzan, M., Wirblich, C., Roy, P.: A capsid protein of nonenveloped Bluetongue virus exhibits membrane fusion activity. Proc. Natl. Acad. Sci. U.S.A. 101, 2100\u20132105 (2004)","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"18_CR001848","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0969-2126(97)00243-8","volume":"5","author":"JM Grimes","year":"1997","unstructured":"Grimes, J.M., et al.: An atomic model of the outer layer of the bluetongue virus core derived from X-ray crystallography and electron cryomicroscopy. Structure 5, 885\u2013893 (1997)","journal-title":"Structure"},{"key":"18_CR001849","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/jsbi.1994.1019","volume":"112","author":"EA Hewat","year":"1994","unstructured":"Hewat, E.A., Booth, T.F., Roy, P.: Structure of correctly self-assembled bluetongue virus-like particles. J. Struct. Biol. 112, 183\u2013191 (1994)","journal-title":"J. Struct. Biol."},{"key":"18_CR001850","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1128\/JVI.75.8.3937-3947.2001","volume":"75","author":"BH Tan","year":"2001","unstructured":"Tan, B.H., et al.: RGD tripeptide of bluetongue virus VP7 protein is responsible for core attach-ment to Culicoides cells. J. Virol. 75, 3937\u20133947 (2001)","journal-title":"J. Virol."},{"key":"18_CR001851","doi-asserted-by":"crossref","first-page":"13746","DOI":"10.1073\/pnas.1108667108","volume":"108","author":"S Lourenco","year":"2011","unstructured":"Lourenco, S., Roy, P.: In vitro reconstitution of Bluetongue virus infectious cores. Proc. Natl. Acad. Sci. U.S.A. 108, 13746\u201313751 (2011)","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"18_CR001852","first-page":"1091","volume":"28","author":"JG Browne","year":"1967","unstructured":"Browne, J.G., Jochim, M.M.: Cytopathologic changes and development of inclusion bodies in cultured cells infected with bluetongue virus. Am. J. Vet. Res. 28, 1091\u20131105 (1967)","journal-title":"Am. J. Vet. Res."},{"key":"18_CR001853","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1128\/JVI.79.15.10023-10031.2005","volume":"79","author":"J Modrof","year":"2005","unstructured":"Modrof, J., Lymperopoulos, K., Roy, P.: Phosphorylation of bluetongue virus nonstructural protein 2 is essential for formation of viral inclusion bodies. J. Virol. 79, 10023\u201310031 (2005)","journal-title":"J. Virol."},{"issue":"Pt 9","key":"18_CR001854","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1099\/0022-1317-71-9-2073","volume":"71","author":"CP Thomas","year":"1990","unstructured":"Thomas, C.P., Booth, T.F., Roy, P.: Synthesis of bluetongue virus-encoded phosphoprotein and formation of inclusion bodies by recombinant baculovirus in insect cells: it binds the single-stranded RNA species. J. Gen. Virol. 71(Pt 9), 2073\u20132083 (1990)","journal-title":"J. Gen. Virol."},{"key":"18_CR001855","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1743-422X-4-7","volume":"4","author":"B Bhattacharya","year":"2007","unstructured":"Bhattacharya, B., Noad, R.J., Roy, P.: Interaction between Bluetongue virus outer capsid protein VP2 and vimentin is necessary for virus egress. Virol. J. 4, 7 (2007)","journal-title":"Virol. J."},{"key":"18_CR001856","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3390\/v2051218","volume":"2","author":"B Bhattacharya","year":"2010","unstructured":"Bhattacharya, B., Roy, P.: Role of lipids on entry and exit of bluetongue virus, a complex non-enveloped virus. Viruses 2, 1218\u20131235 (2010)","journal-title":"Viruses"},{"key":"18_CR001857","doi-asserted-by":"crossref","first-page":"6806","DOI":"10.1128\/JVI.00263-09","volume":"83","author":"CC Celma","year":"2009","unstructured":"Celma, C.C., Roy, P.: A viral nonstructural protein regulates bluetongue virus trafficking and release. J. Virol. 83, 6806\u20136816 (2009)","journal-title":"J. Virol."},{"key":"18_CR001858","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1128\/jvi.62.11.3919-3927.1988","volume":"62","author":"T Urakawa","year":"1988","unstructured":"Urakawa, T., Roy, P.: Bluetongue virus tubules made in insect cells by recombinant baculoviruses: expression of the NS1 gene of bluetongue virus serotype 10. J. Virol. 62, 3919\u20133927 (1988)","journal-title":"J. Virol."},{"key":"18_CR001859","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1743-422X-9-178","volume":"9","author":"M Boyce","year":"2012","unstructured":"Boyce, M., Celma, C.C., Roy, P.: Bluetongue virus non-structural protein 1 is a positive regulator of viral protein synthesis. Virol. J. 9, 178 (2012)","journal-title":"Virol. J."},{"key":"18_CR001860","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1098\/rstb.2009.0091","volume":"364","author":"AJ Wilson","year":"2009","unstructured":"Wilson, A.J., Mellor, P.S.: Bluetongue in Europe: past, present and future. Philos. Trans. R. Soc. Lond. B Biol. Sci. 364, 2669\u20132681 (2009)","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"18_CR001861","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jviromet.2010.02.027","volume":"165","author":"MA Hofmann","year":"2010","unstructured":"Hofmann, M.A., et al.: Detection of Toggenburg Orbivirus by a segment 2-specific quantitative RT-PCR. J. Virol. Methods 165, 325\u2013329 (2010)","journal-title":"J. Virol. Methods"},{"key":"18_CR001862","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3201\/eid1705.101742","volume":"17","author":"S Maan","year":"2011","unstructured":"Maan, S., et al.: Novel bluetongue virus serotype from Kuwait. Emerg. Infect. Dis. 17, 886\u2013889 (2011)","journal-title":"Emerg. Infect. Dis."},{"key":"18_CR001863","first-page":"143","volume":"162","author":"PS Mellor","year":"1990","unstructured":"Mellor, P.S.: The replication of bluetongue virus in Culicoides vectors. Curr. Top. Microbiol. Immunol. 162, 143\u2013161 (1990)","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"18_CR001864","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1007\/s00436-008-1053-x","volume":"103 Suppl 1","author":"A Wilson","year":"2008","unstructured":"Wilson, A., Mellor, P.: Bluetongue in Europe: vectors, epidemiology and climate change. Parasitol. Res. 103 Suppl 1, S69\u2013S77 (2008)","journal-title":"Parasitol. Res."},{"key":"18_CR001865","first-page":"182","volume":"40","author":"D Dargatz","year":"2004","unstructured":"Dargatz, D., et al.: Bluetongue surveillance methods in the United States of America. Vet. Ital. 40, 182\u2013183 (2004)","journal-title":"Vet. Ital."},{"key":"18_CR001866","first-page":"167","volume":"40","author":"PS Mellor","year":"2004","unstructured":"Mellor, P.S.: Infection of the vectors and bluetongue epidemiology in Europe. Vet. Ital. 40, 167\u2013174 (2004)","journal-title":"Vet. Ital."},{"key":"18_CR001867","first-page":"31","volume":"40","author":"TE Walton","year":"2004","unstructured":"Walton, T.E.: The history of bluetongue and a current global overview. Vet. Ital. 40, 31\u201338 (2004)","journal-title":"Vet. Ital."},{"key":"18_CR001868","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1603\/ME09211","volume":"47","author":"ME Becker","year":"2010","unstructured":"Becker, M.E., et al.: Detection of bluetongue virus RNA in field-collected Culicoides spp. (Diptera: Ceratopogonidae) following the discovery of bluetongue virus serotype 1 in white-tailed deer and cattle in Louisiana. J. Med. Entomol. 47, 269\u2013273 (2010)","journal-title":"J. Med. Entomol."},{"key":"18_CR001869","first-page":"89","volume":"40","author":"IA Lager","year":"2004","unstructured":"Lager, I.A.: Bluetongue virus in South America: overview of viruses, vectors, surveillance and unique features. Vet. Ital. 40, 89\u201393 (2004)","journal-title":"Vet. Ital."},{"key":"18_CR001870","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1051\/vetres\/2010007","volume":"41","author":"NJ Maclachlan","year":"2010","unstructured":"Maclachlan, N.J., Guthrie, A.J.: Re-emergence of bluetongue, African horse sickness, and other orbivirus diseases. Vet. Res. 41, 35 (2010)","journal-title":"Vet. Res."},{"key":"18_CR001871","doi-asserted-by":"crossref","unstructured":"Tabachnick, W.J., Smartt, C.T., Connelly, C.R.: Bluetongue. Report No. ENY-743 (IN768), Gainesville (2008)","DOI":"10.32473\/edis-in768-2008"},{"key":"18_CR001872","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.prevetmed.2008.06.003","volume":"87","author":"AR Elbers","year":"2008","unstructured":"Elbers, A.R., et al.: Field observations during the Bluetongue serotype 8 epidemic in 2006. II. Morbidity and mortality rate, case fatality and clinical recovery in sheep and cattle in the Netherlands. Prev. Vet. Med. 87, 31\u201340 (2008)","journal-title":"Prev. Vet. Med."},{"key":"18_CR001873","first-page":"307","volume":"178","author":"L Goldsmit","year":"1985","unstructured":"Goldsmit, L., Barzilai, E.: Isolation and propagation of bluetongue virus in embryonating chicken eggs. Prog. Clin. Biol. Res. 178, 307\u2013318 (1985)","journal-title":"Prog. Clin. Biol. Res."},{"key":"18_CR001874","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0378-1135(94)00119-H","volume":"45","author":"MP Ward","year":"1995","unstructured":"Ward, M.P., Gardner, I.A., Flanagan, M.: Evaluation of an agar gel immunodiffusion test to detect infection of cattle with bluetongue viruses in Queensland, Australia. Vet. Microbiol. 45, 27\u201334 (1995)","journal-title":"Vet. Microbiol."},{"key":"18_CR001875","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0378-1135(92)90043-S","volume":"33","author":"P Roy","year":"1992","unstructured":"Roy, P.: From genes to complex structures of bluetongue virus and their efficacy as vaccines. Vet. Microbiol. 33, 155\u2013168 (1992)","journal-title":"Vet. Microbiol."},{"key":"18_CR001876","first-page":"169","volume":"114","author":"P Roy","year":"2003","unstructured":"Roy, P.: Nature and duration of protective immunity to bluetongue virus infection. Dev. Biol. (Basel) 114, 169\u2013183 (2003)","journal-title":"Dev. Biol. (Basel)"},{"key":"18_CR001877","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/nrmicro2052","volume":"7","author":"P Roy","year":"2009","unstructured":"Roy, P., Boyce, M., Noad, R.: Prospects for improved bluetongue vaccines. Nat. Rev. Microbiol. 7, 120\u2013\u200a128 (2009)","journal-title":"Nat. Rev. Microbiol."},{"key":"18_CR001878","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cimid.2007.07.006","volume":"31","author":"G Savini","year":"2008","unstructured":"Savini, G., MacLachlan, N.J., Sanchez-Vizcaino, J.M., Zientara, S.: Vaccines against bluetongue in Europe. Comp. Immunol. Microbiol. Infect. Dis. 31, 101\u2013120 (2008)","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"18_CR001879","first-page":"206","volume":"25","author":"BI Osburn","year":"1971","unstructured":"Osburn, B.I., et al.: Experimental viral-induced congenital encephalopathies. II. The pathogenesis of bluetongue vaccine virus infection in fetal lambs. Lab. Invest. 25, 206\u2013210 (1971)","journal-title":"Lab. Invest."},{"key":"18_CR001880","first-page":"224","volume":"127","author":"G Schultz","year":"1955","unstructured":"Schultz, G., Delay, P.D.: Losses in newborn lambs associated with bluetongue vaccination of pregnancy ewes. J. Am. Vet. Med. Assoc. 127, 224\u2013226 (1955)","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"18_CR001881","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1751-0813.1995.tb03488.x","volume":"72","author":"M Flanagan","year":"1995","unstructured":"Flanagan, M., Johnson, S.J.: The effects of vaccination of Merino ewes with an attenuated Australian bluetongue virus serotype 23 at different stages of gestation. Aust. Vet. J. 72, 455\u2013457 (1995)","journal-title":"Aust. Vet. J."},{"key":"18_CR001882","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.prevetmed.2004.11.011","volume":"68","author":"G Ferrari","year":"2005","unstructured":"Ferrari, G., et al.: Active circulation of bluetongue vaccine virus serotype-2 among unvaccinated cattle in central Italy. Prev. Vet. Med. 68, 103\u2013113 (2005)","journal-title":"Prev. Vet. Med."},{"key":"18_CR001883","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1128\/jvi.61.9.2670-2674.1987","volume":"61","author":"JL Stott","year":"1987","unstructured":"Stott, J.L., Oberst, R.D., Channell, M.B., Osburn, B.I.: Genome segment reassortment between two serotypes of bluetongue virus in a natural host. J. Virol. 61, 2670\u20132674 (1987)","journal-title":"J. Virol."},{"key":"18_CR001884","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.virusres.2008.05.016","volume":"137","author":"CA Batten","year":"2008","unstructured":"Batten, C.A., Maan, S., Shaw, A.E., Maan, N.S., Mertens, P.P.: A European field strain of bluetongue virus derived from two parental vaccine strains by genome segment reassortment. Virus Res. 137, 56\u201363 (2008)","journal-title":"Virus Res."},{"key":"18_CR001885","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vetmic.2008.05.032","volume":"133","author":"G Savini","year":"2009","unstructured":"Savini, G., et al.: Assessment of efficacy of a bivalent BTV-2 and BTV-4 inactivated vaccine by vaccination and challenge in cattle. Vet. Microbiol. 133, 1\u20138 (2009)","journal-title":"Vet. Microbiol."},{"issue":"31","key":"18_CR001886","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1016\/j.vaccine.2009.04.072","volume":"27","author":"J Gethmann","year":"2009","unstructured":"Gethmann, J., et al.: Comparative safety study of three inactivated BTV-8 vaccines in sheep and cattle under field conditions. Vaccine 27(31), 4118\u20134126 (2009)","journal-title":"Vaccine"},{"key":"18_CR001887","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/vr.b4849","volume":"166","author":"JM Gonz\u00e1lez","year":"2010","unstructured":"Gonz\u00e1lez, J.M., et al.: Possible adverse reactions in sheep after vaccination with inactivated BTV vaccines. Vet. Rec. 166, 757\u2013758 (2010)","journal-title":"Vet. Rec."},{"key":"18_CR001888","first-page":"639","volume":"178","author":"CH Campbell","year":"1985","unstructured":"Campbell, C.H., Barber, T.L., Knudsen, R.C., Swaney, L.M.: Immune response of mice and sheep to bluetongue virus inactivated by gamma irradiation. Prog. Clin. Biol. Res. 178, 639\u2013647 (1985)","journal-title":"Prog. Clin. Biol. Res."},{"key":"18_CR001889","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/vr.96.13.284","volume":"96","author":"J Parker","year":"1975","unstructured":"Parker, J., Herniman, K.A., Gibbs, E.P., Sellers, R.F.: An experimental inactivated vaccine against bluetongue. Vet. Rec. 96, 284\u2013287 (1975)","journal-title":"Vet. Rec."},{"key":"18_CR001890","first-page":"1043","volume":"46","author":"JL Stott","year":"1985","unstructured":"Stott, J.L., Barber, T.L., Osburn, B.I.: Immunologic response of sheep to inactivated and virulent bluetongue virus. Am. J. Vet. Res. 46, 1043\u20131049 (1985)","journal-title":"Am. J. Vet. Res."},{"key":"18_CR001891","first-page":"55","volume":"83","author":"J.L. Stott","year":"1979","unstructured":"Stott, J.L., Osburn, B.I., Barber, T.L.: The current status of research on an experimental inactivated bluetongue virus vaccine. Proc. Ann. Meet. U. S. Anim. Health Assoc. 83, 55\u201362 (1979)","journal-title":"Proc. Ann. Meet. U. S. Anim. Health Assoc."},{"key":"18_CR001892","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1016\/j.vaccine.2010.06.034","volume":"28","author":"A Steinrigl","year":"2010","unstructured":"Steinrigl, A., Revilla-Fernandez, S., Eichinger, M., Koefer, J., Winter, P.: Bluetongue virus RNA detection by RT-qPCR in blood samples of sheep vaccinated with a commercially available inactivated BTV-8 vaccine. Vaccine 28, 5573\u20135581 (2010)","journal-title":"Vaccine"},{"key":"18_CR001893","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0378-1135(02)00106-2","volume":"88","author":"KR Bonneau","year":"2002","unstructured":"Bonneau, K.R., DeMaula, C.D., Mullens, B.A., MacLachlan, N.J.: Duration of viraemia infectious to Culicoides sonorensis in bluetongue virus-infected cattle and sheep. Vet. Microbiol. 88, 115\u2013125 (2002)","journal-title":"Vet. Microbiol."},{"key":"18_CR001894","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1128\/jcm.31.11.3028-3030.1993","volume":"31","author":"JB Katz","year":"1993","unstructured":"Katz, J.B., Alstad, A.D., Gustafson, G.A., Moser, K.M.: Sensitive identification of bluetongue virus serogroup by a colorimetric dual oligonucleotide sorbent assay of amplified viral nucleic acid. J. Clin. Microbiol. 31, 3028\u20133030 (1993)","journal-title":"J. Clin. Microbiol."},{"key":"18_CR001895","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1574-6968.1990.tb03523.x","volume":"2","author":"P Roy","year":"1990","unstructured":"Roy, P.: Use of baculovirus expression vectors: development of diagnostic reagents, vaccines and morphological counterparts of bluetongue virus. FEMS Microbiol. Immunol. 2, 223\u2013234 (1990)","journal-title":"FEMS Microbiol. Immunol."},{"key":"18_CR001896","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0264-410X(94)90289-5","volume":"12","author":"P Roy","year":"1994","unstructured":"Roy, P., Bishop, D.H., LeBlois, H., Erasmus, B.J.: Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. Vaccine 12, 805\u2013811 (1994)","journal-title":"Vaccine"},{"key":"18_CR001897","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.vaccine.2006.08.025","volume":"25","author":"JD Boone","year":"2007","unstructured":"Boone, J.D., et al.: Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 25, 672\u2013678 (2007)","journal-title":"Vaccine"},{"key":"18_CR001898","doi-asserted-by":"crossref","first-page":"e34735","DOI":"10.1371\/journal.pone.0034735","volume":"7","author":"E Calvo-Pinilla","year":"2012","unstructured":"Calvo-Pinilla, E., Navasa, N., Anguita, J., Ortego, J.: Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus. PLoS One 7, e34735 (2012)","journal-title":"PLoS One"},{"issue":"Pt 5","key":"18_CR001899","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1099\/0022-1317-77-5-997","volume":"77","author":"LD Jones","year":"1996","unstructured":"Jones, L.D., Chuma, T., Hails, R., Williams, T., Roy, P.: The non-structural proteins of bluetongue virus are a dominant source of cytotoxic T cell peptide determinants. J. Gen. Virol. 77(Pt 5), 997\u20131003 (1996)","journal-title":"J. Gen. Virol."},{"key":"18_CR0018100","doi-asserted-by":"crossref","first-page":"e34425","DOI":"10.1371\/journal.pone.0034425","volume":"7","author":"G Ma","year":"2012","unstructured":"Ma, G., et al.: An equine herpesvirus type 1 (EHV-1) expressing VP2 and VP5 of serotype 8 bluetongue virus (BTV-8) induces protection in a murine infection model. PLoS One 7, e34425 (2012)","journal-title":"PLoS One"},{"key":"18_CR0018101","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/0042-6822(87)90289-3","volume":"157","author":"S Inumaru","year":"1987","unstructured":"Inumaru, S., Roy, P.: Production and characterization of the neutralization antigen VP2 of bluetongue virus serotype 10 using a baculovirus expression vector. Virology 157, 472\u2013479 (1987)","journal-title":"Virology"},{"key":"18_CR0018102","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1006\/viro.1996.0306","volume":"220","author":"AM Wade-Evans","year":"1996","unstructured":"Wade-Evans, A.M., et al.: Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge. Virology 220, 227\u2013231 (1996)","journal-title":"Virology"},{"key":"18_CR0018103","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/0264-410X(92)90415-G","volume":"10","author":"P Roy","year":"1992","unstructured":"Roy, P., French, T., Erasmus, B.J.: Protective efficacy of virus-like particles for bluetongue disease. Vaccine 10, 28\u201332 (1992)","journal-title":"Vaccine"},{"key":"18_CR0018104","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1016\/j.vaccine.2009.10.072","volume":"28","author":"M Stewart","year":"2010","unstructured":"Stewart, M., et al.: Validation of a novel approach for the rapid production of immunogenic virus-like particles for bluetongue virus. Vaccine 28, 3047\u20133054 (2010)","journal-title":"Vaccine"},{"key":"18_CR0018105","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.vaccine.2012.01.042","volume":"30","author":"M Stewart","year":"2012","unstructured":"Stewart, M., et al.: Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection. Vaccine 30, 2131\u20132139 (2012)","journal-title":"Vaccine"},{"key":"18_CR0018106","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.1128\/jvi.64.12.5695-5700.1990","volume":"64","author":"TJ French","year":"1990","unstructured":"French, T.J., Marshall, J.J., Roy, P.: Assembly of double-shelled, viruslike particles of bluetongue virus by the simultaneous expression of four structural proteins. J. Virol. 64, 5695\u20135700 (1990)","journal-title":"J. Virol."},{"key":"18_CR0018107","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1128\/jvi.63.8.3270-3278.1989","volume":"63","author":"TJ French","year":"1989","unstructured":"French, T.J., Inumaru, S., Roy, P.: Expression of two related nonstructural proteins of bluetongue virus (BTV) type 10 in insect cells by a recombinant baculovirus: production of polyclonal ascitic fluid and characterization of the gene product in BTV-infected BHK cells. J. Virol. 63, 3270\u20133278 (1989)","journal-title":"J. Virol."},{"issue":"Pt 10","key":"18_CR0018108","first-page":"2577","volume":"73","author":"HM Liu","year":"1992","unstructured":"Liu, H.M., Booth, T.F., Roy, P.: Interactions between bluetongue virus core and capsid proteins translated in vitro. J. Gen. Virol. 73(Pt 10), 2577\u20132584 (1992)","journal-title":"J. Gen. Virol."},{"key":"18_CR0018109","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0165-2427(90)90077-6","volume":"24","author":"JA Ellis","year":"1990","unstructured":"Ellis, J.A., et al.: T lymphocyte subset alterations following bluetongue virus infection in sheep and cattle. Vet. Immunol. Immunopathol. 24, 49\u201367 (1990)","journal-title":"Vet. Immunol. Immunopathol."},{"key":"18_CR0018110","first-page":"477","volume":"178","author":"MH Jeggo","year":"1985","unstructured":"Jeggo, M.H., Wardley, R.C., Brownlie, J.: Importance of ovine cytotoxic T cells in protection against bluetongue virus infection. Prog. Clin. Biol. Res. 178, 477\u2013487 (1985)","journal-title":"Prog. Clin. Biol. Res."},{"key":"18_CR0018111","doi-asserted-by":"crossref","first-page":"6848","DOI":"10.1016\/j.vaccine.2011.07.061","volume":"29","author":"JM Rojas","year":"2011","unstructured":"Rojas, J.M., Rodriguez-Calvo, T., Pena, L., Sevilla, N.: T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep. Vaccine 29, 6848\u20136857 (2011)","journal-title":"Vaccine"},{"key":"18_CR0018112","doi-asserted-by":"crossref","first-page":"e26666","DOI":"10.1371\/journal.pone.0026666","volume":"6","author":"AC de Perez de Diego","year":"2011","unstructured":"de Perez de Diego, A.C., et al.: Characterization of protection afforded by a bivalent virus-like particle vaccine against bluetongue virus serotypes 1 and 4 in sheep. PLoS One 6, e26666 (2011)","journal-title":"PLoS One"},{"issue":"3","key":"18_CR0018113","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.vaccine.2012.11.016","volume":"31","author":"M Stewart","year":"2012","unstructured":"Stewart, M., et al.: Bluetongue virus serotype 8 virus-like particles protect sheep against virulent virus infection as a single or multi-serotype cocktail immunogen. Vaccine 31(3), 553\u2013558 (2012)","journal-title":"Vaccine"},{"key":"18_CR0018114","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.vetmic.2007.07.006","volume":"126","author":"UB Balasuriya","year":"2008","unstructured":"Balasuriya, U.B., et al.: The NS3 proteins of global strains of bluetongue virus evolve into regional topotypes through negative (purifying) selection. Vet. Microbiol. 126, 91\u2013100 (2008)","journal-title":"Vet. Microbiol."},{"key":"18_CR0018115","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1099\/vir.0.83023-0","volume":"88","author":"PP Mertens","year":"2007","unstructured":"Mertens, P.P., et al.: Design of primers and use of RT-PCR assays for typing European bluetongue virus isolates: differentiation of field and vaccine strains. J. Gen. Virol. 88, 2811\u20132823 (2007)","journal-title":"J. Gen. Virol."},{"key":"18_CR0018116","doi-asserted-by":"crossref","first-page":"e6437","DOI":"10.1371\/journal.pone.0006437","volume":"4","author":"K Nomikou","year":"2009","unstructured":"Nomikou, K., et al.: Evolution and phylogenetic analysis of full-length VP3 genes of Eastern Mediterranean bluetongue virus isolates. PLoS One 4, e6437 (2009)","journal-title":"PLoS One"},{"key":"18_CR0018117","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.virusres.2004.01.004","volume":"101","author":"LI Pritchard","year":"2004","unstructured":"Pritchard, L.I., et al.: Genetic diversity of bluetongue viruses in south east Asia. Virus Res. 101, 193\u2013201 (2004)","journal-title":"Virus Res."},{"key":"18_CR0018118","doi-asserted-by":"crossref","first-page":"8339","DOI":"10.1128\/JVI.00808-08","volume":"82","author":"M Boyce","year":"2008","unstructured":"Boyce, M., Celma, C.C., Roy, P.: Development of reverse genetics systems for bluetongue virus: recovery of infectious virus from synthetic RNA transcripts. J. Virol. 82, 8339\u20138348 (2008)","journal-title":"J. Virol."},{"key":"18_CR0018119","doi-asserted-by":"crossref","first-page":"8842","DOI":"10.1128\/JVI.00465-09","volume":"83","author":"E Matsuo","year":"2009","unstructured":"Matsuo, E., Roy, P.: Bluetongue virus VP6 acts early in the replication cycle and can form the basis of chimeric virus formation. J. Virol. 83, 8842\u20138848 (2009)","journal-title":"J. Virol."},{"key":"18_CR0018120","doi-asserted-by":"crossref","first-page":"10213","DOI":"10.1128\/JVI.05412-11","volume":"85","author":"E Matsuo","year":"2011","unstructured":"Matsuo, E., et al.: Generation of replication-defective virus-based vaccines that confer full protection in sheep against virulent bluetongue virus challenge. J. Virol. 85, 10213\u201310221 (2011)","journal-title":"J. Virol."},{"key":"18_CR0018121","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.vetmic.2009.01.033","volume":"137","author":"SC Barros","year":"2009","unstructured":"Barros, S.C., et al.: A DIVA system based on the detection of antibodies to non-structural protein 3 (NS3) of bluetongue virus. Vet. Microbiol. 137, 252\u2013259 (2009)","journal-title":"Vet. Microbiol."}],"container-title":["Molecular Vaccines"],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-7091-1419-3_18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T07:28:07Z","timestamp":1706254087000},"score":19.427605,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-7091-1419-3_18"}},"issued":{"date-parts":[[2013]]},"ISBN":["9783709114186","9783709114193"],"references-count":121,"URL":"https:\/\/doi.org\/10.1007\/978-3-7091-1419-3_18","published":{"date-parts":[[2013]]},"assertion":[{"value":"16 August 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]},{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T23:13:56Z","timestamp":1649200436020},"reference-count":0,"publisher":"Medwin Publishers","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["VIJ"],"DOI":"10.23880\/vij-16000176","type":"journal-article","created":{"date-parts":[[2018,11,17]],"date-time":"2018-11-17T05:30:01Z","timestamp":1542432601000},"source":"Crossref","is-referenced-by-count":0,"title":["Development of Methods for Safe Application of Viral Vectors for Production of Gene-Engineering Vaccines"],"prefix":"10.23880","volume":"2","author":[{"given":"Sainova","family":"IV","sequence":"first","affiliation":[]}],"member":"9969","published-online":{"date-parts":[[2018]]},"container-title":["Virology &amp; Immunology Journal"],"original-title":["Development of Methods for Safe Application of Viral Vectors for Production of Gene-Engineering Vaccines"],"deposited":{"date-parts":[[2018,11,17]],"date-time":"2018-11-17T05:30:05Z","timestamp":1542432605000},"score":19.392067,"resource":{"primary":{"URL":"https:\/\/medwinpublishers.com\/VIJ\/VIJ16000176.pdf"}},"issued":{"date-parts":[[2018]]},"references-count":0,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.23880\/vij-16000176","ISSN":["2577-4379"],"issn-type":[{"value":"2577-4379","type":"electronic"}],"published":{"date-parts":[[2018]]}},{"indexed":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T22:26:02Z","timestamp":1725575162449},"publisher-location":"Basel","reference-count":111,"publisher":"Springer Basel","isbn-type":[{"type":"print","value":"9783034602761"},{"type":"electronic","value":"9783034602778"}],"license":[{"start":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T00:00:00Z","timestamp":1285718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T00:00:00Z","timestamp":1285718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T00:00:00Z","timestamp":1285718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T00:00:00Z","timestamp":1285718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"published-print":{"date-parts":[[2011]]},"DOI":"10.1007\/978-3-0346-0277-8_7","type":"book-chapter","created":{"date-parts":[[2011,1,14]],"date-time":"2011-01-14T15:58:20Z","timestamp":1295020700000},"page":"173-193","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Basic Science Paves the Way to Novel Safe and Effective Pestivirus Vaccines"],"prefix":"10.1007","author":[{"given":"Norbert","family":"Tautz","sequence":"first","affiliation":[]},{"given":"Gregor","family":"Meyers","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2010,9,29]]},"reference":[{"key":"7_CR1_7","first-page":"1101","volume-title":"Fields virology","author":"BD Lindenbach","year":"2007","unstructured":"Lindenbach BD, Thiel HJ, Rice CM (2007) Flaviviridae: the viruses and their replication. In: Knipe DM, Howley PM (eds) Fields virology, vol 1, 5th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1101\u20131152","edition":"5"},{"key":"7_CR2_7","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1006\/viro.2001.1001","volume":"286","author":"R Avalos-Ramirez","year":"2001","unstructured":"Avalos-Ramirez R, Orlich M, Thiel H-J, Becher P (2001) Evidence for the presence of two novel pestivirus species. Virology 286:456\u2013465","journal-title":"Virology"},{"key":"7_CR3_7","first-page":"73","volume":"50","author":"JH Gillespie","year":"1960","unstructured":"Gillespie JH, Baker JA, McEntee K (1960) A cytopathogenic strain of virus diarrhea virus. Cornell Vet 50:73\u201379","journal-title":"Cornell Vet"},{"key":"7_CR4_7","first-page":"1449","volume":"190","author":"JC Baker","year":"1987","unstructured":"Baker JC (1987) Bovine viral diarrhea virus: a review. J Am Vet Med Assoc 190:1449\u20131458","journal-title":"J Am Vet Med Assoc"},{"key":"7_CR5_7","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1128\/JVI.79.6.3787-3796.2005","volume":"79","author":"GR Risatti","year":"2005","unstructured":"Risatti GR et al (2005) The E2 glycoprotein of classical swine fever virus is a virulence determinant in swine. J Virol 79:3787\u20133796","journal-title":"J Virol"},{"key":"7_CR6_7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.virol.2007.02.025","volume":"364","author":"GR Risatti","year":"2007","unstructured":"Risatti GR et al (2007) Mutations in the carboxyl terminal region of E2 glycoprotein of classical swine fever virus are responsible for viral attenuation in swine. Virology 364:371\u2013382","journal-title":"Virology"},{"key":"7_CR7_7","doi-asserted-by":"crossref","first-page":"8812","DOI":"10.1128\/JVI.78.16.8812-8823.2004","volume":"78","author":"HG Van Gennip","year":"2004","unstructured":"Van Gennip HG, Vlot AC, Hulst MM, De Smit AJ, Moormann RJ (2004) Determinants of virulence of classical swine fever virus strain Brescia. J Virol 78:8812\u20138823","journal-title":"J Virol"},{"key":"7_CR8_7","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1128\/JVI.75.14.6256-6264.2001","volume":"75","author":"P Becher","year":"2001","unstructured":"Becher P, Orlich M, Thiel H-J (2001) RNA recombination between persisting pestivirus and a vaccine strain: generation of cytopathogenic virus and induction of lethal disease. J Virol 75:6256\u20136264","journal-title":"J Virol"},{"key":"7_CR9_7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0042-6822(88)90672-1","volume":"165","author":"MS Collett","year":"1988","unstructured":"Collett MS et al (1988) Molecular cloning and nucleotide sequence of the pestivirus bovine viral diarrhea virus. Virology 165:191\u2013199","journal-title":"Virology"},{"key":"7_CR10_7","unstructured":"Renard A, Dino D, Martial J (1987) Vaccines and diagnostics derived from bovine diarrhea virus. European Patent application number 86870095.6:publication number 02.08672"},{"key":"7_CR11_7","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0042-6822(95)80003-4","volume":"206","author":"TL Poole","year":"1995","unstructured":"Poole TL et al (1995) Pestivirus translation occurs by internal ribosome entry. Virology 206:750\u2013754","journal-title":"Virology"},{"key":"7_CR12_7","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1128\/jvi.65.9.4705-4712.1991","volume":"65","author":"H-J Thiel","year":"1991","unstructured":"Thiel H-J, Stark R, Weiland E, R\u00fcmenapf T, Meyers G (1991) Hog cholera virus: molecular composition of virions from a pestivirus. J Virol 65:4705\u20134712","journal-title":"J Virol"},{"key":"7_CR13_7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0042-6822(92)90914-B","volume":"190","author":"DJ Paton","year":"1992","unstructured":"Paton DJ, Lowings JP, Barrett AD (1992) Epitope mapping of the gp53 envelope protein of bovine viral diarrhea virus. Virology 190:763\u2013772","journal-title":"Virology"},{"key":"7_CR14_7","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1128\/jvi.66.6.3677-3682.1992","volume":"66","author":"S Weiland","year":"1992","unstructured":"Weiland S, Ahl R, Stark R, Weiland F, Thiel H-J (1992) A second envelope glycoprotein mediates neutralization of a pestivirus, hog cholera virus. J Virol 66:3677\u20133682","journal-title":"J Virol"},{"key":"7_CR15_7","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/jvi.64.8.3563-3569.1990","volume":"64","author":"S Weiland","year":"1990","unstructured":"Weiland S et al (1990) Pestivirus glycoprotein which induces neutralizing antibodies forms part of a disulfide linked heterodimer. J Virol 64:3563\u20133569","journal-title":"J Virol"},{"issue":"10","key":"7_CR16_7","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1099\/0022-1317-74-10-2053","volume":"74","author":"PA van Rijn","year":"1993","unstructured":"van Rijn PA, van Gennip HG, de Meijer EJ, Moormann RJ (1993) Epitope mapping of envelope glycoprotein E1 of hog cholera virus strain Brescia. J Gen Virol 74(10):2053\u20132060","journal-title":"J Gen Virol"},{"issue":"1","key":"7_CR17_7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1099\/0022-1317-69-1-77","volume":"69","author":"RO Donis","year":"1988","unstructured":"Donis RO, Corapi W, Dubovi EJ (1988) Neutralizing monoclonal antibodies to bovine viral diarrhoea virus bind to the 56K to 58K glycoprotein. J Gen Virol 69(1):77\u201386","journal-title":"J Gen Virol"},{"key":"7_CR18_7","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1128\/JVI.78.4.1792-1799.2004","volume":"78","author":"K Maurer","year":"2004","unstructured":"Maurer K, Krey T, Moennig V, Thiel HJ, Rumenapf T (2004) CD46 is a cellular receptor for bovine viral diarrhea virus. J Virol 78:1792\u20131799","journal-title":"J Virol"},{"key":"7_CR19_7","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1128\/JVI.80.8.3912-3922.2006","volume":"80","author":"T Krey","year":"2006","unstructured":"Krey T et al (2006) Function of bovine CD46 as a cellular receptor for bovine viral diarrhea virus is determined by complement control protein 1. J Virol 80:3912\u20133922","journal-title":"J Virol"},{"key":"7_CR20_7","doi-asserted-by":"crossref","first-page":"9553","DOI":"10.1128\/JVI.74.20.9553-9561.2000","volume":"74","author":"MM Hulst","year":"2000","unstructured":"Hulst MM, van Gennip HG, Moormann RJ (2000) Passage of classical swine fever virus in cultured swine kidney cells selects virus variants that bind to heparan sulfate due to a single amino acid change in envelope protein E(rns). J Virol 74:9553\u20139561","journal-title":"J Virol"},{"key":"7_CR21_7","first-page":"451","volume":"81","author":"M Iqbal","year":"2000","unstructured":"Iqbal M, Flick-Smith H, McCauley JW (2000) Interactions of bovine viral diarrhoea virus glycoprotein E(rns) with cell surface glycosaminoglycans. J Gen Virol 81:451\u2013459","journal-title":"J Gen Virol"},{"key":"7_CR22_7","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1099\/0022-1317-83-9-2153","volume":"83","author":"M Iqbal","year":"2002","unstructured":"Iqbal M, McCauley JW (2002) Identification of the glycosaminoglycan-binding site on the glycoprotein E(rns) of bovine viral diarrhoea virus by site-directed mutagenesis. J Gen Virol 83:2153\u20132159","journal-title":"J Gen Virol"},{"key":"7_CR23_7","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1128\/jvi.67.6.3288-3294.1993","volume":"67","author":"T Rumenapf","year":"1993","unstructured":"Rumenapf T, Unger G, Strauss JH, Thiel HJ (1993) Processing of the envelope glycoproteins of pestiviruses. J Virol 67:3288\u20133294","journal-title":"J Virol"},{"key":"7_CR24_7","doi-asserted-by":"crossref","first-page":"11901","DOI":"10.1128\/JVI.79.18.11901-11913.2005","volume":"79","author":"C Fetzer","year":"2005","unstructured":"Fetzer C, Tews BA, Meyers G (2005) The carboxy-terminal sequence of the pestivirus glycoprotein E(rns) represents an unusual type of membrane anchor. J Virol 79:11901\u201311913","journal-title":"J Virol"},{"key":"7_CR25_7","doi-asserted-by":"crossref","first-page":"32730","DOI":"10.1074\/jbc.M706803200","volume":"282","author":"BA Tews","year":"2007","unstructured":"Tews BA, Meyers G (2007) The pestivirus glycoprotein Erns is anchored in plane in the membrane via an amphipathic helix. J Biol Chem 282:32730\u201332741","journal-title":"J Biol Chem"},{"key":"7_CR26_7","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1006\/viro.1994.1218","volume":"200","author":"MM Hulst","year":"1994","unstructured":"Hulst MM, Himes G, Newbigin E, Moormann RJM (1994) Glycoprotein E2 of classical swine fever virus: expression in insect cells and identification as a ribonuclease. Virology 200:558\u2013565","journal-title":"Virology"},{"key":"7_CR27_7","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1126\/science.8356450","volume":"261","author":"R Schneider","year":"1993","unstructured":"Schneider R, Unger G, Stark R, Schneider-Scherzer E, Thiel H-J (1993) Identification of a structural glycoprotein of an RNA virus as a ribonuclease. Science 261:1169\u20131171","journal-title":"Science"},{"key":"7_CR28_7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1128\/jvi.70.1.352-358.1996","volume":"70","author":"JM Windisch","year":"1996","unstructured":"Windisch JM et al (1996) RNase of classical swine fever virus: biochemical characterization and inhibition by virus-neutralizing monoclonal antibodies. J Virol 70:352\u2013358","journal-title":"J Virol"},{"key":"7_CR29_7","doi-asserted-by":"crossref","first-page":"9498","DOI":"10.1128\/JVI.74.20.9498-9506.2000","volume":"74","author":"T Harada","year":"2000","unstructured":"Harada T, Tautz N, Thiel H-J (2000) E2-p7 region of the bovine viral diarrhea virus polyprotein: processing and functional studies. J Virol 74:9498\u20139506","journal-title":"J Virol"},{"key":"7_CR30_7","doi-asserted-by":"crossref","first-page":"12712","DOI":"10.1073\/pnas.0905966106","volume":"106","author":"P Luik","year":"2009","unstructured":"Luik P et al (2009) The 3-dimensional structure of a hepatitis C virus p7 ion channel by electron microscopy. Proc Natl Acad Sci U S A 106:12712\u201312716","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7_CR31_7","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1371\/journal.ppat.0030103","volume":"3","author":"E Steinmann","year":"2007","unstructured":"Steinmann E et al (2007) Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog 3:e103","journal-title":"PLoS Pathog"},{"key":"7_CR32_7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0014-5793(02)03851-6","volume":"535","author":"SD Griffin","year":"2003","unstructured":"Griffin SD et al (2003) The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett 535:34\u201338","journal-title":"FEBS Lett"},{"key":"7_CR33_7","doi-asserted-by":"crossref","first-page":"10765","DOI":"10.1128\/JVI.78.19.10765-10775.2004","volume":"78","author":"T Lackner","year":"2004","unstructured":"Lackner T et al (2004) Temporal modulation of an autoprotease is crucial for replication and pathogenicity of an RNA virus. J Virol 78:10765\u201310775","journal-title":"J Virol"},{"key":"7_CR34_7","doi-asserted-by":"crossref","first-page":"12989","DOI":"10.1073\/pnas.95.22.12989","volume":"95","author":"EV Agapov","year":"1998","unstructured":"Agapov EV et al (1998) Noncytopathic sindbis virus RNA vectors for heterologous gene expression. Proc Natl Acad Sci U S A 95:12989\u201312994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7_CR35_7","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.virol.2007.03.056","volume":"365","author":"HR Moulin","year":"2007","unstructured":"Moulin HR et al (2007) Nonstructural proteins NS2-3 and NS4A of classical swine fever virus: essential features for infectious particle formation. Virology 365:376\u2013389","journal-title":"Virology"},{"key":"7_CR36_7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1006\/viro.2000.0425","volume":"273","author":"N Tautz","year":"2000","unstructured":"Tautz N, Kaiser A, Thiel H-J (2000) NS3 serine protease of bovine viral diarrhea virus: characterization of active site residues, NS4A cofactor domain, and protease-cofactor interactions. Virology 273:351\u2013363","journal-title":"Virology"},{"key":"7_CR37_7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0042-6822(91)90850-B","volume":"184","author":"M Wiskerchen","year":"1991","unstructured":"Wiskerchen M, Collett MS (1991) Pestivirus gene expression: protein p80 of bovine viral diarrhea virus is a proteinase involved in polyprotein processing. Virology 184:341\u2013350","journal-title":"Virology"},{"key":"7_CR38_7","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1128\/jvi.71.7.5312-5322.1997","volume":"71","author":"J Xu","year":"1997","unstructured":"Xu J et al (1997) Bovine viral diarrhea virus NS3 serine proteinase: polyprotein cleavage sites, cofactor requirements, and molecular model of an enzyme essential for pestivirus replication. J Virol 71:5312\u20135322","journal-title":"J Virol"},{"key":"7_CR39_7","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1128\/JVI.00358-06","volume":"80","author":"TL Tellinghuisen","year":"2006","unstructured":"Tellinghuisen TL, Paulson MS, Rice CM (2006) The NS5A protein of bovine viral diarrhea virus contains an essential zinc-binding site similar to that of the hepatitis C virus NS5A protein. J Virol 80:7450\u20137458","journal-title":"J Virol"},{"key":"7_CR40_7","doi-asserted-by":"crossref","first-page":"9365","DOI":"10.1128\/JVI.72.11.9365-9369.1998","volume":"72","author":"W Zhong","year":"1998","unstructured":"Zhong W, Gutshall LL, Del Vecchio AM (1998) Identification and characterization of an RNA-dependent RNA polymerase activity within the nonstructural protein 5B region of bovine viral diarrhea virus. J Virol 72:9365\u20139369","journal-title":"J Virol"},{"key":"7_CR41_7","doi-asserted-by":"crossref","first-page":"8606","DOI":"10.1128\/jvi.70.12.8606-8613.1996","volume":"70","author":"G Meyers","year":"1996","unstructured":"Meyers G, Tautz N, Becher P, Thiel H-J, K\u00fcmmerer B (1996) Recovery of cytopathogenic and noncytopathogenic bovine viral diarrhea viruses from cDNA constructs. J Virol 70:8606\u20138613","journal-title":"J Virol"},{"key":"7_CR42_7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1128\/jvi.70.2.763-770.1996","volume":"70","author":"RJM Moormann","year":"1996","unstructured":"Moormann RJM, van Gennip HGP, Miedema GKW, Hulst MM, van Rijn PA (1996) Infectious RNA transcribed from an engineered full-length cDNA template of the genome of a pestivirus. J Virol 70:763\u2013770","journal-title":"J Virol"},{"key":"7_CR43_7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/vr.114.22.535","volume":"114","author":"J Brownlie","year":"1984","unstructured":"Brownlie J, Clarke MC, Howard CJ (1984) Experimental production of fatal mucosal disease in cattle. Vet Rec 114:535\u2013536","journal-title":"Vet Rec"},{"key":"7_CR44_7","first-page":"200","volume":"127","author":"V Moennig","year":"1990","unstructured":"Moennig V, Frey H-R, Liebler E, Polenz P, Liess B (1990) Reproduction of mucosal disease with cytopathogenic bovine viral diarrhoea virus selected in vitro. Vet Rec 127:200\u2013203","journal-title":"Vet Rec"},{"key":"7_CR45_7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.vetmic.2003.09.004","volume":"96","author":"LS Brackenbury","year":"2003","unstructured":"Brackenbury LS, Carr BV, Charleston B (2003) Aspects of the innate and adaptive immune responses to acute infections with BVDV. Vet Microbiol 96:337\u2013344","journal-title":"Vet Microbiol"},{"key":"7_CR46_7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.virol.2005.09.024","volume":"344","author":"O Haller","year":"2006","unstructured":"Haller O, Kochs G, Weber F (2006) The interferon response circuit: induction and suppression by pathogenic viruses. Virology 344:119\u2013130","journal-title":"Virology"},{"key":"7_CR47_7","first-page":"449","volume":"172","author":"MF Coria","year":"1978","unstructured":"Coria MF, McClurkin AW (1978) Specific immunotolerance in an apparently healthy bull persistently infected with BVD virus. J Am Vet Med Assoc 172:449\u2013451","journal-title":"J Am Vet Med Assoc"},{"key":"7_CR48_7","first-page":"1059","volume-title":"Fields virology","author":"H-J Thiel","year":"1996","unstructured":"Thiel H-J, Plagemann PGW, Moennig V (1996) Pestiviruses. In: Fields BN, Knipe DM, Howley PM (eds) Fields virology, vol 1, 3rd edn. Lippincott Raven, Philadelphia, pp 1059\u20131073","edition":"3"},{"key":"7_CR49_7","unstructured":"Meyers G, Tautz N, Dubovi EJ, Thiel H-J (1996) Origin and diversity of cytopathogenic pestiviruses. International symposium of bovine viral diarrhea virus \u2013 a 50 year review."},{"key":"7_CR50_7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0065-3527(08)60734-4","volume":"47","author":"G Meyers","year":"1996","unstructured":"Meyers G, Thiel H-J (1996) Molecular characterization of pestiviruses. Adv Virus Res 47:53\u2013117","journal-title":"Adv Virus Res"},{"key":"7_CR51_7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0378-1135(00)00268-6","volume":"77","author":"BM K\u00fcmmerer","year":"2000","unstructured":"K\u00fcmmerer BM, Tautz N, Becher P, Thiel H-J, Meyers G (2000) The genetic basis for cytopathogenicity of pestiviruses. Vet Microbiol 77:117\u2013128","journal-title":"Vet Microbiol"},{"key":"7_CR52_7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1006\/viro.1993.1568","volume":"197","author":"N Tautz","year":"1993","unstructured":"Tautz N, Meyers G, Thiel H-J (1993) Processing of poly-ubiquitin in the polyprotein of an RNA virus. Virology 197:74\u201385","journal-title":"Virology"},{"key":"7_CR53_7","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/0042-6822(92)90199-Y","volume":"191","author":"G Meyers","year":"1992","unstructured":"Meyers G et al (1992) Rearrangement of viral sequences in cytopathogenic pestiviruses. Virology 191:368\u2013386","journal-title":"Virology"},{"key":"7_CR54_7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF01313724","volume":"94","author":"DH Pocock","year":"1987","unstructured":"Pocock DH, Howard CJ, Clarke MC, Brownlie J (1987) Variation in the intracellular polypeptide profiles from different isolates of bovine viral diarrhea virus. Arch Virol 94:43\u201353","journal-title":"Arch Virol"},{"key":"7_CR55_7","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1128\/JVI.72.6.4737-4745.1998","volume":"72","author":"E Mendez","year":"1998","unstructured":"Mendez E, Ruggli N, Collett MS, Rice CM (1998) Infectious bovine viral diarrhea virus (strain NADL) RNA from stable cDNA clones: a cellular insert determines NS3 production and viral cytopathogenicity. J Virol 72:4737\u20134745","journal-title":"J Virol"},{"key":"7_CR56_7","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1128\/JVI.75.10.4692-4698.2001","volume":"75","author":"M Schweizer","year":"2001","unstructured":"Schweizer M, Peterhans E (2001) Noncytopathic bovine viral diarrhea virus inhibits double-stranded RNA-induced apoptosis and interferon synthesis. J Virol 75:4692\u20134698","journal-title":"J Virol"},{"key":"7_CR57_7","doi-asserted-by":"crossref","first-page":"9746","DOI":"10.1128\/JVI.79.15.9746-9755.2005","volume":"79","author":"T Lackner","year":"2005","unstructured":"Lackner T, Muller A, Konig M, Thiel HJ, Tautz N (2005) Persistence of bovine viral diarrhea virus is determined by a cellular cofactor of a viral autoprotease. J Virol 79:9746\u20139755","journal-title":"J Virol"},{"key":"7_CR58_7","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1073\/pnas.0508247103","volume":"103","author":"T Lackner","year":"2006","unstructured":"Lackner T, Thiel HJ, Tautz N (2006) Dissection of a viral autoprotease elucidates a function of a cellular chaperone in proteolysis. Proc Natl Acad Sci U S A 103:1510\u20131515","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7_CR59_7","doi-asserted-by":"crossref","first-page":"9717","DOI":"10.1128\/JVI.00782-08","volume":"82","author":"A Gallei","year":"2008","unstructured":"Gallei A et al (2008) Cytopathogenicity of classical swine fever virus correlates with attenuation in the natural host. J Virol 82:9717\u20139729","journal-title":"J Virol"},{"key":"7_CR60_7","doi-asserted-by":"crossref","first-page":"10663","DOI":"10.1128\/JVI.77.19.10663-10669.2003","volume":"77","author":"A M\u00fcller","year":"2003","unstructured":"M\u00fcller A, Rinck G, Thiel H-J, Tautz N (2003) Cell-derived sequences located in the structural genes of a cytopathogenic pestivirus. J Virol 77:10663\u201310669","journal-title":"J Virol"},{"key":"7_CR61_7","doi-asserted-by":"crossref","first-page":"9470","DOI":"10.1128\/JVI.75.19.9470-9482.2001","volume":"75","author":"G Rinck","year":"2001","unstructured":"Rinck G et al (2001) A cellular J-domain protein modulates polyprotein processing and cytopathogenicity of a pestivirus. J Virol 75:9470\u20139482","journal-title":"J Virol"},{"key":"7_CR62_7","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1099\/0022-1317-81-4-881","volume":"81","author":"L Perler","year":"2000","unstructured":"Perler L, Schweizer M, Jungi TW, Peterhans E (2000) Bovine viral diarrhoea virus and bovine herpesvirus-1 prime uninfected macrophages for lipopolysaccharide-triggered apoptosis by interferon-dependent and -independent pathways. J Gen Virol 81:881\u2013887","journal-title":"J Gen Virol"},{"key":"7_CR63_7","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1128\/JVI.72.3.2544-2547.1998","volume":"72","author":"T R\u00fcmenapf","year":"1998","unstructured":"R\u00fcmenapf T, Stark R, Heimann M, Thiel H-J (1998) N-terminal protease of pestiviruses: identification of putative catalytic residues by site-directed mutagenesis. J Virol 72:2544\u20132547","journal-title":"J Virol"},{"key":"7_CR64_7","doi-asserted-by":"crossref","first-page":"7681","DOI":"10.1128\/JVI.72.9.7681-7684.1998","volume":"72","author":"JD Tratschin","year":"1998","unstructured":"Tratschin JD, Moser C, Ruggli N, Hofmann MA (1998) Classical swine fever virus leader proteinase Npro is not required for viral replication in cell culture. J Virol 72:7681\u20137684","journal-title":"J Virol"},{"key":"7_CR65_7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0378-1135(00)00195-4","volume":"74","author":"C Mittelholzer","year":"2000","unstructured":"Mittelholzer C, Moser C, Tratschin JD, Hofmann MA (2000) Analysis of classical swine fever virus replication kinetics allows differentiation of highly virulent from avirulent strains. Vet Microbiol 74:293\u2013308","journal-title":"Vet Microbiol"},{"key":"7_CR66_7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.vaccine.2003.08.006","volume":"22","author":"D Mayer","year":"2004","unstructured":"Mayer D, Hofmann MA, Tratschin JD (2004) Attenuation of classical swine fever virus by deletion of the viral N(pro) gene. Vaccine 22:317\u2013328","journal-title":"Vaccine"},{"key":"7_CR67_7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.virol.2005.06.033","volume":"340","author":"N Ruggli","year":"2005","unstructured":"Ruggli N et al (2005) N(pro) of classical swine fever virus is an antagonist of double-stranded RNA-mediated apoptosis and IFN-alpha\/beta induction. Virology 340:265\u2013276","journal-title":"Virology"},{"key":"7_CR68_7","doi-asserted-by":"crossref","first-page":"7645","DOI":"10.1128\/JVI.77.13.7645-7654.2003","volume":"77","author":"N Ruggli","year":"2003","unstructured":"Ruggli N et al (2003) Classical swine fever virus interferes with cellular antiviral defense: evidence for a novel function of N(pro). J Virol 77:7645\u20137654","journal-title":"J Virol"},{"key":"7_CR69_7","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.1128\/JVI.79.11.7239-7247.2005","volume":"79","author":"SA La Rocca","year":"2005","unstructured":"La Rocca SA et al (2005) Loss of interferon regulatory factor 3 in cells infected with classical swine fever virus involves the N-terminal protease, Npro. J Virol 79:7239\u20137247","journal-title":"J Virol"},{"key":"7_CR70_7","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1128\/JVI.80.2.900-911.2006","volume":"80","author":"LHVG Gil","year":"2006","unstructured":"Gil LHVG et al (2006) The amino-terminal domain of bovine viral diarrhea virus Npro protein is necessary for alpha\/beta interferon antagonism. J Virol 80:900\u2013911","journal-title":"J Virol"},{"key":"7_CR71_7","doi-asserted-by":"crossref","first-page":"11723","DOI":"10.1128\/JVI.01145-06","volume":"80","author":"L Hilton","year":"2006","unstructured":"Hilton L et al (2006) The NPro product of bovine viral diarrhea virus inhibits DNA binding by interferon regulatory factor 3 and targets it for proteasomal degradation. J Virol 80:11723\u201311732","journal-title":"J Virol"},{"key":"7_CR72_7","doi-asserted-by":"crossref","first-page":"8979","DOI":"10.1128\/JVI.76.18.8979-8988.2002","volume":"76","author":"SJ Baigent","year":"2002","unstructured":"Baigent SJ et al (2002) Inhibition of beta interferon transcription by noncytopathogenic bovine viral diarrhea virus is through an interferon regulatory factor 3-dependent mechanism. J Virol 76:8979\u20138988","journal-title":"J Virol"},{"key":"7_CR73_7","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1128\/JVI.02032-06","volume":"81","author":"O Bauhofer","year":"2007","unstructured":"Bauhofer O et al (2007) Classical swine fever virus Npro interacts with interferon regulatory factor 3 and induces its proteasomal degradation. J Virol 81:3087\u20133096","journal-title":"J Virol"},{"key":"7_CR74_7","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1099\/vir.0.82934-0","volume":"88","author":"J Seago","year":"2007","unstructured":"Seago J et al (2007) The Npro product of classical swine fever virus and bovine viral diarrhea virus uses a conserved mechanism to target interferon regulatory factor-3. J Gen Virol 88:3002\u20133006","journal-title":"J Gen Virol"},{"key":"7_CR75_7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.virol.2007.04.023","volume":"366","author":"Z Chen","year":"2007","unstructured":"Chen Z et al (2007) Ubiquitination and proteasomal degradation of interferon regulatory factor-3 induced by Npro from a cytopathic bovine viral diarrhea virus. Virology 366:277\u2013292","journal-title":"Virology"},{"key":"7_CR76_7","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jmb.2009.06.040","volume":"391","author":"MR Szymanski","year":"2009","unstructured":"Szymanski MR et al (2009) Zinc binding in pestivirus N(pro) is required for interferon regulatory factor 3 interaction and degradation. J Mol Biol 391:438\u2013449","journal-title":"J Mol Biol"},{"key":"7_CR77_7","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1128\/JVI.01509-08","volume":"83","author":"N Ruggli","year":"2009","unstructured":"Ruggli N et al (2009) Classical swine fever virus can remain virulent after specific elimination of the interferon regulatory factor 3-degrading function of Npro. J Virol 83:817\u2013829","journal-title":"J Virol"},{"key":"7_CR78_7","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1128\/JVI.74.7.2973-2980.2000","volume":"74","author":"MN Widjojoatmodjo","year":"2000","unstructured":"Widjojoatmodjo MN, van Gennip HG, Bouma A, van Rijn PA, Moormann RJ (2000) Classical swine fever virus E(rns) deletion mutants: trans-complementation and potential use as nontransmissible, modified, live-attenuated marker vaccines. J Virol 74:2973\u20132980","journal-title":"J Virol"},{"key":"7_CR79_7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0076-6879(01)42564-X","volume":"342","author":"MM Hulst","year":"2001","unstructured":"Hulst MM, Moormann RJ (2001) Erns protein of pestiviruses. Methods Enzymol 342:431\u2013440","journal-title":"Methods Enzymol"},{"key":"7_CR80_7","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1128\/JVI.78.10.5507-5512.2004","volume":"78","author":"Y Hausmann","year":"2004","unstructured":"Hausmann Y, Roman-Sosa G, Thiel HJ, Rumenapf T (2004) Classical swine fever virus glycoprotein E rns is an endoribonuclease with an unusual base specificity. J Virol 78:5507\u20135512","journal-title":"J Virol"},{"key":"7_CR81_7","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1128\/JVI.78.1.136-145.2004","volume":"78","author":"M Iqbal","year":"2004","unstructured":"Iqbal M, Poole E, Goodbourn S, McCauley JW (2004) Role for bovine viral diarrhea virus Erns glycoprotein in the control of activation of beta interferon by double-stranded RNA. J Virol 78:136\u2013145","journal-title":"J Virol"},{"key":"7_CR82_7","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1099\/vir.0.2008\/003749-0","volume":"89","author":"I Magkouras","year":"2008","unstructured":"Magkouras I, Matzener P, Rumenapf T, Peterhans E, Schweizer M (2008) RNase-dependent inhibition of extracellular, but not intracellular, dsRNA-induced interferon synthesis by Erns of pestiviruses. J Gen Virol 89:2501\u20132506","journal-title":"J Gen Virol"},{"key":"7_CR83_7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1128\/JVI.72.1.151-157.1998","volume":"72","author":"MM Hulst","year":"1998","unstructured":"Hulst MM, Panoto FE, Hoekman A, van Gennip HG, Moormann RJ (1998) Inactivation of the RNase activity of glycoprotein Erns of classical swine fever virus results in a cytopathogenic virus. J Virol 72:151\u2013157","journal-title":"J Virol"},{"key":"7_CR84_7","doi-asserted-by":"crossref","first-page":"8494","DOI":"10.1128\/JVI.76.16.8494-8503.2002","volume":"76","author":"C Meyer","year":"2002","unstructured":"Meyer C, Von Freyburg M, Elbers K, Meyers G (2002) Recovery of virulent and RNase-negative attenuated type 2 bovine viral diarrhea viruses from infectious cDNA clones. J Virol 76:8494\u20138503","journal-title":"J Virol"},{"key":"7_CR85_7","doi-asserted-by":"crossref","first-page":"10224","DOI":"10.1128\/JVI.73.12.10224-10235.1999","volume":"73","author":"G Meyers","year":"1999","unstructured":"Meyers G, Saalm\u00fcller A, B\u00fcttner M (1999) Mutations abrogating the RNase activity in glycoprotein e(rns) of the pestivirus classical swine fever virus lead to virus attenuation. J Virol 73:10224\u201310235","journal-title":"J Virol"},{"key":"7_CR86_7","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1099\/vir.0.79988-0","volume":"85","author":"M von Freyburg","year":"2004","unstructured":"von Freyburg M, Ege A, Saalmuller A, Meyers G (2004) Comparison of the effects of RNase-negative and wild-type classical swine fever virus on peripheral blood cells of infected pigs. J Gen Virol 85:1899\u20131908","journal-title":"J Gen Virol"},{"key":"7_CR87_7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.virusres.2008.10.015","volume":"140","author":"P Matzener","year":"2009","unstructured":"Matzener P, Magkouras I, Rumenapf T, Peterhans E, Schweizer M (2009) The viral RNase E(rns) prevents IFN type-I triggering by pestiviral single- and double-stranded RNAs. Virus Res 140:15\u201323","journal-title":"Virus Res"},{"issue":"Pt 5","key":"7_CR88_7","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1099\/0022-1317-80-5-1157","volume":"80","author":"F Weiland","year":"1999","unstructured":"Weiland F, Weiland E, Unger G, Saalmuller A, Thiel HJ (1999) Localization of pestiviral envelope proteins E(rns) and E2 at the cell surface and on isolated particles. J Gen Virol 80(Pt 5):1157\u20131165","journal-title":"J Gen Virol"},{"key":"7_CR89_7","doi-asserted-by":"crossref","first-page":"10383","DOI":"10.1128\/JVI.76.20.10383-10392.2002","volume":"76","author":"JP Langedijk","year":"2002","unstructured":"Langedijk JP et al (2002) A structural model of pestivirus E(rns) based on disulfide bond connectivity and homology modeling reveals an extremely rare vicinal disulfide. J Virol 76:10383\u201310392","journal-title":"J Virol"},{"key":"7_CR90_7","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00705-005-0569-y","volume":"150","author":"HG van Gennip","year":"2005","unstructured":"van Gennip HG, Hesselink AT, Moormann RJ, Hulst MM (2005) Dimerization of glycoprotein E(rns) of classical swine fever virus is not essential for viral replication and infection. Arch Virol 150:2271\u20132286","journal-title":"Arch Virol"},{"key":"7_CR91_7","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1128\/JVI.01710-08","volume":"83","author":"BA Tews","year":"2009","unstructured":"Tews BA, Schurmann EM, Meyers G (2009) Mutation of cysteine 171 of pestivirus E rns RNase prevents homodimer formation and leads to attenuation of classical swine fever virus. J Virol 83:4823\u20134834","journal-title":"J Virol"},{"key":"7_CR92_7","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1099\/0022-1317-82-8-1893","volume":"82","author":"B Charleston","year":"2001","unstructured":"Charleston B, Fray MD, Baigent S, Carr BV, Morrison WI (2001) Establishment of persistent infection with non-cytopathic bovine viral diarrhoea virus in cattle is associated with a failure to induce type I interferon. J Gen Virol 82:1893\u20131897","journal-title":"J Gen Virol"},{"key":"7_CR93_7","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1128\/JVI.02372-06","volume":"81","author":"G Meyers","year":"2007","unstructured":"Meyers G et al (2007) Bovine viral diarrhea virus: prevention of persistent fetal infection by a combination of two mutations affecting Erns RNase and Npro protease. J Virol 81:3327\u20133338","journal-title":"J Virol"},{"key":"7_CR94_7","doi-asserted-by":"crossref","first-page":"9422","DOI":"10.1128\/JVI.73.11.9422-9432.1999","volume":"73","author":"N Tautz","year":"1999","unstructured":"Tautz N et al (1999) Establishment and characterization of cytopathogenic and noncytopathogenic pestivirus replicons. J Virol 73:9422\u20139432","journal-title":"J Virol"},{"key":"7_CR95_7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1006\/viro.1998.9425","volume":"251","author":"SK Chon","year":"1998","unstructured":"Chon SK, Perez DR, Donis RO (1998) Genetic analysis of the internal ribosome entry segment of bovine viral diarrhea virus. Virology 251:370\u2013382","journal-title":"Virology"},{"key":"7_CR96_7","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1128\/JVI.75.9.4226-4238.2001","volume":"75","author":"TM Myers","year":"2001","unstructured":"Myers TM et al (2001) Efficient translation initiation is required for replication of bovine viral diarrhea virus subgenomic replicons. J Virol 75:4226\u20134238","journal-title":"J Virol"},{"key":"7_CR97_7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1017\/S1355838201000589","volume":"7","author":"R Rijnbrand","year":"2001","unstructured":"Rijnbrand R et al (2001) The influence of downstream protein-coding sequence on internal ribosome entry on hepatitis C virus and other flavivirus RNAs. RNA 7:585\u2013597","journal-title":"RNA"},{"key":"7_CR98_7","doi-asserted-by":"crossref","first-page":"7884","DOI":"10.1128\/JVI.74.17.7884-7894.2000","volume":"74","author":"P Becher","year":"2000","unstructured":"Becher P, Orlich M, Thiel H-J (2000) Mutations in the 5\u2032 nontranslated region of bovine viral diarrhea virus result in altered growth characteristics. J Virol 74:7884\u20137894","journal-title":"J Virol"},{"key":"7_CR99_7","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1016\/j.vaccine.2004.03.003","volume":"22","author":"B Makoschey","year":"2004","unstructured":"Makoschey B et al (2004) Bovine viral diarrhea virus with deletions in the 5\u2032-nontranslated region: reduction of replication in calves and induction of protective immunity. Vaccine 22:3285\u20133294","journal-title":"Vaccine"},{"key":"7_CR100_7","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.virol.2008.01.008","volume":"374","author":"Y Wang","year":"2008","unstructured":"Wang Y et al (2008) 12-nt insertion in 3\u2032 untranslated region leads to attenuation of classic swine fever virus and protects host against lethal challenge. Virology 374:390\u2013398","journal-title":"Virology"},{"key":"7_CR101_7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.virol.2005.08.015","volume":"343","author":"GR Risatti","year":"2005","unstructured":"Risatti GR et al (2005) Mutation of E1 glycoprotein of classical swine fever virus affects viral virulence in swine. Virology 343:116\u2013127","journal-title":"Virology"},{"key":"7_CR102_7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.virol.2004.08.011","volume":"329","author":"B Sainz Jr","year":"2004","unstructured":"Sainz B Jr, Mossel EC, Peters CJ, Garry RF (2004) Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology 329:11\u201317","journal-title":"Virology"},{"key":"7_CR103_7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.virol.2007.08.028","volume":"370","author":"IF Sainz","year":"2008","unstructured":"Sainz IF, Holinka LG, Lu Z, Risatti GR, Borca MV (2008) Removal of a N-linked glycosylation site of classical swine fever virus strain Brescia Erns glycoprotein affects virulence in swine. Virology 370:122\u2013129","journal-title":"Virology"},{"key":"7_CR104_7","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1016\/S0264-410X(00)00027-X","volume":"18","author":"AJ de Smit","year":"2000","unstructured":"de Smit AJ et al (2000) Recombinant classical swine fever (CSF) viruses derived from the Chinese vaccine strain (C-strain) of CSF virus retain their avirulent and immunogenic characteristics. Vaccine 18:2351\u20132358","journal-title":"Vaccine"},{"key":"7_CR105_7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0264-410X(00)00198-5","volume":"19","author":"HG van Gennip","year":"2000","unstructured":"van Gennip HG, van Rijn PA, Widjojoatmodjo MN, de Smit AJ, Moormann RJ (2000) Chimeric classical swine fever viruses containing envelope protein E(RNS) or E2 of bovine viral diarrhoea virus protect pigs against challenge with CSFV and induce a distinguishable antibody response. Vaccine 19:447\u2013459","journal-title":"Vaccine"},{"key":"7_CR106_7","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1099\/0022-1317-83-3-551","volume":"83","author":"E Armengol","year":"2002","unstructured":"Armengol E et al (2002) Identification of T-cell epitopes in the structural and non-structural proteins of classical swine fever virus. J Gen Virol 83:551\u2013560","journal-title":"J Gen Virol"},{"key":"7_CR107_7","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1016\/j.vaccine.2005.01.076","volume":"23","author":"R Maurer","year":"2005","unstructured":"Maurer R, Stettler P, Ruggli N, Hofmann MA, Tratschin JD (2005) Oronasal vaccination with classical swine fever virus (CSFV) replicon particles with either partial or complete deletion of the E2 gene induces partial protection against lethal challenge with highly virulent CSFV. Vaccine 23:3318\u20133328","journal-title":"Vaccine"},{"key":"7_CR108_7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1051\/vetres:2006028","volume":"37","author":"CF Frey","year":"2006","unstructured":"Frey CF et al (2006) Classical swine fever virus replicon particles lacking the Erns gene: a potential marker vaccine for intradermal application. Vet Res 37:655\u2013670","journal-title":"Vet Res"},{"key":"7_CR109_7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.virol.2007.05.006","volume":"366","author":"I Reimann","year":"2007","unstructured":"Reimann I, Semmler I, Beer M (2007) Packaged replicons of bovine viral diarrhea virus are capable of inducing a protective immune response. Virology 366:377\u2013386","journal-title":"Virology"},{"key":"7_CR110_7","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/S0264-410X(01)00497-2","volume":"20","author":"HG van Gennip","year":"2002","unstructured":"van Gennip HG, Bouma A, van Rijn PA, Widjojoatmodjo MN, Moormann RJ (2002) Experimental non-transmissible marker vaccines for classical swine fever (CSF) by trans-complementation of E(rns) or E2 of CSFV. Vaccine 20:1544\u20131556","journal-title":"Vaccine"},{"key":"7_CR111_7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.vaccine.2006.07.033","volume":"25","author":"XN Dong","year":"2007","unstructured":"Dong XN, Chen YH (2007) Marker vaccine strategies and candidate CSFV marker vaccines. Vaccine 25:205\u2013230","journal-title":"Vaccine"}],"container-title":["Replicating Vaccines"],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-0346-0277-8_7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T13:54:20Z","timestamp":1720792460000},"score":19.267511,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-0346-0277-8_7"}},"issued":{"date-parts":[[2010,9,29]]},"ISBN":["9783034602761","9783034602778"],"references-count":111,"URL":"https:\/\/doi.org\/10.1007\/978-3-0346-0277-8_7","published":{"date-parts":[[2010,9,29]]},"assertion":[{"value":"29 September 2010","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]},{"indexed":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T18:17:00Z","timestamp":1732040220338},"reference-count":19,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The need to cope with the medical, social, and economic storm due to the new coronavirus 2019 (COVID-19) pandemic as quickly as possible has led to the very rapid development of a huge number of vaccines. All these vaccines have been mainly developed in healthy adults and, in some cases, in the elderly. Children were marginally involved as, according to the clinical trial registry Clinical Trials.gov, only very few studies have included children among subjects to enroll, although just a few weeks after the pandemic declaration, the US Food and Drug Administration had highlighted the importance of vaccine evaluation in pediatrics. Availability of an effective and safe pediatric COVID-19 vaccine appears mandatory for several clinical and epidemiological reasons. However, as the development of an effective and safe pediatric vaccine seems far from easy, strong cooperation among governments, researchers, and pharmaceutical companies is highly desirable.<\/jats:p>","DOI":"10.3390\/vaccines9020127","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T13:33:48Z","timestamp":1612532028000},"page":"127","source":"Crossref","is-referenced-by-count":18,"title":["Why It Is Important to Develop an Effective and Safe Pediatric COVID-19 Vaccine"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"http:\/\/orcid.org\/0000-0002-3468-5568","authenticated-orcid":false,"given":"Nicola","family":"Principi","sequence":"first","affiliation":[{"name":"Universit\u00e0 degli Studi di Milano, 20122 Milan, Italy"}]},{"given":"Susanna","family":"Esposito","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Pietro Barilla Children\u2019s Hospital, University of Parma, 43126 Parma, Italy"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Conte, C., Sogni, F., Affanni, P., Veronesi, L., Argentiero, A., and Esposito, S. (2020). Vaccines against coronaviruses: The state of the art. Vaccines, 8.","DOI":"10.3390\/vaccines8020309"},{"key":"ref_2","unstructured":"STAT (2020, October 09). Will Covid-19 Vaccines Be Safe for Children and Pregnant Women? The Data, So Far, Are Lacking. Available online: https:\/\/www.statnews.com\/2020\/08\/19\/will-covid-19-vaccines-be-safe-for-children-and-pregnant-women-the-data-so-far-are-lacking\/."},{"key":"ref_3","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research (2020, October 09). Development and Licensure of Vaccines to Prevent COVID-19. Guidance for Industry, Available online: https:\/\/www.fda.gov\/media\/139638\/download."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Viner, R.M., Mytton, O.T., Bonell, C., Melendez-Torres, G.J., Ward, J., Hudson, L., Waddington, C., Thomas, J., Russell, S., and Van Der Klis, F. (2020). Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: A systematic review and meta-analysis. JAMA Pediatr.","DOI":"10.1101\/2020.05.20.20108126"},{"key":"ref_5","unstructured":"Centers for Disease Control and Prevention (2020, November 19). Coronavirus Disease 2019 (COVID-19). How CDC Is Making COVID-19 Vaccine Recommendations, Available online: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/recommendations-process.html."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e2020495","DOI":"10.1001\/jamanetworkopen.2020.20495","article-title":"Comparison of clinical features of COVID-19 vs. seasonal influenza A and B in US children","volume":"3","author":"Song","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_7","unstructured":"American Academy of Pediatrics (2020, October 09). Children and COVID-19: State-Level Data Report. Available online: https:\/\/services.aap.org\/en\/pages\/2019-novel-coronavirus-covid-19-infections\/children-and-covid-19-state-level-data-report\/."},{"key":"ref_8","unstructured":"Kao, C.M., Orenstein, W.A., and Anderson, E.J. (2020). The importance of advancing SARS-CoV-2 vaccines in children. Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1016\/j.vaccine.2017.09.016","article-title":"Influenza vaccine use to protect healthy children: A debated topic","volume":"36","author":"Principi","year":"2018","journal-title":"Vaccine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2217\/fmb-2020-0195","article-title":"SARS-CoV-2 transmission, the ambiguous role of children and considerations for the reopening of schools in the fall","volume":"5","author":"Anastassopoulou","year":"2020","journal-title":"Future Microbiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.3201\/eid2610.201315","article-title":"Contact tracing during coronavirus disease outbreak, South Korea","volume":"26","author":"Park","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_12","unstructured":"The Guardian (2020, November 19). \u2018Not a Game\u2019: Europe Pleads with Young People to Halt Covid-19 Spread. Available online: https:\/\/www.theguardian.com\/world\/2020\/sep\/08\/how-europe-is-tackling-spread-of-covid-19-with-appeal-to-young-people."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2217\/fmb.15.81","article-title":"Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children","volume":"10","author":"Esposito","year":"2015","journal-title":"Future Microbiol."},{"key":"ref_14","unstructured":"World Health Organization (2020, October 09). Pulse Survey on Continuity of Essential Health Services during the COVID-19 Pandemic. Available online: File:\/\/\/C:\/Users\/PrincipiN\/Downloads\/WHO-2019-nCoV-EHS_continuity-survey-2020.1-eng.pdf."},{"key":"ref_15","first-page":"20143085","article-title":"Evolution of the immune system in humans from infancy to old age","volume":"282","author":"Simon","year":"2015","journal-title":"Proc. Biol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/QCO.0000000000000572","article-title":"Current and new rotavirus vaccines","volume":"32","author":"Burke","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/oxfordjournals.aje.a120954","article-title":"An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine","volume":"89","author":"Kapikian","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials","volume":"324","author":"Xia","year":"2020","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zeichner, S.L., and Cruz, A.T. (2020). Multisystem inflammatory syndrome in children and SARSCoV2 serology. Pediatrics.","DOI":"10.1542\/peds.2020-032888"}],"container-title":["Vaccines"],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/2\/127\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:27:28Z","timestamp":1720398448000},"score":19.223637,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/2\/127"}},"issued":{"date-parts":[[2021,2,5]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["vaccines9020127"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9020127","ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"published":{"date-parts":[[2021,2,5]]}},{"indexed":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T15:07:46Z","timestamp":1725548866490},"reference-count":0,"publisher":"Informa Healthcare","isbn-type":[{"type":"print","value":"9780824740719"},{"type":"electronic","value":"9781439834404"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2004,1,28]]},"DOI":"10.1201\/9781439834404.ch11","type":"book-chapter","created":{"date-parts":[[2010,2,23]],"date-time":"2010-02-23T07:14:56Z","timestamp":1266909296000},"source":"Crossref","is-referenced-by-count":0,"title":["Developing Safe Vaccines"],"prefix":"10.1201","author":[{"given":"Norman","family":"Baylor","sequence":"first","affiliation":[]},{"given":"Karen","family":"Midthun","sequence":"additional","affiliation":[]},{"given":"Lydia","family":"Falk","sequence":"additional","affiliation":[]},{"given":"Leslie","family":"Ball","sequence":"additional","affiliation":[]},{"given":"Robert","family":"Ball","sequence":"additional","affiliation":[]},{"given":"Bruce","family":"Gellin","sequence":"additional","affiliation":[]}],"member":"301","published-online":{"date-parts":[[2009,12,4]]},"container-title":["New Generation Vaccines, Fourth Edition"],"language":"en","deposited":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T10:34:05Z","timestamp":1291372445000},"score":19.21431,"resource":{"primary":{"URL":"http:\/\/www.crcnetbase.com\/doi\/abs\/10.1201\/9781439834404.ch11"}},"issued":{"date-parts":[[2004,1,28]]},"ISBN":["9780824740719","9781439834404"],"references-count":0,"alternative-id":["10.1201\/9781439834404.ch11","10.1201\/9781439834404"],"URL":"https:\/\/doi.org\/10.1201\/9781439834404.ch11","published":{"date-parts":[[2004,1,28]]}},{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T12:25:55Z","timestamp":1648988755002},"reference-count":0,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Vaccines"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.4161\/hv.6.7.12820","type":"journal-article","created":{"date-parts":[[2010,10,26]],"date-time":"2010-10-26T19:38:36Z","timestamp":1288121916000},"page":"524-527","source":"Crossref","is-referenced-by-count":0,"title":["On-time shots are safe for babies"],"prefix":"10.1080","volume":"6","author":[{"given":"Eva M.","family":"Riedmann","sequence":"first","affiliation":[]}],"member":"301","published-online":{"date-parts":[[2014,10,27]]},"container-title":["Human Vaccines"],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.4161\/hv.6.7.12820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,14]],"date-time":"2016-12-14T03:38:46Z","timestamp":1481686726000},"score":19.195679,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/abs\/10.4161\/hv.6.7.12820"}},"issued":{"date-parts":[[2010,7]]},"references-count":0,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,10,27]]},"published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.4161\/hv.6.7.12820"],"URL":"https:\/\/doi.org\/10.4161\/hv.6.7.12820","ISSN":["1554-8600","1554-8619"],"issn-type":[{"value":"1554-8600","type":"print"},{"value":"1554-8619","type":"electronic"}],"published":{"date-parts":[[2010,7]]}},{"indexed":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T08:47:13Z","timestamp":1715244433956},"publisher-location":"New York, NY","edition-number":"2","reference-count":0,"publisher":"Springer Publishing Company","isbn-type":[{"value":"9780826125170","type":"print"},{"value":"9780826125187","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1891\/9780826125187.0026","type":"book-chapter","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T21:58:33Z","timestamp":1529013513000},"source":"Crossref","is-referenced-by-count":0,"title":["Are Vaccines Safe?"],"prefix":"10.1891","member":"793","container-title":["Communication Case Studies for Health Care Professionals"],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1891\/9780826125187.0026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T00:25:46Z","timestamp":1548375946000},"score":19.127167,"resource":{"primary":{"URL":"http:\/\/connect.springerpub.com\/lookup\/doi\/10.1891\/9780826125187.0026"}},"issued":{"date-parts":[[2014,12]]},"ISBN":["9780826125170","9780826125187"],"references-count":0,"alternative-id":["10.1891\/9780826125187"],"URL":"https:\/\/doi.org\/10.1891\/9780826125187.0026","published":{"date-parts":[[2014,12]]}},{"institution":[{"name":"US Dept of the Army","acronym":["USAMRDC"],"department":["Funding"]},{"name":"NATIONAL INSTITUTES OF HEALTH BETHESDA MD","department":["Performing"]}],"indexed":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:06:57Z","timestamp":1724890017958},"publisher-location":"Fort Belvoir, VA","reference-count":0,"publisher":"Defense Technical Information Center","content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[1993,4,1]]},"DOI":"10.21236\/ada266829","type":"report","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T17:41:29Z","timestamp":1504633289000},"source":"Crossref","is-referenced-by-count":0,"title":["Development of Safe, Effective Vaccines for Dengue Virus Disease by Recombinant Baculovirus"],"prefix":"10.21236","author":[{"given":"Ching J.","family":"Lai","sequence":"first","affiliation":[]}],"member":"9879","original-title":[""],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T20:44:52Z","timestamp":1724877892000},"score":19.11861,"resource":{"primary":{"URL":"http:\/\/www.dtic.mil\/docs\/citations\/ADA266829"}},"subtitle":[""],"issued":{"date-parts":[[1993,4,1]]},"references-count":0,"URL":"https:\/\/doi.org\/10.21236\/ada266829","published":{"date-parts":[[1993,4,1]]}},{"indexed":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T01:18:39Z","timestamp":1711070319698},"reference-count":0,"publisher":"Rowman & Littlefield Publishers","isbn-type":[{"value":"9781442215801","type":"print"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2012]]},"DOI":"10.5771\/9781442215801-19","type":"book-chapter","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T08:16:05Z","timestamp":1711008965000},"page":"19-32","source":"Crossref","is-referenced-by-count":0,"title":["Chapter 3. The Biology of Vaccines"],"prefix":"10.5771","author":[{"given":"Stacy  Mintzer","family":"Herlihy","sequence":"first","affiliation":[]},{"given":"E. Allison","family":"Hagood","sequence":"additional","affiliation":[]}],"member":"3821","container-title":["Your Baby's Best Shot"],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T08:37:47Z","timestamp":1711010267000},"score":19.071358,"resource":{"primary":{"URL":"https:\/\/www.nomos-elibrary.de\/index.php?doi=10.5771\/9781442215801-19"}},"issued":{"date-parts":[[2012]]},"ISBN":["9781442215801"],"references-count":0,"URL":"https:\/\/doi.org\/10.5771\/9781442215801-19","published":{"date-parts":[[2012]]}},{"indexed":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T11:14:52Z","timestamp":1717499692083},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1997,1,1]],"date-time":"1997-01-01T00:00:00Z","timestamp":852076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[1997,1]]},"DOI":"10.1038\/nm0197-17","type":"journal-article","created":{"date-parts":[[2004,8,19]],"date-time":"2004-08-19T01:53:10Z","timestamp":1092880390000},"page":"17-18","source":"Crossref","is-referenced-by-count":15,"title":["Live-attenuated HIV vaccines: How safe is safe enough?"],"prefix":"10.1038","volume":"3","author":[{"given":"Michael","family":"Murphey-Corb","sequence":"first","affiliation":[]}],"member":"297","reference":[{"key":"BFnm019717_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/j.1600-0684.1995.tb00161.x","volume":"24","author":"JT Warren","year":"1995","unstructured":"Warren, J.T. & Levinson, M.A. Fourth annual survey of worldwide HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates. J. Med. Primatol. 24, 150\u2013168 (1995).","journal-title":"J. Med. Primatol."},{"key":"BFnm019717_CR2","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1126\/science.1470917","volume":"258","author":"MD Daniel","year":"1992","unstructured":"Daniel, M.D., Kirchhoff, F., Czajak, S.C., Sehgal, P.K. & Desrosiers, R.C. Protective effects of a live-attenuated SIV vaccine with a deletion in the nef gene. Science 258, 1938\u20131941 (1992).","journal-title":"Science"},{"key":"BFnm019717_CR3","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1128\/JVI.70.6.3724-3733.1996","volume":"70","author":"MS Wyand","year":"1996","unstructured":"Wyand, M.S., Manson, K.H., Garcia-Moll, M., Montefiori, D. & Desrosiers, R.C. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 70, 3724 (1996).","journal-title":"J. Virol."},{"key":"BFnm019717_CR4","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1128\/JVI.69.5.2737-2744.1995","volume":"69","author":"JE Clements","year":"1995","unstructured":"Clements, J.E. et al. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J. Virol. 69, 2737\u20132744 (1995).","journal-title":"J. Virol."},{"key":"BFnm019717_CR5","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1128\/JVI.68.11.7021-7029.1994","volume":"68","author":"BL Lohman","year":"1994","unstructured":"Lohman, B.L. et al. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J. Virol. 68, 7021\u20137029 (1994).","journal-title":"J. Virol."},{"key":"BFnm019717_CR6","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1126\/science.7892606","volume":"267","author":"TW Baba","year":"1995","unstructured":"Baba, T.W. et al. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267, 1820\u20131825 (1995).","journal-title":"Science"},{"key":"BFnm019717_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1089\/aid.1994.10.607","volume":"10","author":"JS Gibbs","year":"1994","unstructured":"Gibbs, J.S., Regier, D.A. & Desrosiers, R.C. Construction and in vitro properties of SIVmac mutants with deletions in the \u201cnonessential\u201d genes. AIDS Res. Hum. Retroviruses 10, 607\u2013616 (1994).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"BFnm019717_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nm0197-32","volume":"3","author":"M Wyand","year":"1997","unstructured":"Wyand, M., Manson, K.H., Lackner, A.A. & Desrosiers, R.C. Resistance of neonatal monkeys to live-attenuated vaccine strains of simian immunodeficiency virus. Nature Med. 3, 32\u201336 (1997).","journal-title":"Nature Med."}],"container-title":["Nature Medicine"],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm0197-17","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm0197-17.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm0197-17.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T23:30:07Z","timestamp":1684452607000},"score":19.064913,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm0197-17"}},"issued":{"date-parts":[[1997,1]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1997,1]]}},"alternative-id":["BFnm019717"],"URL":"https:\/\/doi.org\/10.1038\/nm0197-17","ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"published":{"date-parts":[[1997,1]]}},{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T09:08:35Z","timestamp":1726477715482},"reference-count":0,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Vaccines"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.4161\/hv.8627","type":"journal-article","created":{"date-parts":[[2014,7,17]],"date-time":"2014-07-17T13:40:28Z","timestamp":1405604428000},"page":"623-626","source":"Crossref","is-referenced-by-count":27,"title":["DNA vaccines: A safe and efficient platform technology for responding to emerging infectious diseases"],"prefix":"10.1080","volume":"5","author":[{"given":"Julie E.","family":"Ledgerwood","sequence":"first","affiliation":[]},{"given":"Barney S.","family":"Graham","sequence":"additional","affiliation":[]}],"member":"301","published-online":{"date-parts":[[2014,10,27]]},"container-title":["Human Vaccines"],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.4161\/hv.8627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T22:37:15Z","timestamp":1481668635000},"score":18.932446,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/abs\/10.4161\/hv.8627"}},"issued":{"date-parts":[[2009,9]]},"references-count":0,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,10,27]]},"published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.4161\/hv.8627"],"URL":"https:\/\/doi.org\/10.4161\/hv.8627","ISSN":["1554-8600","1554-8619"],"issn-type":[{"value":"1554-8600","type":"print"},{"value":"1554-8619","type":"electronic"}],"published":{"date-parts":[[2009,9]]}},{"indexed":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T05:35:50Z","timestamp":1734500150634,"version":"3.30.2"},"reference-count":0,"publisher":"American Academy of Pediatrics (AAP)","content-domain":{"domain":[],"crossmark-restriction":false},"DOI":"10.1542\/peo_document057","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T15:36:34Z","timestamp":1636731394000},"source":"Crossref","is-referenced-by-count":0,"title":["Immunizations and Vaccines: Keeping Babies, Children, and Teens Safe and Healthy"],"prefix":"10.1542","member":"417","published-online":{"date-parts":[[2024,12,17]]},"container-title":["Pediatric Patient Education"],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/patiented\/article-pdf\/doi\/10.1542\/peo_document057\/1754145\/peo_document057_en.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/patiented\/article-pdf\/doi\/10.1542\/peo_document057\/1754145\/peo_document057_en.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T17:25:54Z","timestamp":1734456354000},"score":18.889652,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/patiented\/article\/doi\/10.1542\/peo_document057\/80040\/Immunizations-and-Vaccines-Keeping-Babies-Children"}},"issued":{"date-parts":[[2024,12,17]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1542\/peo_document057","ISSN":["2156-3012"],"issn-type":[{"type":"electronic","value":"2156-3012"}],"published":{"date-parts":[[2024,12,17]]}},{"indexed":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T17:21:02Z","timestamp":1704907262829},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trop Dis Travel Med Vaccines"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>One-half of all travellers are women; yet, there is a distinct lack of detailed travel health knowledge on topics of unique relevance to women. While there is medical advice relating to stages in the female lifecycle, it neglects women-specific practical aspects despite their ability to harm travellers\u2019 health and cause inconvenience. This paper discusses comprehensively three major aspects of travel as they relate to women. First, it suggests the management of personal hygiene, bodily functions, menstruation and sexual behaviour, and alerts to the limited knowledge on travel mental health issues.<\/jats:p><jats:p>Second, apart from travelling in a female body with its specific demands, being a woman requires special attention to safety and security. Within various travel contexts, women have many opportunities for minimising potential risks.<\/jats:p><jats:p>Finally, guided by travel medicine\u2019s acknowledgment of its role in the concept of responsible travel, this article goes beyond the usual general statements and broad advice and offers detailed and practical suggestions on how the female traveller can contribute to the overall goal of minimising any potential harm to fellow humans and the natural environment. Recognising the scarcity of women-specific travel information, pathways to better education, and a range of suggestions for urgent research facilitate the provision of high-quality travel health care tailored specifically to women\u2019s needs.<\/jats:p>","DOI":"10.1186\/s40794-021-00141-7","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T20:02:51Z","timestamp":1622923371000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Healthy, safe and responsible: the modern female traveller"],"prefix":"10.1186","volume":"7","author":[{"ORCID":"http:\/\/orcid.org\/0000-0002-8305-3700","authenticated-orcid":false,"given":"Irmgard L.","family":"Bauer","sequence":"first","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,6,5]]},"reference":[{"issue":"2","key":"141_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3727\/154427205774791672","volume":"9","author":"E Wilson","year":"2005","unstructured":"Wilson E, Little D. A \u2018relative escape\u2019? The impact of constraints on women who travel solo. Tour Rev Int. 2005;9(2):155\u201375. https:\/\/doi.org\/10.3727\/154427205774791672.","journal-title":"Tour Rev Int"},{"issue":"1","key":"141_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.tmaid.2013.09.003","volume":"12","author":"I Bauer","year":"2014","unstructured":"Bauer I. Romance tourism or female sex tourism? Travel Med Infect Dis. 2014;12(1):20\u20138. https:\/\/doi.org\/10.1016\/j.tmaid.2013.09.003.","journal-title":"Travel Med Infect Dis"},{"key":"141_CR3","volume-title":"Hints to lady travellers: at home and abroad","author":"L Campbell Davison","year":"1889","unstructured":"Campbell Davison L. Hints to lady travellers: at home and abroad. London: Iliffe & Son; 1889."},{"issue":"3","key":"141_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.tmaid.2012.05.002","volume":"10","author":"J Chiodini","year":"2012","unstructured":"Chiodini J, Anderson E, Driver C, et al. Recommendations for the practice of travel medicine. Travel Med Infect Dis. 2012;10(3):109\u201328. https:\/\/doi.org\/10.1016\/j.tmaid.2012.05.002.","journal-title":"Travel Med Infect Dis"},{"key":"141_CR5","volume-title":"MEDCOM: Contraception and period control at altitude","author":"International Climbing and Mountaineering Federation","year":"2010","unstructured":"International Climbing and Mountaineering Federation. MEDCOM: Contraception and period control at altitude, 2010. https:\/\/www.theuiaa.org\/mountaineering\/contraception-and-period-control-at-altitude\/. Accessed 20 Oct 2020."},{"issue":"8","key":"141_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jtm\/taz071","volume":"23","author":"S Borwein","year":"2019","unstructured":"Borwein S. Contraception in female travellers: challenges and solutions. J Travel Med. 2019;23(8):1\u20134. https:\/\/doi.org\/10.1093\/jtm\/taz071.","journal-title":"J Travel Med"},{"key":"141_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.21859\/ijtmgh-040405","volume":"4","author":"W Dandehbor","year":"2016","unstructured":"Dandehbor W, Kazemi M, Shahrbabaki M, et al. Menstrual suppression using oral contraceptives by female hajj pilgrims. Int J Travel Med Glob Health. 2016;4:111\u20134. https:\/\/doi.org\/10.21859\/ijtmgh-040405.","journal-title":"Int J Travel Med Glob Health"},{"issue":"1","key":"141_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.7205\/MILMED.172.1.9","volume":"172","author":"L Christopher","year":"2007","unstructured":"Christopher L, Miller L. Women in war: operational issues of menstruation and unintended pregnancy. Mil Med. 2007;172(1):9\u201316. https:\/\/doi.org\/10.7205\/MILMED.172.1.9.","journal-title":"Mil Med"},{"issue":"1","key":"141_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.whi.2010.08.006","volume":"21","author":"N Powell-Dunford","year":"2011","unstructured":"Powell-Dunford N, Cuda A, Moore J, et al. Menstrual suppression for combat operations: advantages of oral contraceptive pills. Womens Health Issues. 2011;21(1):86\u201391. https:\/\/doi.org\/10.1016\/j.whi.2010.08.006.","journal-title":"Womens Health Issues"},{"issue":"11","key":"141_CR10","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3357\/ASEM.2566.2009","volume":"80","author":"N Powell-Dunford","year":"2009","unstructured":"Powell-Dunford N, Cuda A, Moore J, et al. Menstrual suppression using oral contraception: survey of deployed female aviation personnel. Aviat Space Environ Med. 2009;80(11):971\u20135. https:\/\/doi.org\/10.3357\/ASEM.2566.2009.","journal-title":"Aviat Space Environ Med"},{"issue":"4","key":"141_CR11","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1552-6909.2007.00166.x","volume":"36","author":"L Trego","year":"2007","unstructured":"Trego L. Military Women\u2019s menstrual experiences and interest in menstrual suppression during deployment. JOGNN. 2007;36(4):342\u20137. https:\/\/doi.org\/10.1111\/j.1552-6909.2007.00166.x.","journal-title":"JOGNN"},{"issue":"7","key":"141_CR12","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.socscimed.2010.06.041","volume":"71","author":"J Gunson","year":"2010","unstructured":"Gunson J. \u201cMore natural but less normal\u201d: reconsidering medicalisation and agency through women\u2019s accounts of menstrual suppression. Soc Sci Med. 2010;71(7):1324\u201331. https:\/\/doi.org\/10.1016\/j.socscimed.2010.06.041.","journal-title":"Soc Sci Med"},{"issue":"1","key":"141_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12905-019-0827-x","volume":"125","author":"A DeMaria","year":"2019","unstructured":"DeMaria A, Sundstrom B, Meier S, Wiseley A. The myth of menstruation: how menstrual regulation and suppression impact contraceptive choice. Women Health. 2019;125(1):125. https:\/\/doi.org\/10.1186\/s12905-019-0827-x.","journal-title":"Women Health"},{"issue":"1","key":"141_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1891\/1061-3749.17.1.45","volume":"17","author":"L Trego","year":"2009","unstructured":"Trego L. Development of the military Women's attitudes toward menstrual suppression scale: from construct definition to pilot testing. J Nurs Meas. 2009;17(1):45\u201372. https:\/\/doi.org\/10.1891\/1061-3749.17.1.45.","journal-title":"J Nurs Meas"},{"issue":"7","key":"141_CR15","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1111\/j.1365-2648.2009.05010.x","volume":"65","author":"L Trego","year":"2009","unstructured":"Trego L. Theoretical substruction: establishing links between theory and measurement of military women\u2019s attitudes towards menstrual suppression during military operations. J Adv Nurs. 2009;65(7):1548\u201359. https:\/\/doi.org\/10.1111\/j.1365-2648.2009.05010.x.","journal-title":"J Adv Nurs"},{"issue":"4","key":"141_CR16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.whi.2010.03.002","volume":"20","author":"L Trego","year":"2010","unstructured":"Trego L, Jordan P. Military women's attitudes toward menstruation and menstrual suppression in relation to the deployed environment: development and testing of the MWATMS-9 (short form). Womens Health Issues. 2010;20(4):287\u201393. https:\/\/doi.org\/10.1016\/j.whi.2010.03.002.","journal-title":"Womens Health Issues"},{"key":"141_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.tmaid.2005.06.003","volume":"4","author":"M Cooper","year":"2006","unstructured":"Cooper M. The pregnant traveler. Travel Med Infect Dis. 2006;4:196\u2013201. https:\/\/doi.org\/10.1016\/j.tmaid.2005.06.003.","journal-title":"Travel Med Infect Dis"},{"issue":"apr28 1","key":"141_CR18","doi-asserted-by":"publisher","first-page":"d2506","DOI":"10.1136\/bmj.d2506","volume":"342","author":"N Hezelgrave","year":"2011","unstructured":"Hezelgrave N, Whitty C, Shennan A, Chappell L. Advising on travel during pregnancy. BMJ. 2011;342(apr28 1):d2506. https:\/\/doi.org\/10.1136\/bmj.d2506.","journal-title":"BMJ"},{"issue":"4","key":"141_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.tmaid.2004.11.004","volume":"3","author":"I Carroll","year":"2005","unstructured":"Carroll I, van Gompel A. The pregnant wilderness traveler. Travel Med Infect Dis. 2005;3(4):225\u201338. https:\/\/doi.org\/10.1016\/j.tmaid.2004.11.004.","journal-title":"Travel Med Infect Dis"},{"key":"141_CR20","doi-asserted-by":"crossref","unstructured":"Anderson S. Advice for women travelers. In: Sanford C, Jong E, Pottinger P, editors. The travel and tropical medicine manual e-book: Elsevier Health Sciences; 2016. p. 192\u2013214.\u00a0Available at https:\/\/www.elsevier.com\/books\/the-travel-and-tropical-medicine-manual\/sanford\/978-0-323-37506-1.","DOI":"10.1016\/B978-0-323-37506-1.00014-3"},{"key":"141_CR21","unstructured":"Salas R, Anderson S. Women in the wilderness. In: Auerbach P, editor. Auerbach\u2019s wilderness medicine e-book: Elsevier\u2019s Health Sciences; 2016. p. 2117\u201349.\u00a0Available at https:\/\/www.elsevier.com\/books\/auerbachs-wilderness-medicine-2-volume-set\/auerbach\/978-0-323-35942-9."},{"key":"141_CR22","doi-asserted-by":"publisher","first-page":"taz074","DOI":"10.1093\/jtm\/taz074","volume":"27","author":"R Nasser","year":"2020","unstructured":"Nasser R, Rakedzon S, Dickstein Y, et al. Are all vaccines safe for the pregnant traveller? A systematic review and meta-analysis. J Travel Med. 2020;27:taz074. https:\/\/doi.org\/10.1093\/jtm\/taz074.","journal-title":"J Travel Med"},{"issue":"6","key":"141_CR23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.tmaid.2015.10.001","volume":"6","author":"V Jaeger","year":"2015","unstructured":"Jaeger V, Tschudi N, R\u00fcegg R, et al. The elderly, the young and the pregnant traveler \u2013 a retrospective data analysis from a large SwissTravelCenter with a special focus on malaria prophylaxis and yellow fever vaccination. Travel Med Infect Dis. 2015;6(6):475\u201384. https:\/\/doi.org\/10.1016\/j.tmaid.2015.10.001.","journal-title":"Travel Med Infect Dis"},{"key":"141_CR24","doi-asserted-by":"publisher","first-page":"101525","DOI":"10.1016\/j.tmaid.2019.101525","volume":"32","author":"P Schlagenhauf","year":"2019","unstructured":"Schlagenhauf P, Grobusch M, Leder K, et al. Complex choices: which malaria chemoprophylaxis can be recommended for the pregnant traveller? Travel Med Infect Dis. 2019;32:101525. https:\/\/doi.org\/10.1016\/j.tmaid.2019.101525.","journal-title":"Travel Med Infect Dis"},{"issue":"4","key":"141_CR25","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.tmaid.2015.06.014","volume":"13","author":"J Cardona-Ospina","year":"2015","unstructured":"Cardona-Ospina J, Salazar-Vargas C, Rodr\u00edguez-Morales A, et al. Flying and pregnant? \u2013 regulations of the main airlines in Latin America. Travel Med Infect Dis. 2015;13(4):335\u20137. https:\/\/doi.org\/10.1016\/j.tmaid.2015.06.014.","journal-title":"Travel Med Infect Dis"},{"key":"141_CR26","doi-asserted-by":"publisher","first-page":"taz091","DOI":"10.1093\/jtm\/taz091","volume":"27","author":"D Karsanji","year":"2020","unstructured":"Karsanji D, Bates S, Skeith L. The risk and prevention of venous thromboembolism in the pregnant traveller. J Travel Med. 2020;27:taz091. https:\/\/doi.org\/10.1093\/jtm\/taz091.","journal-title":"J Travel Med"},{"issue":"2","key":"141_CR27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/jtm.12165","volume":"22","author":"E Ben-Chetrit","year":"2015","unstructured":"Ben-Chetrit E, Lachish T, M\u00f8rch K, Atias D, Maguire C, Schwartz E. Schistosomiasis in pregnant travelers: a case series. J Travel Med. 2015;22(2):94\u20138. https:\/\/doi.org\/10.1111\/jtm.12165.","journal-title":"J Travel Med"},{"key":"141_CR28","doi-asserted-by":"publisher","first-page":"taz079","DOI":"10.1093\/jtm\/taz079","volume":"27","author":"R Lau","year":"2020","unstructured":"Lau R, Chris R, Phuong M, et al. Treatment of soil-transmitted helminth infections in pregnancy: a systematic review and meta-analysis of maternal outcomes. J Travel Med. 2020;27:taz079. https:\/\/doi.org\/10.1093\/jtm\/taz079.","journal-title":"J Travel Med"},{"issue":"1","key":"141_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.tmaid.2011.11.003","volume":"10","author":"C Kim","year":"2010","unstructured":"Kim C, Chavez P, Pierce A, Murray A, Sander M, Kenyon C, et al. Rubella tracing associated with air travel. Travel Med Infect Dis. 2010;10(1):48\u201351. https:\/\/doi.org\/10.1016\/j.tmaid.2011.11.003.","journal-title":"Travel Med Infect Dis"},{"key":"141_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1916\/j.tmaid.2016.01.011","volume":"22","author":"A Rodriguez-Morales","year":"2016","unstructured":"Rodriguez-Morales A. Zika and microcephaly in Latin America: an emerging threat for pregnant travelers? Travel Med Infect Dis. 2016;22:75\u20136. https:\/\/doi.org\/10.1916\/j.tmaid.2016.01.011.","journal-title":"Travel Med Infect Dis"},{"key":"141_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tmaid.2018.06.014","volume":"25","author":"L Alvarado-Arnez","year":"2018","unstructured":"Alvarado-Arnez L, Escalera-Antezana J. Zika infection in pregnancy: follow up and outcomes, where are all the data? Travel Med Infect Dis. 2018;25:1\u20132. https:\/\/doi.org\/10.1016\/j.tmaid.2018.06.014.","journal-title":"Travel Med Infect Dis"},{"key":"141_CR32","first-page":"594","volume":"33","author":"S Mohler","year":"1962","unstructured":"Mohler S. Aging and space travel. Aerospace Med. 1962;33:594\u20137.","journal-title":"Aerospace Med"},{"key":"141_CR33","doi-asserted-by":"publisher","unstructured":"Palacios S, Comnalia J, Emsellem C, et al. Therapies for the management of genitourinary syndrome of menopause. Post Reprod Health. 2019:2053369119866341. https:\/\/doi.org\/10.1177\/2053369119866341.","DOI":"10.1177\/2053369119866341"},{"issue":"2","key":"141_CR34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.tmaid.2012.03.002","volume":"10","author":"I Bauer","year":"2012","unstructured":"Bauer I. Australian senior adventure travellers to Peru: maximising older tourists' travel health experience. Travel Med Infect Dis. 2012;10(2):59\u201368. https:\/\/doi.org\/10.1016\/j.tmaid.2012.03.002.","journal-title":"Travel Med Infect Dis"},{"issue":"2","key":"141_CR35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1708-8305.1994.tb00570.x","volume":"1","author":"S Meldon","year":"1994","unstructured":"Meldon S, Hargarten S. Airplane vacuum toilets: an uncommon travel hazard. J Travel Med. 1994;1(2):104\u20135. https:\/\/doi.org\/10.1111\/j.1708-8305.1994.tb00570.x.","journal-title":"J Travel Med"},{"key":"141_CR36","first-page":"18","volume":"3","author":"C Handler","year":"2013","unstructured":"Handler C, Kopelman D, Hatou O. A case report of severe thrombosed hemorrhoids and rectal prolapse due to airplane toilet vacuum injury. World J Colorect Surg. 2013;3:18.","journal-title":"World J Colorect Surg"},{"key":"141_CR37","first-page":"59","volume":"12","author":"I Bauer","year":"2011","unstructured":"Bauer I. Contact lenses and travel: blessing or nightmare? Ann ACTM. 2011;12:59\u201360.","journal-title":"Ann ACTM"},{"issue":"2","key":"141_CR38","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.tmaid.2014.12.005","volume":"13","author":"I Bauer","year":"2015","unstructured":"Bauer I. Contact lens wearers' experiences while trekking in the Khumbu region\/Nepal: a cross-sectional survey. Travel Med Infect Dis. 2015;13(2):178\u201384. https:\/\/doi.org\/10.1016\/j.tmaid.2014.12.005.","journal-title":"Travel Med Infect Dis"},{"issue":"3","key":"141_CR39","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1177\/1745505717731011","volume":"13","author":"Y Chen","year":"2017","unstructured":"Chen Y, Bruning E, Rubino J, Eder S. Role of female intimate hygiene in vulvovaginal health: global hygiene practices and product usage. Women Health. 2017;13(3):58\u201367. https:\/\/doi.org\/10.1177\/1745505717731011.","journal-title":"Women Health"},{"issue":"6","key":"141_CR40","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/000155500300012819","volume":"80","author":"B Runeman","year":"2000","unstructured":"Runeman B, Faergemann J, Lark\u00f6 O. Experimental candida albicans lesions in healthy humans: dependence on skin pH. Acta Derm Venerol. 2000;80(6):421\u20134. https:\/\/doi.org\/10.1080\/000155500300012819.","journal-title":"Acta Derm Venerol"},{"issue":"2","key":"141_CR41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/00015550310007409","volume":"83","author":"B Runeman","year":"2003","unstructured":"Runeman B, Rybo G, Lark\u00f6 O, Faergemann J. The vulva skin microclimate: influence of panty liners on temperature, humidity and pH. Acta Derm Venereol. 2003;83(2):88\u201392. https:\/\/doi.org\/10.1080\/00015550310007409.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"141_CR42","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/200484277284","volume":"84","author":"B Runeman","year":"2004","unstructured":"Runeman B, Rybo G, Forsgren-Brusk U, Lark\u00f6 O, Larsson P, Faergemann J. The vulvar skin microenvironment: influence of different panty liners on temperature, pH and microflora. Acta Derm Venerol. 2004;84(4):277\u201384. https:\/\/doi.org\/10.1080\/200484277284.","journal-title":"Acta Derm Venerol"},{"issue":"4","key":"141_CR43","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1600-0536.1985.tb02575.x","volume":"13","author":"W Sterry","year":"1985","unstructured":"Sterry W, Schmoll M. Contact urticaria and dermatitis from self-adhesive pads. Contact Dermatitis. 1985;13(4):284\u20135. https:\/\/doi.org\/10.1111\/j.1600-0536.1985.tb02575.x.","journal-title":"Contact Dermatitis"},{"issue":"1","key":"141_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/trstmh\/try107","volume":"113","author":"A Singh","year":"2019","unstructured":"Singh A, Kaur J. Occurrence of human urogenital myiasis due to neglected personal hygiene: a review. Trans R Soc Trop Med. 2019;113(1):1\u20134. https:\/\/doi.org\/10.1093\/trstmh\/try107.","journal-title":"Trans R Soc Trop Med"},{"key":"141_CR45","first-page":"1526","volume-title":"Manson\u2019s tropical diseases","author":"G White","year":"1996","unstructured":"White G. Myasis. In: Cook G, editor. Manson\u2019s tropical diseases. 20th ed. London: WB Saunders; 1996. p. 1526\u201332.","edition":"20"},{"key":"141_CR46","first-page":"888","volume-title":"Wilderness medicine","author":"S Minton","year":"2001","unstructured":"Minton S, Bechtel B, Erickson T. Non-north American arthropod envenomation and parasitism. In: Auerbach P, editor. Wilderness medicine. 4th ed. St Louis: Mosby; 2001. p. 888\u201395.","edition":"4"},{"issue":"12","key":"141_CR47","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/milmed\/166.12.1033","volume":"166","author":"E Ritchie","year":"2001","unstructured":"Ritchie E. Issues for military women in deployment: an overview. Mil Med. 2001;166(12):1033\u20137. https:\/\/doi.org\/10.1093\/milmed\/166.12.1033.","journal-title":"Mil Med"},{"key":"141_CR48","volume-title":"Climbing the seven summits: a comprehensive guide to the continents' highest peak","author":"M Hamill","year":"2012","unstructured":"Hamill M. Climbing the seven summits: a comprehensive guide to the continents' highest peak. Seattle: The Mountaineers Book; 2012."},{"key":"141_CR49","volume-title":"How to shit around the worlds. The art of staying clean and healthy while traveling","author":"J Wilson-Howarth","year":"2006","unstructured":"Wilson-Howarth J. How to shit around the worlds. The art of staying clean and healthy while traveling. San Francisco: Travelers\u2019 Tales; 2006."},{"issue":"4","key":"141_CR50","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1745-7599.2001.tb00245.x","volume":"13","author":"D Wardell","year":"2005","unstructured":"Wardell D, Czerwinksi B. A military challenge to managing feminine and personal hygiene. J Am Acad Nurse Pract. 2005;13(4):187\u201393. https:\/\/doi.org\/10.1111\/j.1745-7599.2001.tb00245.x.","journal-title":"J Am Acad Nurse Pract"},{"issue":"2","key":"141_CR51","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2310\/7060.2003.31793","volume":"10","author":"V Zeller","year":"2003","unstructured":"Zeller V, Didier B, Dos Santos G, et al. Upper urinary tract infection as a leading cause of fever among female travelers returning from the tropics. J Travel Med. 2003;10(2):139\u201340. https:\/\/doi.org\/10.2310\/7060.2003.31793.","journal-title":"J Travel Med"},{"issue":"2","key":"141_CR52","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1177\/105477380000900204","volume":"9","author":"N Lowe","year":"2000","unstructured":"Lowe N, Ryan-Wenger N. A clinical test of women\u2019s self-diagnosis of genitourinary infections. Clin Nurs Res. 2000;9(2):144\u201360. https:\/\/doi.org\/10.1177\/105477380000900204.","journal-title":"Clin Nurs Res"},{"key":"141_CR53","doi-asserted-by":"publisher","first-page":"111624","DOI":"10.1016\/j.bios.2019.111624","volume":"145","author":"I Alves","year":"2019","unstructured":"Alves I, Reis N. Microfluidic smartphone quantitation of Escherichia coli in synthetic urine. Biosens Bioelectron. 2019;145:111624. https:\/\/doi.org\/10.1016\/j.bios.2019.111624.","journal-title":"Biosens Bioelectron"},{"issue":"5","key":"141_CR54","doi-asserted-by":"publisher","first-page":"337","DOI":"10.5271\/sjweh.740","volume":"29","author":"B Grajewski","year":"2003","unstructured":"Grajewski B, Nguyen MM, Whelan EA, Cole RJ, Hein MJ. Measuring and identifying large-study metrics for circadian rhythm disruption in female flight attendants. Scand J Work Environ Health. 2003;29(5):337\u201346. https:\/\/doi.org\/10.5271\/sjweh.740.","journal-title":"Scand J Work Environ Health"},{"key":"141_CR55","first-page":"809","volume":"34","author":"M Radowicka","year":"2013","unstructured":"Radowicka M, Pietrzak B, Wielgo\u015b M. Assessment of the occurrence of menstrual disorders in female flight attendants - preliminary report and literature review. Neuro Endocrinol Lett. 2013;34:809\u201313.","journal-title":"Neuro Endocrinol Lett"},{"issue":"3","key":"141_CR56","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1580\/1080-6032(2004)15[175:GDALBA]2.0.CO;2","volume":"15","author":"D Boulware","year":"2004","unstructured":"Boulware D. Gender differences among long-distance backpackers: a prospective study of women Appalachian Trail backpackers. Wild Environ Med. 2004;15(3):175\u201380. https:\/\/doi.org\/10.1580\/1080-6032(2004)15[175:GDALBA]2.0.CO;2.","journal-title":"Wild Environ Med"},{"key":"141_CR57","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2310\/7060.2003.2690","volume":"10","author":"P Leutscher","year":"2003","unstructured":"Leutscher P, Nagley S. Health-related challenges in United States Peace Corps volunteers serving for two years in Madagascar. J Travel Med. 2003;10:263\u20137. https:\/\/doi.org\/10.2310\/7060.2003.2690.","journal-title":"J Travel Med"},{"issue":"6","key":"141_CR58","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.whi.2004.08.006","volume":"14","author":"M McPherson","year":"2004","unstructured":"McPherson M, Korfine L. Menstruation across time: menarche, menstrual attitudes, experiences, and behaviors. Womens Health Issues. 2004;14(6):193\u2013200. https:\/\/doi.org\/10.1016\/j.whi.2004.08.006.","journal-title":"Womens Health Issues"},{"issue":"5","key":"141_CR59","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/00006842-198009000-00005","volume":"42","author":"J Brooks-Gunn","year":"1980","unstructured":"Brooks-Gunn J, Ruble D. The menstrual attitude questionnaire. Psychosom Med. 1980;42(5):503\u201312. https:\/\/doi.org\/10.1097\/00006842-198009000-00005.","journal-title":"Psychosom Med"},{"key":"141_CR60","volume-title":"Tracks","author":"R Davidson","year":"1980","unstructured":"Davidson R. Tracks. London: Jonathan Cape; 1980."},{"issue":"1","key":"141_CR61","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.yrtph.2014.07.020","volume":"70","author":"S Ishii","year":"2014","unstructured":"Ishii S, Katagiri R, Kataoka T, Wada M, Imai S, Yamasaki K. Risk assessment study of dioxins in sanitary napkins produced in Japan. Regul Toxic Pharm. 2014;70(1):357\u201362. https:\/\/doi.org\/10.1016\/j.yrtph.2014.07.020.","journal-title":"Regul Toxic Pharm"},{"issue":"1","key":"141_CR62","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2114\/jpa.24.7","volume":"24","author":"M Park","year":"2005","unstructured":"Park M, Watanuki S. Unpleasantness and physiological responses in using sanitary napkins. J Physiol Anthropol Appl Hum Sci. 2005;24(1):7\u201314. https:\/\/doi.org\/10.2114\/jpa.24.7.","journal-title":"J Physiol Anthropol Appl Hum Sci"},{"issue":"8","key":"141_CR63","first-page":"1173","volume":"154","author":"E Eason","year":"1996","unstructured":"Eason E, Feldman P. Contact dermatitis associated with the use of always sanitary napkins. Can Med Assoc J. 1996;154(8):1173\u20136.","journal-title":"Can Med Assoc J"},{"issue":"3","key":"141_CR64","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1001\/archderm.1979.04010030065027","volume":"115","author":"W Larsen","year":"1979","unstructured":"Larsen W. Sanitary napkin dermatitis due to the perfume. Arch Dermatol. 1979;115(3):363. https:\/\/doi.org\/10.1001\/archderm.1979.04010030065027.","journal-title":"Arch Dermatol"},{"issue":"1","key":"141_CR65","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1289\/ehp.0211023","volume":"110","author":"M DeVito","year":"2002","unstructured":"DeVito M, Schecter A. Exposure assessment to dioxins from the use of tampons and diapers. Environ Health Perspect. 2002;110(1):23\u20138. https:\/\/doi.org\/10.1289\/ehp.0211023.","journal-title":"Environ Health Perspect"},{"issue":"4","key":"141_CR66","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1440-0960.2012.00938.x","volume":"54","author":"S Dixit","year":"2013","unstructured":"Dixit S, Fischer G, Wittekind C. Recurrent menstrual toxic shock syndrome despite discontinuation of tampon use: is menstrual toxic shock syndrome really caused by tampons? Australas J Dermatol. 2013;54(4):283\u20136. https:\/\/doi.org\/10.1111\/j.1440-0960.2012.00938.x.","journal-title":"Australas J Dermatol"},{"key":"141_CR67","unstructured":"Starr M. Smart Bluetooth menstrual cup tracks your period. https:\/\/www.cnet.com\/news\/smart-bluetooth-menstrual-cup-tracks-your-period\/. Accessed 17 Sept 2010."},{"key":"141_CR68","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1089\/jwh.2009.1929","volume":"20","author":"B North","year":"2011","unstructured":"North B, Oldham M. Preclinical, clinical, and over-the-counter postmarketing experience with a new vaginal cup: menstrual collection. J Women's Health. 2011;20:303\u201311. https:\/\/doi.org\/10.1089\/jwh.2009.1929.","journal-title":"J Women's Health"},{"issue":"8","key":"141_CR69","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1016\/S2468-2667(19)30111-2","volume":"4","author":"AM Van Eijk","year":"2019","unstructured":"Van Eijk AM, Zulaika G, Lenchner M, et al. Menstrual cup use, leakage, acceptability, safety, and availability: a systematic review and meta-analysis. Lancet Public Health. 2019;4(8):e376\u201393. https:\/\/doi.org\/10.1016\/S2468-2667(19)30111-2.","journal-title":"Lancet Public Health"},{"issue":"5","key":"141_CR70","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1258\/ijsa.2011.011277","volume":"23","author":"S Day","year":"2012","unstructured":"Day S. A retained menstrual cup. Int J STD AIDS. 2012;23(5):367\u20138. https:\/\/doi.org\/10.1258\/ijsa.2011.011277.","journal-title":"Int J STD AIDS"},{"issue":"2","key":"141_CR71","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/milmed\/166.2.152","volume":"166","author":"B Czerwinski","year":"2001","unstructured":"Czerwinski B, Wardell D, Yoder L, et al. Variations in feminine hygiene practices of military women in deployed and noncombat environments. Mil Med. 2001;166(2):152\u20138. https:\/\/doi.org\/10.1093\/milmed\/166.2.152.","journal-title":"Mil Med"},{"key":"141_CR72","volume-title":"Woman searched at airport when feminine hygiene product alerts scanner","author":"E Gillis","year":"2017","unstructured":"Gillis E. Woman searched at airport when feminine hygiene product alerts scanner, 2017. https:\/\/www.wsoctv.com\/news\/local\/women-searched-at-airport-after-feminine-hygiene-product-alerts-scanner\/541755851\/. Accessed 13 Feb 2020."},{"key":"141_CR73","unstructured":"Mama Instincts. The TSA full body scanner CAN see your menstrual cup \u2013 here\u2019s what you need to know. https:\/\/mamainstincts.com\/scanner-can-see-menstrual-cup\/. Accessed 13 Feb 2020."},{"key":"141_CR74","first-page":"270","volume":"5","author":"B Cushing","year":"1983","unstructured":"Cushing B. Reponses of polar bears to human menstrual odors. Int Conf Bear Res Manage. 1983;5:270\u20134.","journal-title":"Int Conf Bear Res Manage"},{"issue":"6","key":"141_CR75","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.tmaid.2009.09.002","volume":"7","author":"I Bauer","year":"2009","unstructured":"Bauer I. Relationships between female tourists and male locals in Cuzco\/Peru: implications for travel health education. Travel Med Infect Dis. 2009;7(6):350\u20138. https:\/\/doi.org\/10.1016\/j.tmaid.2009.09.002.","journal-title":"Travel Med Infect Dis"},{"issue":"5","key":"141_CR76","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.tmaid.2008.04.004","volume":"6","author":"D Berger","year":"2008","unstructured":"Berger D, Eames D, Prados-Ruano P. Mental health care of Western expatriates in Tokyo. Travel Med Infect Dis. 2008;6(5):321\u20135. https:\/\/doi.org\/10.1016\/j.tmaid.2008.04.004.","journal-title":"Travel Med Infect Dis"},{"key":"141_CR77","doi-asserted-by":"publisher","first-page":"101455","DOI":"10.1016\/j.tmaid.2019.07.011","volume":"32","author":"I Bauer","year":"2019","unstructured":"Bauer I. Itchy critters: preparing volunteer travellers for head lice infestation. Travel Med Infect Dis. 2019;32:101455. https:\/\/doi.org\/10.1016\/j.tmaid.2019.07.011.","journal-title":"Travel Med Infect Dis"},{"issue":"3","key":"141_CR78","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.tmaid.2004.09.002","volume":"3","author":"T Lankester","year":"2005","unstructured":"Lankester T. Health care of the long-term travellers. Travel Med Infect Dis. 2005;3(3):143\u201355. https:\/\/doi.org\/10.1016\/j.tmaid.2004.09.002.","journal-title":"Travel Med Infect Dis"},{"key":"141_CR79","doi-asserted-by":"publisher","first-page":"e44948","DOI":"10.1371\/journal.pone.0044948","volume":"7","author":"B Lopes Cardozo","year":"2012","unstructured":"Lopes Cardozo B, Gotway Crawford C, Eriksson C, et al. Psychological distress, depression, anxiety, and burnout among international humanitarian aid workers: a longitudinal study. PLoS One. 2012;7:e44948. https:\/\/doi.org\/10.1371\/journal.pone.0044948.","journal-title":"PLoS One"},{"issue":"4","key":"141_CR80","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.tmaid.2007.03.003","volume":"5","author":"R Bor","year":"2007","unstructured":"Bor R. Psychological factors in airline passenger and crew behaviour: a clinical overview. Travel Med Infect Dis. 2007;5(4):207\u201316. https:\/\/doi.org\/10.1016\/j.tmaid.2007.03.003.","journal-title":"Travel Med Infect Dis"},{"issue":"6","key":"141_CR81","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.tmaid.2010.10.001","volume":"8","author":"M Oakes","year":"2010","unstructured":"Oakes M, Bor R. The psychology of fear of flying (part I): a critical evaluation of current perspectives on the nature, prevalence and etiology of fear of flying. Travel Med Infect Dis. 2010;8(6):327\u201338. https:\/\/doi.org\/10.1016\/j.tmaid.2010.10.001.","journal-title":"Travel Med Infect Dis"},{"issue":"6","key":"141_CR82","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.tmaid.2010.10.002","volume":"8","author":"M Oakes","year":"2010","unstructured":"Oakes M, Bor R. The psychology of fear of flying (part II): a critical evaluation of current perspectives on approaches to treatment. Travel Med Infect Dis. 2010;8(6):339\u201363. https:\/\/doi.org\/10.1016\/j.tmaid.2010.10.002.","journal-title":"Travel Med Infect Dis"},{"key":"141_CR83","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.tmaid.2018.02.001","volume":"22","author":"I Bauer","year":"2018","unstructured":"Bauer I. When travel is a challenge: travel medicine and the \u2018dis-abled\u2019 traveler. Travel Med Infect Dis. 2018;22:66\u201372. https:\/\/doi.org\/10.1016\/j.tmaid.2018.02.001.","journal-title":"Travel Med Infect Dis"},{"key":"141_CR84","doi-asserted-by":"publisher","first-page":"taaa013","DOI":"10.1093\/jtm\/taaa013","volume":"27","author":"P Felkai","year":"2020","unstructured":"Felkai P, Marcolongo T, Van Aswegen M. Stranded abroad: a travel medicine approach to psychiatric repatriation. J Travel Med. 2020;27:taaa013. https:\/\/doi.org\/10.1093\/jtm\/taaa013.","journal-title":"J Travel Med"},{"key":"141_CR85","doi-asserted-by":"publisher","first-page":"100613","DOI":"10.1016\/j.tmp.2019.100613","volume":"33","author":"M Mirehie","year":"2020","unstructured":"Mirehie M, Gibson H. The relationship between female snow-sport tourists' travel behaviors and well-being. Tour Manag Perspect. 2020;33:100613. https:\/\/doi.org\/10.1016\/j.tmp.2019.100613.","journal-title":"Tour Manag Perspect"},{"issue":"6","key":"141_CR86","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1037\/0022-3514.58.6.1073","volume":"58","author":"M Levenson","year":"1990","unstructured":"Levenson M. Risk taking and personality. J Pers Soc Psychol. 1990;58(6):1073\u201380. https:\/\/doi.org\/10.1037\/0022-3514.58.6.1073.","journal-title":"J Pers Soc Psychol"},{"issue":"3","key":"141_CR87","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/0047287504272017","volume":"43","author":"Y Reisinger","year":"2005","unstructured":"Reisinger Y, Mavondo F. Travel anxiety and intentions to travel internationally: implications of travel risk perception. J Travel Res. 2005;43(3):212\u201325. https:\/\/doi.org\/10.1177\/0047287504272017.","journal-title":"J Travel Res"},{"issue":"1","key":"141_CR88","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1300\/J073v20n01_02","volume":"20","author":"Y Reisinger","year":"2006","unstructured":"Reisinger Y, Mavondo F. Cultural differences in travel risk perception. J Travel Tour Mark. 2006;20(1):13\u201331. https:\/\/doi.org\/10.1300\/J073v20n01_02.","journal-title":"J Travel Tour Mark"},{"issue":"6","key":"141_CR89","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3727\/108354210X12645141401269","volume":"14","author":"Y Reisinger","year":"2009","unstructured":"Reisinger Y, Crotts J. The influence of gender on travel risk perceptions, safety, and travel intentions. Tour Anal. 2009;14(6):793\u2013807. https:\/\/doi.org\/10.3727\/108354210X12645141401269.","journal-title":"Tour Anal"},{"issue":"4","key":"141_CR90","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1080\/14616688.2018.1545251","volume":"21","author":"D AlSaleh","year":"2019","unstructured":"AlSaleh D, Moufakkir O. An exploratory study of the experience of VFR tourists: a culture shock perspective. Tour Geogr. 2019;21(4):565\u201385. https:\/\/doi.org\/10.1080\/14616688.2018.1545251.","journal-title":"Tour Geogr"},{"key":"141_CR91","doi-asserted-by":"publisher","first-page":"104073","DOI":"10.1016\/j.tourman.2019.104073","volume":"78","author":"O Moufakkir","year":"2020","unstructured":"Moufakkir O. Experience of Arab\/Muslim women visiting relatives in the west and the management of stigma by association. Tour Manag. 2020;78:104073. https:\/\/doi.org\/10.1016\/j.tourman.2019.104073.","journal-title":"Tour Manag"},{"key":"141_CR92","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j\/annals.2015.04.004","volume":"53","author":"O Moufakkir","year":"2015","unstructured":"Moufakkir O. The stigmatized tourist. Ann Tour Res. 2015;53:17\u201330. https:\/\/doi.org\/10.1016\/j\/annals.2015.04.004.","journal-title":"Ann Tour Res"},{"issue":"4","key":"141_CR93","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/jtm.12202","volume":"22","author":"V Choovichian","year":"2015","unstructured":"Choovichian V, Chatapat L, Piyaphanee W. A bubble turtle: bullous contact dermatitis after a black henna tattoo in a backpacker in Thailand. J Travel Med. 2015;22(4):287\u20138. https:\/\/doi.org\/10.1111\/jtm.12202.","journal-title":"J Travel Med"},{"key":"141_CR94","doi-asserted-by":"publisher","first-page":"528.e1","DOI":"10.1016\/j.ajog.2014.01.036","volume":"210","author":"A DeMaria","year":"2014","unstructured":"DeMaria A, Flores M, Hirth J, Rerenson A. Complications related to pubic hair removal. Am J Obstet Gynecol. 2014;210:528.e1\u20135. https:\/\/doi.org\/10.1016\/j.ajog.2014.01.036.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"141_CR95","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/sextrans-2012-050982","volume":"89","author":"F Desruelles","year":"2013","unstructured":"Desruelles F, Cunningham S, Dubois D. Pubic hair removal: a risk factor for \u2018minor\u2019 STI such as molluscum contagiosum? Sex Transm Infect. 2013;89(3):216. https:\/\/doi.org\/10.1136\/sextrans-2012-050982.","journal-title":"Sex Transm Infect"},{"issue":"6","key":"141_CR96","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.ajog.2014.07.063","volume":"211","author":"L Baxi","year":"2014","unstructured":"Baxi L, Dziadosz M. Complications following \u201cBrazilian\u201d waxing for pubic hair removal. Am J Obstet Gynecol. 2014;211(6):713\u20134. https:\/\/doi.org\/10.1016\/j.ajog.2014.07.063.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"141_CR97","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/sextrans-2016-052687","volume":"93","author":"E Osterberg","year":"2017","unstructured":"Osterberg E, Gaither T, Awad M, et al. Correlation between pubic hair grooming and STIs: results from a nationally representative probability sample. Sex Transm Infect. 2017;93(3):162\u20136. https:\/\/doi.org\/10.1136\/sextrans-2016-052687.","journal-title":"Sex Transm Infect"},{"issue":"1","key":"141_CR98","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/0956462417740292","volume":"29","author":"S Veraldi","year":"2018","unstructured":"Veraldi S, Schianchi R, Ramoni S, Nazzaro G. Pubic hair removal and Phthirus pubis infestation. Int J STD AIDS. 2018;29(1):103\u20134. https:\/\/doi.org\/10.1177\/0956462417740292.","journal-title":"Int J STD AIDS"},{"key":"141_CR99","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.tmaid.2018.01.002","volume":"21","author":"I Bauer","year":"2018","unstructured":"Bauer I. Ayahuasca: a risk for travellers? Travel Med Infect Dis. 2018;21:74\u20136. https:\/\/doi.org\/10.1016\/j.tmaid.2018.01.002.","journal-title":"Travel Med Infect Dis"},{"issue":"6","key":"141_CR100","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.tmaid.2015.11.001","volume":"13","author":"M Callaghan","year":"2015","unstructured":"Callaghan M. A drink to die for: arak and methanol poisoning in Indonesia. Travel Med Infect Dis. 2015;13(6):507\u20138. https:\/\/doi.org\/10.1016\/j.tmaid.2015.11.001.","journal-title":"Travel Med Infect Dis"},{"issue":"3","key":"141_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1468797620930036","volume":"20","author":"L Brown","year":"2020","unstructured":"Brown L, de Coteau D, Lavrushkina N. Taking a walk: the female tourist experience. Tour Stud. 2020;20(3):1\u201317. https:\/\/doi.org\/10.1177\/1468797620930036.","journal-title":"Tour Stud"},{"key":"141_CR102","volume-title":"Wayward women","author":"J Robinson","year":"1990","unstructured":"Robinson J. Wayward women. Oxford: Oxford University Press; 1990."},{"issue":"2\/3","key":"141_CR103","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1023\/A:1010652521379","volume":"22","author":"A Barton","year":"2000","unstructured":"Barton A. \u2018Wayward girls and wicked women\u2019: two centuries of \u2018semi-penal\u2019 control. Liverpool Law Rev. 2000;22(2\/3):157\u201371. https:\/\/doi.org\/10.1023\/A:1010652521379.","journal-title":"Liverpool Law Rev"},{"issue":"3","key":"141_CR104","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1177\/1468797618771691","volume":"18","author":"T Weatherby","year":"2018","unstructured":"Weatherby T, Vidon E. Delegitimizing wilderness as the man cave: the role of social media in female wilderness empowerment. Tour Stud. 2018;18(3):332\u201352. https:\/\/doi.org\/10.1177\/1468797618771691.","journal-title":"Tour Stud"},{"issue":"3","key":"141_CR105","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3727\/109830414X13911221027443","volume":"13","author":"B Heimtun","year":"2013","unstructured":"Heimtun B, Abelsen B. Singles and solo travel: gender and type of holiday. Tour Cult Comm. 2013;13(3):161\u201374. https:\/\/doi.org\/10.3727\/109830414X13911221027443.","journal-title":"Tour Cult Comm"},{"issue":"2","key":"141_CR106","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2167\/cit342.0","volume":"11","author":"E Wilson","year":"2008","unstructured":"Wilson E, Little D. The solo female travel experience: exploring the \u2018geography of women's fear\u2019. Curr Issue Tour. 2008;11(2):167\u201386. https:\/\/doi.org\/10.2167\/cit342.0.","journal-title":"Curr Issue Tour"},{"issue":"2","key":"141_CR107","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1177\/1468797619878307","volume":"20","author":"H Osman","year":"2019","unstructured":"Osman H, Brown L, Phung T. The travel motivations and experiences of female Vietnamese solo travelers. Tour Stud. 2019;20(2):248\u201367. https:\/\/doi.org\/10.1177\/1468797619878307.","journal-title":"Tour Stud"},{"key":"141_CR108","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.tourman.2018.02.017","volume":"68","author":"E Yang","year":"2018","unstructured":"Yang E, Khoo-Lattimore C, Arcodia C. Power and empowerment: how Asian solo female travellers perceive and negotiate risks. Tour Manag. 2018;68:32\u201345. https:\/\/doi.org\/10.1016\/j.tourman.2018.02.017.","journal-title":"Tour Manag"},{"issue":"1","key":"141_CR109","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1093\/trstmh\/try107","volume":"21","author":"D Seow","year":"2018","unstructured":"Seow D, Brown L. The solo female Asian tourist. Curr Issue Tour. 2018;21(1):1187\u2013206. https:\/\/doi.org\/10.1093\/trstmh\/try107.","journal-title":"Curr Issue Tour"},{"issue":"3","key":"141_CR110","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/1467358417751025","volume":"12","author":"M Khan","year":"2019","unstructured":"Khan M, Chelliah S, Ahmed S. Intention to visit India among potential travellers: role of travel motivation, perceived travel risks, and travel constraints. Tour Hosp Res. 2019;12(3):351\u201367. https:\/\/doi.org\/10.1177\/1467358417751025.","journal-title":"Tour Hosp Res"},{"issue":"1","key":"141_CR111","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/02508281.2018.1494872","volume":"44","author":"T Thomas","year":"2019","unstructured":"Thomas T, Mura P. The \u2018normality of unsafety\u2019- foreign solo female travellers in India. Tour Recreat Res. 2019;44(1):33\u201340. https:\/\/doi.org\/10.1080\/02508281.2018.1494872.","journal-title":"Tour Recreat Res"},{"issue":"9929","key":"141_CR112","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1016\/S0140-6736(13)62243-6","volume":"383","author":"N Abrahams","year":"2014","unstructured":"Abrahams N, Devries K, Watts C, Pallitto C, Petzold M, Shamu S, et al. Worldwide prevalence of non-partner sexual violence: a systematic review. Lancet. 2014;383(9929):1648\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(13)62243-6.","journal-title":"Lancet"},{"issue":"4","key":"141_CR113","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10508-012-9979-6","volume":"42","author":"A Calafat","year":"2013","unstructured":"Calafat A, Hughes K, Blay N, Bellis MA, Mendes F, Juan M, et al. Sexual harassment among young tourists visiting Mediterranean resorts. Arch Sex Behav. 2013;42(4):603\u201312. https:\/\/doi.org\/10.1007\/s10508-012-9979-6.","journal-title":"Arch Sex Behav"},{"key":"141_CR114","doi-asserted-by":"publisher","unstructured":"Deliv C, Flaherty G. Risk of in-flight sexual assaults: time to wake up? J Travel Med. 2020:taaa026. https:\/\/doi.org\/10.1093\/jtm\/taaa026.","DOI":"10.1093\/jtm\/taaa026"},{"issue":"2","key":"141_CR115","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/inthealth\/ihz033","volume":"12","author":"S Tardivo","year":"2020","unstructured":"Tardivo S, Zenere A, Moretti F, Marchiori F, Berti D, Migliorini M, et al. The Traveller\u2019s Risk Perception (TRiP) questionnaire: pre-travel assessment and post-travel changes. Int Health. 2020;12(2):116\u201324. https:\/\/doi.org\/10.1093\/inthealth\/ihz033.","journal-title":"Int Health"},{"key":"141_CR116","doi-asserted-by":"publisher","first-page":"tay064","DOI":"10.1093\/jtm\/tay064","volume":"25","author":"A Farnham","year":"2018","unstructured":"Farnham A, Ziegler S, Blanke U, et al. Does the DOSPERT scale predict risk-taking behaviour during travel? A study using smartphones. J Travel Med. 2018;25:tay064. https:\/\/doi.org\/10.1093\/jtm\/tay064.","journal-title":"J Travel Med"},{"issue":"3","key":"141_CR117","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1057\/s41284-019-00166-w","volume":"32","author":"T Sorell","year":"2019","unstructured":"Sorell T, Whitty M. Online romance scams and victimhood. Security J. 2019;32(3):342\u201361. https:\/\/doi.org\/10.1057\/s41284-019-00166-w.","journal-title":"Security J"},{"issue":"4","key":"141_CR118","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1057\/sj.2012.57","volume":"28","author":"M Whitty","year":"2015","unstructured":"Whitty M. Anatomy of the online dating romance scam. Security J. 2015;28(4):443\u201355. https:\/\/doi.org\/10.1057\/sj.2012.57.","journal-title":"Security J"},{"issue":"2","key":"141_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1748895815603773","volume":"16","author":"M Whitty","year":"2015","unstructured":"Whitty M, Buchanan T. The online dating romance scam: the psychological impact on victims \u2013 both financial and non-financial. Criminol Crim Just. 2015;16(2):1\u20139. https:\/\/doi.org\/10.1177\/1748895815603773.","journal-title":"Criminol Crim Just"},{"issue":"1","key":"141_CR120","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.fsigss.2019.10.029","volume":"7","author":"M Bu\u015b","year":"2019","unstructured":"Bu\u015b M, Schellberg T, Budowle B. Human trafficking \u2013 multinational challenge for forensic science. Forensic Sci Int-Gen. 2019;7(1):403\u20135. https:\/\/doi.org\/10.1016\/j.fsigss.2019.10.029.","journal-title":"Forensic Sci Int-Gen"},{"issue":"2","key":"141_CR121","doi-asserted-by":"publisher","first-page":"117021","DOI":"10.1097\/JFN.0000000000000203","volume":"14","author":"M Scannell","year":"2018","unstructured":"Scannell M, MacDonald A, Berger A, Boyer N. Human trafficking: how nurses can make a difference. J Forensic Nurs. 2018;14(2):117021\u2013121. https:\/\/doi.org\/10.1097\/JFN.0000000000000203.","journal-title":"J Forensic Nurs"},{"key":"141_CR122","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejpoleco.2015.02.002","volume":"38","author":"D Hernandez","year":"2015","unstructured":"Hernandez D, Rudolph A. Modern day slavery: what drives human trafficking in Europe? Eur J Polit Econ. 2015;38:118\u201339. https:\/\/doi.org\/10.1016\/j.ejpoleco.2015.02.002.","journal-title":"Eur J Polit Econ"},{"issue":"1","key":"141_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-018-2570-4","volume":"11","author":"M McCauley","year":"2019","unstructured":"McCauley M, van den Broek N. Challenges in the eradication of female genital mutilation\/cutting. Int Health. 2019;11(1):1\u20134. https:\/\/doi.org\/10.1186\/s12936-018-2570-4.","journal-title":"Int Health"},{"issue":"3","key":"141_CR124","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1093\/pubmed\/fdy128","volume":"41","author":"E Plugge","year":"2019","unstructured":"Plugge E, Adam S, El Hindi L, et al. The prevention of female genital mutilation in England: what can be done? J Public Health. 2019;41(3):e261\u20136. https:\/\/doi.org\/10.1093\/pubmed\/fdy128.","journal-title":"J Public Health"},{"issue":"1","key":"141_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jtm\/tax090","volume":"25","author":"C Tantet","year":"2018","unstructured":"Tantet C, Aupiais C, Bourdon M, Sorge F, Pag\u00e8s A, Levy D, et al. Female genital mutilation: an evaluation of the knowledge of French general and specialized travel medicine practitioners. J Travel Med. 2018;25(1):1\u20133. https:\/\/doi.org\/10.1093\/jtm\/tax090.","journal-title":"J Travel Med"},{"key":"141_CR126","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.tmaid.2017.08.007","volume":"18","author":"J Chiodini","year":"2017","unstructured":"Chiodini J. Female genital mutilation, \"vacation cutting\" and the travel medicine consultation. Travel Med Infect Dis. 2017;18:87\u201391. https:\/\/doi.org\/10.1016\/j.tmaid.2017.08.007.","journal-title":"Travel Med Infect Dis"},{"key":"141_CR127","unstructured":"RCPSG. Travel Medicine Updates: Ten years gone, and female genital mutilation. https:\/\/rcpsg.ac.uk\/elearning\/product\/ten-years-gone-and-female-genital-mutilation. Accessed 3.5.2020."},{"issue":"6","key":"141_CR128","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/jtm.12229","volume":"22","author":"A Heywood","year":"2015","unstructured":"Heywood A, Forssman B, Seale H, et al. General practitioners' perception of risk for travelers visiting friends and relatives. J Travel Med. 2015;22(6):368\u201374. https:\/\/doi.org\/10.1111\/jtm.12229.","journal-title":"J Travel Med"},{"key":"141_CR129","volume-title":"Sustainable development goals","author":"United Nations","year":"2015","unstructured":"United Nations. Sustainable development goals. 2015. https:\/\/sustainabledevelopment.un.org\/?menu=1300. Accessed 6.2.2019."},{"key":"141_CR130","unstructured":"United Nations. The Sustainable Development Goals Report 2019. New York: United Nations. https:\/\/unstats.un.org\/sdgs\/report\/2019\/The-Sustainable-Development-Goals-Report-2019.pdf. Accessed 13 Nov 2019."},{"issue":"1","key":"141_CR131","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/17441692.2015.1094109","volume":"12","author":"I Bauer","year":"2017","unstructured":"Bauer I. Improving global health \u2013 is tourism\u2019s role in poverty elimination perpetuating poverty, powerlessness and \u2018ill-being\u2019? Glob Public Health. 2017;12(1):45\u201364. https:\/\/doi.org\/10.1080\/17441692.2015.1094109.","journal-title":"Glob Public Health"},{"key":"141_CR132","unstructured":"One Health Initiative. (n.d.).Retrieved from http:\/\/www.onehealthinitiative.com\/mission.php. Accessed 3 Mar 2020."},{"issue":"2","key":"141_CR133","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/14724049.2016.1206551","volume":"16","author":"I Bauer","year":"2017","unstructured":"Bauer I. The plight of the cute little lambs: travel medicine\u2019s role in animal welfare. J Ecotour. 2017;16(2):95\u2013111. https:\/\/doi.org\/10.1080\/14724049.2016.1206551.","journal-title":"J Ecotour"},{"issue":"5","key":"141_CR134","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.tmaid.2008.05.005","volume":"6","author":"I Bauer","year":"2008","unstructured":"Bauer I. The health impact of tourism on local and indigenous populations in resource-poor countries. Travel Med Infect Dis. 2008;6(5):276\u201391. https:\/\/doi.org\/10.1016\/j.tmaid.2008.05.005.","journal-title":"Travel Med Infect Dis"},{"issue":"2","key":"141_CR135","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/1467358419848139","volume":"20","author":"S Amaro","year":"2019","unstructured":"Amaro S, Morgado Ferreira B, Henriques C. Towards a deeper understanding of the purchase of souvenirs. Tour Hosp Res. 2019;20(2):223\u201336. https:\/\/doi.org\/10.1177\/1467358419848139.","journal-title":"Tour Hosp Res"},{"key":"141_CR136","doi-asserted-by":"publisher","first-page":"104069","DOI":"10.1016\/j.tourman.2019.104069","volume":"78","author":"M Alrwajfah","year":"2020","unstructured":"Alrwajfah M, Almeida-Garc\u00eda F, Cort\u00e9s-Mac\u00edas R. Females' perspectives on tourism's impact and their employment in the sector: the case of Petra, Jordan. Tour Manag. 2020;78:104069. https:\/\/doi.org\/10.1016\/j.tourman.2019.104069.","journal-title":"Tour Manag"},{"issue":"4","key":"141_CR137","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1177\/1467358418768661","volume":"19","author":"W Hillman","year":"2019","unstructured":"Hillman W. \u2018Risky business\u2019: the future for female trekking guides in Nepal. Tour Hosp Res. 2019;19(4):397\u2013407. https:\/\/doi.org\/10.1177\/1467358418768661.","journal-title":"Tour Hosp Res"},{"key":"141_CR138","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.annals.2016.08.002","volume":"61","author":"D Fan","year":"2016","unstructured":"Fan D, Zhang H, Jenkins C, Lin P. Does social contact lessen perceived cultural distance? Evidence from tourist-host social contact. Ann Tour Res. 2016;61:223\u20135. https:\/\/doi.org\/10.1016\/j.annals.2016.08.002.","journal-title":"Ann Tour Res"},{"issue":"3","key":"141_CR139","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/trstmh\/try123","volume":"113","author":"M Traugott","year":"2018","unstructured":"Traugott M, Singh M, Raj D, Kutalek R. Geophagy in India: a qualitative exploratory study on motivation and perception of female consumers. Trans R Soc Trop Med Hyg. 2018;113(3):123\u201330. https:\/\/doi.org\/10.1093\/trstmh\/try123.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"6","key":"141_CR140","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/13691050802155376","volume":"10","author":"I Bauer","year":"2008","unstructured":"Bauer I. 'They don't just come for Machu Picchu': locals' views of tourist-local sexual relationships in Cuzco, Peru. Cult Health Sex. 2008;10(6):611\u201324. https:\/\/doi.org\/10.1080\/13691050802155376.","journal-title":"Cult Health Sex"},{"issue":"2","key":"141_CR141","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2310\/7060.2003.31654","volume":"10","author":"I Bauer","year":"2003","unstructured":"Bauer I. Inca Trail porters: the health of local tourism employees as a challenge for travel medicine. J Travel Med. 2003;10(2):94\u20139. https:\/\/doi.org\/10.2310\/7060.2003.31654.","journal-title":"J Travel Med"},{"key":"141_CR142","unstructured":"Malm S. Youths are boiling sanitary pads to get high in Indonesia... creating hallucinogenic drink that makes them feel as if they are flying, officials warn Some Indonesian teens are drinking water boiled with used menstrual pads to get high \u2013 here\u2019s what it does to the body. 2018. https:\/\/www.dailymail.co.uk\/news\/article-6388633\/Indonesian-teenagers-boiling-sanitary-pads-high-officials-warn.html. Accessed 10 Nov 2020."},{"key":"141_CR143","volume-title":"Teenagers in Indonesia are reportedly boiling menstrual pads to get high","author":"E Webster","year":"2018","unstructured":"Webster E. Teenagers in Indonesia are reportedly boiling menstrual pads to get high. 2018. https:\/\/www.teenvogue.com\/story\/teenagers-in-indonesia-are-reportedly-boiling-menstrual-pads-to-get-high. Accessed 13 Nov 2020."},{"issue":"8","key":"141_CR144","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/S2468-2667(19)30126-4","volume":"4","author":"J Hennegan","year":"2019","unstructured":"Hennegan J. Inserting informed choice into global menstrual product use and provision. Lancet Public Health. 2019;4(8):e361\u20132. https:\/\/doi.org\/10.1016\/S2468-2667(19)30126-4.","journal-title":"Lancet Public Health"},{"issue":"7","key":"141_CR145","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.2105\/AJPH.2014.302525","volume":"105","author":"M Sommer","year":"2015","unstructured":"Sommer M, Hirsch J, Nathanson C, Parker R. Comfortably, safely, and without shame: defining menstrual hygiene management as a public health issue. Am J Public Health. 2015;105(7):1302\u201311. https:\/\/doi.org\/10.2105\/AJPH.2014.302525.","journal-title":"Am J Public Health"},{"key":"141_CR146","unstructured":"28 May - Menstrual Hygiene Day https:\/\/menstrualhygieneday.org\/. Accessed 31 May 2020."},{"key":"141_CR147","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/pubmed\/fdaa192","volume":"fdaa192","author":"S Mehta","year":"2020","unstructured":"Mehta S, Grover A, Mittal N, Nanda P, Khatuja R, et al. Reusable sanitary napkins\u2014time to revisit. J Public Health. 2020;fdaa192:1\u20137. https:\/\/doi.org\/10.1093\/pubmed\/fdaa192.","journal-title":"J Public Health"},{"key":"141_CR148","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/jtr.741","volume":"12","author":"H Zamani-Farahani","year":"2010","unstructured":"Zamani-Farahani H, Henderson J. Islamic tourism and managing tourism development in Islamic societies: the cases of Iran and Saudi Arabia. Int J Tour Res. 2010;12:79\u201389. https:\/\/doi.org\/10.1002\/jtr.741.","journal-title":"Int J Tour Res"},{"key":"141_CR149","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.tourman.2019.05.010","volume":"75","author":"M Sobhy Temerak","year":"2019","unstructured":"Sobhy Temerak M. Bikini or burkini? The role of swimwear and age as determinants of beach interaction with others. Tour Manag. 2019;75:269\u201383. https:\/\/doi.org\/10.1016\/j.tourman.2019.05.010.","journal-title":"Tour Manag"},{"key":"141_CR150","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.annals.2016.12.005","volume":"63","author":"L Brown","year":"2017","unstructured":"Brown L, Osman H. The female tourist experience in Egypt as an Islamic destination. Ann Tour Res. 2017;63:12\u201322. https:\/\/doi.org\/10.1016\/j.annals.2016.12.005.","journal-title":"Ann Tour Res"},{"issue":"1","key":"141_CR151","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2310\/7060.2005.00008","volume":"12","author":"I Bauer","year":"2005","unstructured":"Bauer I. Educational issues and concerns in travel health advice: is all the effort a waste of time? J Travel Med. 2005;12(1):45\u201352. https:\/\/doi.org\/10.2310\/7060.2005.00008.","journal-title":"J Travel Med"},{"issue":"3","key":"141_CR152","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/pubmed\/fdy113","volume":"41","author":"R Brown","year":"2019","unstructured":"Brown R, Maslen H, Savulescu J. Responsibility, prudence and health promotion. J Public Health (Oxf). 2019;41(3):561\u20135. https:\/\/doi.org\/10.1093\/pubmed\/fdy113.","journal-title":"J Public Health (Oxf)"},{"issue":"4","key":"141_CR153","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1177\/0047287519851171","volume":"59","author":"P Passafaro","year":"2019","unstructured":"Passafaro P. Attitudes and tourists\u2019 sustainable behavior: an overview of the literature and discussion of some theoretical and methodological issues. J Travel Res. 2019;59(4):579\u2013601. https:\/\/doi.org\/10.1177\/0047287519851171.","journal-title":"J Travel Res"},{"key":"141_CR154","doi-asserted-by":"publisher","unstructured":"Le\u00f3n C, Ara\u00f1a J. Tourist sustainable behaviour and personal communication. Ann Tour Res. 2020:102897. https:\/\/doi.org\/10.1016\/j.annals.2020.102897.","DOI":"10.1016\/j.annals.2020.102897"},{"key":"141_CR155","doi-asserted-by":"publisher","first-page":"67097","DOI":"10.1016\/j.tourman.2017.08.005","volume":"64","author":"H Han","year":"2018","unstructured":"Han H, Hyun S. What influences water conservation and towel reuse practices of hotel guests? Tour Manag. 2018;64:67097. https:\/\/doi.org\/10.1016\/j.tourman.2017.08.005.","journal-title":"Tour Manag"},{"key":"141_CR156","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/jtm.12197","volume":"22","author":"I Bauer","year":"2015","unstructured":"Bauer I. Looking over the fence \u2013 how travel medicine can benefit from tourism research. J Travel Med. 2015;22:206\u20137. https:\/\/doi.org\/10.1111\/jtm.12197.","journal-title":"J Travel Med"},{"key":"141_CR157","doi-asserted-by":"publisher","first-page":"taw056","DOI":"10.1093\/jtm\/taw056","volume":"23","author":"A Farnham","year":"2016","unstructured":"Farnham A, Blanke U, Stone E, et al. Travel medicine and mHealth technology: a study using smartphones to collect health data during travel. J Travel Med. 2016;23:taw056. https:\/\/doi.org\/10.1093\/jtm\/taw056.","journal-title":"J Travel Med"},{"key":"141_CR158","doi-asserted-by":"publisher","first-page":"101912","DOI":"10.1016\/j.tmaid.2020.101912","volume":"39","author":"V Baroutsou","year":"2020","unstructured":"Baroutsou V, Hatz C, Blanke U, Haile S, Fehr J, Neumayr A, et al. TOURIST2 \u2013 Tracking of urgent risks in Swiss travellers to the 6 main travel destinations \u2013 feasibility and ethical considerations of a smartphone application-based study. Travel Med Infect Dis. 2020;39:101912. https:\/\/doi.org\/10.1016\/j.tmaid.2020.101912.","journal-title":"Travel Med Infect Dis"}],"container-title":["Tropical Diseases, Travel Medicine and Vaccines"],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40794-021-00141-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40794-021-00141-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40794-021-00141-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T20:06:38Z","timestamp":1622923598000},"score":18.879316,"resource":{"primary":{"URL":"https:\/\/tdtmvjournal.biomedcentral.com\/articles\/10.1186\/s40794-021-00141-7"}},"issued":{"date-parts":[[2021,6,5]]},"references-count":158,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["141"],"URL":"https:\/\/doi.org\/10.1186\/s40794-021-00141-7","ISSN":["2055-0936"],"issn-type":[{"value":"2055-0936","type":"electronic"}],"published":{"date-parts":[[2021,6,5]]},"assertion":[{"value":"4 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"},{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T17:00:30Z","timestamp":1648659630052},"reference-count":0,"publisher":"OMICS Publishing Group","issue":"S1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Vaccines Vaccin"],"published-print":{"date-parts":[[2012]]},"DOI":"10.4172\/2157-7560.s1.007","type":"journal-article","created":{"date-parts":[[2012,9,4]],"date-time":"2012-09-04T12:52:30Z","timestamp":1346763150000},"source":"Crossref","is-referenced-by-count":0,"title":["Nutritive components as safe immune-enhancers in novel and existing vaccine delivery systems"],"prefix":"10.4172","volume":"01","author":[{"given":"Michael","family":"Vajdy","sequence":"first","affiliation":[]}],"member":"2674","container-title":["Journal of Vaccines &amp; Vaccination"],"deposited":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T18:35:55Z","timestamp":1492108555000},"score":18.879316,"resource":{"primary":{"URL":"https:\/\/www.omicsonline.org\/2157-7560\/2157-7560-Vaccines-2012_Track_3ii_3iii_3iv_3v.digital\/2157-7560-Vaccines-2012_Track_3ii_3iii_3iv_3v.html"}},"issued":{"date-parts":[[2012]]},"references-count":0,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.4172\/2157-7560.s1.007","ISSN":["2157-7560"],"issn-type":[{"value":"2157-7560","type":"electronic"}],"published":{"date-parts":[[2012]]}},{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T20:36:37Z","timestamp":1649104597433},"reference-count":0,"publisher":"Springer Science and Business Media LLC","issue":"982","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reactions Weekly"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.2165\/00128415-200309820-00005","type":"journal-article","created":{"date-parts":[[2006,1,26]],"date-time":"2006-01-26T05:07:10Z","timestamp":1138252030000},"page":"3","source":"Crossref","is-referenced-by-count":0,"title":["Vaccines: additives and preservatives 'safe'"],"prefix":"10.1007","volume":"&NA;","author":[{"family":"&NA;","sequence":"first","affiliation":[]}],"member":"297","container-title":["Reactions Weekly"],"language":"en","deposited":{"date-parts":[[2013,3,2]],"date-time":"2013-03-02T10:51:39Z","timestamp":1362221499000},"score":18.846283,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2165\/00128415-200309820-00005"}},"subtitle":[""],"issued":{"date-parts":[[2003,12]]},"references-count":0,"journal-issue":{"issue":"982"},"URL":"https:\/\/doi.org\/10.2165\/00128415-200309820-00005","ISSN":["0114-9954"],"issn-type":[{"value":"0114-9954","type":"print"}],"published":{"date-parts":[[2003,12]]}},{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T09:17:48Z","timestamp":1649150268470},"reference-count":2,"publisher":"Springer Science and Business Media LLC","issue":"1367","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Inpharma Weekly"],"published-print":{"date-parts":[[2002,12]]},"DOI":"10.2165\/00128413-200213670-00046","type":"journal-article","created":{"date-parts":[[2006,1,23]],"date-time":"2006-01-23T00:09:49Z","timestamp":1137974989000},"page":"21","source":"Crossref","is-referenced-by-count":0,"title":["Thiomersal 'safe' in childhood vaccines"],"prefix":"10.1007","volume":"&NA;","author":[{"family":"&NA;","sequence":"first","affiliation":[]}],"member":"297","reference":[{"key":"R1-46","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0140-6736(02)11682-5","volume":"360","author":"Pichichero","year":"2002","journal-title":"Lancet"},{"key":"R2-46","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(02)11723-5","volume":"360","author":"Henderson","year":"2002","journal-title":"Lancet"}],"container-title":["Inpharma Weekly"],"language":"en","deposited":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T15:47:21Z","timestamp":1553183241000},"score":18.846283,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2165\/00128413-200213670-00046"}},"subtitle":[""],"issued":{"date-parts":[[2002,12]]},"references-count":2,"journal-issue":{"issue":"1367"},"URL":"https:\/\/doi.org\/10.2165\/00128413-200213670-00046","ISSN":["1173-8324"],"issn-type":[{"value":"1173-8324","type":"print"}],"published":{"date-parts":[[2002,12]]}},{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T13:19:15Z","timestamp":1648819155626},"reference-count":2,"publisher":"Springer Science and Business Media LLC","issue":"931","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reactions Weekly"],"published-print":{"date-parts":[[2002,12]]},"DOI":"10.2165\/00128415-200209310-00006","type":"journal-article","created":{"date-parts":[[2006,1,26]],"date-time":"2006-01-26T05:15:59Z","timestamp":1138252559000},"page":"5","source":"Crossref","is-referenced-by-count":0,"title":["Thiomersal 'safe' in childhood vaccines"],"prefix":"10.1007","volume":"&NA;","author":[{"family":"&NA;","sequence":"first","affiliation":[]}],"member":"297","reference":[{"key":"R1-6-3309","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0140-6736(02)11682-5","volume":"360","author":"Pichichero","year":"2002","journal-title":"Lancet"},{"key":"R2-6-3309","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(02)11723-5","volume":"360","author":"Henderson","year":"2002","journal-title":"Lancet"}],"container-title":["Reactions Weekly"],"language":"en","deposited":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T22:46:17Z","timestamp":1553208377000},"score":18.835648,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2165\/00128415-200209310-00006"}},"subtitle":[""],"issued":{"date-parts":[[2002,12]]},"references-count":2,"journal-issue":{"issue":"931"},"URL":"https:\/\/doi.org\/10.2165\/00128415-200209310-00006","ISSN":["0114-9954"],"issn-type":[{"value":"0114-9954","type":"print"}],"published":{"date-parts":[[2002,12]]}},{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T17:45:13Z","timestamp":1694627113702},"reference-count":0,"publisher":"Springer Science and Business Media LLC","issue":"5067","license":[{"start":{"date-parts":[[1966,12,1]],"date-time":"1966-12-01T00:00:00Z","timestamp":-97372800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[1966,12]]},"DOI":"10.1038\/2121177b0","type":"journal-article","created":{"date-parts":[[2006,7,6]],"date-time":"2006-07-06T02:43:39Z","timestamp":1152153819000},"page":"1177-1178","source":"Crossref","is-referenced-by-count":0,"title":["Cells for Safe Vaccines"],"prefix":"10.1038","volume":"212","member":"297","published-online":{"date-parts":[[1966,12,1]]},"container-title":["Nature"],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/2121177b0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/2121177b0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/2121177b0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T18:57:33Z","timestamp":1638385053000},"score":18.824217,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2121177b0"}},"issued":{"date-parts":[[1966,12]]},"references-count":0,"journal-issue":{"issue":"5067","published-print":{"date-parts":[[1966,12]]}},"alternative-id":["BF2121177b0"],"URL":"https:\/\/doi.org\/10.1038\/2121177b0","ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"published":{"date-parts":[[1966,12]]}},{"indexed":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:46:23Z","timestamp":1732034783428},"reference-count":52,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.4161\/hv.27449","type":"journal-article","created":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T11:58:59Z","timestamp":1387281539000},"page":"797-807","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":111,"title":["Chitosan"],"prefix":"10.1080","volume":"10","author":[{"given":"Alan","family":"Smith","sequence":"first","affiliation":[]},{"given":"Michael","family":"Perelman","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Hinchcliffe","sequence":"additional","affiliation":[]}],"member":"301","published-online":{"date-parts":[[2013,12,17]]},"reference":[{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(00)00120-5"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2011.12.039"},{"key":"R4","unstructured":"ASDReports. Stakeholder opinions: vaccine administration technologies\u2013beyond needles. Report code: ASDR\u20101755. 2009. Published by Datamonitor Healthcare."},{"key":"R5","first-page":"808","volume":"77","author":"Miller MA","year":"1999","journal-title":"Bull World Health Organ"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2012.697455"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.3109\/1061186X.2010.523790"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"O'Hagan DT. New generation vaccine adjuvants. In: Encyclopedia of Life Sciences (eLS): John Wiley & Sons Ltd, 2007:[doi: 10.1002\/9780470015902.a0020177].","DOI":"10.1002\/9780470015902.a0020177"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(93)90190-9"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2008.09.006"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.7774\/cevr.2012.1.1.50"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00155-X"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.9.4778"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030595"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.10.4962-4970.2006"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.4161\/hv.19568"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2009.11.009"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.01.024"},{"key":"R22","unstructured":"Dornish M, Hagen A, Hansson E, Pecheur C, Verdier F, Skaugrud \u00d8. Safety of Protasan\u2122: ultrapure chitosan salts for biomedical and pharmaceutical use. In: Domard A, Roberts GAF, V\u00e5rum KM, eds. Advances in Chitin Science, Vol II, Andre Publisher, Lyon, France, 1997: 664-670."},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1101245"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1213\/ane.0b013e318187b952"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1086\/657087"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.2.726-732.2003"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.04.021"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00894.x"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2007.00300.x"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Br\u00fcck WM, Slater JW, Carney BF. Chitin and chitosan from marine organisms. In: Kim S.K, ed. Chitin, Chitosan, Oligosaccharides and Their Derivatives, CRC Press New York, 2011:11-23.","DOI":"10.1201\/EBK1439816035-c2"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Knezevic-Jugovic Z, Petronijevic Z, Smelcerovic A. Chitin and chitosan from microorganisms. In: Kim S.K, ed. Chitin, Chitosan, Oligosaccharides and Their Derivatives, CRC Press New York, 2011:25-36.","DOI":"10.1201\/EBK1439816035-c3"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Nwe N, Furuike T, Tamura H. Chitin and chitosan from terrestrial organisms. In: Kim S.K, ed. Chitin, Chitosan, Oligosaccharides and Their Derivatives, CRC Press New York, 2011:3-10.","DOI":"10.1201\/EBK1439816035-c1"},{"key":"R37","unstructured":"Rinaudo M, Domard A. Solution properties of chitosan. In: Skjak-Br\u00e6k G, Anthonsen T, Sandford P eds. Chitin and Chitosan, Sources, Chemistry, Biochemistry, Physical Properties and Applications: Elsevier, 1989:71-86."},{"key":"R38","doi-asserted-by":"crossref","unstructured":"Roberts GAF. Chitin Chemistry: The Macmillan Press Ltd, London, 1992.","DOI":"10.1007\/978-1-349-11545-7"},{"key":"R39","unstructured":"Harding S. Characterisation of chitosan-mucin complexes by sedimentation velocity analytical ultracentrifugation. In: Muzzarelli RAA, Peter MG eds. Chitin Handbook. European Chitin Society, 1997:457-466."},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1080\/02648725.2010.10648153"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.1586\/erv.09.47"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2009.09.015"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2009.09.004"},{"key":"R44","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/jn\/119.8.1100","volume":"119","author":"Ebihara K","year":"1989","journal-title":"J Nutr"},{"key":"R45","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(98)00045-8"},{"key":"R46","doi-asserted-by":"crossref","unstructured":"Furda I. Chitin and chitosan \u2013 a special class of dietary fiber. In: Spiller GA, ed. CRC Handbook of Dietary Fiber in Human Nutrition, Third Edition, CRC Press, 2001:45\u201347.","DOI":"10.1201\/9781420038514.ch2.8"},{"key":"R47","first-page":"89","volume":"56","author":"Arai K","year":"1968","journal-title":"Bull Tokai Reg Fish Res Lab"},{"key":"R48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.05.050"},{"key":"R49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2006.02590.x"},{"key":"R50","doi-asserted-by":"publisher","DOI":"10.7205\/MILMED-D-11-00150"},{"key":"R51","unstructured":"Newman SP, Simpson M, Fisher T, Iqbal K. Quantification of lung deposition and nasal mucociliary clearance for a nasally administered drug formulation containing chitosan. In: Dalby RN, Byron PR, Peart J, Suman JD and Farr SJ eds. Respiratory Drug Delivery IX, Virginia Commonwealth University, Virginia, 2004:617-19."},{"key":"R52","doi-asserted-by":"publisher","DOI":"10.1021\/js960182o"},{"key":"R53","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00309-1"},{"key":"R55","author":"Mann AJ","journal-title":"PLoS ONE"},{"key":"R56","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-6-150"},{"key":"R57","doi-asserted-by":"publisher","DOI":"10.1038\/nm860"},{"key":"R61","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21523"},{"key":"R62","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(01)00171-5"},{"key":"R63","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.11.034"},{"key":"R64","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2010.09.058"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.4161\/hv.27449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T21:15:05Z","timestamp":1564953305000},"score":18.782173,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/abs\/10.4161\/hv.27449"}},"subtitle":["A promising safe and immune-enhancing adjuvant for intranasal vaccines"],"issued":{"date-parts":[[2013,12,17]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3]]},"published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.4161\/hv.27449"],"URL":"https:\/\/doi.org\/10.4161\/hv.27449","ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"published":{"date-parts":[[2013,12,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"}]},{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T13:44:24Z","timestamp":1648561464239},"reference-count":0,"publisher":"Springer Science and Business Media LLC","issue":"1114","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Inpharma Weekly"],"published-print":{"date-parts":[[1997,11]]},"DOI":"10.2165\/00128413-199711140-00019","type":"journal-article","created":{"date-parts":[[2007,12,5]],"date-time":"2007-12-05T12:27:31Z","timestamp":1196857651000},"page":"9","source":"Crossref","is-referenced-by-count":0,"title":["HIV-1 envelope-based vaccines ???safe???"],"prefix":"10.1007","volume":"&NA;","author":[{"family":"&NA;","sequence":"first","affiliation":[]}],"member":"297","container-title":["Inpharma Weekly"],"language":"en","deposited":{"date-parts":[[2013,2,27]],"date-time":"2013-02-27T16:29:31Z","timestamp":1361982571000},"score":18.577751,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2165\/00128413-199711140-00019"}},"subtitle":[""],"issued":{"date-parts":[[1997,11]]},"references-count":0,"journal-issue":{"issue":"1114"},"URL":"https:\/\/doi.org\/10.2165\/00128413-199711140-00019","ISSN":["1173-8324"],"issn-type":[{"value":"1173-8324","type":"print"}],"published":{"date-parts":[[1997,11]]}},{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T17:48:14Z","timestamp":1694627294089},"reference-count":0,"publisher":"Springer Science and Business Media LLC","issue":"5123","license":[{"start":{"date-parts":[[1968,1,1]],"date-time":"1968-01-01T00:00:00Z","timestamp":-63158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[1968,1]]},"DOI":"10.1038\/217013a0","type":"journal-article","created":{"date-parts":[[2006,7,6]],"date-time":"2006-07-06T05:15:19Z","timestamp":1152162919000},"page":"13-13","source":"Crossref","is-referenced-by-count":0,"title":["Making Safe Vaccines"],"prefix":"10.1038","volume":"217","author":[{"name":"A Correspondent","sequence":"first","affiliation":[]}],"member":"297","container-title":["Nature"],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/217013a0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/217013a0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/217013a0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T20:51:14Z","timestamp":1638391874000},"score":18.577751,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/217013a0"}},"issued":{"date-parts":[[1968,1]]},"references-count":0,"journal-issue":{"issue":"5123","published-print":{"date-parts":[[1968,1]]}},"alternative-id":["BF217013a0"],"URL":"https:\/\/doi.org\/10.1038\/217013a0","ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"published":{"date-parts":[[1968,1]]}},{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T03:43:00Z","timestamp":1648870980616},"reference-count":1,"publisher":"Springer Science and Business Media LLC","issue":"590","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reactions Weekly"],"published-print":{"date-parts":[[1996,3]]},"DOI":"10.2165\/00128415-199605900-00007","type":"journal-article","created":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T00:08:43Z","timestamp":1138147723000},"page":"5","source":"Crossref","is-referenced-by-count":0,"title":["Concomitant influenza and pneumococcal vaccines 'safe'"],"prefix":"10.1007","volume":"&NA;","author":[{"family":"&NA;","sequence":"first","affiliation":[]}],"member":"297","reference":[{"key":"R1-7-2712","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/archinte.1996.00440020115015","volume":"156","author":"Honkanen","year":"1996","journal-title":"Archives of Internal Medicine"}],"container-title":["Reactions Weekly"],"language":"en","deposited":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T15:15:12Z","timestamp":1553181312000},"score":18.577751,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2165\/00128415-199605900-00007"}},"subtitle":[""],"issued":{"date-parts":[[1996,3]]},"references-count":1,"journal-issue":{"issue":"590"},"URL":"https:\/\/doi.org\/10.2165\/00128415-199605900-00007","ISSN":["0114-9954"],"issn-type":[{"value":"0114-9954","type":"print"}],"published":{"date-parts":[[1996,3]]}},{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T06:27:01Z","timestamp":1648880821188},"reference-count":0,"publisher":"Springer Science and Business Media LLC","issue":"672","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reactions Weekly"],"published-print":{"date-parts":[[1997,10]]},"DOI":"10.2165\/00128415-199706720-00009","type":"journal-article","created":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T05:04:25Z","timestamp":1138165465000},"page":"5","source":"Crossref","is-referenced-by-count":0,"title":["Concomitant 'traveller vaccines' immunogenic and 'safe'"],"prefix":"10.1007","volume":"&NA;","author":[{"family":"&NA;","sequence":"first","affiliation":[]}],"member":"297","container-title":["Reactions Weekly"],"language":"en","deposited":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T12:58:14Z","timestamp":1362142694000},"score":18.57353,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2165\/00128415-199706720-00009"}},"subtitle":[""],"issued":{"date-parts":[[1997,10]]},"references-count":0,"journal-issue":{"issue":"672"},"URL":"https:\/\/doi.org\/10.2165\/00128415-199706720-00009","ISSN":["0114-9954"],"issn-type":[{"value":"0114-9954","type":"print"}],"published":{"date-parts":[[1997,10]]}},{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T14:40:56Z","timestamp":1649083256229},"reference-count":0,"publisher":"Royal Pharmaceutical Society","content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2020]]},"DOI":"10.1211\/pj.2020.20208627","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T11:23:02Z","timestamp":1607426582000},"source":"Crossref","is-referenced-by-count":0,"title":["Hospital pharmacists oversee 'safe handling' of COVID-19 vaccines in vaccination centres"],"prefix":"10.1211","member":"162","container-title":["The Pharmaceutical Journal"],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T14:24:10Z","timestamp":1607523850000},"score":18.56285,"resource":{"primary":{"URL":"http:\/\/www.pharmaceutical-journal.com\/news-and-analysis\/news\/hospital-pharmacists-oversee-safe-handling-of-covid-19-vaccines-in-vaccination-centres\/20208627.article"}},"issued":{"date-parts":[[2020]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1211\/pj.2020.20208627","ISSN":["2053-6186"],"issn-type":[{"value":"2053-6186","type":"print"}],"published":{"date-parts":[[2020]]}},{"indexed":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T05:04:32Z","timestamp":1695877472010},"reference-count":0,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2000,9,13]]},"DOI":"10.1001\/jama.284.10.1231-jmn0913-3-1","type":"journal-article","created":{"date-parts":[[2014,3,8]],"date-time":"2014-03-08T08:32:15Z","timestamp":1394267535000},"page":"1231","source":"Crossref","is-referenced-by-count":3,"title":["FDA Calls Bovine-Based Vaccines Currently Safe"],"prefix":"10.1001","volume":"284","author":[{"given":"Charles","family":"Marwick","sequence":"first","affiliation":[]}],"member":"10","container-title":["JAMA"],"language":"en","link":[{"URL":"http:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/1843322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T18:32:38Z","timestamp":1481826758000},"score":18.551437,"resource":{"primary":{"URL":"http:\/\/jama.jamanetwork.com\/article.aspx?doi=10.1001\/jama.284.10.1231-JMN0913-3-1"}},"issued":{"date-parts":[[2000,9,13]]},"references-count":0,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2000,9,13]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.284.10.1231-jmn0913-3-1","ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"published":{"date-parts":[[2000,9,13]]}},{"indexed":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T01:19:35Z","timestamp":1711070375018},"reference-count":0,"publisher":"Rowman & Littlefield Publishers","isbn-type":[{"value":"9781442215801","type":"print"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2012]]},"DOI":"10.5771\/9781442215801-51","type":"book-chapter","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T08:16:05Z","timestamp":1711008965000},"page":"51-68","source":"Crossref","is-referenced-by-count":0,"title":["Chapter 5. A Real Mother: The World Before Vaccines"],"prefix":"10.5771","author":[{"given":"Stacy  Mintzer","family":"Herlihy","sequence":"first","affiliation":[]},{"given":"E. Allison","family":"Hagood","sequence":"additional","affiliation":[]}],"member":"3821","container-title":["Your Baby's Best Shot"],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T08:37:50Z","timestamp":1711010270000},"score":18.468819,"resource":{"primary":{"URL":"https:\/\/www.nomos-elibrary.de\/index.php?doi=10.5771\/9781442215801-51"}},"issued":{"date-parts":[[2012]]},"ISBN":["9781442215801"],"references-count":0,"URL":"https:\/\/doi.org\/10.5771\/9781442215801-51","published":{"date-parts":[[2012]]}},{"indexed":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T06:40:00Z","timestamp":1674628800890},"reference-count":0,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,1,24]]},"DOI":"10.1001\/jama.2022.23561","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T16:34:48Z","timestamp":1674578088000},"page":"278","source":"Crossref","is-referenced-by-count":0,"title":["Ebola Vaccines Safe and Immunogenic in 2 Trials"],"prefix":"10.1001","volume":"329","author":[{"given":"Anita","family":"Slomski","sequence":"first","affiliation":[]}],"member":"10","container-title":["JAMA"],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2800665\/jama_slomski_2023_nt_220047_1674242710.48138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T16:34:51Z","timestamp":1674578091000},"score":18.35125,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2800665"}},"issued":{"date-parts":[[2023,1,24]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,1,24]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.23561","ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"published":{"date-parts":[[2023,1,24]]}},{"indexed":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T23:14:16Z","timestamp":1648509256369},"reference-count":0,"publisher":"American Medical Association (AMA)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2020,12,15]]},"DOI":"10.1001\/jama.2020.24252","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T16:03:30Z","timestamp":1608048210000},"page":"2356","source":"Crossref","is-referenced-by-count":0,"title":["Global Regulators Set Standards for Safe Vaccines"],"prefix":"10.1001","volume":"324","author":[{"given":"Bridget M.","family":"Kuehn","sequence":"first","affiliation":[]}],"member":"10","container-title":["JAMA"],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2774065\/jama_kuehn_2020_wm_200033_1607124667.811.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T16:03:30Z","timestamp":1608048210000},"score":18.35125,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2774065"}},"issued":{"date-parts":[[2020,12,15]]},"references-count":0,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2020,12,15]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2020.24252","ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"published":{"date-parts":[[2020,12,15]]}},{"indexed":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T18:28:11Z","timestamp":1723746491712},"reference-count":179,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Q fever is an infectious zoonotic disease, caused by the Gram-negative bacterium <jats:italic>Coxiella burnetii<\/jats:italic>. Transmission occurs from livestock to humans through inhalation of a survival form of the bacterium, the Small Cell Variant, often via handling of animal parturition products. Q fever manifests as an acute self-limiting febrile illness or as a chronic disease with complications such as vasculitis and endocarditis. The current preventative human Q fever vaccine Q-VAX poses limitations on its worldwide implementation due to reactogenic responses in pre-sensitized individuals. Many strategies have been undertaken to develop a universal Q fever vaccine but with little success to date. The mechanisms of the underlying reactogenic responses remain only partially understood and are important factors in the development of a safe Q fever vaccine. This review provides an overview of previous and current experimental vaccines developed for use against Q fever and proposes approaches to develop a vaccine that establishes immunological memory while eliminating harmful reactogenic responses.<\/jats:p>","DOI":"10.1038\/s41541-023-00727-6","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T19:01:51Z","timestamp":1694113311000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Q fever immunology: the quest for a safe and effective vaccine"],"prefix":"10.1038","volume":"8","author":[{"given":"Gayathri","family":"Sam","sequence":"first","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0001-5465-2926","authenticated-orcid":false,"given":"John","family":"Stenos","sequence":"additional","affiliation":[]},{"given":"Stephen R.","family":"Graves","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0003-3908-8903","authenticated-orcid":false,"given":"Bernd H. A.","family":"Rehm","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"727_CR1","doi-asserted-by":"crossref","unstructured":"Derrick, E. \u201cQ\u201d fever, a new fever entity: clinical features, diagnosis and laboratory investigation. Med. J. Aust. 2, 281\u2013299 (1937).","DOI":"10.5694\/j.1326-5377.1937.tb43743.x"},{"key":"727_CR2","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.2307\/4582746","volume":"53","author":"GE Davis","year":"1938","unstructured":"Davis, G. E. et al. A filter-passing infectious agent isolated from ticks. Public Health Rep. 53, 2259\u20132311 (1938).","journal-title":"Public Health Rep."},{"key":"727_CR3","doi-asserted-by":"crossref","unstructured":"Cox, H. R. & Beli, E. J. The cultivation of Rickettsia diaporica in tissue culture and in the tissues of developing chick embryos. Public Health Rep. 54, 2171\u20132178 (1939).","DOI":"10.2307\/4583112"},{"key":"727_CR4","doi-asserted-by":"crossref","unstructured":"Cutler, S. J. Bacteria: Coxiella burnetii. In Encyclopedia of Food Safety (ed. Motarjemi, Y.) 410\u2013416 (Academic Press, 2014).","DOI":"10.1016\/B978-0-12-378612-8.00094-9"},{"key":"727_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.micinf.2019.09.001","volume":"22","author":"AL Dragan","year":"2020","unstructured":"Dragan, A. L. & Voth, D. E. Coxiella burnetii: international pathogen of mystery. Microbes Infect. 22, 100\u2013110 (2020).","journal-title":"Microbes Infect."},{"key":"727_CR6","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.3390\/microorganisms10081530","volume":"10","author":"Q Ullah","year":"2022","unstructured":"Ullah, Q. et al. Q fever\u2014a neglected zoonosis. Microorganisms 10, 1530 (2022).","journal-title":"Microorganisms"},{"key":"727_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1128\/CMR.00045-16","volume":"30","author":"C Eldin","year":"2017","unstructured":"Eldin, C. et al. From Q fever to Coxiella burnetii Infection: a paradigm change. Clin. Microbiol. Rev. 30, 115\u2013190 (2017).","journal-title":"Clin. Microbiol. Rev."},{"key":"727_CR8","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1128\/iai.55.5.1144-1150.1987","volume":"55","author":"A Moos","year":"1987","unstructured":"Moos, A. & Hackstadt, T. Comparative virulence of intra-and interstrain lipopolysaccharide variants of Coxiella burnetii in the guinea pig model. Infect. Immun. 55, 1144\u20131150 (1987).","journal-title":"Infect. Immun."},{"key":"727_CR9","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jinf.2015.04.024","volume":"71","author":"M Million","year":"2015","unstructured":"Million, M. & Raoult, D. Recent advances in the study of Q fever epidemiology, diagnosis and management. J. Infect. 71, S2\u2013S9 (2015).","journal-title":"J. Infect."},{"key":"727_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.5694\/mja2.13004","volume":"210","author":"HF Gidding","year":"2019","unstructured":"Gidding, H. F. et al. Seroprevalence of Q fever among metropolitan and non-metropolitan blood donors in New South Wales and Queensland, 2014-2015. Med. J. Aust. 210, 309\u2013315 (2019).","journal-title":"Med. J. Aust."},{"key":"727_CR11","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/j.1467-842X.1997.tb01787.x","volume":"21","author":"MG Garner","year":"1997","unstructured":"Garner, M. G. et al. A review of Q fever in Australia 1991\u20131994. Aust. N.Z. J. Public Health 21, 722\u2013730 (1997).","journal-title":"Aust. N.Z. J. Public Health"},{"key":"727_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1017\/S0950268811000136","volume":"140","author":"B Schimmer","year":"2012","unstructured":"Schimmer, B. et al. Low seroprevalence of Q fever in the Netherlands prior to a series of large outbreaks. Epidemiol. Infect. 140, 27\u201335 (2012).","journal-title":"Epidemiol. Infect."},{"key":"727_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1099\/mic.0.000707","volume":"165","author":"EI Shaw","year":"2019","unstructured":"Shaw, E. I. & Voth, D. E. Coxiella burnetii: a pathogenic intracellular acidophile. Microbiology 165, 1\u20133 (2019).","journal-title":"Microbiology"},{"key":"727_CR14","doi-asserted-by":"publisher","first-page":"754455","DOI":"10.3389\/fcimb.2021.754455","volume":"11","author":"G Sireci","year":"2021","unstructured":"Sireci, G. et al. Recent advances on the innate immune response to Coxiella burnetii. Front. Cell Infect. Microbiol. 11, 754455 (2021).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"727_CR15","doi-asserted-by":"publisher","first-page":"e0041022","DOI":"10.1128\/iai.00410-22","volume":"90","author":"D Park","year":"2022","unstructured":"Park, D. et al. Developmental transitions coordinate assembly of the Coxiella burnetii Dot\/Icm type IV secretion system. Infect. Immun. 90, e0041022 (2022).","journal-title":"Infect. Immun."},{"key":"727_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1196\/annals.1355.026","volume":"1063","author":"M Andoh","year":"2005","unstructured":"Andoh, M. et al. Comparative virulence of phase I and II Coxiella burnetii in immunodeficient mice. Ann. N. Y. Acad. Sci. 1063, 167\u2013170 (2005).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"727_CR17","doi-asserted-by":"publisher","first-page":"101903","DOI":"10.1016\/j.jbc.2022.101903","volume":"298","author":"AR Cross","year":"2022","unstructured":"Cross, A. R. et al. Spinning sugars in antigen biosynthesis: characterization of the Coxiella burnetii and Streptomyces griseus TDP-sugar epimerases. J. Biol. Chem. 298, 101903 (2022).","journal-title":"J. Biol. Chem."},{"key":"727_CR18","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.3390\/vaccines10091393","volume":"10","author":"SR Graves","year":"2022","unstructured":"Graves, S. R. et al. An O-specific polysaccharide\/tetanus toxoid conjugate vaccine induces protection in guinea pigs against virulent challenge with Coxiella burnetii. Vaccines 10, 1393 (2022).","journal-title":"Vaccines"},{"key":"727_CR19","doi-asserted-by":"publisher","first-page":"e1006922","DOI":"10.1371\/journal.ppat.1006922","volume":"14","author":"PA Beare","year":"2018","unstructured":"Beare, P. A. et al. Genetic mechanisms of Coxiella burnetii lipopolysaccharide phase variation. PLoS Pathog. 14, e1006922 (2018).","journal-title":"PLoS Pathog."},{"key":"727_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00296-6","volume":"6","author":"CM Long","year":"2021","unstructured":"Long, C. M. et al. Contributions of lipopolysaccharide and the type IVB secretion system to Coxiella burnetii vaccine efficacy and reactogenicity. NPJ Vaccines 6, 38 (2021).","journal-title":"NPJ Vaccines"},{"key":"727_CR21","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3389\/fmicb.2014.00726","volume":"5","author":"S Ruiz","year":"2014","unstructured":"Ruiz, S. & Wolfe, D. N. Vaccination against Q fever for biodefense and public health indications. Front. Microbiol. 5, 726 (2014).","journal-title":"Front. Microbiol."},{"key":"727_CR22","doi-asserted-by":"crossref","unstructured":"Miller, J., Shaw, E. & Thompson, H. Coxiella burnetii, Q fever, and bioterrorism. In Microorganisms and Bioterrorism (eds Anderson, B., Friedman, H. & Bendinelli, M.). 181\u2013208 (Springer, 2006).","DOI":"10.1007\/0-387-28159-2_10"},{"key":"727_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0733-8627(01)00002-5","volume":"20","author":"DL Noah","year":"2002","unstructured":"Noah, D. L. et al. The history and threat of biological warfare and terrorism. Emerg. Med. Clin. 20, 255\u2013271 (2002).","journal-title":"Emerg. Med. Clin."},{"key":"727_CR24","doi-asserted-by":"publisher","first-page":"13708","DOI":"10.1073\/pnas.1914892117","volume":"117","author":"M Burette","year":"2020","unstructured":"Burette, M. et al. Modulation of innate immune signaling by a Coxiella burnetii eukaryotic-like effector protein. Proc. Natl Acad. Sci. USA 117, 13708\u201313718 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"727_CR25","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrmicro3049","volume":"11","author":"EJ van Schaik","year":"2013","unstructured":"van Schaik, E. J. et al. Molecular pathogenesis of the obligate intracellular bacterium Coxiella burnetii. Nat. Rev. Microbiol. 11, 561\u2013573 (2013).","journal-title":"Nat. Rev. Microbiol."},{"key":"727_CR26","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/j.1462-5822.2007.00901.x","volume":"9","author":"DE Voth","year":"2007","unstructured":"Voth, D. E. & Heinzen, R. A. Lounging in a lysosome: the intracellular lifestyle of Coxiella burnetii. Cell Microbiol. 9, 829\u2013840 (2007).","journal-title":"Cell Microbiol."},{"key":"727_CR27","doi-asserted-by":"publisher","first-page":"e39348","DOI":"10.1371\/journal.pone.0039348","volume":"7","author":"EM Rosales","year":"2012","unstructured":"Rosales, E. M. et al. Cortactin is involved in the entry of Coxiella burnetii into non-phagocytic cells. PLoS ONE 7, e39348 (2012).","journal-title":"PLoS ONE"},{"key":"727_CR28","doi-asserted-by":"publisher","first-page":"e1004013","DOI":"10.1371\/journal.ppat.1004013","volume":"10","author":"E Martinez","year":"2014","unstructured":"Martinez, E. et al. Identification of OmpA, a Coxiella burnetii protein involved in host cell invasion, by multi-phenotypic high-content screening. PLoS Pathog. 10, e1004013 (2014).","journal-title":"PLoS Pathog."},{"key":"727_CR29","doi-asserted-by":"publisher","first-page":"6078","DOI":"10.4049\/jimmunol.163.11.6078","volume":"163","author":"C Capo","year":"1999","unstructured":"Capo, C. et al. Subversion of monocyte functions by Coxiella burnetii: impairment of the cross-talk between \u03b1v\u03b23 integrin and CR3. J. Immunol. 163, 6078\u20136085 (1999).","journal-title":"J. Immunol."},{"key":"727_CR30","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.4049\/jimmunol.170.8.4217","volume":"170","author":"C Capo","year":"2003","unstructured":"Capo, C. et al. Coxiella burnetii avoids macrophage phagocytosis by interfering with spatial distribution of complement receptor 3. J. Immunol. 170, 4217\u20134225 (2003).","journal-title":"J. Immunol."},{"key":"727_CR31","doi-asserted-by":"publisher","first-page":"7288","DOI":"10.1016\/j.vaccine.2007.08.002","volume":"25","author":"DM Waag","year":"2007","unstructured":"Waag, D. M. Coxiella burnetii: host and bacterial responses to infection. Vaccine 25, 7288\u20137295 (2007).","journal-title":"Vaccine"},{"key":"727_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1128\/iai.56.1.40-44.1988","volume":"56","author":"S Vishwanath","year":"1988","unstructured":"Vishwanath, S. & Hackstadt, T. Lipopolysaccharide phase variation determines the complement-mediated serum susceptibility of Coxiella burnetii. Infect. Immun. 56, 40\u201344 (1988).","journal-title":"Infect. Immun."},{"key":"727_CR33","doi-asserted-by":"publisher","first-page":"e0145211","DOI":"10.1371\/journal.pone.0145211","volume":"10","author":"RP Salinas","year":"2015","unstructured":"Salinas, R. P. et al. Coxiella burnetii phagocytosis is regulated by GTPases of the Rho family and the RhoA effectors mDia1 and ROCK. PLoS ONE 10, e0145211 (2015).","journal-title":"PLoS ONE"},{"key":"727_CR34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nrm2515","volume":"9","author":"JM Kinchen","year":"2008","unstructured":"Kinchen, J. M. & Ravichandran, K. S. Phagosome maturation: going through the acid test. Nat. Rev. Mol. Cell Biol. 9, 781\u2013795 (2008).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"727_CR35","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.3389\/fimmu.2020.01066","volume":"11","author":"E Uribe-Querol","year":"2020","unstructured":"Uribe-Querol, E. & Rosales, C. Phagocytosis: our current understanding of a universal biological process. Front. Immunol. 11, 1066 (2020).","journal-title":"Front. Immunol."},{"key":"727_CR36","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.it.2012.03.003","volume":"33","author":"GD Fairn","year":"2012","unstructured":"Fairn, G. D. & Grinstein, S. How nascent phagosomes mature to become phagolysosomes. Trends Immunol. 33, 397\u2013405 (2012).","journal-title":"Trends Immunol."},{"key":"727_CR37","doi-asserted-by":"publisher","first-page":"4488","DOI":"10.4049\/jimmunol.169.8.4488","volume":"169","author":"E Ghigo","year":"2002","unstructured":"Ghigo, E. et al. Coxiella burnetii survival in THP-1 monocytes involves the impairment of phagosome maturation: IFN-gamma mediates its restoration and bacterial killing. J. Immunol. 169, 4488\u20134495 (2002).","journal-title":"J. Immunol."},{"key":"727_CR38","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/j.1462-5822.2005.00527.x","volume":"7","author":"MG Gutierrez","year":"2005","unstructured":"Gutierrez, M. G. et al. Autophagy induction favours the generation and maturation of the Coxiella-replicative vacuoles. Cell Microbiol. 7, 981\u2013993 (2005).","journal-title":"Cell Microbiol."},{"key":"727_CR39","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1462-5822.2005.00641.x","volume":"8","author":"D Howe","year":"2006","unstructured":"Howe, D. & Heinzen, R. A. Coxiella burnetii inhabits a cholesterol-rich vacuole and influences cellular cholesterol metabolism. Cell Microbiol. 8, 496\u2013507 (2006).","journal-title":"Cell Microbiol."},{"key":"727_CR40","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/j.1462-5822.2006.00838.x","volume":"9","author":"PS Romano","year":"2007","unstructured":"Romano, P. S. et al. The autophagic pathway is actively modulated by phase II Coxiella burnetii to efficiently replicate in the host cell. Cell Microbiol. 9, 891\u2013909 (2007).","journal-title":"Cell Microbiol."},{"key":"727_CR41","doi-asserted-by":"publisher","first-page":"5816","DOI":"10.1128\/IAI.70.10.5816-5821.2002","volume":"70","author":"W Beron","year":"2002","unstructured":"Beron, W. et al. Coxiella burnetii localizes in a Rab7-labeled compartment with autophagic characteristics. Infect. Immun. 70, 5816\u20135821 (2002).","journal-title":"Infect. Immun."},{"key":"727_CR42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nature09782","volume":"469","author":"B Levine","year":"2011","unstructured":"Levine, B., Mizushima, N. & Virgin, H. W. Autophagy in immunity and inflammation. Nature 469, 323\u2013335 (2011).","journal-title":"Nature"},{"key":"727_CR43","doi-asserted-by":"publisher","first-page":"e01127-16","DOI":"10.1128\/mBio.01127-16","volume":"7","author":"LJ Kohler","year":"2016","unstructured":"Kohler, L. J. et al. Effector protein Cig2 decreases host tolerance of infection by directing constitutive fusion of autophagosomes with the coxiella-containing vacuole. mBio 7, e01127-16 (2016).","journal-title":"mBio"},{"key":"727_CR44","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3389\/fcimb.2017.00112","volume":"7","author":"ME Mansilla Pareja","year":"2017","unstructured":"Mansilla Pareja, M. E. et al. Alterations of the Coxiella burnetii replicative vacuole membrane integrity and interplay with the autophagy pathway. Front. Cell Infect. Microbiol. 7, 112 (2017).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"727_CR45","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1034\/j.1600-0854.2002.030302.x","volume":"3","author":"MS Swanson","year":"2002","unstructured":"Swanson, M. S. & Fernandez\u2010Moreia, E. A microbial strategy to multiply in macrophages: the pregnant pause. Traffic 3, 170\u2013177 (2002).","journal-title":"Traffic"},{"key":"727_CR46","doi-asserted-by":"publisher","first-page":"5140","DOI":"10.1128\/IAI.70.9.5140-5147.2002","volume":"70","author":"D Howe","year":"2002","unstructured":"Howe, D. et al. Nitric oxide inhibits Coxiella burnetii replication and parasitophorous vacuole maturation. Infect. Immun. 70, 5140\u20135147 (2002).","journal-title":"Infect. Immun."},{"key":"727_CR47","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1128\/IAI.00594-07","volume":"75","author":"DE Voth","year":"2007","unstructured":"Voth, D. E., Howe, D. & Heinzen, R. A. Coxiella burnetii inhibits apoptosis in human THP-1 cells and monkey primary alveolar macrophages. Infect. Immun. 75, 4263\u20134271 (2007).","journal-title":"Infect. Immun."},{"key":"727_CR48","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1128\/IAI.01124-08","volume":"77","author":"DE Voth","year":"2009","unstructured":"Voth, D. E. & Heinzen, R. A. Sustained activation of Akt and Erk1\/2 is required for Coxiella burnetii antiapoptotic activity. Infect. Immun. 77, 205\u2013213 (2009).","journal-title":"Infect. Immun."},{"key":"727_CR49","doi-asserted-by":"publisher","first-page":"e30841","DOI":"10.1371\/journal.pone.0030841","volume":"7","author":"Y Zhang","year":"2012","unstructured":"Zhang, Y. et al. Coxiella burnetii induces apoptosis during early stage infection via a caspase-independent pathway in human monocytic THP-1 cells. PLoS ONE 7, e30841 (2012).","journal-title":"PLoS ONE"},{"key":"727_CR50","doi-asserted-by":"publisher","first-page":"e03545-22","DOI":"10.1128\/mbio.03545-22","volume":"14","author":"S Ganesan","year":"2023","unstructured":"Ganesan, S. et al. Syntaxin 11 contributes to the interferon-inducible restriction of Coxiella burnetii intracellular infection. Mbio 14, e03545-22 (2023).","journal-title":"Mbio"},{"key":"727_CR51","doi-asserted-by":"crossref","unstructured":"Peters, N. C., Khan, N. & Mody, C. H. Novel approaches to preventing phagosomal infections: timing is key. Trends Immunol. 44, 22\u201331 (2022).","DOI":"10.1016\/j.it.2022.11.004"},{"key":"727_CR52","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.pt.2022.08.007","volume":"38","author":"B Rayamajhee","year":"2022","unstructured":"Rayamajhee, B. et al. Acanthamoeba, an environmental phagocyte enhancing survival and transmission of human pathogens. Trends Parasitol. 38, 975\u2013990 (2022).","journal-title":"Trends Parasitol."},{"key":"727_CR53","doi-asserted-by":"publisher","first-page":"10","DOI":"10.15212\/ZOONOSES-2021-0011","volume":"1","author":"JR Fisher","year":"2021","unstructured":"Fisher, J. R. et al. Pattern recognition receptors in innate immunity to obligate intracellular bacteria. Zoonoses 1, 10 (2021).","journal-title":"Zoonoses"},{"key":"727_CR54","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.4049\/jimmunol.181.6.3733","volume":"181","author":"M Benoit","year":"2008","unstructured":"Benoit, M., Desnues, B. & Mege, J. L. Macrophage polarization in bacterial infections. J. Immunol. 181, 3733\u20133739 (2008).","journal-title":"J. Immunol."},{"key":"727_CR55","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3389\/fimmu.2014.00500","volume":"5","author":"MB Ka","year":"2014","unstructured":"Ka, M. B. et al. Phenotypic diversity and emerging new tools to study macrophage activation in bacterial infectious diseases. Front. Immunol. 5, 500 (2014).","journal-title":"Front. Immunol."},{"key":"727_CR56","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3389\/fimmu.2014.00532","volume":"5","author":"M Rath","year":"2014","unstructured":"Rath, M. et al. Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages. Front. Immunol. 5, 532 (2014).","journal-title":"Front. Immunol."},{"key":"727_CR57","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/nri957","volume":"2","author":"J Savill","year":"2002","unstructured":"Savill, J. et al. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat. Rev. Immunol. 2, 965\u2013975 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"727_CR58","doi-asserted-by":"publisher","first-page":"e1000066","DOI":"10.1371\/journal.ppat.1000066","volume":"4","author":"M Benoit","year":"2008","unstructured":"Benoit, M. et al. The uptake of apoptotic cells drives Coxiella burnetii replication and macrophage polarization: a model for Q fever endocarditis. PLoS Pathog. 4, e1000066 (2008).","journal-title":"PLoS Pathog."},{"key":"727_CR59","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1128\/iai.19.1.194-198.1978","volume":"19","author":"R Kishimoto","year":"1978","unstructured":"Kishimoto, R. et al. Cell-mediated immune responses of guinea pigs to an inactivated phase I Coxiella burnetii vaccine. Infect. Immun. 19, 194\u2013198 (1978).","journal-title":"Infect. Immun."},{"key":"727_CR60","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3389\/fimmu.2020.01276","volume":"11","author":"EM Muntjewerff","year":"2020","unstructured":"Muntjewerff, E. M., Meesters, L. D. & van den Bogaart, G. Antigen cross-presentation by macrophages. Front. Immunol. 11, 1276 (2020).","journal-title":"Front. Immunol."},{"key":"727_CR61","doi-asserted-by":"publisher","first-page":"e00602-17","DOI":"10.1128\/IAI.00602-17","volume":"86","author":"L Buttrum","year":"2018","unstructured":"Buttrum, L. et al. Both major histocompatibility complex class I (MHC-I) and MHC-II molecules are required, while MHC-I appears to play a critical role in host defense against primary Coxiella burnetii infection. Infect. Immun. 86, e00602-17 (2018).","journal-title":"Infect. Immun."},{"key":"727_CR62","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1196\/annals.1355.025","volume":"1063","author":"S Meghari","year":"2005","unstructured":"Meghari, S. et al. TLR2 is necessary to inflammatory response in Coxiella burnetii infection. Ann. N. Y. Acad. Sci. 1063, 161\u2013166 (2005).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"727_CR63","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3389\/fimmu.2014.00491","volume":"5","author":"G Arango Duque","year":"2014","unstructured":"Arango Duque, G. & Descoteaux, A. Macrophage cytokines: involvement in immunity and infectious diseases. Front. Immunol. 5, 491 (2014).","journal-title":"Front. Immunol."},{"key":"727_CR64","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1128\/IAI.00973-13","volume":"81","author":"A Elliott","year":"2013","unstructured":"Elliott, A., Peng, Y. & Zhang, G. Coxiella burnetii interaction with neutrophils and macrophages in vitro and in SCID mice following aerosol infection. Infect. Immun. 81, 4604\u20134614 (2013).","journal-title":"Infect. Immun."},{"key":"727_CR65","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1128\/IAI.00042-15","volume":"83","author":"A Elliott","year":"2015","unstructured":"Elliott, A. et al. Neutrophils play an important role in protective immunity against Coxiella burnetii infection. Infect. Immun. 83, 3104\u20133113 (2015).","journal-title":"Infect. Immun."},{"key":"727_CR66","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/infdis\/jiz146","volume":"220","author":"C Chen","year":"2019","unstructured":"Chen, C. et al. Chemokine receptor 7 is essential for Coxiella burnetii whole-cell vaccine-induced cellular immunity but dispensable for vaccine-mediated protective immunity. J. Infect. Dis. 220, 624\u2013634 (2019).","journal-title":"J. Infect. Dis."},{"key":"727_CR67","doi-asserted-by":"publisher","first-page":"8722","DOI":"10.1073\/pnas.0501863102","volume":"102","author":"JG Shannon","year":"2005","unstructured":"Shannon, J. G., Howe, D. & Heinzen, R. A. Virulent Coxiella burnetii does not activate human dendritic cells: role of lipopolysaccharide as a shielding molecule. Proc. Natl Acad. Sci. 102, 8722\u20138727 (2005).","journal-title":"Proc. Natl Acad. Sci."},{"key":"727_CR68","doi-asserted-by":"publisher","first-page":"e99420","DOI":"10.1371\/journal.pone.0099420","volume":"9","author":"L Gorvel","year":"2014","unstructured":"Gorvel, L. et al. Intracellular bacteria interfere with dendritic cell functions: role of the type I interferon pathway. PLoS ONE 9, e99420 (2014).","journal-title":"PLoS ONE"},{"key":"727_CR69","doi-asserted-by":"publisher","first-page":"e00323-22","DOI":"10.1128\/iai.00323-22","volume":"91","author":"S Matthiesen","year":"2023","unstructured":"Matthiesen, S. et al. TGF-\u03b2\/IFN-\u03b3 antagonism in subversion and self-defense of phase II Coxiella burnetii-infected dendritic cells. Infect. Immun. 91, e00323-22 (2023).","journal-title":"Infect. Immun."},{"key":"727_CR70","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s00262-008-0489-2","volume":"57","author":"AC Boullart","year":"2008","unstructured":"Boullart, A. C. et al. Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7\/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol. Immunother. 57, 1589\u20131597 (2008).","journal-title":"Cancer Immunol. Immunother."},{"key":"727_CR71","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/imr.12758","volume":"289","author":"B Leon","year":"2019","unstructured":"Leon, B. & Lund, F. E. Compartmentalization of dendritic cell and T-cell interactions in the lymph node: anatomy of T-cell fate decisions. Immunol. Rev. 289, 84\u2013100 (2019).","journal-title":"Immunol. Rev."},{"key":"727_CR72","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/infdis\/jiq037","volume":"203","author":"Y Wei","year":"2011","unstructured":"Wei, Y. et al. Coxiella burnetii antigen-stimulated dendritic cells mediated protection against Coxiella burnetii in BALB\/c mice. J. Infect. Dis. 203, 283\u2013291 (2011).","journal-title":"J. Infect. Dis."},{"key":"727_CR73","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nri3536","volume":"13","author":"V Lazarevic","year":"2013","unstructured":"Lazarevic, V., Glimcher, L. H. & Lord, G. M. T-bet: a bridge between innate and adaptive immunity. Nat. Rev. Immunol. 13, 777\u2013789 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"727_CR74","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.3389\/fmicb.2020.01546","volume":"11","author":"S Mezouar","year":"2020","unstructured":"Mezouar, S. et al. T-Bet controls susceptibility of mice to Coxiella burnetii infection. Front. Microbiol 11, 1546 (2020).","journal-title":"Front. Microbiol"},{"key":"727_CR75","doi-asserted-by":"publisher","first-page":"e00824-19","DOI":"10.1128\/IAI.00824-19","volume":"88","author":"L Ledbetter","year":"2020","unstructured":"Ledbetter, L. et al. Major histocompatibility complex class II-Restricted, CD4+ T cell-dependent and-independent mechanisms are required for vaccine-induced protective immunity against Coxiella burnetii. Infect. Immun. 88, e00824-19 (2020).","journal-title":"Infect. Immun."},{"key":"727_CR76","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1128\/IAI.01767-06","volume":"75","author":"M Andoh","year":"2007","unstructured":"Andoh, M. et al. T cells are essential for bacterial clearance, and gamma interferon, tumor necrosis factor alpha, and B cells are crucial for disease development in Coxiella burnetii infection in mice. Infect. Immun. 75, 3245\u20133255 (2007).","journal-title":"Infect. Immun."},{"key":"727_CR77","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1128\/IAI.00101-10","volume":"78","author":"AJ Read","year":"2010","unstructured":"Read, A. J., Erickson, S. & Harmsen, A. G. Role of CD4+ and CD8+ T cells in clearance of primary pulmonary infection with Coxiella burnetii. Infect. Immun. 78, 3019\u20133026 (2010).","journal-title":"Infect. Immun."},{"key":"727_CR78","doi-asserted-by":"publisher","first-page":"8372","DOI":"10.4049\/jimmunol.179.12.8372","volume":"179","author":"G Zhang","year":"2007","unstructured":"Zhang, G. et al. Mechanisms of vaccine-induced protective immunity against Coxiella burnetii infection in BALB\/c mice. J. Immunol. 179, 8372\u20138380 (2007).","journal-title":"J. Immunol."},{"key":"727_CR79","doi-asserted-by":"crossref","unstructured":"Nash, A. A., Dalziel, R. G. & Fitzgerald, J. R. Early stages of infection after pathogen entry. In Mims\u2019 Pathogenesis of Infectious Disease (ed. Fitzgerald, J. R.) 51\u201365 (Academic Press, 2015).","DOI":"10.1016\/B978-0-12-397188-3.00003-2"},{"key":"727_CR80","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1365-2249.1991.tb05689.x","volume":"85","author":"A Izzo","year":"1991","unstructured":"Izzo, A., Marmion, B. & Hackstadt, T. Analysis of the cells involved in the lymphoproliferative response to Coxiella burnetii antigens. Clin. Exp. Immunol. 85, 98\u2013108 (1991).","journal-title":"Clin. Exp. Immunol."},{"key":"727_CR81","doi-asserted-by":"publisher","first-page":"901372","DOI":"10.3389\/fimmu.2022.901372","volume":"13","author":"AE Sluder","year":"2022","unstructured":"Sluder, A. E. et al. Evaluation of a human T cell-targeted multi-epitope vaccine for Q fever in animal models of Coxiella burnetii immunity. Front. Immunol. 13, 901372 (2022).","journal-title":"Front. Immunol."},{"key":"727_CR82","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3389\/fmicb.2019.02022","volume":"10","author":"J Dresler","year":"2019","unstructured":"Dresler, J. et al. Quantitative proteome profiling of Coxiella burnetii reveals major metabolic and stress differences under axenic and cell culture cultivation. Front. Microbiol. 10, 2022 (2019).","journal-title":"Front. Microbiol."},{"key":"727_CR83","doi-asserted-by":"publisher","first-page":"6666","DOI":"10.1128\/IAI.72.11.6666-6675.2004","volume":"72","author":"RE Brennan","year":"2004","unstructured":"Brennan, R. E. et al. Both inducible nitric oxide synthase and NADPH oxidase contribute to the control of virulent phase I Coxiella burnetii infections. Infect. Immun. 72, 6666\u20136675 (2004).","journal-title":"Infect. Immun."},{"key":"727_CR84","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S1471-4906(03)00228-X","volume":"24","author":"A Casadevall","year":"2003","unstructured":"Casadevall, A. & Pirofski, L.-A. Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol. 24, 474\u2013478 (2003).","journal-title":"Trends Immunol."},{"key":"727_CR85","doi-asserted-by":"crossref","unstructured":"Casadevall, A. & Pirofski, L. A. A reappraisal of humoral immunity based on mechanisms of antibody\u2010mediated protection against intracellular pathogens. Adv. Immunol. 91, 1\u201344 (2006).","DOI":"10.1016\/S0065-2776(06)91001-3"},{"key":"727_CR86","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1128\/IAI.00297-13","volume":"81","author":"G Zhang","year":"2013","unstructured":"Zhang, G. et al. Formalin-inactivated Coxiella burnetii phase I vaccine-induced protection depends on B cells to produce protective IgM and IgG. Infect. Immun. 81, 2112\u20132122 (2013).","journal-title":"Infect. Immun."},{"key":"727_CR87","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2172-10-26","volume":"10","author":"JG Shannon","year":"2009","unstructured":"Shannon, J. G. et al. Antibody-mediated immunity to the obligate intracellular bacterial pathogen Coxiella burnetii is Fc receptor- and complement-independent. BMC Immunol. 10, 26 (2009).","journal-title":"BMC Immunol."},{"key":"727_CR88","doi-asserted-by":"publisher","first-page":"996","DOI":"10.4049\/jimmunol.117.3.996","volume":"117","author":"DJ Hinrichs","year":"1976","unstructured":"Hinrichs, D. J. & Jerrells, T. R. In vitro evaluation of immunity to Coxiella burnetii. J. Immunol. 117, 996\u20131003 (1976).","journal-title":"J. Immunol."},{"key":"727_CR89","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1128\/IAI.01073-15","volume":"83","author":"L Schoenlaub","year":"2015","unstructured":"Schoenlaub, L. et al. Role of B cells in host defense against primary Coxiella burnetii infection. Infect. Immun. 83, 4826\u20134836 (2015).","journal-title":"Infect. Immun."},{"key":"727_CR90","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1128\/am.27.4.777-783.1974","volume":"27","author":"DM Robinson","year":"1974","unstructured":"Robinson, D. M. & Hasty, S. E. Production of a potent vaccine from the attenuated M-44 strain of Coxiella burneti. Appl. Microbiol. 27, 777\u2013783 (1974).","journal-title":"Appl. Microbiol."},{"key":"727_CR91","unstructured":"Genig, V. et al. Experience on the mass immunization of humans with the M-44 live vaccine against Q-fever. I. Subcutaneous method of immunization. Vopr. Virusol. 3, 319\u2013323 (1966)."},{"key":"727_CR92","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/infdis\/135.6.995","volume":"135","author":"JW Johnson","year":"1977","unstructured":"Johnson, J. W. et al. Lesions in guinea pigs infected with Coxiella burnetii strain M-44. J. Infect. Dis. 135, 995\u2013998 (1977).","journal-title":"J. Infect. Dis."},{"key":"727_CR93","doi-asserted-by":"publisher","first-page":"754690","DOI":"10.3389\/fimmu.2021.754690","volume":"12","author":"V Kumaresan","year":"2021","unstructured":"Kumaresan, V. et al. The feasibility of using Coxiella burnetii avirulent nine mile phase II viable bacteria as a live attenuated vaccine against Q fever. Front. Immunol. 12, 754690 (2021).","journal-title":"Front. Immunol."},{"key":"727_CR94","first-page":"71","volume":"47","author":"JE Smadel","year":"1948","unstructured":"Smadel, J. E., Snyder, M. J. & Robbins, F. C. Vaccination against Q fever. Am. J. Hyg. 47, 71\u201381 (1948).","journal-title":"Am. J. Hyg."},{"key":"727_CR95","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1017\/S0950268800059458","volume":"104","author":"B Marmion","year":"1990","unstructured":"Marmion, B. et al. Vaccine prophylaxis of abattoir-associated Q fever: eight years\u2019 experience in Australian abattoirs. Epidemiol. Infect. 104, 275\u2013287 (1990).","journal-title":"Epidemiol. Infect."},{"key":"727_CR96","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/S0140-6736(84)91617-9","volume":"324","author":"B Marmion","year":"1984","unstructured":"Marmion, B. et al. Vaccine prophylaxis of abattoir-associated Q fever. Lancet 324, 1411\u20131414 (1984).","journal-title":"Lancet"},{"key":"727_CR97","doi-asserted-by":"publisher","first-page":"704","DOI":"10.5694\/j.1326-5377.1994.tb125909.x","volume":"160","author":"JR Ackland","year":"1994","unstructured":"Ackland, J. R., Worswick, D. A. & Marmion, B. P. Vaccine prophylaxis of Q fever: a follow\u2010up study of the efficacy of Q\u2010Vax (CSL) 1985\u20101990. Med. J. Aust. 160, 704\u2013708 (1994).","journal-title":"Med. J. Aust."},{"key":"727_CR98","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/vaccines6040083","volume":"6","author":"E Sellens","year":"2018","unstructured":"Sellens, E. et al. Frequency of adverse events following Q fever immunisation in young adults. Vaccines 6, 83 (2018).","journal-title":"Vaccines"},{"key":"727_CR99","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/milmed\/129.7.591","volume":"129","author":"JF Bell","year":"1964","unstructured":"Bell, J. F. et al. Recurrent reaction at site of Q fever vaccination in a sensitized person. Mil. Med. 129, 591\u2013595 (1964).","journal-title":"Mil. Med."},{"key":"727_CR100","doi-asserted-by":"publisher","first-page":"6622","DOI":"10.1016\/j.vaccine.2014.09.061","volume":"32","author":"T Schoffelen","year":"2014","unstructured":"Schoffelen, T. et al. Adverse events and association with age, sex and immunological parameters of Q fever vaccination in patients at risk for chronic Q fever in the Netherlands 2011. Vaccine 32, 6622\u20136630 (2014).","journal-title":"Vaccine"},{"key":"727_CR101","doi-asserted-by":"publisher","first-page":"754712","DOI":"10.3389\/fimmu.2021.754712","volume":"12","author":"AP Fratzke","year":"2021","unstructured":"Fratzke, A. P. et al. Coxiella burnetii whole cell vaccine produces a Th1 delayed-type hypersensitivity response in a novel sensitized mouse model. Front. Immunol. 12, 754712 (2021).","journal-title":"Front. Immunol."},{"key":"727_CR102","first-page":"389","volume":"60","author":"J Kazar","year":"1982","unstructured":"Kazar, J. et al. Immunogenicity and reactogenicity of a Q fever chemovaccine in persons professionally exposed to Q fever in Czechoslovakia. Bull. World Health Organ. 60, 389 (1982).","journal-title":"Bull. World Health Organ."},{"key":"727_CR103","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1749-6632.1992.tb19633.x","volume":"653","author":"JC Williams","year":"1992","unstructured":"Williams, J. C. et al. Vaccines against coxiellosis and Q fever. Development of a chloroform:methanol residue subunit of phase I Coxiella burnetti for the immunization of animals. Ann. N. Y. Acad. Sci. 653, 88\u2013111 (1992).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"727_CR104","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1016\/S0264-410X(02)00176-7","volume":"20","author":"DM Waag","year":"2002","unstructured":"Waag, D. M. et al. Comparative efficacy and immunogenicity of Q fever chloroform: methanol residue (CMR) and phase I cellular (Q-Vax) vaccines in cynomolgus monkeys challenged by aerosol. Vaccine 20, 2623\u20132634 (2002).","journal-title":"Vaccine"},{"key":"727_CR105","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0264-410X(97)00107-2","volume":"15","author":"DM Waag","year":"1997","unstructured":"Waag, D. M., England, M. J. & Pitt, M. L. M. Comparative efficacy of a Coxiella burnetii chloroform: methanol residue (CMR) vaccine and a licensed cellular vaccine (Q-Vax) in rodents challenged by aerosol. Vaccine 15, 1779\u20131783 (1997).","journal-title":"Vaccine"},{"key":"727_CR106","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1128\/iai.61.4.1251-1258.1993","volume":"61","author":"L Fries","year":"1993","unstructured":"Fries, L., Waag, D. & Williams, J. Safety and immunogenicity in human volunteers of a chloroform-methanol residue vaccine for Q fever. Infect. Immun. 61, 1251\u20131258 (1993).","journal-title":"Infect. Immun."},{"key":"727_CR107","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1128\/jb.85.5.1165-1170.1963","volume":"85","author":"R Anacker","year":"1963","unstructured":"Anacker, R. et al. Conversion of the phase I antigen of Coxiella burnetii to hapten by phenol treatment. J. Bacteriol. 85, 1165\u20131170 (1963).","journal-title":"J. Bacteriol."},{"key":"727_CR108","doi-asserted-by":"publisher","first-page":"100461","DOI":"10.1016\/j.xcrm.2021.100461","volume":"2","author":"AE Gregory","year":"2021","unstructured":"Gregory, A. E. et al. Soluble antigens derived from Coxiella burnetii elicit protective immunity in three animal models without inducing hypersensitivity. Cell Rep. Med. 2, 100461 (2021).","journal-title":"Cell Rep. Med."},{"key":"727_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0132-6","volume":"4","author":"C Herve","year":"2019","unstructured":"Herve, C. et al. The how\u2019s and what\u2019s of vaccine reactogenicity. npj Vaccines 4, 39 (2019).","journal-title":"npj Vaccines"},{"key":"727_CR110","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jaci.2017.12.971","volume":"141","author":"MM McNeil","year":"2018","unstructured":"McNeil, M. M. & DeStefano, F. Vaccine-associated hypersensitivity. J. Allergy Clin. Immunol. 141, 463\u2013472 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"727_CR111","doi-asserted-by":"publisher","first-page":"886810","DOI":"10.3389\/fimmu.2022.886810","volume":"13","author":"AP Fratzke","year":"2022","unstructured":"Fratzke, A. P., van Schaik, E. J. & Samuel, J. E. Immunogenicity and reactogenicity in Q fever vaccine development. Front. Immunol. 13, 886810 (2022).","journal-title":"Front. Immunol."},{"key":"727_CR112","doi-asserted-by":"publisher","first-page":"927306","DOI":"10.3389\/fmicb.2022.927306","volume":"13","author":"M Heidary","year":"2022","unstructured":"Heidary, M. et al. A comprehensive review of the protein subunit vaccines against COVID-19. Front. Microbiol. 13, 927306 (2022).","journal-title":"Front. Microbiol."},{"key":"727_CR113","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/cmdc.201200487","volume":"8","author":"PM Moyle","year":"2013","unstructured":"Moyle, P. M. & Toth, I. Modern subunit vaccines: development, components, and research opportunities. ChemMedChem 8, 360\u2013376 (2013).","journal-title":"ChemMedChem"},{"key":"727_CR114","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/vaccines4020012","volume":"4","author":"A Vartak","year":"2016","unstructured":"Vartak, A. & Sucheck, S. J. Recent advances in subunit vaccine carriers. Vaccines 4, 12 (2016).","journal-title":"Vaccines"},{"key":"727_CR115","doi-asserted-by":"publisher","first-page":"1131057","DOI":"10.3389\/fimmu.2023.1131057","volume":"14","author":"S Chen","year":"2023","unstructured":"Chen, S. et al. Precision-engineering of subunit vaccine particles for prevention of infectious diseases. Front. Immunol. 14, 1131057 (2023).","journal-title":"Front. Immunol."},{"key":"727_CR116","doi-asserted-by":"publisher","first-page":"611","DOI":"10.4049\/jimmunol.1900991","volume":"204","author":"AP Gilkes","year":"2020","unstructured":"Gilkes, A. P. et al. Tuning subunit vaccines with novel TLR triagonist adjuvants to generate protective immune responses against Coxiella burnetii. J. Immunol. 204, 611\u2013621 (2020).","journal-title":"J. Immunol."},{"key":"727_CR117","doi-asserted-by":"publisher","first-page":"653092","DOI":"10.3389\/fimmu.2021.653092","volume":"12","author":"AP Fratzke","year":"2021","unstructured":"Fratzke, A. P. et al. Subunit vaccines using TLR triagonist combination adjuvants provide protection against Coxiella burnetii while minimizing reactogenic responses. Front. Immunol. 12, 653092 (2021).","journal-title":"Front. Immunol."},{"key":"727_CR118","doi-asserted-by":"publisher","first-page":"4909","DOI":"10.4049\/jimmunol.1201622","volume":"189","author":"Y Peng","year":"2012","unstructured":"Peng, Y. et al. Development of a lipopolysaccharide-targeted peptide mimic vaccine against Q fever. J. Immunol. 189, 4909\u20134920 (2012).","journal-title":"J. Immunol."},{"key":"727_CR119","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ijbiomac.2022.12.158","volume":"227","author":"Y Feng","year":"2023","unstructured":"Feng, Y. et al. DEC-205 receptor targeted poly(lactic-co-glycolic acid) nanoparticles containing Eucommia ulmoides polysaccharide enhances the immune response of foot-and-mouth disease vaccine in mice. Int. J. Biol. Macromol. 227, 576\u2013589 (2023).","journal-title":"Int. J. Biol. Macromol."},{"key":"727_CR120","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4049\/jimmunol.175.1.196","volume":"175","author":"GT Belz","year":"2005","unstructured":"Belz, G. T. et al. CD8alpha+ dendritic cells selectively present MHC class I-restricted noncytolytic viral and intracellular bacterial antigens in vivo. J. Immunol. 175, 196\u2013200 (2005).","journal-title":"J. Immunol."},{"key":"727_CR121","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1182\/blood-2011-08-373944","volume":"119","author":"G Schreibelt","year":"2012","unstructured":"Schreibelt, G. et al. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood 119, 2284\u20132292 (2012).","journal-title":"Blood"},{"key":"727_CR122","doi-asserted-by":"publisher","first-page":"786144","DOI":"10.3389\/fimmu.2021.786144","volume":"12","author":"V Ceglia","year":"2021","unstructured":"Ceglia, V. et al. Anti-CD40 antibody fused to CD40 ligand is a superagonist platform for adjuvant intrinsic DC-targeting vaccines. Front. Immunol. 12, 786144 (2021).","journal-title":"Front. Immunol."},{"key":"727_CR123","doi-asserted-by":"publisher","first-page":"745016","DOI":"10.3389\/fcimb.2021.745016","volume":"11","author":"GH Ong","year":"2021","unstructured":"Ong, G. H. et al. Exploration of pattern recognition receptor agonists as candidate adjuvants. Front. Cell Infect. Microbiol. 11, 745016 (2021).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"727_CR124","doi-asserted-by":"publisher","first-page":"102172","DOI":"10.1016\/j.cbpa.2022.102172","volume":"70","author":"A Kaur","year":"2022","unstructured":"Kaur, A. et al. Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics. Curr. Opin. Chem. Biol. 70, 102172 (2022).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"727_CR125","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s11094-020-02111-3","volume":"53","author":"NA Alpatova","year":"2020","unstructured":"Alpatova, N. A. et al. Adjuvant properties of cytokines in vaccination (Review). Pharm. Chem. J. 53, 991\u2013996 (2020).","journal-title":"Pharm. Chem. J."},{"key":"727_CR126","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.2147\/IJN.S317113","volume":"16","author":"H Zhao","year":"2021","unstructured":"Zhao, H. et al. Chitosan nanovaccines as efficient carrier adjuvant system for IL-12 with enhanced protection against HBV. Int. J. Nanomed. 16, 4913\u20134928 (2021).","journal-title":"Int. J. Nanomed."},{"key":"727_CR127","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cell.2019.11.032","volume":"180","author":"L Mesin","year":"2020","unstructured":"Mesin, L. et al. Restricted clonality and limited germinal center reentry characterize memory B cell reactivation by boosting. Cell 180, 92\u2013106.e11 (2020).","journal-title":"Cell"},{"key":"727_CR128","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-021-00657-1","volume":"22","author":"BJ Laidlaw","year":"2022","unstructured":"Laidlaw, B. J. & Ellebedy, A. H. The germinal centre B cell response to SARS-CoV-2. Nat. Rev. Immunol. 22, 7\u201318 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"727_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29978-y","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Recycling of memory B cells between germinal center and lymph node subcapsular sinus supports affinity maturation to antigenic drift. Nat. Commun. 13, 2460 (2022).","journal-title":"Nat. Commun."},{"key":"727_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05772-7","volume":"9","author":"I Moran","year":"2018","unstructured":"Moran, I. et al. Memory B cells are reactivated in subcapsular proliferative foci of lymph nodes. Nat. Commun. 9, 3372 (2018).","journal-title":"Nat. Commun."},{"key":"727_CR131","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/ni1139","volume":"5","author":"RL Lindquist","year":"2004","unstructured":"Lindquist, R. L. et al. Visualizing dendritic cell networks in vivo. Nat. Immunol. 5, 1243\u201350 (2004).","journal-title":"Nat. Immunol."},{"key":"727_CR132","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.immuni.2007.06.007","volume":"27","author":"YR Carrasco","year":"2007","unstructured":"Carrasco, Y. R. & Batista, F. D. B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. Immunity 27, 160\u2013171 (2007).","journal-title":"Immunity"},{"key":"727_CR133","doi-asserted-by":"publisher","first-page":"110901","DOI":"10.1016\/j.celrep.2022.110901","volume":"39","author":"DM Hinke","year":"2022","unstructured":"Hinke, D. M. et al. Antigen bivalency of antigen-presenting cell-targeted vaccines increases B cell responses. Cell Rep. 39, 110901 (2022).","journal-title":"Cell Rep."},{"key":"727_CR134","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.immuni.2020.08.001","volume":"53","author":"Y Kato","year":"2020","unstructured":"Kato, Y. et al. Multifaceted effects of antigen valency on B cell response composition and differentiation in vivo. Immunity 53, 548\u2013563.e8 (2020).","journal-title":"Immunity"},{"key":"727_CR135","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.15252\/embj.201694177","volume":"35","author":"C Volkmann","year":"2016","unstructured":"Volkmann, C. et al. Molecular requirements of the B-cell antigen receptor for sensing monovalent antigens. EMBO J. 35, 2371\u20132381 (2016).","journal-title":"EMBO J."},{"key":"727_CR136","doi-asserted-by":"publisher","first-page":"e2102089","DOI":"10.1002\/adhm.202102089","volume":"11","author":"S Chen","year":"2022","unstructured":"Chen, S. et al. Ambient temperature stable, scalable COVID-19 polymer particle vaccines induce protective immunity. Adv. Health. Mater. 11, e2102089 (2022).","journal-title":"Adv. Health. Mater."},{"key":"727_CR137","doi-asserted-by":"crossref","unstructured":"Chen, S. et al. Assembly of immunogenic protein particles toward advanced synthetic vaccines. Small 19, e2205819 (2022).","DOI":"10.1002\/smll.202205819"},{"key":"727_CR138","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1080\/08820139.2021.1903033","volume":"50","author":"W Luo","year":"2021","unstructured":"Luo, W. & Yin, Q. B cell response to vaccination. Immunol. Invest. 50, 780\u2013801 (2021).","journal-title":"Immunol. Invest."},{"key":"727_CR139","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1126\/science.aat9120","volume":"363","author":"T Tokatlian","year":"2019","unstructured":"Tokatlian, T. et al. Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers. Science 363, 649\u2013654 (2019).","journal-title":"Science"},{"key":"727_CR140","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41565-020-00790-3","volume":"16","author":"A Singh","year":"2021","unstructured":"Singh, A. Eliciting B cell immunity against infectious diseases using nanovaccines. Nat. Nanotechnol. 16, 16\u201324 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"727_CR141","doi-asserted-by":"publisher","first-page":"101702","DOI":"10.1016\/j.smim.2022.101702","volume":"65","author":"S This","year":"2023","unstructured":"This, S. et al. What\u2019s self got to do with it: sources of heterogeneity among naive T cells. Semin. Immunol. 65, 101702 (2023).","journal-title":"Semin. Immunol."},{"key":"727_CR142","doi-asserted-by":"publisher","first-page":"e2250305","DOI":"10.1002\/eji.202250305","volume":"53","author":"K van Gisbergen","year":"2023","unstructured":"van Gisbergen, K. & Gerlach, C. No-shows in T-cell responses are frequent for clones of low T-cell receptor affinity. Eur. J. Immunol. 53, e2250305 (2023).","journal-title":"Eur. J. Immunol."},{"key":"727_CR143","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nri778","volume":"2","author":"SM Kaech","year":"2002","unstructured":"Kaech, S. M., Wherry, E. J. & Ahmed, R. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2, 251\u2013262 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"727_CR144","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1021\/acsbiomaterials.8b00579","volume":"4","author":"M Gonz\u00e1lez-Mir\u00f3","year":"2018","unstructured":"Gonz\u00e1lez-Mir\u00f3, M. et al. Design and biological assembly of polyester beads displaying pneumococcal antigens as particulate vaccine. ACS Biomater. Sci. Eng. 4, 3413\u20133424 (2018).","journal-title":"ACS Biomater. Sci. Eng."},{"key":"727_CR145","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1021\/acsinfecdis.1c00434","volume":"8","author":"ZJC Gonzaga","year":"2022","unstructured":"Gonzaga, Z. J. C., Zhang, J. & Rehm, B. H. Intranasal delivery of antigen-coated polymer particles protects against Pseudomonas aeruginosa infection. ACS Infect. Dis. 8, 744\u2013756 (2022).","journal-title":"ACS Infect. Dis."},{"key":"727_CR146","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jconrel.2022.09.044","volume":"351","author":"Z Teng","year":"2022","unstructured":"Teng, Z. et al. Bridging nanoplatform and vaccine delivery, a landscape of strategy to enhance nasal immunity. J. Control Release 351, 456\u2013475 (2022).","journal-title":"J. Control Release"},{"key":"727_CR147","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1080\/21645515.2015.1114195","volume":"12","author":"F Su","year":"2016","unstructured":"Su, F. et al. Induction of mucosal immunity through systemic immunization: phantom or reality? Hum. Vaccin. Immunother. 12, 1070\u20131079 (2016).","journal-title":"Hum. Vaccin. Immunother."},{"key":"727_CR148","doi-asserted-by":"publisher","first-page":"M110.006304","DOI":"10.1074\/mcp.M110.006304","volume":"10","author":"A Vigil","year":"2011","unstructured":"Vigil, A. et al. Profiling the humoral immune response of acute and chronic Q fever by protein microarray. Mol. Cell Proteom. 10, M110.006304 (2011).","journal-title":"Mol. Cell Proteom."},{"key":"727_CR149","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1099\/mic.0.082131-0","volume":"160","author":"J Jiao","year":"2014","unstructured":"Jiao, J. et al. Serological characterization of surface-exposed proteins of Coxiella burnetii. Microbiology 160, 2718\u20132731 (2014).","journal-title":"Microbiology"},{"key":"727_CR150","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1128\/CVI.00300-08","volume":"15","author":"PA Beare","year":"2008","unstructured":"Beare, P. A. et al. Candidate antigens for Q fever serodiagnosis revealed by immunoscreening of a Coxiella burnetii protein microarray. Clin. Vaccin. Immunol. 15, 1771\u20131779 (2008).","journal-title":"Clin. Vaccin. Immunol."},{"key":"727_CR151","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-12-35","volume":"12","author":"X Xiong","year":"2012","unstructured":"Xiong, X. et al. Potential serodiagnostic markers for Q fever identified in Coxiella burnetii by immunoproteomic and protein microarray approaches. BMC Microbiol. 12, 35 (2012).","journal-title":"BMC Microbiol."},{"key":"727_CR152","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1002\/pmic.201000064","volume":"10","author":"A Vigil","year":"2010","unstructured":"Vigil, A. et al. Genome-wide profiling of humoral immune response to Coxiella burnetii infection by protein microarray. Proteomics 10, 2259\u20132269 (2010).","journal-title":"Proteomics"},{"key":"727_CR153","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3389\/fimmu.2019.00207","volume":"10","author":"A Scholzen","year":"2019","unstructured":"Scholzen, A. et al. Promiscuous Coxiella burnetii CD4 epitope clusters associated with human recall responses are candidates for a novel T-cell targeted multi-epitope Q fever vaccine. Front. Immunol. 10, 207 (2019).","journal-title":"Front. Immunol."},{"key":"727_CR154","doi-asserted-by":"publisher","first-page":"e00213-19","DOI":"10.1128\/IAI.00213-19","volume":"87","author":"A Scholzen","year":"2019","unstructured":"Scholzen, A. et al. Coxiella burnetii epitope-specific T-cell responses in patients with chronic Q fever. Infect. Immun. 87, e00213-19 (2019).","journal-title":"Infect. Immun."},{"key":"727_CR155","doi-asserted-by":"publisher","first-page":"e87206","DOI":"10.1371\/journal.pone.0087206","volume":"9","author":"X Xiong","year":"2014","unstructured":"Xiong, X. et al. Exploratory study on Th1 epitope-induced protective immunity against Coxiella burnetii infection. PLoS ONE 9, e87206 (2014).","journal-title":"PLoS ONE"},{"key":"727_CR156","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1016\/j.vaccine.2023.04.012","volume":"41","author":"C Dold","year":"2023","unstructured":"Dold, C. et al. Immunisation with purified Coxiella burnetii phase I lipopolysaccharide confers partial protection in mice independently of co-administered adenovirus vectored vaccines. Vaccine 41, 3047\u20133057 (2023).","journal-title":"Vaccine"},{"key":"727_CR157","first-page":"1580","volume":"215","author":"X Xiong","year":"2017","unstructured":"Xiong, X. et al. Identification of Coxiella burnetii CD8+ T-cell epitopes and delivery by attenuated listeria monocytogenes as a vaccine vector in a C57BL\/6 mouse model. J. Infect. Dis. 215, 1580\u20131589 (2017).","journal-title":"J. Infect. Dis."},{"key":"727_CR158","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","volume":"10","author":"MF Bachmann","year":"2010","unstructured":"Bachmann, M. F. & Jennings, G. T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787\u2013796 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"727_CR159","doi-asserted-by":"publisher","first-page":"120597","DOI":"10.1016\/j.biomaterials.2020.120597","volume":"268","author":"D Wibowo","year":"2021","unstructured":"Wibowo, D. et al. Polymeric nanoparticle vaccines to combat emerging and pandemic threats. Biomaterials 268, 120597 (2021).","journal-title":"Biomaterials"},{"key":"727_CR160","doi-asserted-by":"publisher","first-page":"607945","DOI":"10.3389\/fimmu.2020.607945","volume":"11","author":"MV Baranov","year":"2020","unstructured":"Baranov, M. V. et al. Modulation of immune responses by particle size and shape. Front. Immunol. 11, 607945 (2020).","journal-title":"Front. Immunol."},{"key":"727_CR161","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.3390\/nano11082060","volume":"11","author":"S Chen","year":"2021","unstructured":"Chen, S. et al. Particulate mycobacterial vaccines induce protective immunity against tuberculosis in mice. Nanomaterials 11, 2060 (2021).","journal-title":"Nanomaterials"},{"key":"727_CR162","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1096\/fj.201802501RR","volume":"33","author":"S Chen","year":"2019","unstructured":"Chen, S. et al. Innovative antigen carrier system for the development of tuberculosis vaccines. FASEB J. 33, 7505\u20137518 (2019).","journal-title":"FASEB J."},{"key":"727_CR163","doi-asserted-by":"publisher","first-page":"828784","DOI":"10.3389\/fcimb.2022.828784","volume":"12","author":"M Tesfamariam","year":"2022","unstructured":"Tesfamariam, M., Binette, P. & Long, C. M. Preclinical animal models for Q fever vaccine development. Front. Cell Infect. Microbiol. 12, 828784 (2022).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"727_CR164","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1099\/mic.0.077230-0","volume":"160","author":"IH Norville","year":"2014","unstructured":"Norville, I. H. et al. Galleria mellonella as an alternative model of Coxiella burnetii infection. Microbiology 160, 1175\u20131181 (2014).","journal-title":"Microbiology"},{"key":"727_CR165","doi-asserted-by":"publisher","first-page":"e29726","DOI":"10.1371\/journal.pone.0029726","volume":"7","author":"M Arras","year":"2012","unstructured":"Arras, M. et al. Multiparameter telemetry as a sensitive screening method to detect vaccine reactogenicity in mice. PLoS ONE 7, e29726 (2012).","journal-title":"PLoS ONE"},{"key":"727_CR166","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56994-8","volume":"9","author":"J Weiner","year":"2019","unstructured":"Weiner, J. et al. Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium. Sci. Rep. 9, 20362 (2019).","journal-title":"Sci. Rep."},{"key":"727_CR167","doi-asserted-by":"publisher","first-page":"e96031","DOI":"10.1172\/jci.insight.96031","volume":"2","author":"CY Chan","year":"2017","unstructured":"Chan, C. Y. et al. Early molecular correlates of adverse events following yellow fever vaccination. JCI Insight 2, e96031 (2017).","journal-title":"JCI Insight"},{"key":"727_CR168","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.vaccine.2019.02.015","volume":"37","author":"W Burny","year":"2019","unstructured":"Burny, W. et al. Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans. Vaccine 37, 2004\u20132015 (2019).","journal-title":"Vaccine"},{"key":"727_CR169","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/21645515.2019.1697110","volume":"16","author":"P Gonzalez-Dias","year":"2020","unstructured":"Gonzalez-Dias, P. et al. Methods for predicting vaccine immunogenicity and reactogenicity. Hum. Vaccin. Immunother. 16, 269\u2013276 (2020).","journal-title":"Hum. Vaccin. Immunother."},{"key":"727_CR170","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1586\/14760584.2015.1081067","volume":"14","author":"L Zhang","year":"2015","unstructured":"Zhang, L., Wang, W. & Wang, S. Effect of vaccine administration modality on immunogenicity and efficacy. Expert Rev. Vaccines 14, 1509\u201323 (2015).","journal-title":"Expert Rev. Vaccines"},{"key":"727_CR171","unstructured":"Frieden, T. R. Public health then and now: celebrating 50 years of MMWR at CDC: foreward. (2011)."},{"key":"727_CR172","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1038\/nm1213","volume":"11","author":"J Holmgren","year":"2005","unstructured":"Holmgren, J. & Czerkinsky, C. Mucosal immunity and vaccines. Nat. Med. 11, S45\u2013S53 (2005).","journal-title":"Nat. Med."},{"key":"727_CR173","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.immuni.2022.04.013","volume":"55","author":"RC Mettelman","year":"2022","unstructured":"Mettelman, R. C., Allen, E. K. & Thomas, P. G. Mucosal immune responses to infection and vaccination in the respiratory tract. Immunity 55, 749\u2013780 (2022).","journal-title":"Immunity"},{"key":"727_CR174","doi-asserted-by":"publisher","first-page":"6019","DOI":"10.1128\/JVI.03101-13","volume":"88","author":"GE Price","year":"2014","unstructured":"Price, G. E. et al. Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model. J. Virol. 88, 6019\u20136030 (2014).","journal-title":"J. Virol."},{"key":"727_CR175","doi-asserted-by":"publisher","first-page":"6076","DOI":"10.1016\/j.vaccine.2019.08.041","volume":"37","author":"J Feng","year":"2019","unstructured":"Feng, J. et al. Enhanced protection against Q fever in BALB\/c mice elicited by immunization of chloroform-methanol residue of Coxiella burnetii via intratracheal inoculation. Vaccine 37, 6076\u20136084 (2019).","journal-title":"Vaccine"},{"key":"727_CR176","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/eji.200738067","volume":"38","author":"M Benoit","year":"2008","unstructured":"Benoit, M. et al. Coxiella burnetii, the agent of Q fever, stimulates an atypical M2 activation program in human macrophages. Eur. J. Immunol. 38, 1065\u201370 (2008).","journal-title":"Eur. J. Immunol."},{"key":"727_CR177","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3390\/vaccines11030511","volume":"11","author":"SE Williams-Macdonald","year":"2023","unstructured":"Williams-Macdonald, S. E. et al. Efficacy of phase I and phase II Coxiella burnetii bacterin vaccines in a pregnant Ewe challenge model. Vaccines 11, 511 (2023).","journal-title":"Vaccines"},{"key":"727_CR178","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00607-z","volume":"8","author":"S Tomaiuolo","year":"2023","unstructured":"Tomaiuolo, S. et al. QuilA(R) adjuvanted Coxevac(R) sustains Th1-CD8(+)-type immunity and increases protection in Coxiella burnetii-challenged goats. npj Vaccines 8, 17 (2023).","journal-title":"npj Vaccines"},{"key":"727_CR179","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1128\/CVI.00119-08","volume":"15","author":"DM Waag","year":"2008","unstructured":"Waag, D. M. et al. Low-dose priming before vaccination with the phase I chloroform-methanol residue vaccine against Q fever enhances humoral and cellular immune responses to Coxiella burnetii. Clin. Vaccin. Immunol. 15, 1505\u20131512 (2008).","journal-title":"Clin. Vaccin. Immunol."}],"container-title":["npj Vaccines"],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00727-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00727-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00727-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T03:04:38Z","timestamp":1700449478000},"score":18.326576,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00727-6"}},"issued":{"date-parts":[[2023,9,7]]},"references-count":179,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["727"],"URL":"https:\/\/doi.org\/10.1038\/s41541-023-00727-6","ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"published":{"date-parts":[[2023,9,7]]},"assertion":[{"value":"2 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"},{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T17:37:35Z","timestamp":1649093855760},"reference-count":2,"publisher":"Springer Science and Business Media LLC","issue":"637","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reactions Weekly"],"published-print":{"date-parts":[[1997,2]]},"DOI":"10.2165\/00128415-199706370-00005","type":"journal-article","created":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T05:16:48Z","timestamp":1138166208000},"page":"3","source":"Crossref","is-referenced-by-count":0,"title":["HIV vaccines: is live-attenuated 'safe enough'?"],"prefix":"10.1007","volume":"&NA;","author":[{"family":"&NA;","sequence":"first","affiliation":[]}],"member":"297","reference":[{"key":"R1-5-2801","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nm0197-17","volume":"3","author":"Murphey-Corb","year":"1997","journal-title":"Nature Medicine"},{"key":"R2-5-2801","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nm0197-32","volume":"3","author":"Wyand","year":"1997","journal-title":"Nature Medicine"}],"container-title":["Reactions Weekly"],"language":"en","deposited":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T19:15:25Z","timestamp":1553195725000},"score":18.313015,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2165\/00128415-199706370-00005"}},"subtitle":[""],"issued":{"date-parts":[[1997,2]]},"references-count":2,"journal-issue":{"issue":"637"},"URL":"https:\/\/doi.org\/10.2165\/00128415-199706370-00005","ISSN":["0114-9954"],"issn-type":[{"value":"0114-9954","type":"print"}],"published":{"date-parts":[[1997,2]]}},{"indexed":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T07:41:51Z","timestamp":1661499711336},"reference-count":1,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T00:00:00Z","timestamp":1661558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T00:00:00Z","timestamp":1661558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reactions Weekly"],"DOI":"10.1007\/s40278-022-22002-3","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T07:06:01Z","timestamp":1661497561000},"page":"8-8","source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 mRNA vaccines safe in pregnancy"],"prefix":"10.1007","volume":"1921","member":"297","published-online":{"date-parts":[[2022,8,27]]},"reference":[{"key":"22002_CR1","doi-asserted-by":"crossref","unstructured":"Sadarangani M, et al. Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study The Lancet Infectious Diseases : 18 Aug 2022. Available from: URL: \nhttps:\/\/bit.ly\/3Qxp5k5","DOI":"10.1016\/S1473-3099(22)00426-1"}],"container-title":["Reactions Weekly"],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40278-022-22002-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40278-022-22002-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40278-022-22002-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T07:19:07Z","timestamp":1661498347000},"score":18.313015,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40278-022-22002-3"}},"issued":{"date-parts":[[2022,8,27]]},"references-count":1,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["22002"],"URL":"https:\/\/doi.org\/10.1007\/s40278-022-22002-3","ISSN":["1179-2051"],"issn-type":[{"value":"1179-2051","type":"electronic"}],"published":{"date-parts":[[2022,8,27]]}},{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T01:01:30Z","timestamp":1649120490838},"reference-count":0,"publisher":"Royal Pharmaceutical Society","content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2017]]},"DOI":"10.1211\/pj.2017.20203605","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T13:14:31Z","timestamp":1505913271000},"source":"Crossref","is-referenced-by-count":0,"title":["Patients told by GP practice that flu vaccines from pharmacists are 'less safe'"],"prefix":"10.1211","member":"162","container-title":["The Pharmaceutical Journal"],"deposited":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T17:00:41Z","timestamp":1509382841000},"score":18.308558,"resource":{"primary":{"URL":"http:\/\/www.pharmaceutical-journal.com\/news-and-analysis\/news\/patients-told-by-gp-practice-that-flu-vaccines-from-pharmacists-are-less-safe\/20203605.article"}},"issued":{"date-parts":[[2017]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1211\/pj.2017.20203605","ISSN":["2053-6186"],"issn-type":[{"value":"2053-6186","type":"print"}],"published":{"date-parts":[[2017]]}},{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:57:46Z","timestamp":1648601866289},"reference-count":0,"publisher":"Springer Science and Business Media LLC","issue":"1072","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Inpharma Weekly"],"published-print":{"date-parts":[[1997,2]]},"DOI":"10.2165\/00128413-199710720-00018","type":"journal-article","created":{"date-parts":[[2007,12,5]],"date-time":"2007-12-05T12:49:43Z","timestamp":1196858983000},"page":"12","source":"Crossref","is-referenced-by-count":0,"title":["HIV vaccines: is live-attenuated ???safe enough????"],"prefix":"10.1007","volume":"&NA;","author":[{"family":"&NA;","sequence":"first","affiliation":[]}],"member":"297","container-title":["Inpharma Weekly"],"language":"en","deposited":{"date-parts":[[2013,2,27]],"date-time":"2013-02-27T16:09:20Z","timestamp":1361981360000},"score":18.3003,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2165\/00128413-199710720-00018"}},"subtitle":[""],"issued":{"date-parts":[[1997,2]]},"references-count":0,"journal-issue":{"issue":"1072"},"URL":"https:\/\/doi.org\/10.2165\/00128413-199710720-00018","ISSN":["1173-8324"],"issn-type":[{"value":"1173-8324","type":"print"}],"published":{"date-parts":[[1997,2]]}},{"indexed":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T01:45:22Z","timestamp":1725673522959},"publisher-location":"Berlin, Heidelberg","reference-count":43,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"type":"print","value":"9783540556466"},{"type":"electronic","value":"9783642483912"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[1992]]},"DOI":"10.1007\/978-3-642-48391-2_23","type":"book-chapter","created":{"date-parts":[[2012,4,5]],"date-time":"2012-04-05T07:47:53Z","timestamp":1333612073000},"page":"226-232","source":"Crossref","is-referenced-by-count":1,"title":["Liposomes as Safe Carriers of Drugs and Vaccines"],"prefix":"10.1007","author":[{"given":"Carl R.","family":"Alving","sequence":"first","affiliation":[]}],"member":"297","reference":[{"key":"23_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0022-510X(77)90104-6","volume":"31","author":"DH Adams","year":"1977","unstructured":"Adams DH, Joyce G, Richardson VJ, Ryman BE, Wisniewski HM (1977) Liposome toxicity in the mouse central nervous system. J Neurol Sci 31:173\u2013179","journal-title":"J Neurol Sci"},{"key":"23_CR2","first-page":"267","volume":"229","author":"TM Allen","year":"1984","unstructured":"Allen TM, Murray L, MacKeigan S, Shah M (1984) Chronic liposome administration in mice. Effects on reticuloendothelial function and tissue distribution. J Pharmacol Exper Ther 229:267\u2013275","journal-title":"J Pharmacol Exper Ther"},{"key":"23_CR3","first-page":"281","volume":"50","author":"TM Allen","year":"1985","unstructured":"Allen TM, Smuckler EA (1985) Liver pathology accompanying chronic liposome administration in mouse. Res Commun Chem Pathol Pharmacol 50:281\u2013290","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"23_CR4","first-page":"37","volume-title":"Liposomes as drug carriers","author":"TM Allen","year":"1987","unstructured":"Allen TM (1987) Interactions of liposomes and other drug carriers with the mononuclear phagocyte system. In: Gregoriadis G (ed) Liposomes as drug carriers. Wiley, London, pp 37\u201350"},{"key":"23_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0163-7258(83)90010-4","volume":"22","author":"CR Alving","year":"1983","unstructured":"Alving CR (1983) Delivery of liposome-encapsulated drugs to macrophages. Pharmacol Ther 22:407\u2013424","journal-title":"Pharmacol Ther"},{"key":"23_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0022-1759(91)90120-5","volume":"40","author":"CR Alving","year":"1991","unstructured":"Alving CR (1991) Liposomes as carriers of antigens and adjuvants. J Immunol Meth 40:1\u201313","journal-title":"J Immunol Meth"},{"key":"23_CR7","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1042\/bst0120342","volume":"12","author":"CR Alving","year":"1984","unstructured":"Alving CR (1984) Natural antibodies against phospholipids and liposomes in humans. Biochem Soc Trans 12:342\u2013344","journal-title":"Biochem Soc Trans"},{"key":"23_CR8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4049\/jimmunol.118.1.342","volume":"118","author":"CR Alving","year":"1977","unstructured":"Alving CR, Richards RL, Guirguis AA (1977) Cholesterol-dependent complement activation resulting in damage to liposomal model membranes. J Immunol 118:342\u2013347","journal-title":"J Immunol"},{"key":"23_CR9","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0140-6736(74)91213-6","volume":"ii","author":"JWB Bradfield","year":"1974","unstructured":"Bradfield JWB (1974) Control of spillover. The importance of Kupffer-cell function in clinical medicine. Lancet ii:883\u2013886","journal-title":"Lancet"},{"key":"23_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/260331a0","volume":"260","author":"A Bruni","year":"1976","unstructured":"Bruni A, Toffano G, Leon A, Boarato E (1976) Pharmacological effects of phospha-tidylserine liposomes. Nature 260:331\u2013333","journal-title":"Nature"},{"key":"23_CR11","first-page":"21","volume":"37","author":"PI Campbell","year":"1983","unstructured":"Campbell PI (1983) Toxicity of some charged lipids used in liposome preparations. Cytobios 37:21\u201326","journal-title":"Cytobios"},{"key":"23_CR12","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1159\/000123261","volume":"33","author":"PL Canonico","year":"1981","unstructured":"Canonico PL, Annunziato L, Toffano G, Bernardini R, Stanzani S, Foti M, Clementi G, Drago F, Scapagnini U (1981) In vivo and in vitro interference of phosphatidylser-ine liposomes on prolactin secretion in the rat. Neuroendocrinology 33:358\u2013362","journal-title":"Neuroendocrinology"},{"key":"23_CR13","first-page":"1031","volume":"67","author":"A Coune","year":"1983","unstructured":"Coune A, Sculier JP, Fr\u00fchling J, Stryckmans P, Brassinne C, Ghanem G, Laduron C, Atassi G, Ruysschaert JM, Hildebrand J (1983) IV administration of a water-insoluble antimitotic compound entrapped in liposomes. Preliminary report on infusion of large volumes of liposomes to man. Cancer Treat Rep 67:1031\u20131033","journal-title":"Cancer Treat Rep"},{"key":"23_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1056\/NEJM197704072961401","volume":"296","author":"PR Craddock","year":"1977","unstructured":"Craddock PR, Fehr J, Brigham KL, Kronenberg RS, Jacob HS (1977) Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med 296:769\u2013774","journal-title":"N Engl J Med"},{"key":"23_CR15","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/0167-4889(86)90020-0","volume":"888","author":"J Dave","year":"1986","unstructured":"Dave J, Patel HM (1986) Differentiation in hepatic and splenic phagocytic activity during reticuloendothelial blockage with cholesterol-free and cholesterol-rich liposomes. Biochim Biophys Acta 888:184\u2013190","journal-title":"Biochim Biophys Acta"},{"key":"23_CR16","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.4049\/jimmunol.138.8.2663","volume":"138","author":"J Dijkstra","year":"1987","unstructured":"Dijkstra J, Mellors JW, Ryan JL, Szoka F (1987) Modulation of the biological activity of bacterial endotoxin by incorporation into liposomes. J Immunol 138:2663\u20132670","journal-title":"J Immunol"},{"key":"23_CR17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/0304-4165(82)90157-X","volume":"714","author":"H Ellens","year":"1982","unstructured":"Ellens H, Mayhew E, Rustum YM (1982) Reversible depression of the reticuloendothelial system by liposomes. Biochim Biophys Acta 714:479\u2013485","journal-title":"Biochim Biophys Acta"},{"key":"23_CR18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1073\/pnas.89.1.358","volume":"83","author":"LF Fries","year":"1992","unstructured":"Fries LF, Gordon DM, Richards RL, Egan JE, Hollingdale MR, Gross M, Silverman C, Alving CR (1992) Liposomal malaria vaccine in humans: a novel, safe, and potent adjuvant strategy. Proc Natl Acad Sci USA 83:358\u2013362","journal-title":"Proc Natl Acad Sci USA"},{"key":"23_CR19","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1056\/NEJM198410043111403","volume":"311","author":"RM Hakim","year":"1984","unstructured":"Hakim RM, Breillat J, Lazarus JM, Port FK (1984) Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med 311:878\u2013882","journal-title":"N Engl J Med"},{"key":"23_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/BF00205887","volume":"10","author":"IR Hart","year":"1981","unstructured":"Hart IR, Fogler WE, Poste G, Fidler IJ (1981) Toxicity studies of liposome-encapsu-lated immunomodulators administered intravenously to dogs and mice. Cancer Immunol Immunother 10:157\u2013166","journal-title":"Cancer Immunol Immunother"},{"key":"23_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/0304-4165(81)90259-2","volume":"677","author":"YJ Kao","year":"1981","unstructured":"Kao YJ, Juliano RL (1981) Interactions of liposomes with the reticuloendothelial system. Effects of reticuloendothelial blockade on the clearance of large unilamellar vesicles. Biochim Biophys Acta 677:453\u2013461","journal-title":"Biochim Biophys Acta"},{"key":"23_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/BF01120305","volume":"4","author":"N Latif","year":"1984","unstructured":"Latif N, Bachhawat BK (1984) The effect of surface charges of liposomes in immuno-potentiation. Biosci Rep 4:99\u2013107","journal-title":"Biosci Rep"},{"key":"23_CR23","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/0014-2964(80)90025-0","volume":"16","author":"D Layton","year":"1980","unstructured":"Layton D, Luckenbach GA, Andreesen R, Munder PG (1980) The interaction of liposomes with cells: the relation of cell specific toxicity to lipid composition. Eur J Cancer 16:1529\u20131538","journal-title":"Eur J Cancer"},{"key":"23_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1471-4159.1978.tb07030.x","volume":"30","author":"A Leon","year":"1978","unstructured":"Leon A, Benvegnu D, Toffano G, Orlando P, Massari P (1978) Effect of brain cortex phospholipids on adenylate-cyclase activity of mouse brain. J Neurochem 30:23\u201326","journal-title":"J Neurochem"},{"key":"23_CR25","doi-asserted-by":"crossref","first-page":"664","DOI":"10.7326\/0003-4819-114-8-664","volume":"114","author":"SJ Levine","year":"1991","unstructured":"Levine SJ, Walsh TJ, Martinez A, Eichacker PQ, Lopez-Berestein G, Natanson C (1991) Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Int Med 114:664\u2013666","journal-title":"Ann Int Med"},{"key":"23_CR26","first-page":"427","volume-title":"Kupffer cells and other liver sinusoidal cells","author":"H Liehr","year":"1977","unstructured":"Liehr H, Gr\u00fcn M (1977) Clinical aspects of Kupffer cell failure in liver diseases. In: Wisse E, Knook DL (eds) Kupffer cells and other liver sinusoidal cells. Elsevier\/ North-Holland, Amsterdam, pp 427\u2013436"},{"key":"23_CR27","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/infdis\/151.4.704","volume":"151","author":"G Lopez-Berestein","year":"1985","unstructured":"Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M, Rosenblum MG, Mehta R, Luna M, Hersh EM, Reuben J, Juliano RL, Bodey GP (1985) Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer. A preliminary study. J Infect Dis 151:704\u2013710","journal-title":"J Infect Dis"},{"key":"23_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0162-3109(87)90031-2","volume":"14","author":"F Marceau","year":"1987","unstructured":"Marceau F, Lundberg C, Hugli TE (1987) Effects of the anaphylatoxins on circulation. Immunopharmacology 14:67\u201384","journal-title":"Immunopharmacology"},{"key":"23_CR29","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/clinids\/6.4.553","volume":"6","author":"I Mattsby-Baltzer","year":"1984","unstructured":"Mattsby-Baltzer I, Alving CR (1984) Antibodies to lipid A: occurrence in humans. Rev Infect Dis 6:553\u2013557","journal-title":"Rev Infect Dis"},{"key":"23_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/00007890-198507000-00017","volume":"40","author":"RM Merion","year":"1985","unstructured":"Merion RM (1985) Measurements of reticuloendothelial system phagocytic activity in the rat after treatment with silica, liposomes, and cyclosporine. Transplantation 40:86\u201390","journal-title":"Transplantation"},{"key":"23_CR31","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1152\/jappl.1988.64.3.1143","volume":"64","author":"K Miyamoto","year":"1988","unstructured":"Miyamoto K, Schultz E, Heath T, Mitchell MD, Albertine KH, Staub NC (1988) Pulmonary intravascular macrophages and hemodynamic effects of liposomes in sheep. J Appl Physiol 64:1143\u20131152","journal-title":"J Appl Physiol"},{"key":"23_CR32","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S0016-5085(19)32333-9","volume":"69","author":"JP Nolan","year":"1975","unstructured":"Nolan JP (1975) The role of endotoxin in liver injury. Gastroenterology 69:1346\u20131356","journal-title":"Gastroenterology"},{"key":"23_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/BF00411106","volume":"95","author":"EA Panzner","year":"1979","unstructured":"Panzner EA, Jansons VK (1979) Control of in vitro cytotoxicity of positively charged liposomes. J Cancer Res Clin Oncol 95:29\u201337","journal-title":"J Cancer Res Clin Oncol"},{"key":"23_CR34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/blood.V56.2.307.307","volume":"56","author":"RB Ramsey","year":"1980","unstructured":"Ramsey RB, Hamner MB, Alving BM, Finlayson JS, Alving CR, Evatt BL (1980) Effects of lipid A and liposomes containing lipid A on platelet and fibrinogen production in rabbits. Blood 56:307\u2013310","journal-title":"Blood"},{"key":"23_CR35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3109\/08982108809035984","volume":"1","author":"EC Richardson","year":"1988","unstructured":"Richardson EC, Swartz GM Jr, Moe JB, Alving CR (1988\u20131989) Life-long administration of liposomes and lipid A in mice. Studies of effects on longevity, antibodies to liposomes, and terminal histopathological patterns. J Liposome Res 1:93\u2013110","journal-title":"J Liposome Res"},{"key":"23_CR36","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1128\/IAI.39.3.1385-1391.1983","volume":"39","author":"EC Richardson","year":"1983","unstructured":"Richardson EC, Banerji B, Seid RC Jr, Levin J, Alving CR (1983) Interactions of lipid A and liposome-associated lipid A with Limulus polyphemus ameobocytes. Infect Immun 39:1385\u20131391","journal-title":"Infect Immun"},{"key":"23_CR37","first-page":"123","volume":"3","author":"J Senior","year":"1987","unstructured":"Senior J (1987) Fate and behavior of liposomes in vivo: a review of controlling factors. CRC Crit Rev Ther Drug Carrier Systems 3:123\u2013193","journal-title":"CRC Crit Rev Ther Drug Carrier Systems"},{"key":"23_CR38","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/0024-3205(78)90671-9","volume":"23","author":"G Toffano","year":"1978","unstructured":"Toffano G, Leon A, Mazzari S, Savoini G, Teolato S, Orlando P (1978) Modification of noradrenergic hypothalamic system in rat injected with phosphatidylserine liposomes. Life Sci 23:1093\u20131102","journal-title":"Life Sci"},{"key":"23_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/BF00205743","volume":"18","author":"GJ Vosika","year":"1984","unstructured":"Vosika GJ, Barr C, Gilbertson D (1984) Phase-I study of intravenous modified lipid-A. Cancer Immunol Immunother 18:107\u2013112","journal-title":"Cancer Immunol Immunother"},{"key":"23_CR40","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.4049\/jimmunol.143.9.2990","volume":"143","author":"NM Wassef","year":"1989","unstructured":"Wassef NM, Johnson SH, Graeber GM, Swartz GM Jr, Schultz CL, Hailey JR, Johnson AJ, Taylor DG, Ridgway RL, Alving CR (1989) Anaphylactoid reactions mediated by autoantibodies to cholesterol in miniature pigs. J Immunol 143:2990\u20132995","journal-title":"J Immunol"},{"key":"23_CR41","first-page":"676","volume":"64","author":"EAH Weereratne","year":"1983","unstructured":"Weereratne EAH, Gregoriadis G, Crow J (1983) Toxicity of sphingomyelin-contain-ing liposomes after chronic injection into mice. Br J Exp Pathol 64:676","journal-title":"Br J Exp Pathol"},{"key":"23_CR42","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0005-2736(86)90068-4","volume":"854","author":"E Yoshihara","year":"1986","unstructured":"Yoshihara E, Nakae T (1986) Cytolytic activity of liposomes containing stearylamine. Biochim Biophys Acta 854:93\u2013101","journal-title":"Biochim Biophys Acta"},{"key":"23_CR43","first-page":"795","volume-title":"Liposomes as drug carriers","author":"GM Zonneveld","year":"1988","unstructured":"Zonneveld GM, Crommelin DJA (1988) Liposomes: parenteral administration to man. In: Gregoriadis G (ed) Liposomes as drug carriers. Wiley, London, pp 795\u2013817"}],"container-title":["Liposome Dermatics"],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-48391-2_23.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T19:46:10Z","timestamp":1687376770000},"score":18.3003,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-642-48391-2_23"}},"issued":{"date-parts":[[1992]]},"ISBN":["9783540556466","9783642483912"],"references-count":43,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-48391-2_23","published":{"date-parts":[[1992]]}},{"indexed":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T10:34:20Z","timestamp":1709548460428},"reference-count":1,"publisher":"Pan American League of Associations of Rheumatology (PANLAR)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Global Rheumatology"],"abstract":"<jats:p>What is the safety and efficacy of vaccines in Latin America and specifically in rheumatic patients in the region? Different research groups set themselves the task of carrying out these different studies and analyzes that allow greater security and support in decision-making<\/jats:p>","DOI":"10.46856\/grp.27.et132","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T14:40:07Z","timestamp":1660056007000},"source":"Crossref","is-referenced-by-count":0,"title":["Safe and effective vaccines against covid-19 in rheumatic patients"],"prefix":"10.46856","author":[{"given":"Estefan\u00eda","family":"Fajardo","sequence":"first","affiliation":[]}],"member":"26241","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"key":"1254","unstructured":"JCR: Journal of Clinical Rheumatology: July 2022 - Volume 28 - Issue S1 - p S1-S95 . Disponible en https:\/\/journals.lww.com\/jclinrheum\/Citation\/2022\/07001\/PANLAR_Abstracts_2022.1.aspx"}],"container-title":["Global Rheumatology"],"language":"es","deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T14:40:08Z","timestamp":1660056008000},"score":18.297844,"resource":{"primary":{"URL":"https:\/\/globalrheumpanlar.org\/articulo\/vacunas-seguras-y-eficaces-contra-el-covid-19-en-pacientes-reumaticos-796?language=en"}},"issued":{"date-parts":[[2022,8,9]]},"references-count":1,"URL":"https:\/\/doi.org\/10.46856\/grp.27.et132","archive":["Internet Archive"],"relation":{"is-translation-of":[{"id-type":"doi","id":"10.46856\/grp.27.e132","asserted-by":"subject"}]},"ISSN":["2709-5533"],"issn-type":[{"value":"2709-5533","type":"electronic"}],"published":{"date-parts":[[2022,8,9]]}},{"indexed":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T01:14:44Z","timestamp":1711070084644},"reference-count":0,"publisher":"Rowman & Littlefield Publishers","isbn-type":[{"value":"9781442215801","type":"print"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2012]]},"DOI":"10.5771\/9781442215801-81","type":"book-chapter","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T08:16:05Z","timestamp":1711008965000},"page":"81-94","source":"Crossref","is-referenced-by-count":0,"title":["Chapter 7. Vaccines and Autism: The Creation of a Modern Myth"],"prefix":"10.5771","author":[{"given":"Stacy  Mintzer","family":"Herlihy","sequence":"first","affiliation":[]},{"given":"E. Allison","family":"Hagood","sequence":"additional","affiliation":[]}],"member":"3821","container-title":["Your Baby's Best Shot"],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T08:37:53Z","timestamp":1711010273000},"score":18.149715,"resource":{"primary":{"URL":"https:\/\/www.nomos-elibrary.de\/index.php?doi=10.5771\/9781442215801-81"}},"issued":{"date-parts":[[2012]]},"ISBN":["9781442215801"],"references-count":0,"URL":"https:\/\/doi.org\/10.5771\/9781442215801-81","published":{"date-parts":[[2012]]}},{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T07:40:43Z","timestamp":1648712443543},"reference-count":2,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.4161\/hv.27481","type":"journal-article","created":{"date-parts":[[2013,12,19]],"date-time":"2013-12-19T15:27:54Z","timestamp":1387466874000},"page":"692-692","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Apropos \u201cVaccination for safe travel to India\u201d"],"prefix":"10.1080","volume":"10","author":[{"given":"Subhash C","family":"Arya","sequence":"first","affiliation":[]},{"given":"Nirmala","family":"Agarwal","sequence":"additional","affiliation":[]}],"member":"301","published-online":{"date-parts":[[2013,12,19]]},"reference":[{"key":"R1","volume":"10","author":"Mehta B","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"R2","first-page":"5","volume":"3","author":"Novak R","year":"1992","journal-title":"Wing Beats"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.4161\/hv.27481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,14]],"date-time":"2016-12-14T03:44:01Z","timestamp":1481687041000},"score":18.091936,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/abs\/10.4161\/hv.27481"}},"issued":{"date-parts":[[2013,12,19]]},"references-count":2,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3]]},"published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.4161\/hv.27481"],"URL":"https:\/\/doi.org\/10.4161\/hv.27481","ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"published":{"date-parts":[[2013,12,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"}]},{"indexed":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T15:28:27Z","timestamp":1733326107171,"version":"3.30.1"},"update-to":[{"updated":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"DOI":"10.17352\/jvi.000037","type":"new_edition","source":"publisher","label":"New edition"}],"reference-count":16,"publisher":"Peertechz Publications Private Limited","license":[{"start":{"date-parts":[[2013,11,25]],"date-time":"2013-11-25T00:00:00Z","timestamp":1385337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2015,5,25]],"date-time":"2015-05-25T00:00:00Z","timestamp":1432512000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/www.peertechzpublications.com\/journals\/journal-of-vaccines-and-immunology\/copyright-policy"}],"content-domain":{"domain":["www.peertechzpublications.com"],"crossmark-restriction":true},"short-container-title":["J Vaccines Immunol"],"published-print":{"date-parts":[[2021,1,25]]},"DOI":"10.17352\/jvi.000037","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T11:26:31Z","timestamp":1612178791000},"page":"001-003","update-policy":"https:\/\/doi.org\/10.17352\/jvi","source":"Crossref","is-referenced-by-count":0,"title":["Considerations to accelerating and maximize the preclinical studies to a safe and effective COVID-19 vaccine"],"prefix":"10.17352","author":[{"given":"Oliva-Hernandez","family":"Reynaldo","sequence":"first","affiliation":[]}],"member":"6959","published-online":{"date-parts":[[2021,1,25]]},"reference":[{"key":"ref0","unstructured":"1. Li Q, Guan X, Wu P, Wang X, Zhou L, et al. (2020) Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 382: 1199-1207. Link: https:\/\/bit.ly\/3a1iev1"},{"key":"ref1","unstructured":"2. World Health Organization (WHO) (2021) COVID-19 Weekly Epidemiological Update. Link: https:\/\/bit.ly\/3pe3zD6"},{"key":"ref2","unstructured":"3. World Health Organization (WHO) (2020) Update on WHO Solidarity Trial - Accelerating a safe and effective COVID-19 vaccine. Link: https:\/\/bit.ly\/3pjvYYG"},{"key":"ref3","unstructured":"4. International Coalition of Medicines Regulatory Authorities (ICMRA) (2020) Global regulatory workshop on COVID-19 vaccine development. Link: https:\/\/bit.ly\/3sW30A0"},{"key":"ref4","unstructured":"5. International Committee of Harmonization (ICH) (1992) Non-clinical local tolerance testing of medicinal products. CPMP\/ICH\/286\/95, III (Addendum 2):137-148."},{"key":"ref5","unstructured":"6. International Committee of Harmonization (ICH) (1997) Non-clinical safety studies for the performance of human clinical trials for Pharmaceuticals. CPMP\/ICH\/286\/95. Link: https:\/\/bit.ly\/3ojku5P"},{"key":"ref6","unstructured":"7. International Committee of Harmonization (ICH) (1997) Requirements for Registration of Pharmaceuticals for human Use. Preclinical Safety evaluation of Biotechnology-Derived Pharmaceuticals. CPMP\/ICH\/302\/95."},{"key":"ref7","unstructured":"8. Food & Drug Administration (FDA) (1997) S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. Link: https:\/\/bit.ly\/39dQeFc ."},{"key":"ref8","unstructured":"9. World Health Organization (WHO) (2005) Guidelines on nonclinical evaluation of vaccine. Technical Report Series, No. 927. Link: https:\/\/bit.ly\/3phpo4C"},{"key":"ref9","unstructured":"10. World Health Organization (WHO) (2013) Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines Annex 2. WHO Technical Report Series 1-56. Link: https:\/\/bit.ly\/39bVtFE ."},{"key":"ref10","unstructured":"11. Sierra VG (2020) Cuban meningococcal vaccine VA-MENGOC-BC\u00ae: 30 Years of use and future potential. VacciMonitor 29: 31-43. Link: https:\/\/bit.ly\/3iGHP0n"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Gonz\u00e1lez N, Paredes B, P\u00e9rez S, Mirabal M, Rivero I, et al. (2015) Safety and Immunogenicity of Cuban Antipneumococcal Conjugate Vaccine PCV7-TT in Healthy Adults. MEDICC Review 17: 32-37. Link: https:\/\/bit.ly\/2KIQMcQ","DOI":"10.37757\/MR2015.V17.N4.7"},{"key":"ref12","unstructured":"13. International Committee of Harmonization (2001) ICH\/S7A. Harmonised Tripartite Guideline. Guidelines on safety Pharmacology studies for human drugs. Link: https:\/\/bit.ly\/3qMBK57"},{"key":"ref13","unstructured":"14. Oliva R (2019) Preclinical toxicology considerations for vaccines. VacciMonitor 28: 48-51. Link: https:\/\/bit.ly\/369xVz6"},{"key":"ref14","unstructured":"15. European Medicines Agency (EMA) (2000) Note for guidance on repeated dose toxicity. London: CPMP\/9. SWP\/1042\/99. Link: https:\/\/bit.ly\/3sOntad"},{"key":"ref15","unstructured":"16. Food & Drug Administration (FDA) (2020) Development and Licensure of Vaccines to Prevent COVID-19. Guidance for Industry. Link: https:\/\/bit.ly\/3sW3gPu"}],"updated-by":[{"updated":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"DOI":"10.17352\/jvi.000037","type":"new_edition","source":"publisher","label":"New edition"}],"container-title":["Journal of Vaccines and Immunology"],"link":[{"URL":"https:\/\/www.peertechzpublications.com\/articles\/JVI-7-137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T13:15:29Z","timestamp":1712236529000},"score":18.091936,"resource":{"primary":{"URL":"https:\/\/www.healthdisgroup.us\/articles\/JVI-7-137.php"}},"issued":{"date-parts":[[2021,1,25]]},"references-count":16,"URL":"https:\/\/doi.org\/10.17352\/jvi.000037","ISSN":["2640-7590"],"issn-type":[{"type":"electronic","value":"2640-7590"}],"published":{"date-parts":[[2021,1,25]]}},{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T09:44:52Z","timestamp":1648633492788},"reference-count":0,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2022,2,15]]},"DOI":"10.1001\/jama.2022.1114","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T17:20:52Z","timestamp":1644945652000},"page":"614","source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 Vaccines Safe, Effective in Rheumatic Diseases"],"prefix":"10.1001","volume":"327","author":[{"given":"Bridget M.","family":"Kuehn","sequence":"first","affiliation":[]}],"member":"10","container-title":["JAMA"],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2789015\/jama_kuehn_2022_wm_220003_1644783365.40479.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T17:20:53Z","timestamp":1644945653000},"score":18.055721,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2789015"}},"issued":{"date-parts":[[2022,2,15]]},"references-count":0,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,2,15]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.1114","ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"published":{"date-parts":[[2022,2,15]]}},{"institution":[{"name":"The University of Queensland","department":["School of Chemistry and Molecular Biosciences"]}],"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T08:33:02Z","timestamp":1648974782913},"reference-count":0,"publisher":"University of Queensland Library","content-domain":{"domain":[],"crossmark-restriction":false},"DOI":"10.14264\/87e3af6","type":"dissertation","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T04:34:31Z","timestamp":1620275671000},"approved":{"date-parts":[[2021,4,23]]},"source":"Crossref","is-referenced-by-count":0,"title":["Exploring the use of chimeric insect-specific viruses to develop safe and effective vaccines against flavivirus pathogens"],"prefix":"10.14264","author":[{"sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0001-7587-2936","authenticated-orcid":true,"given":"Laura Janneke","family":"Vet","sequence":"first","affiliation":[]}],"member":"5387","deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T04:34:32Z","timestamp":1620275672000},"score":18.05104,"degree":["PhD Thesis"],"resource":{"primary":{"URL":"https:\/\/espace.library.uq.edu.au\/view\/UQ:87e3af6"}},"issued":{"date-parts":[[null]]},"references-count":0,"URL":"https:\/\/doi.org\/10.14264\/87e3af6"},{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T09:58:58Z","timestamp":1648634338339},"posted":{"date-parts":[[2021,8,23]]},"group-title":"Ground Vehicle","reference-count":0,"publisher":"SAE International","content-domain":{"domain":[],"crossmark-restriction":false},"DOI":"10.47953\/sae-pp-00172","type":"posted-content","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T20:33:13Z","timestamp":1629750793000},"source":"Crossref","is-referenced-by-count":0,"title":["Blockchain as Key Factor for Safe Transportation and Delivery of Vaccines"],"prefix":"10.47953","author":[{"given":"Marcos","family":"Gutierrez","sequence":"first","affiliation":[{"name":"Universidad Internacional del Ecuador - Tablet School"}]},{"given":"Andres","family":"Castillo","sequence":"additional","affiliation":[{"name":"Universidad Internacional del Ecuador"}]},{"given":"Juan","family":"Iniguez","sequence":"additional","affiliation":[{"name":"Universidad Internacional del Ecuador"}]}],"member":"2796","deposited":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T20:33:14Z","timestamp":1629750794000},"score":18.040295,"resource":{"primary":{"URL":"https:\/\/mobilityrxiv.sae.org\/preprint\/blockchain-as-key-factor-for-safe-transportation-and-delivery-of-vaccines--sae-pp-00172"}},"issued":{"date-parts":[[2021,8,23]]},"references-count":0,"URL":"https:\/\/doi.org\/10.47953\/sae-pp-00172","published":{"date-parts":[[2021,8,23]]},"subtype":"preprint"},{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T07:49:52Z","timestamp":1716018592947},"reference-count":0,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[1991,1,1]]},"abstract":"<jats:p>The development of safe and effective vaccines for the prevention of infectious diseases associated with high mortality or morbidity is among the most significant accomplishments in medicine. The ultimate goal of eradication of a disease through immunization is an elusive one, having been achieved for only one disease\u2014smallpox. However, a significant reduction in the number of childhood cases of diphtheria, tetanus, pertussis, poliomyelitis, measles, mumps, and rubella has been realized through the use of modern immunizing agents. Recent introduction of vaccines for the prevention of invasive disease caused by Haemophilus influenzae will hopefully provide similar results in the near future.<\/jats:p>\n               <jats:p>The success of a vaccine in preventing disease is dependent on both the quality of the immunizing agent and the degree to which it is utilized. Obviously, the safest and most effective vaccine in the world will contribute nothing to the decline of a disease without clinicians' efforts to immunize at-risk individuals and without a willingness on the part of these at-risk individuals (or their parents) to receive the vaccine. This critical issue of vaccine utilization deservingly receives attention in the medical literature with some frequency.1,2 Similarly, the quality of vaccines is frequently addressed in publications concerning aspects such as reactogenicity, immunogenicity, and overall efficacy.3-6 One important factor that can influence efficacy, however, is rarely discussed\u2014how vaccines are handled during shipment and storage.<\/jats:p>\n               <jats:p>Discussions concerning preservation of vaccine potency through proper storage and maintenance of the \"cold chain\" may seem more pertinent to developing countries of the world, where refrigeration is not readily available and exposure of stored product to extreme environmental conditions can be expected.7-9<\/jats:p>","DOI":"10.1542\/peds.87.1.108","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T03:25:37Z","timestamp":1639193137000},"page":"108-112","source":"Crossref","is-referenced-by-count":19,"title":["Safe Handling of Vaccines"],"prefix":"10.1542","volume":"87","author":[{"given":"Daniel T.","family":"Casto","sequence":"first","affiliation":[{"name":"From the College of Pharmacy, The University of Texas at Austin; Departments of Pharmacology and Pediatrics, The University of Texas Health Science Center at San Antonio; and Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, California"}]},{"given":"Philip A.","family":"Brunell","sequence":"additional","affiliation":[{"name":"From the College of Pharmacy, The University of Texas at Austin; Departments of Pharmacology and Pediatrics, The University of Texas Health Science Center at San Antonio; and Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, California"}]}],"member":"417","published-online":{"date-parts":[[1991,1,1]]},"container-title":["Pediatrics"],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/87\/1\/108\/1027641\/108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/87\/1\/108\/1027641\/108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T03:25:37Z","timestamp":1639193137000},"score":17.842686,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/87\/1\/108\/56754\/Safe-Handling-of-Vaccines"}},"issued":{"date-parts":[[1991,1,1]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[1991,1,1]]},"published-print":{"date-parts":[[1991,1,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.87.1.108","ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"published":{"date-parts":[[1991,1,1]]}},{"indexed":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T11:51:41Z","timestamp":1707652301446},"reference-count":0,"publisher":"American Society for Microbiology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2006,1,1]]},"DOI":"10.1128\/microbe.1.110.1","type":"journal-article","created":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T12:11:27Z","timestamp":1463573487000},"page":"110-111","source":"Crossref","is-referenced-by-count":0,"title":["New Rotavirus Vaccines Appear Safe, Effective"],"prefix":"10.1128","volume":"1","author":[{"given":"Jeffrey L.","family":"Fox","sequence":"first","affiliation":[]}],"member":"235","container-title":["Microbe Magazine"],"language":"en","deposited":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T12:11:27Z","timestamp":1463573487000},"score":17.805555,"resource":{"primary":{"URL":"http:\/\/www.asmscience.org\/content\/journal\/microbe\/10.1128\/microbe.1.110.1"}},"issued":{"date-parts":[[2006,1,1]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1128\/microbe.1.110.1","ISSN":["1558-7452","1558-7460"],"issn-type":[{"value":"1558-7452","type":"print"},{"value":"1558-7460","type":"electronic"}],"published":{"date-parts":[[2006,1,1]]}},{"indexed":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T04:49:54Z","timestamp":1692420594284},"reference-count":1,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reactions Weekly"],"DOI":"10.1007\/s40278-023-44852-2","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T09:02:05Z","timestamp":1692349325000},"page":"11-11","source":"Crossref","is-referenced-by-count":0,"title":["Bivalent mRNA COVID-19 booster vaccines safe in adults"],"prefix":"10.1007","volume":"1970","member":"297","published-online":{"date-parts":[[2023,8,19]]},"reference":[{"key":"44852_CR1","doi-asserted-by":"crossref","unstructured":"Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study BMJ : 25 Jul 2023. Available from: URL: \nhttps:\/\/doi.org\/10.1136\/bmj-2023-075015","DOI":"10.1136\/bmj-2023-075015"}],"container-title":["Reactions Weekly"],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40278-023-44852-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40278-023-44852-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40278-023-44852-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T09:13:57Z","timestamp":1692350037000},"score":17.805555,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40278-023-44852-2"}},"issued":{"date-parts":[[2023,8,19]]},"references-count":1,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["44852"],"URL":"https:\/\/doi.org\/10.1007\/s40278-023-44852-2","ISSN":["1179-2051"],"issn-type":[{"value":"1179-2051","type":"electronic"}],"published":{"date-parts":[[2023,8,19]]}},{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T23:47:09Z","timestamp":1648943229120},"reference-count":0,"publisher":"Elsevier BV","issue":"9125","license":[{"start":{"date-parts":[[1998,8,1]],"date-time":"1998-08-01T00:00:00Z","timestamp":901929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[1998,8]]},"DOI":"10.1016\/s0140-6736(98)23031-5","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T13:37:16Z","timestamp":1027604236000},"page":"375","source":"Crossref","is-referenced-by-count":0,"title":["Lyme disease vaccines are safe and effective"],"prefix":"10.1016","volume":"352","author":[{"given":"Dorothy","family":"Bonn","sequence":"first","affiliation":[]}],"member":"78","container-title":["The Lancet"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673698230315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673698230315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T07:56:31Z","timestamp":1556524591000},"score":17.792597,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673698230315"}},"issued":{"date-parts":[[1998,8]]},"references-count":0,"journal-issue":{"issue":"9125","published-print":{"date-parts":[[1998,8]]}},"alternative-id":["S0140673698230315"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(98)23031-5","ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"published":{"date-parts":[[1998,8]]}},{"institution":[{"name":"Qeios"}],"indexed":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T16:40:22Z","timestamp":1722098422891},"posted":{"date-parts":[[2023,8,9]]},"reference-count":0,"publisher":"Qeios Ltd","license":[{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"abstract":"<jats:p>The use of thorough clinical trials, open scientific debate and the building of trust in public institutions have been key factors in the acceptance of vaccines in the past. The Covid-19 vaccination programmes were Implemented under emergency legislation, limiting safety assessments and traditional vaccine protocols. Transparency and potential conflicts of interest were an issue, with serious side effects neglected. This has fed public distrust nurturing vaccine hesitancy. Studies on the possible relations between Covid-19 vaccines and an increase in all-cause mortality rates have not merited official concern. This Opinion argues that in order to negate a growing public perception of a causal relationship between Covid-19 vaccinations and serious adverse effects, raw data should be released further research promoted, and open debate permitted without exclusion.\n<\/jats:p>","DOI":"10.32388\/b1o99r","type":"posted-content","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T03:54:35Z","timestamp":1691553275000},"source":"Crossref","is-referenced-by-count":0,"title":["Vaccination campaigns against Covid-19 may promote vaccine hesitancy toward well-established, safe, and effective vaccines"],"prefix":"10.32388","author":[{"given":"Eduardo","family":"Missoni","sequence":"first","affiliation":[]},{"given":"Kasturi","family":"Sen","sequence":"additional","affiliation":[]}],"member":"17262","link":[{"URL":"https:\/\/www.qeios.com\/read\/B1O99R\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/www.qeios.com\/read\/B1O99R\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T16:22:28Z","timestamp":1722097348000},"score":17.792597,"resource":{"primary":{"URL":"https:\/\/www.qeios.com\/read\/B1O99R"}},"issued":{"date-parts":[[2023,8,9]]},"references-count":0,"URL":"https:\/\/doi.org\/10.32388\/b1o99r","published":{"date-parts":[[2023,8,9]]},"subtype":"preprint"},{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T10:45:40Z","timestamp":1649155540833},"reference-count":0,"publisher":"Springer Science and Business Media LLC","issue":"1313","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reactions Weekly"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.2165\/00128415-201013130-00017","type":"journal-article","created":{"date-parts":[[2010,8,6]],"date-time":"2010-08-06T11:15:19Z","timestamp":1281093319000},"page":"6","source":"Crossref","is-referenced-by-count":0,"title":["Rotavirus vaccines still safe and effective, says Health Canada"],"prefix":"10.1007","volume":"&NA;","author":[{"family":"&NA;","sequence":"first","affiliation":[]}],"member":"297","container-title":["Reactions Weekly"],"language":"en","deposited":{"date-parts":[[2013,3,3]],"date-time":"2013-03-03T03:58:58Z","timestamp":1362283138000},"score":17.778557,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2165\/00128415-201013130-00017"}},"subtitle":[""],"issued":{"date-parts":[[2010,8]]},"references-count":0,"journal-issue":{"issue":"1313"},"URL":"https:\/\/doi.org\/10.2165\/00128415-201013130-00017","ISSN":["0114-9954"],"issn-type":[{"value":"0114-9954","type":"print"}],"published":{"date-parts":[[2010,8]]}},{"indexed":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T07:54:12Z","timestamp":1717487652997},"reference-count":26,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"unspecified","delay-in-days":70,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2020,9,1]]},"DOI":"10.1080\/14760584.2020.1825946","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T08:49:27Z","timestamp":1600850967000},"page":"781-784","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Exploit T cell Immunity for Rapid, Safe and Effective COVID-19 Vaccines"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"http:\/\/orcid.org\/0000-0002-4410-865X","authenticated-orcid":false,"given":"Leonard","family":"Moise","sequence":"first","affiliation":[{"name":"EpiVax, Inc., Providence, RI, USA"},{"name":"Institute for Immunology and Informatics, University of Rhode Island, Providence, RI, USA"},{"name":"Center for Vaccines and Immunology, University of Georgia, Athens, GA, USA"}]},{"ORCID":"http:\/\/orcid.org\/0000-0003-1947-7469","authenticated-orcid":false,"given":"Ted M.","family":"Ross","sequence":"additional","affiliation":[{"name":"Center for Vaccines and Immunology, University of Georgia, Athens, GA, USA"}]},{"given":"Daniel F.","family":"Hoft","sequence":"additional","affiliation":[{"name":"Departments of Molecular Microbiology & Immunology and Internal Medicine, Division of Infectious Diseases, Allergy & Immunology, Saint Louis University, St. Louis, MO, USA"}]},{"ORCID":"http:\/\/orcid.org\/0000-0001-8694-494X","authenticated-orcid":false,"given":"William D.","family":"Martin","sequence":"additional","affiliation":[{"name":"EpiVax, Inc., Providence, RI, USA"}]},{"ORCID":"http:\/\/orcid.org\/0000-0001-5911-1459","authenticated-orcid":false,"given":"Anne S.","family":"De Groot","sequence":"additional","affiliation":[{"name":"EpiVax, Inc., Providence, RI, USA"},{"name":"Center for Vaccines and Immunology, University of Georgia, Athens, GA, USA"}]}],"member":"301","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.03.045"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1740560"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15562-9"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243283"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav9033"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202003.0138.v1"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2608-y"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0819-2"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-019-1909-6"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2014.06.004"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7833"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2107"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137244"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.004"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.21037\/apm.2020.03.26"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01505-14"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit504"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2006.05.002"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052664"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.03.002"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2550-z"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.05.015"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd2071"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.17.20061440"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00442"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2020.104236"}],"container-title":["Expert Review of Vaccines"],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2020.1825946","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T13:28:33Z","timestamp":1620480513000},"score":17.655296,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2020.1825946"}},"issued":{"date-parts":[[2020,9,1]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9,1]]}},"alternative-id":["10.1080\/14760584.2020.1825946"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2020.1825946","ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"published":{"date-parts":[[2020,9,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]},{"indexed":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T06:56:47Z","timestamp":1725519407792},"publisher-location":"Basel","reference-count":78,"publisher":"Birkh\u00e4user Basel","isbn-type":[{"type":"print","value":"9783764383701"},{"type":"electronic","value":"9783764383718"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2008]]},"DOI":"10.1007\/978-3-7643-8371-8_10","type":"book-chapter","created":{"date-parts":[[2008,10,2]],"date-time":"2008-10-02T18:17:10Z","timestamp":1222971430000},"page":"221-244","source":"Crossref","is-referenced-by-count":2,"title":["MF59: A safe and potent oil in water emulsion adjuvant for influenza vaccines, which induces enhanced protection against virus challenge"],"prefix":"10.1007","author":[{"given":"Derek T.","family":"O\u2019Hagan","sequence":"first","affiliation":[]},{"given":"Audino","family":"Podda","sequence":"additional","affiliation":[]}],"member":"297","reference":[{"key":"10_CR1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3181\/00379727-37-9625","volume":"37","author":"J. Freund","year":"1937","unstructured":"Freund J, Casals J, Hosmer EP (1937) Sensitization and antibody formation after injection of turbecle bacili and paraffin oil. Proc Soc Exp Biol Med 37: 509\u2013513","journal-title":"Proc Soc Exp Biol Med"},{"key":"10_CR2","first-page":"131","volume":"8","author":"M.R. Hilleman","year":"1966","unstructured":"Hilleman MR (1966) Critical appraisal of emulsified oil adjuvants applied to viral vaccines. Prog Med Virol 8: 131\u2013182","journal-title":"Prog Med Virol"},{"key":"10_CR3","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.vaccine.2004.08.023","volume":"23","author":"T. Jansen","year":"2005","unstructured":"Jansen T, Hofmans MP, Theelen MJ, Schijns VE (2005) Structure-activity relations of water-in-oil vaccine formulations and induced antigen-specific antibody responses. Vaccine 23: 1053\u20131060","journal-title":"Vaccine"},{"key":"10_CR4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2105\/AJPH.41.6.669","volume":"41","author":"J.E. Salk","year":"1951","unstructured":"Salk JE, Laurent AM, Bailey ML (1951) Direction of research on vaccination against influenza; new studies with immunologic adjuvants. Am J Public Health 41: 669\u2013677","journal-title":"Am J Public Health"},{"key":"10_CR5","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/clinids\/2.3.370","volume":"2","author":"R. Edelman","year":"1980","unstructured":"Edelman R (1980) Vaccine adjuvants. Rev Infect Dis 2: 370\u2013383","journal-title":"Rev Infect Dis"},{"key":"10_CR6","first-page":"141","volume":"2","author":"W. Page","year":"1993","unstructured":"Page W (1993) Long-term followup of Army recruits immunized with Freund\u2019s incomplete adjuvanted vaccine. Vaccine Research 2: 141\u2013149","journal-title":"Vaccine Research"},{"key":"10_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1586\/14760584.1.1.111","volume":"1","author":"J. Aucouturier","year":"2002","unstructured":"Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V (2002) Montanide ISA 720 and 51: A new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 1: 111\u2013118","journal-title":"Expert Rev Vaccines"},{"key":"10_CR8","doi-asserted-by":"publisher","first-page":"8017","DOI":"10.1128\/IAI.73.12.8017-8026.2005","volume":"73","author":"R. Audran","year":"2005","unstructured":"Audran R, Cachat M, Lurati F, Soe S, Leroy O, Corradin G, Druilhe P, Spertini F (2005) Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun 73: 8017\u20138026","journal-title":"Infect Immun"},{"key":"10_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0022-1759(86)90402-3","volume":"95","author":"A.C. Allison","year":"1986","unstructured":"Allison AC, Byars NE (1986) An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J Immunol Methods 95: 157\u2013168","journal-title":"J Immunol Methods"},{"key":"10_CR10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-1-4615-1823-5_7","volume-title":"Vaccine Design: The Subunit and Adjuvant Approach","author":"F.R. Vogel","year":"1995","unstructured":"Vogel FR, Pruett MF (1995) A compendium of vaccine adjuvants and excipients. In: MF Powell, MJ Newman (eds): Vaccine Design: The Subunit and Adjuvant Approach. Plenum Press, New York, 141\u2013228"},{"key":"10_CR11","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/0006-291X(74)90458-6","volume":"59","author":"F. Ellouz","year":"1974","unstructured":"Ellouz F, Adam A, Ciorbaru R, Lederer E (1974) Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun 59: 1317\u20131325","journal-title":"Biochem Biophys Res Commun"},{"key":"10_CR12","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1128\/IAI.51.3.816-825.1986","volume":"51","author":"R.V. Waters","year":"1986","unstructured":"Waters RV, Terrell TG, Jones GH (1986) Uveitis induction in the rabbit by muramyl dipeptides. Infect Immun 51: 816\u2013825","journal-title":"Infect Immun"},{"key":"10_CR13","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/ni1412","volume":"7","author":"J.H. Fritz","year":"2006","unstructured":"Fritz JH, Ferrero RL, Philpott DJ, Girardin SE (2006) Nod-like proteins in immunity, inflammation and disease. Nat Immunol 7: 1250\u20131257","journal-title":"Nat Immunol"},{"key":"10_CR14","volume-title":"New Generation Vaccines","author":"R.T. Kenney","year":"2004","unstructured":"Kenney RT, Edelman R (2004) New Generation Vaccines. Marcel Dekker, New York"},{"key":"10_CR15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/infdis\/163.2.219","volume":"163","author":"J. Wintsch","year":"1991","unstructured":"Wintsch J, Chaignat CL, Braun DG, Jeannet M, Stalder H, Abrignani S, Montagna D, Clavijo F, Moret P, Dayer JM et al (1991) Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine. J Infect Dis 163: 219\u2013225","journal-title":"J Infect Dis"},{"key":"10_CR16","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/0264-410X(93)90376-9","volume":"11","author":"W. Keitel","year":"1993","unstructured":"Keitel W, Couch R, Bond N, Adair S, Van Nest G, Dekker C (1993) Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine 11: 909\u2013913","journal-title":"Vaccine"},{"key":"10_CR17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1089\/aid.1996.12.683","volume":"12","author":"M.C. Keefer","year":"1996","unstructured":"Keefer MC, Graham BS, McElrath MJ, Matthews TJ, Stablein DM, Corey L, Wright PF, Lawrence D, Fast PE, Weinhold K et al (1996) Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE\/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 12: 683\u2013693","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10_CR18","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/infdis\/170.5.1288","volume":"170","author":"J.O. Kahn","year":"1994","unstructured":"Kahn JO, Sinangil F, Baenziger J, Murcar N, Wynne D, Coleman RL, Steimer KS, Dekker CL, Chernoff D (1994) Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J Infect Dis 170: 1288\u20131291","journal-title":"J Infect Dis"},{"key":"10_CR19","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/0264-410X(95)00089-J","volume":"13","author":"G. Ott","year":"1995","unstructured":"Ott G, Barchfeld GL, Van Nest G (1995) Enhancement of humoral response against human influenza vaccine with the simple submicron oil\/water emulsion adjuvant MF59. Vaccine 13: 1557\u20131562","journal-title":"Vaccine"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/S0264-410X(97)00115-1","volume":"15","author":"D.M. Cataldo","year":"1997","unstructured":"Cataldo DM, Van Nest G (1997) The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine 15: 1710\u20131715","journal-title":"Vaccine"},{"key":"10_CR21","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/0264-410X(95)00240-2","volume":"14","author":"D.A. Higgins","year":"1996","unstructured":"Higgins DA, Carlson JR, Van Nest G (1996) MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 14: 478\u2013484","journal-title":"Vaccine"},{"key":"10_CR22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-1-4615-1823-5_10","volume-title":"Vaccine Design: The Subunit and Adjuvant Approach","author":"G. Ott","year":"1995","unstructured":"Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G (1995) MF59: Design and evaluation of a safe and potent adjuvant for human vaccines. In: MF Powell, MJ Newman (eds.): Vaccine Design: The Subunit and Adjuvant Approach. Plenum Press, New York, 277\u2013296"},{"key":"10_CR23","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0264-410X(99)00263-7","volume":"18","author":"M. Dupuis","year":"1999","unstructured":"Dupuis M, McDonald DM, Ott G (1999) Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. Vaccine 18: 434\u2013439","journal-title":"Vaccine"},{"key":"10_CR24","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.4049\/jimmunol.153.9.4029","volume":"153","author":"J.P. Valensi","year":"1994","unstructured":"Valensi JP, Carlson JR, Van Nest GA (1994) Systemic cytokine profiles in BALB\/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J Immunol 153: 4029\u20134039","journal-title":"J Immunol"},{"key":"10_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1006\/cimm.1998.1283","volume":"186","author":"M. Dupuis","year":"1998","unstructured":"Dupuis M, Murphy TJ, Higgins D, Ugozzoli M, Van Nest G, Ott G, McDonald DM (1998) Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 186: 18\u201327","journal-title":"Cell Immunol"},{"key":"10_CR26","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1002\/1521-4141(2001010)31:10<2910::AID-IMMU2910>3.0.CO;2-3","volume":"31","author":"M. Dupuis","year":"2001","unstructured":"Dupuis M, Denis-Mize K, La Barbara A, Peters W, Charo IF, McDonald DM, Ott G (2001) Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur J Immunol 31: 2910\u20132918","journal-title":"Eur J Immunol"},{"key":"10_CR27","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.4049\/jimmunol.180.8.5402","volume":"180","author":"A. Seubert","year":"2008","unstructured":"Seubert A, Monaci E, Pizza M, O\u2019Hagan DT, Wack A (2008) The adjuvants aluminium hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation towards dendritic cells. J Immunol 180: 5402\u20135412","journal-title":"J Immunol"},{"key":"10_CR28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1385\/1-59259-083-7:211","volume-title":"Vaccine Adjuvants: Preparation Methods and Research Protocols","author":"G. Ott","year":"2000","unstructured":"Ott G (2000) The Adjuvant MF59: A ten year perspective. In: D O\u2019Hagan (ed): Vaccine Adjuvants: Preparation Methods and Research Protocols. Humana Press, Totowa, 211\u2013228"},{"key":"10_CR29","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/infdis\/174.6.1168","volume":"174","author":"P. Traquina","year":"1996","unstructured":"Traquina P, Morandi M, Contorni M, Van Nest G (1996) MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J Infect Dis 174: 1168\u20131175","journal-title":"J Infect Dis"},{"key":"10_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1586\/14760584.2.2.197","volume":"2","author":"A. Podda","year":"2003","unstructured":"Podda A, Del Giudice G (2003) MF59-adjuvanted vaccines: Increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2: 197\u2013203","journal-title":"Expert Rev Vaccines"},{"key":"10_CR31","first-page":"149","volume-title":"Immunopotentiators in Modern Vaccines","author":"A. Podda","year":"2005","unstructured":"Podda A, Del Giudice G, O\u2019Hagan DT (2005) MF59: A safe and potent adjuvant for human use. In: V Schijns, DT O\u2019Hagan (eds): Immunopotentiators in Modern Vaccines, Chapter 9. Elsevier Press, Amsterdam, 149"},{"key":"10_CR32","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.vaccine.2005.09.046","volume":"24","author":"M. Singh","year":"2006","unstructured":"Singh M, Ugozzoli M, Kazzaz J, Chesko J, Soenawan E, Mannucci D, Titta F, Contorni M, Volpini G, Del Guidice G, O\u2019Hagan DT (2006) A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine 24: 1680\u20131686","journal-title":"Vaccine"},{"key":"10_CR33","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1128\/IAI.65.5.1710-1715.1997","volume":"65","author":"D.M. Granoff","year":"1997","unstructured":"Granoff DM, McHugh YE, Raff HV, Mokatrin AS, Van Nest GA (1997) MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine. Infect Immun 65: 1710\u20131715","journal-title":"Infect Immun"},{"key":"10_CR34","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.vaccine.2007.11.054","volume":"26","author":"A. Wack","year":"2008","unstructured":"Wack A, Baudner BC, Hilbert AK, Manini I, Nuti S, Tavarini S, Scheffczik H, Ugozzoli M, Singh M, Kazzaz J et al (2008) Combination adjuvants for the induction of potent, long-lasting antibody and T cell responses to influenza vaccine. Vaccine 26: 552\u2013561","journal-title":"Vaccine"},{"key":"10_CR35","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1016\/S0264-410X(00)00499-0","volume":"19","author":"A. Podda","year":"2001","unstructured":"Podda A (2001) The adjuvanted influenza vaccines with novel adjuvants: Experience with the MF59-adjuvanted vaccine. Vaccine 19: 2673\u20132680","journal-title":"Vaccine"},{"key":"10_CR36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0264-410X(86)80002-0","volume":"4","author":"M.A. Strassburg","year":"1986","unstructured":"Strassburg MA, Greenland S, Sorvillo FJ, Lieb LE, Habel LA (1986) Influenza in the elderly: Report of an outbreak and a review of vaccine effectiveness reports. Vaccine 4: 38\u201344","journal-title":"Vaccine"},{"key":"10_CR37","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000069172","volume":"49","author":"A. Banzhoff","year":"2003","unstructured":"Banzhoff A, Nacci P, Podda A (2003) A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: Results from an immunogenicity meta-analysis. Gerontology 49: 177\u2013184","journal-title":"Gerontology"},{"key":"10_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0264-410X(98)00185-6","volume":"17","author":"M. Minutello","year":"1999","unstructured":"Minutello M, Senatore F, Cecchinelli G, Bianchi M, Andreani T, Podda A, Crovari P (1999) Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 17: 99\u2013104","journal-title":"Vaccine"},{"key":"10_CR39","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1016\/S0264-410X(99)00138-3","volume":"17","author":"S Donato","year":"1999","unstructured":"De Donato S, Granoff D, Minutello M, Lecchi G, Faccini M, Agnello M, Senatore F, Verweij P, Fritzell B, Podda A (1999) Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 17: 3094-3101","journal-title":"Vaccine"},{"key":"10_CR40","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1016\/j.vaccine.2006.01.015","volume":"24","author":"G. Giudice Del","year":"2006","unstructured":"Del Giudice G, Hilbert AK, Bugarini R, Minutello A, Popova O, Toneatto D, Schoendorf I, Borkowski A, Rappuoli R, Podda A (2006) An MF59-adjuvanted inactivated influenza vaccine containing A\/Panama\/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A\/Fujian\/2002 than a subunit and a split influenza vaccine. Vaccine 24: 3063\u20133065","journal-title":"Vaccine"},{"key":"10_CR41","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1016\/S0264-410X(03)00408-0","volume":"21","author":"A.M. Iorio","year":"2003","unstructured":"Iorio AM, Francisci D, Camilloni B, Stagni G, De Martino M, Toneatto D, Bugarini R, Neri M, Podda A (2003) Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine 21: 3629\u20133637","journal-title":"Vaccine"},{"key":"10_CR42","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1016\/j.vaccine.2007.02.045","volume":"25","author":"V. Baldo","year":"2007","unstructured":"Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R (2007) MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine 25: 3955\u20133961","journal-title":"Vaccine"},{"key":"10_CR43","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.vaccine.2004.07.017","volume":"23","author":"J. Puig-Barbera","year":"2004","unstructured":"Puig-Barbera J, Diez-Domingo J, Perez Hoyos S, Belenguer Varea A, Gonzalez Vidal D (2004) Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine 23: 283\u2013289","journal-title":"Vaccine"},{"key":"10_CR44","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1017\/S0950268805003936","volume":"133","author":"A. Iob","year":"2005","unstructured":"Iob A, Brianti G, Zamparo E, Gallo T (2005) Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect 133: 687\u2013693","journal-title":"Epidemiol Infect"},{"key":"10_CR45","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1586\/14760584.6.5.659","volume":"6","author":"J. Puig-Barbera","year":"2007","unstructured":"Puig-Barbera J, Gonzalez Vidal D (2007) MF59-adjuvanted subunit influenza vaccine: An improved interpandemic influenza vaccine for vulnerable populations. Expert Rev Vaccines 6: 659\u2013665","journal-title":"Expert Rev Vaccines"},{"key":"10_CR46","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1016\/j.vaccine.2006.10.002","volume":"25","author":"D.M. Skowronski","year":"2007","unstructured":"Skowronski DM, Masaro C, Kwindt TL, Mak A, Petric M, Li Y, Sebastian R, Chong M, Tam T, De Serres G (2007) Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: Results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 25: 2842\u20132851","journal-title":"Vaccine"},{"key":"10_CR47","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s10875-007-9100-4","volume":"27","author":"V. Baldo","year":"2007","unstructured":"Baldo V, Baldovin T, Floreani A, Fragapane E, Trivello R (2007) Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases. J Clin Immunol 27: 542\u2013547","journal-title":"J Clin Immunol"},{"key":"10_CR48","unstructured":"D\u2019Agosto V, Berardi S, Burroni D, Hennig R (2006) Tolerability and safety of an MF59-adjuvanted subunit influenza vaccine (FLUAD\u00ae). IVW 2006-The Second International Conference on Influenza Vaccines for the World"},{"key":"10_CR49","doi-asserted-by":"crossref","unstructured":"Schultze V, D\u2019Agosto V, Hennig R, Novicki D, Wack A, Zorn J (2008) Safety of MF59 adjuvant. Vaccine (in press)","DOI":"10.1016\/j.vaccine.2008.03.093"},{"key":"10_CR50","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1128\/CVI.00191-06","volume":"13","author":"G. Giudice Del","year":"2006","unstructured":"Del Giudice G, Fragapane E, Bugarini R, Hora M, Henriksson T, Palla E, O\u2019Hagan D, Donnelly J, Rappuoli R, Podda A (2006) Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin Vaccine Immunol 13: 1010\u20131013","journal-title":"Clin Vaccine Immunol"},{"key":"10_CR51","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/00006454-200202000-00009","volume":"21","author":"D.K. Mitchell","year":"2002","unstructured":"Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SP (2002) Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J 21: 133\u2013138","journal-title":"Pediatr Infect Dis J"},{"key":"10_CR52","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1086\/323994","volume":"184","author":"E.J. McFarland","year":"2001","unstructured":"McFarland EJ, Borkowsky W, Fenton T, Wara D, McNamara J, Samson P, Kang M, Mofenson L, Cunningham C, Duliege AM et al (2001) Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J Infect Dis 184: 1331\u20131335","journal-title":"J Infect Dis"},{"key":"10_CR53","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJMoa055778","volume":"354","author":"J.J. Treanor","year":"2006","unstructured":"Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354: 1343\u20131351","journal-title":"N Engl J Med"},{"key":"10_CR54","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(00)05066-2","volume":"357","author":"K.G. Nicholson","year":"2001","unstructured":"Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A\/Duck\/Singapore\/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza. Lancet 357: 1937\u20131943","journal-title":"Lancet"},{"key":"10_CR55","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0264-410X(02)00632-1","volume":"21","author":"I. Stephenson","year":"2003","unstructured":"Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E, Zambon M (2003) Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A\/Duck\/Singapore\/97 vaccine in a primed human population. Vaccine 21: 1687\u20131693","journal-title":"Vaccine"},{"key":"10_CR56","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1086\/508174","volume":"43","author":"R.L. Atmar","year":"2006","unstructured":"Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB (2006) Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A\/H9N2 vaccine preparations. Clin Infect Dis 43: 1135\u20131142","journal-title":"Clin Infect Dis"},{"key":"10_CR57","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S0140-6736(06)68656-X","volume":"367","author":"J.L. Bresson","year":"2006","unstructured":"Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Hoschler K, Zambon MC (2006) Safety and immunogenicity of an inactivated split-virion influenza A\/Vietnam\/1194\/2004 (H5N1) vaccine: Phase I randomised trial. Lancet 367: 1657\u20131664","journal-title":"Lancet"},{"key":"10_CR58","first-page":"357","volume":"9272","author":"K. Nicholson","year":"2001","unstructured":"Nicholson K, Colegate A, Podda A, Stephenson I, Wood J, Ypma E, Zambon M (2001) Confronting a potential H5N1 pandemic: A randomised controlled trial of conventional and MF59 adjuvanted influenza A\/Duck\/Singapore\/97 (H5N3) surface antigen vaccine. Lancet 9272: 357","journal-title":"Lancet"},{"key":"10_CR59","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1086\/428948","volume":"191","author":"I. Stephenson","year":"2005","unstructured":"Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood J, Zambon M, Katz J (2005) Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF-59-adjuvanted influenza A\/Duck\/ Singapore\/97 (H5N3) vaccine: A potential priming strategy. J Infect Dis 191: 1210\u20131215","journal-title":"J Infect Dis"},{"key":"10_CR60","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.1016\/j.vaccine.2005.10.011","volume":"23","author":"R. Daems","year":"2005","unstructured":"Daems R, Del Giudice G, Rappuoli R (2005) Anticipating crisis: Towards a pandemic flu vaccination strategy through alignment of public health and industrial policy. Vaccine 23: 5732\u20135742","journal-title":"Vaccine"},{"key":"10_CR61","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0264-410X(99)00088-2","volume":"17","author":"T.C. Heineman","year":"1999","unstructured":"Heineman TC, Clements-Mann ML, Poland GA, Jacobson RM, Izu AE, Sakamoto D, Eiden J, Van Nest GA, Hsu HH (1999) A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 17: 2769\u20132778","journal-title":"Vaccine"},{"key":"10_CR62","doi-asserted-by":"crossref","first-page":"889","DOI":"10.7326\/0003-4819-122-12-199506150-00001","volume":"122","author":"A.G. Langenberg","year":"1995","unstructured":"Langenberg AG, Burke RL, Adair SF, Sekulovich R, Tigges M, Dekker CL, Corey L (1995) A recombinant glycoprotein vaccine for herpes simplex virus type 2: Safety and immunogenicity [published erratum appears in Ann Intern Med (1995) 123: 395]. Ann Intern Med 122: 889\u2013898","journal-title":"Ann Intern Med"},{"key":"10_CR63","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/jama.282.4.331","volume":"282","author":"L. Corey","year":"1999","unstructured":"Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM Jr, Handsfield HH, Warren T, Marr L, Tyring S et al (1999) Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: Two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282: 331\u2013340","journal-title":"JAMA"},{"key":"10_CR64","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1086\/315298","volume":"181","author":"W. Borkowsky","year":"2000","unstructured":"Borkowsky W, Wara D, Fenton T, McNamara J, Kang M, Mofenson L, McFarland E, Cunningham C, Duliege AM, Francis D et al (2000) Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. J Infect Dis 181: 890\u2013896","journal-title":"J Infect Dis"},{"key":"10_CR65","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1086\/319215","volume":"32","author":"C.K. Cunningham","year":"2001","unstructured":"Cunningham CK, Wara DW, Kang M, Fenton T, Hawkins E, McNamara J, Mofenson L, Duliege AM, Francis D, McFarland EJ, Borkowsky W (2001) Safety of 2 recombinant human immunodeficiency virus type 1 (hiv-1) envelope vaccines in neonates born to hiv-1-infected women. Clin Infect Dis 32: 801\u2013807","journal-title":"Clin Infect Dis"},{"key":"10_CR66","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1517\/14712598.4.6.937","volume":"4","author":"D.M. Klinman","year":"2004","unstructured":"Klinman DM (2004) Use of CpG oligodeoxynucleotides as immunoprotective agents. Expert Opin Biol Ther 4: 937\u2013946","journal-title":"Expert Opin Biol Ther"},{"key":"10_CR67","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1016\/S0264-410X(02)00272-4","volume":"20","author":"D.T. O\u2019Hagan","year":"2002","unstructured":"O\u2019Hagan DT, Singh M, Kazzaz J, Ugozzoli M, Briones M, Donnelly J, Ott G (2002) Synergistic adjuvant activity of immunostimulatory DNA and oil\/water emulsions for immunization with HIV p55 gag antigen. Vaccine 20: 3389\u20133398","journal-title":"Vaccine"},{"key":"10_CR68","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/infdis\/170.5.1110","volume":"170","author":"R.L. Burke","year":"1994","unstructured":"Burke RL, Goldbeck C, Ng P, Stanberry L, Ott G, Van Nest G (1994) The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. J Infect Dis 170: 1110\u20131119","journal-title":"J Infect Dis"},{"key":"10_CR69","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/S0264-410X(99)00522-8","volume":"18","author":"D.T. O\u2019Hagan","year":"2000","unstructured":"O\u2019Hagan DT, Ugozzoli M, Barackman J, Singh M, Kazzaz J, Higgins K, Van Cott TC, Ott G (2000) Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. Vaccine 18: 1793\u20131801","journal-title":"Vaccine"},{"key":"10_CR70","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1128\/JVI.75.3.1547-1550.2001","volume":"75","author":"S. Cherpelis","year":"2001","unstructured":"Cherpelis S, Srivastava I, Gettie A, Jin X, Ho DD, Barnett SW, Stamatatos L (2001) DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian\/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques. J Virol 75: 1547\u20131550","journal-title":"J Virol"},{"key":"10_CR71","doi-asserted-by":"publisher","first-page":"6087","DOI":"10.1128\/JVI.77.10.6087-6092.2003","volume":"77","author":"G.R. Otten","year":"2003","unstructured":"Otten GR, Schaefer M, Greer C, Calderon-Cacia M, Coit D, Kazzaz J, Medina-Selby A, Selby M, Singh M, Ugozzoli M et al (2003) Induction of broad and potent anti-HIV immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed PLG microparticles. J Virol 77: 6087\u20136092","journal-title":"J Virol"},{"key":"10_CR72","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/j.vaccine.2003.11.073","volume":"22","author":"G. Otten","year":"2004","unstructured":"Otten G, Schaefer M, Doe B, Liu H, Srivastava I, zur Megede J, O\u2019Hagan D, Donnelly J, Widera G, Rabussay D et al (2004) Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22: 2489\u20132493","journal-title":"Vaccine"},{"key":"10_CR73","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1016\/j.vaccine.2005.08.017","volume":"24","author":"G.R. Otten","year":"2006","unstructured":"Otten GR, Schaefer M, Doe B, Liu H, Megede JZ, Donnelly J, Rabussay D, Barnett S, Ulmer JB (2006) Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine 24: 4503\u20134509","journal-title":"Vaccine"},{"key":"10_CR74","doi-asserted-by":"publisher","first-page":"8189","DOI":"10.1128\/JVI.79.13.8189-8200.2005","volume":"79","author":"G.R. Otten","year":"2005","unstructured":"Otten GR, Schaefer M, Doe B, Liu H, Srivastava I, Megede J, Kazzaz J, Lian Y, Singh M, Ugozzoli M et al (2005) Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J Virol 79: 8189\u20138200","journal-title":"J Virol"},{"key":"10_CR75","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.vaccine.2004.06.037","volume":"23","author":"D.T. O\u2019Hagan","year":"2004","unstructured":"O\u2019Hagan DT, Singh M, Dong C, Ugozzoli M, Berger K, Glazer E, Selby M, Wininger M, Ng P, Crawford K et al (2004) Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine 23: 672\u2013680","journal-title":"Vaccine"},{"key":"10_CR76","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1086\/318523","volume":"183","author":"AIDS Vaccine Evaluation Group 022 Protocol Team","year":"2001","unstructured":"AIDS Vaccine Evaluation Group 022 Protocol Team (2001) Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J Infect Dis 183: 563\u2013570","journal-title":"J Infect Dis"},{"key":"10_CR77","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1086\/339003","volume":"185","author":"D.I. Bernstein","year":"2002","unstructured":"Bernstein DI, Schleiss MR, Berencsi K, Gonczol E, Dickey M, Khoury P, Cadoz M, Meric C, Zahradnik J, Duliege AM, Plotkin S (2002) Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J Infect Dis 185: 686\u2013690","journal-title":"J Infect Dis"},{"key":"10_CR78","doi-asserted-by":"publisher","first-page":"10834","DOI":"10.1073\/pnas.0603940103","volume":"103","author":"M.M. Giuliani","year":"2006","unstructured":"Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B et al (2006) A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 103: 10834\u201310839","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Influenza Vaccines for the Future"],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-7643-8371-8_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T06:19:24Z","timestamp":1684563564000},"score":17.639744,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-7643-8371-8_10"}},"issued":{"date-parts":[[2008]]},"ISBN":["9783764383701","9783764383718"],"references-count":78,"URL":"https:\/\/doi.org\/10.1007\/978-3-7643-8371-8_10","published":{"date-parts":[[2008]]}},{"indexed":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T16:38:51Z","timestamp":1721666331819},"reference-count":20,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2016,8,2]]},"DOI":"10.1080\/21645515.2016.1160178","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T20:34:54Z","timestamp":1463085294000},"page":"1960-1964","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":18,"title":["Is HPV vaccination in pregnancy safe?"],"prefix":"10.1080","volume":"12","author":[{"given":"Ulla","family":"Bonde","sequence":"first","affiliation":[]},{"given":"Jan Stener","family":"Joergensen","sequence":"additional","affiliation":[]},{"given":"Ronald F.","family":"Lamont","sequence":"additional","affiliation":[]},{"given":"Ole","family":"Mogensen","sequence":"additional","affiliation":[]}],"member":"301","published-online":{"date-parts":[[2016,5,12]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29210"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70230-8"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.4065\/80.5.601"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405044"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2015.10.001"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00047-9"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.10.021"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1111\/1753-6405.12218"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1111\/j.1728-4465.2010.00250.x"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c712"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4358"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181c2ca21"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181c2a122"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3554"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.2198"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.16946"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f5906"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000793"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.4161\/hv.5.5.7211"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.07.102"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2016.1160178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,14]],"date-time":"2016-12-14T03:52:01Z","timestamp":1481687521000},"score":17.603382,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2016.1160178"}},"issued":{"date-parts":[[2016,5,12]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,3,17]]},"published-print":{"date-parts":[[2016,8,2]]}},"alternative-id":["10.1080\/21645515.2016.1160178"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2016.1160178","ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"published":{"date-parts":[[2016,5,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"}]},{"indexed":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T13:10:20Z","timestamp":1723727420225},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1097\/01.naj.0000978100.13578.47","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T13:02:15Z","timestamp":1692882135000},"page":"14-14","update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["News Brief: COVID vaccines are safe for young children."],"prefix":"10.1097","volume":"123","member":"276","container-title":["AJN, American Journal of Nursing"],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.NAJ.0000978100.13578.47","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T12:38:31Z","timestamp":1723725511000},"score":17.598831,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.NAJ.0000978100.13578.47"}},"issued":{"date-parts":[[2023,9]]},"references-count":0,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/01.naj.0000978100.13578.47","ISSN":["0002-936X"],"issn-type":[{"type":"print","value":"0002-936X"}],"published":{"date-parts":[[2023,9]]}},{"indexed":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T09:56:30Z","timestamp":1722160590187},"reference-count":24,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Uniwersytet Medyczny im. Piast\u00f3w Slaskich we Wroclawiu","doi-asserted-by":"publisher","award":["SUB.C.180.20.039"],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Allergen immunotherapy (AIT) is a standard treatment for venom allergy. Our purpose was to determine if the administration of both allergen and protective vaccines during one visit is safe and if such a procedure does not deteriorate the tolerance of both vaccines. As current guidelines are based on theoretical assumptions, our aim was to establish the safety and tolerance of shortening the recommended interval between vaccinations. During two influenza seasons, 44 adult patients, with a history of systemic allergic reactions after a Hymenoptera sting, underwent 58 simultaneous allergen and seasonal influenza vaccinations (study group) while in the maintenance phase of venom immunotherapy (VIT). The control group consisted of 57 healthy adults who were vaccinated against influenza only. The conditions of the patients were monitored during hospital visits, and via telecommunication methods to evaluate the safety and tolerance of the procedure. Within the study group, there were no immediate or delayed allergic reactions after vaccinations. The presence of common, adverse influenza vaccine reactions among study group patients (29%) and control group patients (32%) did not differ significantly (p = 0.841). We did not observe a difference in the frequency of various adverse reactions in either group or a dependence of previous vaccinations against influenza on the occurrence of adverse reactions. The most frequent occurrences were local adverse reactions. All adverse reactions were resolved without treatment. These findings demonstrate the safety and tolerance of an influenza vaccination and Hymenoptera venom immunotherapy administration during one visit.<\/jats:p>","DOI":"10.3390\/vaccines9040344","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T14:34:09Z","timestamp":1617374049000},"page":"344","source":"Crossref","is-referenced-by-count":2,"title":["Simultaneous Influenza Vaccination and Hymenoptera Venom Immunotherapy Is Safe"],"prefix":"10.3390","volume":"9","author":[{"given":"Ewa","family":"Czerwi\u0144ska","sequence":"first","affiliation":[{"name":"Department of Paediatrics and Infectious Diseases, Wroclaw Medical University, ul. Tytusa Cha\u0142ubi\u0144skiego 2-2a, 50-368 Wroclaw, Poland"}]},{"ORCID":"http:\/\/orcid.org\/0000-0002-2327-419X","authenticated-orcid":false,"given":"Marita","family":"Nittner-Marszalska","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pneumology and Allergology, Wroclaw Medical University, ul. Marii Sk\u0142odowskiej-Curie 66, 50-369 Wroclaw, Poland"}]},{"given":"Robert","family":"Paw\u0142owicz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pneumology and Allergology, Wroclaw Medical University, ul. Marii Sk\u0142odowskiej-Curie 66, 50-369 Wroclaw, Poland"}]},{"given":"Leszek","family":"Szenborn","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Infectious Diseases, Wroclaw Medical University, ul. Tytusa Cha\u0142ubi\u0144skiego 2-2a, 50-368 Wroclaw, Poland"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,2]]},"reference":[{"key":"ref_1","unstructured":"Pawankar, R., Canonica, G., Holgate, S., and Lockey, R. (2013). WAO White Book on Allergy: Update 2013, World Allergy Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1365-2796.2012.02556.x","article-title":"Allergen-specific immunotherapy: From therapeutic vaccines to prophylactic approaches","volume":"272","author":"Valenta","year":"2012","journal-title":"J. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2010.09.034","article-title":"Allergen immunotherapy: A practice parameter third update","volume":"127","author":"Cox","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1398-9995.2006.01020.x","article-title":"Standards for practical allergen-specific immunotherapy","volume":"61","author":"Bousquet","year":"2006","journal-title":"Allergy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/ACI.0000000000000335","article-title":"Allergen immunotherapy: An updated review of safety","volume":"17","author":"James","year":"2017","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_6","first-page":"10","article-title":"Vaccination during concurrent subcutaneous immunotherapy: Safety of simultaneous application","volume":"47","author":"Ullrich","year":"2015","journal-title":"Eur. Ann. Allergy Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jinf.2017.09.010","article-title":"Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A systematic review and meta-analysis of test-negative design case-control studies","volume":"75","author":"Rondy","year":"2017","journal-title":"J. Infect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/infdis\/jiu185","article-title":"Effectiveness of influenza vaccine against life-threatening rt-pcr-confirmed influenza illness in us children, 2010\u20132012","volume":"210","author":"Ferdinands","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e20164244","DOI":"10.1542\/peds.2016-4244","article-title":"Influenza vaccine effectiveness against pediatric deaths: 2010\u20132014","volume":"139","author":"Flannery","year":"2017","journal-title":"Pediatrics"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.4161\/hv.29669","article-title":"Infants and the seasonal influenza vaccine","volume":"10","author":"Moriarty","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Cox, L., Larenas-Linnemann, D., Lockey, R.F., and Passalacqua, G. (2010). Speaking the same language: The world allergy organization subcutaneous immunotherapy systemic reaction grading system. J. Allergy Clin. Immunol., 125.","DOI":"10.1016\/j.jaci.2009.10.060"},{"key":"ref_12","unstructured":"(2021, April 01). Charakterystyka Produktu Leczniczego Vaxigrip 2016\/2017. Available online: https:\/\/gdziepolek.blob.core.windows.net\/product-documents\/doc19465\/vaxigrip-dokument.pdf."},{"key":"ref_13","unstructured":"(2021, April 01). Charakterystyka Produktu Leczniczego Vaxigrip Tetra 2018\/2019, Available online (English version): https:\/\/data.health.gov.il\/drugs\/alonim\/Rishum_8_97497818.pdf."},{"key":"ref_14","unstructured":"(2021, April 01). Charakterystyka Produktu Leczniczego Vaxigrip Tetra 2017\/2018, Available online: http:\/\/leki.urpl.gov.pl\/files\/40_VaxigripTetra.pdf."},{"key":"ref_15","unstructured":"Kroger, A.T., Duchin, J., V\u00e1zquez, M., and General Best Practice Guidelines for Immunization (2021, April 01). Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP), Available online: www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/downloads\/general-recs.pdf."},{"key":"ref_16","unstructured":"(2021, April 01). Pharmalgen Wasp Venom\u2014Summary of Product Characteristics (SmPC). Available online: https:\/\/www.medicines.org.uk\/emc\/product\/319\/smpc#gref."},{"key":"ref_17","unstructured":"(2021, April 01). Alutard Wasp Venom Maintenance\u2014Summary of Product Characteristics (SmPC). Available online: https:\/\/www.medicines.org.uk\/emc\/product\/10764\/smpc."},{"key":"ref_18","unstructured":"(2021, April 01). Alutard Bee Venom Maintenance\u2014Summary of Product Characteristics (SmPC). Available online: https:\/\/www.medicines.org.uk\/emc\/product\/10748\/smpc#gref."},{"key":"ref_19","unstructured":"(2021, April 01). Charakterystyka Produktu Leczniczego Allergovit, Available online: http:\/\/leki.urpl.gov.pl\/files\/Allergovit.pdf."},{"key":"ref_20","unstructured":"(2021, April 01). GRAZAX 75,000 SQ-T Oral Lyophilisate\u2014Summary of Product Characteristics (SmPC). Available online: https:\/\/www.medicines.org.uk\/emc\/product\/315."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/j.vaccine.2018.03.076","article-title":"Allergic patients with and without allergen-specific immunotherapy mount protective immune responses to tick-borne encephalitis vaccination in absence of enhanced side effects or propagation of their Th2 Bias","volume":"36","author":"Zwazl","year":"2018","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.7774\/cevr.2017.6.1.22","article-title":"Tetanus-diphtheria-acellular pertussis vaccination for adults: An update","volume":"6","author":"Lee","year":"2017","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_23","unstructured":"National Institute for Health and Clinical Excellence (2021, April 01). Pharmalgen for the Treatment of Bee and Wasp Venom. Allergy\u2014Final Appraisal Determination, Available online: https:\/\/www.nice.org.uk\/guidance\/ta246\/resources\/pharmalgen-for-the-treatment-of-bee-and-wasp-venom-allergy-pdf-82600434418885."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.anai.2017.10.020","article-title":"Administration of influenza vaccines to egg allergic recipients: A practice parameter update 2017","volume":"120","author":"Greenhawt","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."}],"container-title":["Vaccines"],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/4\/344\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T16:55:50Z","timestamp":1720630550000},"score":17.589495,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/4\/344"}},"issued":{"date-parts":[[2021,4,2]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["vaccines9040344"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9040344","ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"published":{"date-parts":[[2021,4,2]]}},{"indexed":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T06:10:06Z","timestamp":1720073406885},"reference-count":48,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>After years of global collaboration; we are steps away from a polio-free world. However, the currently conventional inactivated polio vaccine (cIPV) is suboptimal for the post eradication era. cIPV production cost and biosafety hazards hinder its availability and coverage of the global demands. Production of IPV from the attenuated Sabin strains (sIPV) was an ideal solution and scientists work extensively to perfect a safe, effective and affordable sIPV. This study investigated the ability of hydrogen peroxide (H2O2), ascorbic acid (AA) and epigallocatechin-3-gallate (EGCG) as alternatives for Formaldehyde (HCHO) to inactivate Sabin-polioviruses strains for sIPV production. Sabin-polioviruses vaccine strains were individually treated with AA, EGCG or H2O2 and were compared to HCHO. This was investigated by determination of the inactivation kinetics on HEP2C cells, testing of D-antigen preservation by ELISA and the immune response in Wistar rats of the four vaccine preparations. H2O2, AA and EGCG were able to inactivate polioviruses within 24 h while HCHO required 96 h. Significant high D-antigen levels were observed using AA, EGCG and H2O2 compared to HCHO. Rat sera tested for neutralizing antibodies showed comparable results. These findings support the idea of using these inactivating agents as safe and time- saving alternatives for HCHO to produce sIPV.<\/jats:p>","DOI":"10.3390\/vaccines8040601","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T01:48:38Z","timestamp":1602640118000},"page":"601","source":"Crossref","is-referenced-by-count":4,"title":["In-Vitro Inactivation of Sabin-Polioviruses for Development of Safe and Effective Polio Vaccine"],"prefix":"10.3390","volume":"8","author":[{"given":"Asmaa A.","family":"Abd-Elghaffar","sequence":"first","affiliation":[{"name":"Biotechnology Unit, National Organization for Research and Control of Biological (NORCB), Giza 12654, Egypt"}]},{"given":"Mohamed E.","family":"Rashed","sequence":"additional","affiliation":[{"name":"Bacterial Control Unit, National Organization for Research and Control of Biological (NORCB), Giza 12654, Egypt"}]},{"given":"Amal E.","family":"Ali","sequence":"additional","affiliation":[{"name":"Microbiology and Immunology Department, Faculty of Pharmaceutical Sciences &amp; Pharmaceutical Industries, Future University in Egypt, New Cairo 12311, Egypt"}]},{"given":"Magdy A.","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"key":"ref_1","unstructured":"(2020, July 03). WHO|Oral Polio Vaccine (OPV). Available online: https:\/\/www.who.int\/biologicals\/areas\/vaccines\/polio\/opv\/en\/."},{"key":"ref_2","unstructured":"(2020, July 03). GPEI-Polio Endgame Strategy. Available online: http:\/\/polioeradication.org\/who-we-are\/polio-endgame-strategy-2019-2023\/."},{"key":"ref_3","unstructured":"WHO (2020, August 03). WHO|SAGE Meeting of April 2020. Available online: http:\/\/www.who.int\/immunization\/sage\/meetings\/2020\/april\/en\/."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Thompson, K.M., and Kalkowska, D.A. (2020). Potential Future Use, Costs, and Value of Poliovirus Vaccines. Risk Anal.","DOI":"10.1111\/risa.13557"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Tobin, G.J., Tobin, J.K., Gaidamakova, E.K., Wiggins, T.J., Bushnell, R.V., Lee, W.-M., Matrosova, V.Y., Dollery, S.J., Meeks, H.N., and Kouiavskaia, D. (2020). A novel gamma radiation-inactivated sabin-based polio vaccine. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0228006"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.vaccine.2017.03.008","article-title":"Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule","volume":"35","author":"Anand","year":"2017","journal-title":"Vaccine"},{"key":"ref_7","unstructured":"(2020, August 03). WHO|Fractional Dose IPV. Available online: http:\/\/www.who.int\/immunization\/diseases\/poliomyelitis\/endgame_objective2\/inactivated_polio_vaccine\/fractional_dose\/en\/."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"(2020, August 03). 1,25-Dihydroxyvitamin D3 Enhances Systemic and Mucosal Immune Responses to Inactivated Poliovirus Vaccine in Mice|The Journal of Infectious Diseases|Oxford Academic. Available online: https:\/\/academic.oup.com\/jid\/article\/193\/4\/598\/827482.","DOI":"10.1086\/499970"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.vaccine.2012.12.076","article-title":"Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains","volume":"31","author":"Westdijk","year":"2013","journal-title":"Vaccine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.vaccine.2016.12.027","article-title":"First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age","volume":"35","author":"Lindgren","year":"2017","journal-title":"Vaccine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.1016\/j.vaccine.2018.09.068","article-title":"An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6\u00ae cell culture platform is immunogenic and safe in a non-human primate model","volume":"36","author":"Bockstal","year":"2018","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.biologicals.2016.08.005","article-title":"Development of inactivated poliovirus vaccine from Sabin strains: A progress report","volume":"44","author":"Okayasu","year":"2016","journal-title":"Biologicals"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/infdis\/jiy736","article-title":"Immunogenicity and Safety of a Sabin Strain\u2013Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial","volume":"220","author":"Hu","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/cid\/cix110","article-title":"Immune Serum from Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses","volume":"64","author":"Sun","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"11955","DOI":"10.1128\/JVI.01809-14","article-title":"Effect of Formaldehyde Inactivation on Poliovirus","volume":"88","author":"Wilton","year":"2014","journal-title":"J. Virol."},{"key":"ref_16","unstructured":"Rutala, W.A. (2008). Guideline for Disinfection and Sterilization in Healthcare Facilities, DCD."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.vaccine.2015.12.041","article-title":"Inactivation of rabies virus by hydrogen peroxide","volume":"34","author":"Ali","year":"2016","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/nm.2763","article-title":"Development of a new hydrogen peroxide\u2013based vaccine platform","volume":"18","author":"Amanna","year":"2012","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/0264-410X(91)90289-I","article-title":"Safety and immunogenicity of hydrogen peroxide-inactivated pertussis toxoid in 18-month-old children","volume":"9","author":"Siber","year":"1991","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijid.2003.09.002","article-title":"In vitro inactivation of the rabies virus by ascorbic acid","volume":"8","author":"Madhusudana","year":"2004","journal-title":"Int. J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Olayan, E., El-Khadragy, M., Mohamed, A.F., Mohamed, A.K., Shebl, R.I., and Yehia, H.M. (2020, June 16). Evaluation of Different Stabilizers and Inactivating Compounds for the Enhancement of Vero Cell Rabies Vaccine Stability and Immunogenicity: In Vitro Study. Available online: https:\/\/www.hindawi.com\/journals\/bmri\/2019\/4518163\/.","DOI":"10.1155\/2019\/4518163"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Lee, Y.H., Jang, Y.H., Byun, Y.H., Cheong, Y., Kim, P., Lee, Y.J., Lee, Y.J., Sung, J.M., Son, A., and Lee, H.M. (2017). Green Tea Catechin-Inactivated Viral Vaccine Platform. Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.02469"},{"key":"ref_23","unstructured":"WHO (2020, March 22). WHO Expert Committee on Biological Standardization\u2014WHO Technical Report Series, No. 980\u2014Sixty-Third Report_Annex 2_Recommendations to Assure the Quality, Safety and Efficacy of Poliomyelitis Vaccines (Oral, Live, Attenuated). Available online: https:\/\/apps.who.int\/medicinedocs\/en\/m\/abstract\/Js21348en\/."},{"key":"ref_24","unstructured":"American Veterinary Medical Association (2007). AVMA Guidelines on Euthanasia 2007, AVMA."},{"key":"ref_25","unstructured":"Wilson, D.E., and Chosewood, L.C. (2009). Biosafety in Microbiological and Biomedical Laboratories, CDC. [5th ed.]."},{"key":"ref_26","unstructured":"WHO (1997). Manual of Laboratory Methods for Testing of Vaccines Used in the WHO Expanded Programme on Immunization."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1128\/JVI.02903-12","article-title":"A Hydrogen Peroxide-Inactivated Virus Vaccine Elicits Humoral and Cellular Immunity and Protects against Lethal West Nile Virus Infection in Aged Mice","volume":"87","author":"Pinto","year":"2013","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0092-1157(86)90028-4","article-title":"Inactivation of poliovirus with beta-propiolactone","volume":"14","author":"Jiang","year":"1986","journal-title":"J. Biol. Stand."},{"key":"ref_29","unstructured":"WHO (2002). WHO_TRS_910_Annex2. Recommendations for the Production and Control of Poliomyelitis Vaccine (inactivated), WHO Expert Committee on Biological Standardization: Fifty-First Report."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Crowther, J.R. (2009). The ELISA Guidebook: Second Edition. Methods in Molecular Biology, Humana Press. [2nd ed.].","DOI":"10.1007\/978-1-60327-254-4"},{"key":"ref_31","first-page":"114","article-title":"Evaluation of inactivation efficacy of Sabin Polio virus using different inactivating agents and its immunogenicity post nano and micro incapsulation","volume":"1","author":"Ali","year":"2010","journal-title":"Int. J. Microbiol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-1-4939-3292-4_15","article-title":"Methods for the Quality Control of Inactivated Poliovirus Vaccines","volume":"Volume 1387","year":"2016","journal-title":"Poliovirus"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1590\/0074-02760160119","article-title":"Calculation of the ELISA\u2019s cut-off based on the change-point analysis method for detection of Trypanosoma cruzi infection in Bolivian dogs in the absence of controls","volume":"111","author":"Lardeux","year":"2016","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_34","unstructured":"WHO (2020, April 29). Guidelines for WHO\/EPI Collaborative Studies on Poliomyelitis: Standard Procedure for Determining Immunity to Poliovirus Using the Microneutralization Test. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/70486."},{"key":"ref_35","first-page":"979","article-title":"Inactivation of poliovirus by formaldehyde","volume":"17","author":"Gard","year":"1957","journal-title":"Bull. World Health Organ."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7041","DOI":"10.1016\/j.vaccine.2007.07.060","article-title":"Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains","volume":"25","author":"Tano","year":"2007","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1016\/j.vaccine.2011.02.085","article-title":"Characterization and standardization of Sabin based inactivated polio vaccine: Proposal for a new antigen unit for inactivated polio vaccines","volume":"29","author":"Westdijk","year":"2011","journal-title":"Vaccine"},{"key":"ref_38","first-page":"544","article-title":"Differences in Antigenic Structure of Inactivated Polio Vaccines Made from Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays","volume":"221","author":"Crawt","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.provac.2011.10.002","article-title":"Non-animal replacement methods for human vaccine potency testing: State of the science and future directions","volume":"5","author":"McFarland","year":"2011","journal-title":"Procedia Vaccinol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1016\/j.vaccine.2020.03.027","article-title":"Effects of the thermal denaturation of Sabin-derived inactivated polio vaccines on the D-antigenicity and the immunogenicity in rats","volume":"38","author":"Murakami","year":"2020","journal-title":"Vaccine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1128\/cdli.4.6.659-664.1997","article-title":"Evaluation of a poliovirus-binding inhibition assay as an alternative to the virus neutralization test","volume":"4","author":"Herremans","year":"1997","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_42","unstructured":"Plotkin, S.A., Orenstein, W.A., and Offit, P.A. (2012). Vaccines, Elsevier\/Saunders. [6th ed.]."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Gao, J. (2020). P-values\u2014A chronic conundrum. BMC Med. Res. Methodol., 20.","DOI":"10.1186\/s12874-020-01051-6"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41586-019-00857-9","article-title":"Scientists rise up against statistical significance","volume":"567","author":"Amrhein","year":"2019","journal-title":"Nature"},{"key":"ref_45","unstructured":"(2020, September 15). P-Values and Statistical Significance|Simply Psychology. Available online: https:\/\/www.simplypsychology.org\/p-value.html."},{"key":"ref_46","unstructured":"(2020, September 15). Strategy for the Response to Type 2 Circulating Vaccine-Derived Poliovirus 2020\u20132021. Available online: http:\/\/polioeradication.org\/wp-content\/uploads\/2020\/04\/Strategy-for-the-response-to-type-2-circulating-Vaccine-Derived-Poliovirus-20200406.pdf."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(19)31279-6","article-title":"The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: A double-blind, single-centre phase 1 study","volume":"394","author":"Damme","year":"2019","journal-title":"Lancet"},{"key":"ref_48","unstructured":"(2020, September 15). Advancing Novel Polio Vaccines. Available online: https:\/\/path.azureedge.net\/media\/documents\/nOPV-Fact-Oct2020.pdf."}],"container-title":["Vaccines"],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/601\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T05:00:04Z","timestamp":1720069204000},"score":17.570354,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/601"}},"issued":{"date-parts":[[2020,10,13]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["vaccines8040601"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8040601","ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"published":{"date-parts":[[2020,10,13]]}},{"indexed":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T05:42:57Z","timestamp":1670046177914},"reference-count":1,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reactions Weekly"],"DOI":"10.1007\/s40278-022-28804-8","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T09:05:02Z","timestamp":1669971902000},"page":"9-9","source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 vaccines safe in patients with systemic lupus erythematosus"],"prefix":"10.1007","volume":"1935","member":"297","published-online":{"date-parts":[[2022,12,3]]},"reference":[{"key":"28804_CR1","doi-asserted-by":"crossref","unstructured":"R N, et al. Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study Rheumatology : 22 Nov 2022. Available from: URL: \nhttp:\/\/doi.org\/10.1093\/rheumatology\/keac661","DOI":"10.1093\/rheumatology\/keac661"}],"container-title":["Reactions Weekly"],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40278-022-28804-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40278-022-28804-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40278-022-28804-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T09:35:58Z","timestamp":1669973758000},"score":17.557142,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40278-022-28804-8"}},"issued":{"date-parts":[[2022,12,3]]},"references-count":1,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["28804"],"URL":"https:\/\/doi.org\/10.1007\/s40278-022-28804-8","ISSN":["1179-2051"],"issn-type":[{"value":"1179-2051","type":"electronic"}],"published":{"date-parts":[[2022,12,3]]}},{"indexed":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T15:32:40Z","timestamp":1690990360571},"reference-count":1,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reactions Weekly"],"DOI":"10.1007\/s40278-022-27962-3","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T05:03:12Z","timestamp":1668834192000},"page":"11-11","source":"Crossref","is-referenced-by-count":1,"title":["Pfizer-BioNTech and Moderna COVID-19 vaccines safe in Japan"],"prefix":"10.1007","volume":"1933","member":"297","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"key":"27962_CR1","doi-asserted-by":"crossref","unstructured":"Takeuchi Y, et al. A post-marketing safety assessment of COVID-19 mRNA vaccination for serious adverse outcomes using administrative claims data linked with vaccination registry in a city of Japan Vaccine : 15 Nov 2022. Available from: URL: \nhttps:\/\/doi.org\/10.1016\/j.vaccine.2022.10.088","DOI":"10.1016\/j.vaccine.2022.10.088"}],"container-title":["Reactions Weekly"],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40278-022-27962-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40278-022-27962-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40278-022-27962-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T05:44:39Z","timestamp":1668836679000},"score":17.557142,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40278-022-27962-3"}},"issued":{"date-parts":[[2022,11,19]]},"references-count":1,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["27962"],"URL":"https:\/\/doi.org\/10.1007\/s40278-022-27962-3","ISSN":["1179-2051"],"issn-type":[{"value":"1179-2051","type":"electronic"}],"published":{"date-parts":[[2022,11,19]]}},{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T19:22:27Z","timestamp":1648840947962},"reference-count":0,"publisher":"Springer Science and Business Media LLC","issue":"1046","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Inpharma Weekly"],"published-print":{"date-parts":[[1996,7]]},"DOI":"10.2165\/00128413-199610460-00022","type":"journal-article","created":{"date-parts":[[2007,12,5]],"date-time":"2007-12-05T12:23:40Z","timestamp":1196857420000},"page":"12","source":"Crossref","is-referenced-by-count":0,"title":["??? and conjugate vaccine ???safe??? to give with other infant vaccines"],"prefix":"10.1007","volume":"&NA;","author":[{"family":"&NA;","sequence":"first","affiliation":[]}],"member":"297","container-title":["Inpharma Weekly"],"language":"en","deposited":{"date-parts":[[2013,2,27]],"date-time":"2013-02-27T14:25:58Z","timestamp":1361975158000},"score":17.557142,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2165\/00128413-199610460-00022"}},"subtitle":[""],"issued":{"date-parts":[[1996,7]]},"references-count":0,"journal-issue":{"issue":"1046"},"URL":"https:\/\/doi.org\/10.2165\/00128413-199610460-00022","ISSN":["1173-8324"],"issn-type":[{"value":"1173-8324","type":"print"}],"published":{"date-parts":[[1996,7]]}},{"indexed":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T01:41:27Z","timestamp":1649209287841},"reference-count":0,"publisher":"Test accounts","issue":"7","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric News"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/s0031-398x(05)70351-9","type":"journal-article","created":{"date-parts":[[2009,9,16]],"date-time":"2009-09-16T09:56:02Z","timestamp":1253094962000},"page":"18","source":"Crossref","is-referenced-by-count":0,"title":["Pentacel Vaccine as Safe as Component Vaccines"],"prefix":"10.5555","volume":"39","author":[{"given":"MICHELE G.","family":"SULLIVAN","sequence":"first","affiliation":[]}],"member":"7822","container-title":["Pediatric News"],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0031398X05703519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0031398X05703519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T16:28:58Z","timestamp":1457627338000},"score":17.557142,"resource":{"primary":{"URL":"http:\/\/www.pediatricnews.com\/"}},"issued":{"date-parts":[[2005,7]]},"references-count":0,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S0031398X05703519"],"URL":"https:\/\/doi.org\/10.1016\/s0031-398x(05)70351-9","ISSN":["0031-398X"],"issn-type":[{"value":"0031-398X","type":"print"}],"published":{"date-parts":[[2005,7]]}},{"indexed":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T04:30:21Z","timestamp":1726201821162},"reference-count":97,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1586\/erv.12.35","type":"journal-article","created":{"date-parts":[[2012,8,8]],"date-time":"2012-08-08T13:12:33Z","timestamp":1344431553000},"page":"733-744","source":"Crossref","is-referenced-by-count":101,"title":["Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines"],"prefix":"10.1586","volume":"11","author":[{"given":"Carl R","family":"Alving","sequence":"first","affiliation":[]},{"given":"Mangala","family":"Rao","sequence":"additional","affiliation":[]},{"given":"Nicholas J","family":"Steers","sequence":"additional","affiliation":[]},{"given":"Gary R","family":"Matyas","sequence":"additional","affiliation":[]},{"given":"Alexander V","family":"Mayorov","sequence":"additional","affiliation":[]}],"member":"301","published-online":{"date-parts":[[2014,1,9]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"CIT0002","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","volume":"365","author":"Agnandji","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"CIT0003","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1473-3099(11)70100-1","volume":"11","author":"Asante","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"CIT0004","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/icb.2009.30","volume":"87","author":"Sullivan","year":"2009","journal-title":"Immunol. Cell Biol."},{"key":"CIT0005","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1016\/j.vaccine.2009.12.084","volume":"28","author":"Harandi","year":"2010","journal-title":"Vaccine"},{"key":"CIT0006","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature10124","volume":"473","author":"Rappuoli","year":"2011","journal-title":"Nature"},{"key":"CIT0007","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrmicro1681","volume":"5","author":"Guy","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"CIT0008","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1016\/j.vaccine.2010.05.033","volume":"28","author":"Casares","year":"2010","journal-title":"Vaccine"},{"key":"CIT0009","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1586\/erv.10.154","volume":"10","author":"Mutwiri","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"CIT0010","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/erv.11.29","volume":"10","author":"Gar\u00e7on","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"CIT0011","doi-asserted-by":"crossref","first-page":"C25","DOI":"10.1016\/j.vaccine.2010.07.021","volume":"28","author":"Leroux-Roels","year":"2010","journal-title":"Vaccine"},{"key":"CIT0012","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1586\/erv.10.142","volume":"10","author":"Dey","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.8.3.293"},{"key":"CIT0014","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1016\/j.vaccine.2011.03.052","volume":"29","author":"Clark","year":"2011","journal-title":"Vaccine"},{"key":"CIT0015","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1096\/fj.10-0503","volume":"24","author":"Deamer","year":"2010","journal-title":"FASEB J."},{"key":"CIT0016","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11095-010-0301-9","volume":"28","author":"Nordly","year":"2011","journal-title":"Pharm. Res."},{"key":"CIT0017","doi-asserted-by":"crossref","first-page":"591325","DOI":"10.1155\/2011\/591325","volume":"2011","author":"Wagner","year":"2011","journal-title":"J. Drug Deliv."},{"key":"CIT0018","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/j.carres.2003.07.010","volume":"338","author":"Caroff","year":"2003","journal-title":"Carbohydr. Res."},{"key":"CIT0019","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nri1004","volume":"3","author":"Beutler","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"CIT0020","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1016\/j.vaccine.2007.12.002","volume":"26","author":"Alving","year":"2008","journal-title":"Vaccine"},{"key":"CIT0021","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.plipres.2009.06.002","volume":"49","author":"Wang","year":"2010","journal-title":"Prog. Lipid Res."},{"key":"CIT0022","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/nrmicro2266","volume":"8","author":"Bryant","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"CIT0023","first-page":"2654","volume":"41","author":"Takayama","year":"1981","journal-title":"Cancer Res."},{"key":"CIT0024","doi-asserted-by":"crossref","first-page":"11808","DOI":"10.1016\/S0021-9258(18)33836-5","volume":"257","author":"Qureshi","year":"1982","journal-title":"J. Biol. Chem."},{"key":"CIT0025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00205365","volume":"12","author":"Ribi","year":"1982","journal-title":"Cancer Immunol. Immunother."},{"key":"CIT0026","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1128\/IAI.45.2.350-355.1984","volume":"45","author":"Takayama","year":"1984","journal-title":"Infect. Immun."},{"key":"CIT0027","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1194\/jlr.M600027-JLR200","volume":"47","author":"Raetz","year":"2006","journal-title":"J. Lipid Res."},{"key":"CIT0028","doi-asserted-by":"crossref","first-page":"322","DOI":"10.2183\/pjab.86.322","volume":"86","author":"Kusumoto","year":"2010","journal-title":"Proc. Jpn. Acad. Ser. B, Phys. Biol. Sci."},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1021\/jm990222b"},{"key":"CIT0030","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1128\/IAI.49.1.225-237.1985","volume":"49","author":"Kotani","year":"1985","journal-title":"Infect. Immun."},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.3109\/10408418909104475"},{"key":"CIT0032","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1128\/IAI.51.1.110-114.1986","volume":"51","author":"Brade","year":"1986","journal-title":"Infect. Immun."},{"key":"CIT0033","doi-asserted-by":"crossref","first-page":"e13677","DOI":"10.1371\/journal.pone.0013677","volume":"5","author":"Coler","year":"2010","journal-title":"PLoS ONE"},{"key":"CIT0034","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1128\/IAI.05257-11","volume":"79","author":"Lumsden","year":"2011","journal-title":"Infect. Immun."},{"key":"CIT0035","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/infdis\/jir769","volume":"205","author":"Behzad","year":"2012","journal-title":"J. Infect. Dis."},{"key":"CIT0036","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1128\/IAI.63.1.168-174.1995","volume":"63","author":"Myers","year":"1995","journal-title":"Infect. Immun."},{"key":"CIT0037","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s00018-008-8228-6","volume":"65","author":"Casella","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"CIT0038","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.addr.2004.09.008","volume":"57","author":"Storni","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"CIT0039","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1073\/pnas.0804897106","volume":"106","author":"Sharp","year":"2009","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"CIT0040","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.coi.2009.05.003","volume":"21","author":"De Gregorio","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"CIT0041","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1096\/fj.11-184556","volume":"26","author":"Hutchison","year":"2012","journal-title":"FASEB J."},{"key":"CIT0042","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jconrel.2009.10.022","volume":"142","author":"Henriksen-Lacey","year":"2010","journal-title":"J. Control. Release"},{"key":"CIT0043","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jconrel.2011.10.012","volume":"158","author":"Kaur","year":"2012","journal-title":"J. Control. Release"},{"key":"CIT0044","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1016\/j.vaccine.2009.05.059","volume":"27","author":"Watson","year":"2009","journal-title":"Vaccine"},{"key":"CIT0045","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.vaccine.2010.11.049","volume":"29","author":"Rao","year":"2011","journal-title":"Vaccine"},{"key":"CIT0046","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/infdis\/174.2.361","volume":"174","author":"Heppner","year":"1996","journal-title":"J. Infect. Dis."},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.1.358"},{"key":"CIT0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-1759(91)90120-5","volume":"140","author":"Alving","year":"1991","journal-title":"J. Immunol. Methods"},{"key":"CIT0049","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0165-2478(82)90118-3","volume":"5","author":"Shek","year":"1982","journal-title":"Immunol. Lett."},{"key":"CIT0050","first-page":"237","volume":"4","author":"van Rooijen","year":"1992","journal-title":"Semin. Immunol."},{"key":"CIT0051","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/0264-410X(93)90090-K","volume":"11","author":"van Rooijen","year":"1993","journal-title":"Vaccine"},{"key":"CIT0052","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.4049\/jimmunol.1001205","volume":"185","author":"Kamphorst","year":"2010","journal-title":"J. Immunol."},{"key":"CIT0053","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.imbio.2005.06.002","volume":"210","author":"Peachman","year":"2005","journal-title":"Immunobiology"},{"key":"CIT0054","doi-asserted-by":"crossref","first-page":"e15225","DOI":"10.1371\/journal.pone.0015225","volume":"5","author":"Tanaka","year":"2010","journal-title":"PLoS ONE"},{"key":"CIT0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.imlet.2004.05.013","volume":"95","author":"Peachman","year":"2004","journal-title":"Immunol. Lett."},{"key":"CIT0056","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0169-409X(99)00064-2","volume":"41","author":"Rao","year":"2000","journal-title":"Adv. Drug Deliv. Rev."},{"key":"CIT0057","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bbamcr.2004.10.004","volume":"1695","author":"Kloetzel","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"CIT0058","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1023\/A:1006897801858","volume":"24","author":"Kuehn","year":"1997","journal-title":"Mol. Biol. Rep."},{"key":"CIT0059","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0161-5890(02)00099-8","volume":"39","author":"Sijts","year":"2002","journal-title":"Mol. Immunol."},{"key":"CIT0060","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1016\/j.vaccine.2008.03.065","volume":"26","author":"Steers","year":"2008","journal-title":"Vaccine"},{"key":"CIT0061","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1016\/j.vaccine.2009.08.105","volume":"27","author":"Steers","year":"2009","journal-title":"Vaccine"},{"key":"CIT0062","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0065-2776(06)92006-9","volume":"92","author":"Loureiro","year":"2006","journal-title":"Adv. Immunol."},{"key":"CIT0063","doi-asserted-by":"crossref","first-page":"7815","DOI":"10.4049\/jimmunol.174.12.7815","volume":"174","author":"Ossendorp","year":"2005","journal-title":"J. Immunol."},{"key":"CIT0064","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/nri1960","volume":"6","author":"Wu","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"CIT0065","doi-asserted-by":"crossref","first-page":"e20479","DOI":"10.1371\/journal.pone.0020479","volume":"6","author":"Li","year":"2011","journal-title":"PLoS ONE"},{"key":"CIT0066","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1128\/CVI.00008-10","volume":"17","author":"Aboud","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"CIT0067","doi-asserted-by":"crossref","first-page":"e21225","DOI":"10.1371\/journal.pone.0021225","volume":"6","author":"Churchyard","year":"2011","journal-title":"PLoS ONE"},{"key":"CIT0068","doi-asserted-by":"crossref","first-page":"7049","DOI":"10.1128\/JVI.00327-09","volume":"83","author":"Steers","year":"2009","journal-title":"J. Virol."},{"key":"CIT0069","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1128\/JVI.01790-10","volume":"85","author":"Steers","year":"2011","journal-title":"J. Virol."},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1586\/erv.09.160"},{"key":"CIT0071","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1126\/science.1135299","volume":"314","author":"Gavin","year":"2006","journal-title":"Science"},{"key":"CIT0072","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2174\/092986709788682001","volume":"16","author":"Brandenburg","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"CIT0073","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00205743","volume":"18","author":"Vosika","year":"1984","journal-title":"Cancer Immunol. Immunother."},{"key":"CIT0074","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/0264-410X(89)90274-0","volume":"7","author":"Richards","year":"1989","journal-title":"Vaccine"},{"key":"CIT0075","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.colsurfb.2009.08.022","volume":"75","author":"Anderson","year":"2010","journal-title":"Colloids Surf. B. Biointerfaces"},{"key":"CIT0076","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.vaccine.2007.12.038","volume":"26","author":"Vandepapeli\u00e8re","year":"2008","journal-title":"Vaccine"},{"key":"CIT0077","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1016\/j.vaccine.2011.05.042","volume":"29","author":"Matyas","year":"2011","journal-title":"Vaccine"},{"key":"CIT0078","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.bbrc.2010.10.124","volume":"402","author":"Matyas","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"CIT0079","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1097\/QAD.0b013e32832faea5","volume":"23","author":"Matyas","year":"2009","journal-title":"AIDS"},{"key":"CIT0080","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0005-2736(01)00383-2","volume":"1514","author":"Batenjany","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"CIT0081","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1073\/pnas.022627199","volume":"99","author":"Nicolau","year":"2002","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"CIT0082","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-1-60327-360-2_18","volume":"605","author":"Frisch","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"CIT0083","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1995.tb00075.x"},{"key":"CIT0084","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev.biochem.75.101304.123901","volume":"75","author":"Chiti","year":"2006","journal-title":"Annu. Rev. Biochem."},{"key":"CIT0085","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00109-003-0464-5","volume":"81","author":"Stefani","year":"2003","journal-title":"J. Mol. Med."},{"key":"CIT0086","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0079-6123(09)17506-4","volume":"175","author":"Lemere","year":"2009","journal-title":"Prog. Brain Res."},{"key":"CIT0087","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"CIT0088","doi-asserted-by":"crossref","first-page":"9810","DOI":"10.1073\/pnas.0703137104","volume":"104","author":"Muhs","year":"2007","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"CIT0089","doi-asserted-by":"crossref","first-page":"13966","DOI":"10.1074\/jbc.M110.186338","volume":"286","author":"Hickman","year":"2011","journal-title":"J. Biol. Chem."},{"key":"CIT0090","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/600120","volume":"200","author":"Kester","year":"2009","journal-title":"J. Infect. Dis."},{"key":"CIT0091","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.immuni.2007.11.018","volume":"28","author":"Sun","year":"2008","journal-title":"Immunity"},{"key":"CIT0092","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/1044-579X(95)90007-1","volume":"6","author":"McElrath","year":"1995","journal-title":"Semin. Cancer Biol."},{"key":"CIT0093","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.vaccine.2011.11.084","volume":"30","author":"Zollinger","year":"2012","journal-title":"Vaccine"},{"key":"CIT0094","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S0264-410X(02)00174-3","volume":"20","author":"Alving","year":"2002","journal-title":"Vaccine"},{"key":"CIT0095","first-page":"439","volume":"26","author":"Harris","year":"1999","journal-title":"Semin. Oncol."},{"key":"CIT0096","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.08.021"},{"key":"CIT0097","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0022-5347(06)00494-0","volume":"176","author":"North","year":"2006","journal-title":"J. Urol."}],"container-title":["Expert Review of Vaccines"],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/erv.12.35","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T23:11:00Z","timestamp":1643152260000},"score":17.434387,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1586\/erv.12.35"}},"issued":{"date-parts":[[2012,6]]},"references-count":97,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,1,9]]},"published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1586\/erv.12.35"],"URL":"https:\/\/doi.org\/10.1586\/erv.12.35","ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"published":{"date-parts":[[2012,6]]}},{"indexed":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T01:23:48Z","timestamp":1711070628816},"reference-count":0,"publisher":"Rowman & Littlefield Publishers","isbn-type":[{"value":"9781442215801","type":"print"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2012]]},"DOI":"10.5771\/9781442215801-183","type":"book-chapter","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T08:16:05Z","timestamp":1711008965000},"page":"183-202","source":"Crossref","is-referenced-by-count":0,"title":["Bibliography"],"prefix":"10.5771","author":[{"given":"Stacy  Mintzer","family":"Herlihy","sequence":"first","affiliation":[]},{"given":"E. Allison","family":"Hagood","sequence":"additional","affiliation":[]}],"member":"3821","container-title":["Your Baby's Best Shot"],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T08:38:02Z","timestamp":1711010282000},"score":17.36155,"resource":{"primary":{"URL":"https:\/\/www.nomos-elibrary.de\/index.php?doi=10.5771\/9781442215801-183"}},"issued":{"date-parts":[[2012]]},"ISBN":["9781442215801"],"references-count":0,"URL":"https:\/\/doi.org\/10.5771\/9781442215801-183","published":{"date-parts":[[2012]]}},{"indexed":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T01:16:29Z","timestamp":1711070189960},"reference-count":0,"publisher":"Rowman & Littlefield Publishers","isbn-type":[{"value":"9781442215801","type":"print"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2012]]},"DOI":"10.5771\/9781442215801-161","type":"book-chapter","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T08:16:05Z","timestamp":1711008965000},"page":"161-182","source":"Crossref","is-referenced-by-count":0,"title":["Notes"],"prefix":"10.5771","author":[{"given":"Stacy  Mintzer","family":"Herlihy","sequence":"first","affiliation":[]},{"given":"E. Allison","family":"Hagood","sequence":"additional","affiliation":[]}],"member":"3821","container-title":["Your Baby's Best Shot"],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T08:38:01Z","timestamp":1711010281000},"score":17.36155,"resource":{"primary":{"URL":"https:\/\/www.nomos-elibrary.de\/index.php?doi=10.5771\/9781442215801-161"}},"issued":{"date-parts":[[2012]]},"ISBN":["9781442215801"],"references-count":0,"URL":"https:\/\/doi.org\/10.5771\/9781442215801-161","published":{"date-parts":[[2012]]}},{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T12:52:59Z","timestamp":1648903979984},"reference-count":1,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reactions Weekly"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40278-019-63899-8","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T07:25:59Z","timestamp":1561706759000},"page":"9-9","source":"Crossref","is-referenced-by-count":0,"title":["Live attenuated vaccines safe in paediatric rheumatic diseases?"],"prefix":"10.1007","volume":"1759","member":"297","published-online":{"date-parts":[[2019,6,29]]},"reference":[{"key":"63899_CR1","doi-asserted-by":"crossref","unstructured":"Uziel Y, et al. Live Attenuated Vaccines in Pediatric Rheumatic Diseases Are Safe: Multicenter, Retrospective Data Collection. 20th Annual Congress of the European League Against Rheumatism :  abstr. OP0205, 12 Jun 2019. Available from: URL: \n                    http:\/\/scientific.sparx-ip.net\/archiveeular\/index.cfm?view=2&c=a&item=2019OP0205","DOI":"10.1136\/annrheumdis-2019-eular.3770"}],"container-title":["Reactions Weekly"],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40278-019-63899-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40278-019-63899-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40278-019-63899-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T23:28:21Z","timestamp":1593300501000},"score":17.325459,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40278-019-63899-8"}},"issued":{"date-parts":[[2019,6]]},"references-count":1,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["63899"],"URL":"https:\/\/doi.org\/10.1007\/s40278-019-63899-8","ISSN":["0114-9954","1179-2051"],"issn-type":[{"value":"0114-9954","type":"print"},{"value":"1179-2051","type":"electronic"}],"published":{"date-parts":[[2019,6]]}},{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T07:22:00Z","timestamp":1648538520923},"reference-count":1,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reactions Weekly"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s40278-018-42261-0","type":"journal-article","created":{"date-parts":[[2018,3,3]],"date-time":"2018-03-03T09:41:45Z","timestamp":1520070105000},"page":"6-6","source":"Crossref","is-referenced-by-count":0,"title":["Maternal influenza and DTaP vaccines safe during pregnancy"],"prefix":"10.1007","volume":"1691","member":"297","published-online":{"date-parts":[[2018,3,3]]},"reference":[{"key":"42261_CR1","doi-asserted-by":"crossref","unstructured":"Sukumaran L, et al. Infant Hospitalizations and Mortality After Maternal Vaccination. Pediatrics 141: [11 pages], No. 3, 20 Feb 2018. Available from: URL: http:\/\/dx.doi.org\/10.1542\/peds.2017-3310","DOI":"10.1542\/peds.2017-3310"}],"container-title":["Reactions Weekly"],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40278-018-42261-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40278-018-42261-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40278-018-42261-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,3]],"date-time":"2019-03-03T00:19:51Z","timestamp":1551572391000},"score":17.325459,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40278-018-42261-0"}},"issued":{"date-parts":[[2018,3]]},"references-count":1,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["42261"],"URL":"https:\/\/doi.org\/10.1007\/s40278-018-42261-0","ISSN":["0114-9954","1179-2051"],"issn-type":[{"value":"0114-9954","type":"print"},{"value":"1179-2051","type":"electronic"}],"published":{"date-parts":[[2018,3]]}},{"indexed":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T05:23:23Z","timestamp":1678339403230},"reference-count":4,"publisher":"BMJ","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/bmj.com\/coronavirus\/usage"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj.o2013","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T17:35:11Z","timestamp":1660325711000},"page":"o2013","update-policy":"http:\/\/dx.doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Covid-19: Study provides further evidence that mRNA vaccines are safe in pregnancy"],"prefix":"10.1136","author":[{"given":"Jacqui","family":"Wise","sequence":"first","affiliation":[]}],"member":"239","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"2023030808115028000_378.aug12_15.o2013.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00426-1"},{"key":"2023030808115028000_378.aug12_15.o2013.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o27"},{"key":"2023030808115028000_378.aug12_15.o2013.3","unstructured":"UK Health Security Agency. Vaccine uptake among pregnant women increasing but inequalities persist [press release]. Gov.UK. May 2022. https:\/\/www.gov.uk\/government\/news\/vaccine-uptake-among-pregnant-women-increasing-but-inequalities-persist."},{"key":"2023030808115028000_378.aug12_15.o2013.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00443-1"}],"container-title":["BMJ"],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.o2013","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.o2013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T17:17:06Z","timestamp":1678295826000},"score":17.325459,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.o2013"}},"issued":{"date-parts":[[2022,8,12]]},"references-count":4,"alternative-id":["10.1136\/bmj.o2013"],"URL":"https:\/\/doi.org\/10.1136\/bmj.o2013","ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"published":{"date-parts":[[2022,8,12]]}},{"indexed":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T01:18:30Z","timestamp":1711070310007},"reference-count":0,"publisher":"Rowman & Littlefield Publishers","isbn-type":[{"value":"9781442215801","type":"print"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2012]]},"DOI":"10.5771\/9781442215801-i","type":"book-chapter","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T08:16:05Z","timestamp":1711008965000},"page":"i-x","source":"Crossref","is-referenced-by-count":0,"title":["Preface"],"prefix":"10.5771","author":[{"given":"Stacy  Mintzer","family":"Herlihy","sequence":"first","affiliation":[]},{"given":"E. Allison","family":"Hagood","sequence":"additional","affiliation":[]}],"member":"3821","container-title":["Your Baby's Best Shot"],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T08:37:43Z","timestamp":1711010263000},"score":17.320192,"resource":{"primary":{"URL":"https:\/\/www.nomos-elibrary.de\/index.php?doi=10.5771\/9781442215801-i"}},"issued":{"date-parts":[[2012]]},"ISBN":["9781442215801"],"references-count":0,"URL":"https:\/\/doi.org\/10.5771\/9781442215801-i","published":{"date-parts":[[2012]]}},{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T05:45:28Z","timestamp":1649051128474},"reference-count":0,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1053\/j.gastro.2006.01.058","type":"journal-article","created":{"date-parts":[[2006,3,14]],"date-time":"2006-03-14T08:50:18Z","timestamp":1142326218000},"page":"627-628","source":"Crossref","is-referenced-by-count":0,"title":["New Rotavirus Vaccines Safe and Effective in Large Clinical Trials"],"prefix":"10.1053","volume":"130","author":[{"given":"Les","family":"Lang","sequence":"first","affiliation":[]}],"member":"78","container-title":["Gastroenterology"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508506000849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508506000849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T17:26:09Z","timestamp":1547745969000},"score":17.312305,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508506000849"}},"issued":{"date-parts":[[2006,3]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S0016508506000849"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2006.01.058","ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"published":{"date-parts":[[2006,3]]}},{"indexed":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T01:14:44Z","timestamp":1711070084666},"reference-count":0,"publisher":"Rowman & Littlefield Publishers","isbn-type":[{"value":"9781442215801","type":"print"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2012]]},"DOI":"10.5771\/9781442215801-203","type":"book-chapter","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T08:16:05Z","timestamp":1711008965000},"page":"203-212","source":"Crossref","is-referenced-by-count":0,"title":["Index"],"prefix":"10.5771","author":[{"given":"Stacy  Mintzer","family":"Herlihy","sequence":"first","affiliation":[]},{"given":"E. Allison","family":"Hagood","sequence":"additional","affiliation":[]}],"member":"3821","container-title":["Your Baby's Best Shot"],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T08:38:03Z","timestamp":1711010283000},"score":17.312305,"resource":{"primary":{"URL":"https:\/\/www.nomos-elibrary.de\/index.php?doi=10.5771\/9781442215801-203"}},"issued":{"date-parts":[[2012]]},"ISBN":["9781442215801"],"references-count":0,"URL":"https:\/\/doi.org\/10.5771\/9781442215801-203","published":{"date-parts":[[2012]]}},{"indexed":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T17:53:22Z","timestamp":1721843602675},"reference-count":2,"publisher":"BMJ","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/bmj.com\/coronavirus\/usage"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj.n3030","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T12:38:09Z","timestamp":1638880689000},"page":"n3030","update-policy":"http:\/\/dx.doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Covid-19: \u201cMix and match\u201d primary vaccines are safe and effective, study finds"],"prefix":"10.1136","author":[{"given":"Elisabeth","family":"Mahase","sequence":"first","affiliation":[]}],"member":"239","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"2023030805154623000_375.dec07_7.n3030.1","unstructured":"Stuart ASV, Shaw RH, Liu X, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet 2021 (published online 6 Dec). https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(21)02718-5\/fulltext"},{"key":"2023030805154623000_375.dec07_7.n3030.2","unstructured":"Our World in Data. Coronavirus (covid-19) vaccinations. https:\/\/ourworldindata.org\/covid-vaccinations"}],"container-title":["BMJ"],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.n3030","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.n3030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T13:27:56Z","timestamp":1678282076000},"score":17.298111,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.n3030"}},"issued":{"date-parts":[[2021,12,7]]},"references-count":2,"alternative-id":["10.1136\/bmj.n3030"],"URL":"https:\/\/doi.org\/10.1136\/bmj.n3030","ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"published":{"date-parts":[[2021,12,7]]}},{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T05:37:09Z","timestamp":1648964229022},"reference-count":6,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2014,4,28]]},"DOI":"10.4161\/hv.27234","type":"journal-article","created":{"date-parts":[[2013,11,27]],"date-time":"2013-11-27T22:13:50Z","timestamp":1385590430000},"page":"1111-1113","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Vaccination for safe travel to India"],"prefix":"10.1080","volume":"10","author":[{"given":"Bharti","family":"Mehta","sequence":"first","affiliation":[]},{"given":"Harashish","family":"Jindal","sequence":"additional","affiliation":[]},{"given":"Bhumika","family":"Bhatt","sequence":"additional","affiliation":[]},{"given":"Vijay","family":"Kumar Dharma","sequence":"additional","affiliation":[]},{"given":"Satvinder","family":"Choudhary","sequence":"additional","affiliation":[]}],"member":"301","published-online":{"date-parts":[[2013,11,27]]},"reference":[{"key":"R1","unstructured":"United Nations World Tourism Organization. UNWTO Tourism Highlights 2013 Edition:UNWTO;2013 Available from http:\/\/mkt.unwto.org\/en\/publication\/unwto-tourism-highlights-2013-edition [Accessed on 20 October2013]"},{"key":"R2","unstructured":"Report A. (English) for the Year 2012-13. New Delhi: Ministry of tourism;2013 Available from: http:\/\/tourism.gov.in\/Pages\/AnualReportArc.aspx[Accessed on 1 october2013]"},{"key":"R3","unstructured":"World Health Organization. International travel and health 2012. Geneva:WHO;2013 Available from http:\/\/www.who.int\/ith\/en\/[Accessed on 30 October 2013]"},{"key":"R4","unstructured":"Major Infectious Disease.In:The World Factbook. CIA library: Central Intelligence Agency;2013 Available from https:\/\/www.cia.gov\/library\/publications\/the-world-factbook\/fields\/2193.html[Accessed on 17 October 2013]"},{"key":"R5","unstructured":"Centers for Disease Control and Prevention. CDC Health Information for International Travel 2014. New York: Oxford University Press; 2014. Available from http:\/\/wwwnc.cdc.gov\/travel\/yellowbook\/2014\/chapter-1-introduction\/perspectives-why-guidelines-differ[Accessed on 19 October 2013]"},{"key":"R6","unstructured":"Chart WI. IAMAT elibrary: International Association for Medical assistance to Travellers;2013 July Available from: www.iamat.org\/pdf\/world_immunization_chart.pdf [Accessed on 2 November 2013]"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.4161\/hv.27234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,14]],"date-time":"2016-12-14T03:44:24Z","timestamp":1481687064000},"score":17.280254,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/abs\/10.4161\/hv.27234"}},"issued":{"date-parts":[[2013,11,27]]},"references-count":6,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,4]]},"published-print":{"date-parts":[[2014,4,28]]}},"alternative-id":["10.4161\/hv.27234"],"URL":"https:\/\/doi.org\/10.4161\/hv.27234","ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"published":{"date-parts":[[2013,11,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"}]},{"indexed":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T15:10:36Z","timestamp":1726758636249},"reference-count":73,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2007,10,1]]},"DOI":"10.1586\/14760584.6.5.699","type":"journal-article","created":{"date-parts":[[2007,10,12]],"date-time":"2007-10-12T09:03:53Z","timestamp":1192179833000},"page":"699-710","source":"Crossref","is-referenced-by-count":227,"title":["MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection"],"prefix":"10.1586","volume":"6","author":[{"given":"Derek T","family":"O\u2019Hagan","sequence":"first","affiliation":[{"name":"Head of Vaccine Delivery Research, Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy."}]}],"member":"301","published-online":{"date-parts":[[2014,1,9]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-37-9625"},{"key":"CIT0002","first-page":"131","volume":"8","author":"Hilleman","year":"1966","journal-title":"Prog. Med. Virol."},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.08.023"},{"key":"CIT0004","doi-asserted-by":"crossref","unstructured":"Salk JE, Laurent AM, Bailey ML. Direction of research on vaccination against influenza; new studies with immunologic adjuvants.Am. J. Public Health41(6), 669\u2013677 (1951).","DOI":"10.2105\/AJPH.41.6.669"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/2.3.370"},{"key":"CIT0006","first-page":"141","volume":"2","author":"Page","year":"1993","journal-title":"Vaccine Res."},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.1.1.111"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.12.8017-8026.2005"},{"key":"CIT0009","doi-asserted-by":"crossref","unstructured":"Allison AC, Byars NE. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity.J. Immunol Methods95(2), 157\u2013168 (1986).","DOI":"10.1016\/0022-1759(86)90402-3"},{"key":"CIT0010","doi-asserted-by":"crossref","unstructured":"Vogel FR, Powell MF. In:Vaccine Design: The Subunit and Adjuvant Approach.Powell MF, Newman MJ (Eds). Plenum Press, NY, USA 141\u2013228 (1995).","DOI":"10.1007\/978-1-4615-1823-5_7"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(74)90458-6"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1128\/iai.51.3.816-825.1986"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1038\/ni1412"},{"key":"CIT0014","unstructured":"Kenney RT, Edelman R.New Generation Vaccines.Levine MM, Kaper JB, Rappuoli R, Liu M, Good M (Eds). Marcel Dekker, Inc., NY, USA (2004)."},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/163.2.219"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(93)90376-9"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1996.12.683"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/170.5.1288"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(95)00089-J"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(97)00115-1"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(95)00240-2"},{"key":"CIT0022","doi-asserted-by":"crossref","unstructured":"Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59: design and evaluation of a safe and potent adjuvant for human vaccines. In:Vaccine Design: The Subunit and Adjuvant Approach.Powell MF, Newman MJ (Eds.) Plenum Press, NY, USA 277\u2013296 (1995).","DOI":"10.1007\/978-1-4615-1823-5_10"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00263-7"},{"key":"CIT0024","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.4049\/jimmunol.153.9.4029","volume":"153","author":"Valensi","year":"1994","journal-title":"J. Immunol."},{"key":"CIT0025","unstructured":"Ott G. Vaccine Adjuvants: preparation methods and research protocols. In:Vaccine Adjuvants: Preparation Methods and Research Protocols.O\u2019Hagan D (Ed.). Humana Press, NJ, USA (2000)."},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/174.6.1168"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2.2.197"},{"key":"CIT0028","doi-asserted-by":"crossref","unstructured":"Podda A, Del Giudice G, O\u2019Hagan DT. MF59: a safe and potent adjuvant for human use. In:Immunopotentiators in Modern Vaccines.Schijns V, O\u2019Hagan DT (Eds). Elsevier Press, USA 149 (2006).","DOI":"10.1016\/B978-012088403-2\/50010-1"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.09.046"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1128\/iai.65.5.1710-1715.1997"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(86)80002-0"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00499-0"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00060-3"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1023\/A:1017919305501"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1159\/000069172"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.07.017"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268805003936"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00408-0"},{"key":"CIT0039","first-page":"79","volume":"44","author":"Paschke","year":"2003","journal-title":"J. Prev. Med. Hyg."},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.02.045"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00185-6"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-007-9100-4"},{"key":"CIT0043","unstructured":"D\u2019Agosto V, Berardi S, Burroni D, Hennig R. Tolerability and safety of an MF59-adjuvanted subunit influenza vaccine (FLUAD\u00ae).IVW 2006\u2013The Second International Conference on Influenza Vaccines for the World, 18\u201320 October (2006)."},{"key":"CIT0044","author":"Schultze","year":"2007","journal-title":"Vaccine"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00191-06"},{"key":"CIT0046","first-page":"357","volume":"9272","author":"Nicholson","year":"2001","journal-title":"Lancet"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00632-1"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1086\/508174"},{"key":"CIT0049","first-page":"191","author":"Stephenson","year":"2005","journal-title":"J. Infect. Dis."},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00088-2"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-12-199506150-00001"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.4.331"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200202000-00009"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1086\/315298"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1086\/319215"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1086\/323994"},{"key":"CIT0057","unstructured":"Ott G.Vaccine Design: The Subunit and Adjuvant Approach.Plenum Press, NY, USA (1995)."},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.4.6.937"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00272-4"},{"key":"CIT0060","author":"Wack","year":"2007","journal-title":"Vaccine"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/170.5.1110"},{"key":"CIT0062","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00522-8"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.3.1547-1550.2001"},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.10.6087-6092.2003"},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.11.073"},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.08.017"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.13.8189-8200.2005"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.06.037"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1086\/318523"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1086\/339003"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000230318.40170.60"},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.10.011"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0603940103"}],"container-title":["Expert Review of Vaccines"],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/14760584.6.5.699","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T11:49:07Z","timestamp":1684064947000},"score":17.280254,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/14760584.6.5.699"}},"issued":{"date-parts":[[2007,10,1]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,10,1]]}},"alternative-id":["10.1586\/14760584.6.5.699"],"URL":"https:\/\/doi.org\/10.1586\/14760584.6.5.699","ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"published":{"date-parts":[[2007,10,1]]}},{"indexed":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T16:35:38Z","timestamp":1723221338354},"reference-count":1,"publisher":"BMJ","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/bmj.com\/coronavirus\/usage"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj.o1170","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T19:31:39Z","timestamp":1652988699000},"page":"o1170","update-policy":"http:\/\/dx.doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Covid-19: Fourth dose of mRNA vaccines is safe and boosts immunity, study finds"],"prefix":"10.1136","author":[{"given":"Gareth","family":"Iacobucci","sequence":"first","affiliation":[]}],"member":"239","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"2023030806593958000_377.may10_7.o1170.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00271-7"}],"container-title":["BMJ"],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.o1170","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.o1170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T15:09:51Z","timestamp":1678288191000},"score":17.130585,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.o1170"}},"issued":{"date-parts":[[2022,5,10]]},"references-count":1,"alternative-id":["10.1136\/bmj.o1170"],"URL":"https:\/\/doi.org\/10.1136\/bmj.o1170","ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"published":{"date-parts":[[2022,5,10]]}},{"indexed":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T12:00:58Z","timestamp":1726920058875},"reference-count":66,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:00:00Z","timestamp":1608681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012895","name":"Zoetis","doi-asserted-by":"publisher","award":["Ri-0613"],"id":[{"id":"10.13039\/100012895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Capripox virus (CaPV)-induced diseases (lumpy skin disease, sheeppox, goatpox) are described as the most serious pox diseases of livestock animals, and therefore are listed as notifiable diseases under guidelines of the World Organisation for Animal Health (OIE). Until now, only live-attenuated vaccines are commercially available for the control of CaPV. Due to numerous potential problems after vaccination (e.g., loss of the disease-free status of the respective country, the possibility of vaccine virus shedding and transmission as well as the risk of recombination with field strains during natural outbreaks), the use of these vaccines must be considered carefully and is not recommended in CaPV-free countries. Therefore, innocuous and efficacious inactivated vaccines against CaPV would provide a great tool for control of these diseases. Unfortunately, most inactivated Capripox vaccines were reported as insufficient and protection seemed to be only short-lived. Nevertheless, a few studies dealing with inactivated vaccines against CaPV are published, giving evidence for good clinical protection against CaPV-infections. In our studies, a low molecular weight copolymer-adjuvanted vaccine formulation was able to induce sterile immunity in the respective animals after severe challenge infection. Our findings strongly support the possibility of useful inactivated vaccines against CaPV-infections, and indicate a marked impact of the chosen adjuvant for the level of protection.<\/jats:p>","DOI":"10.3390\/vaccines9010004","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T17:19:51Z","timestamp":1608743991000},"page":"4","source":"Crossref","is-referenced-by-count":36,"title":["Development of a Safe and Highly Efficient Inactivated Vaccine Candidate against Lumpy Skin Disease Virus"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"http:\/\/orcid.org\/0000-0002-2434-687X","authenticated-orcid":false,"given":"Janika","family":"Wolff","sequence":"first","affiliation":[{"name":"Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, S\u00fcdufer 10, D-17493 Greifswald-Insel Riems, Germany"}]},{"given":"Tom","family":"Moritz","sequence":"additional","affiliation":[{"name":"Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, S\u00fcdufer 10, D-17493 Greifswald-Insel Riems, Germany"}]},{"given":"Kore","family":"Schlottau","sequence":"additional","affiliation":[{"name":"Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, S\u00fcdufer 10, D-17493 Greifswald-Insel Riems, Germany"}]},{"ORCID":"http:\/\/orcid.org\/0000-0003-4552-031X","authenticated-orcid":false,"given":"Donata","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, S\u00fcdufer 10, D-17493 Greifswald-Insel Riems, Germany"}]},{"given":"Martin","family":"Beer","sequence":"additional","affiliation":[{"name":"Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, S\u00fcdufer 10, D-17493 Greifswald-Insel Riems, Germany"}]},{"ORCID":"http:\/\/orcid.org\/0000-0001-5358-6445","authenticated-orcid":false,"given":"Bernd","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, S\u00fcdufer 10, D-17493 Greifswald-Insel Riems, Germany"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,23]]},"reference":[{"key":"ref_1","unstructured":"King, A.M.Q., Adams, M.J., Carstens, E.B., and Lefkowitz, E. (2012). Virus Taxonomy-Classification and Nomenclature of Viruses: Ninth Report of the International Committee on Taxonomy of Viruses, Elsevier Academic Press."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/0264-410X(93)90094-E","article-title":"Control of capripoxvirus infections","volume":"11","author":"Carn","year":"1993","journal-title":"Vaccine"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1865-1682.2008.01043.x","article-title":"Capripoxviruses: An emerging worldwide threat to sheep, goats and cattle","volume":"55","author":"Babiuk","year":"2008","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1017\/S0950268800052067","article-title":"An investigation of possible routes of transmission of lumpy skin disease virus (Neethling)","volume":"114","author":"Carn","year":"1995","journal-title":"Epidemiol. Infect."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0034-5288(18)30753-7","article-title":"Mechanical transmission of capripox virus and African swine fever virus by Stomoxys calcitrans","volume":"43","author":"Mellor","year":"1987","journal-title":"Res. Vet. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1017\/S0950268801005179","article-title":"Mechanical transmission of lumpy skin disease virus by Aedes aegypti (Diptera: Culicidae)","volume":"126","author":"Chihota","year":"2001","journal-title":"Epidemiol. Infect."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1046\/j.1365-2915.2003.00445.x","article-title":"Attempted mechanical transmission of lumpy skin disease virus by biting insects","volume":"17","author":"Chihota","year":"2003","journal-title":"Med. Vet. Entomol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1017\/S0950268812000805","article-title":"Mechanical transmission of lumpy skin disease virus by Rhipicephalus appendiculatus male ticks","volume":"141","author":"Tuppurainen","year":"2013","journal-title":"Epidemiol. Infect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ttbdis.2013.01.006","article-title":"Evidence of vertical transmission of lumpy skin disease virus in Rhipicephalus decoloratus ticks","volume":"4","author":"Tuppurainen","year":"2013","journal-title":"Ticks Tick Borne Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1865-1682.2010.01184.x","article-title":"A potential role for ixodid (hard) tick vectors in the transmission of lumpy skin disease virus in cattle","volume":"58","author":"Tuppurainen","year":"2011","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ttbdis.2014.11.002","article-title":"Lumpy skin disease: Attempted propagation in tick cell lines and presence of viral DNA in field ticks collected from naturally-infected cattle","volume":"6","author":"Tuppurainen","year":"2015","journal-title":"Ticks Tick Borne Dis."},{"key":"ref_12","first-page":"421","article-title":"Lumpy skin disease","volume":"5","author":"Haig","year":"1957","journal-title":"Bull. Epizoot. Dis. Afr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/tbed.12045","article-title":"Seminal transmission of lumpy skin disease virus in heifers","volume":"61","author":"Annandale","year":"2014","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/tbed.12444","article-title":"Review: Capripoxvirus Diseases: Current Status and Opportunities for Control","volume":"64","author":"Tuppurainen","year":"2017","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1865-1682.2008.01024.x","article-title":"Quantification of lumpy skin disease virus following experimental infection in cattle","volume":"55","author":"Babiuk","year":"2008","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01718427","article-title":"The clinical response of cattle experimentally infected with lumpy skin disease (Neethling) virus","volume":"140","author":"Carn","year":"1995","journal-title":"Arch. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0007-1935(91)90019-J","article-title":"Lumpy skin disease, an African capripox virus disease of cattle","volume":"147","author":"Davies","year":"1991","journal-title":"Br. Vet. J."},{"key":"ref_18","unstructured":"Spickler, A.R. (2020, June 26). Lumpy Skin Disease. Available online: http:\/\/www.cfsph.iastate.edu\/Factsheets\/pdfs\/lumpy_skin_disease.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"20076","DOI":"10.1038\/s41598-019-56605-6","article-title":"Experimental evidence of mechanical lumpy skin disease virus transmission by Stomoxys calcitrans biting flies and Haematopota spp. horseflies","volume":"9","author":"Sohier","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1865-1682.2011.01242.x","article-title":"Review: Lumpy skin disease: An emerging threat to Europe, the Middle East and Asia","volume":"59","author":"Tuppurainen","year":"2012","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4102\/ojvr.v72i2.213","article-title":"The detection of lumpy skin disease virus in samples of experimentally infected cattle using different diagnostic techniques","volume":"72","author":"Tuppurainen","year":"2005","journal-title":"Onderstepoort J. Vet. Res."},{"key":"ref_22","first-page":"37","article-title":"Lumpy skin disease of cattle: A growing problem in Africa and the Near East","volume":"68","author":"Davies","year":"1991","journal-title":"World Anim Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-662-39771-8_3","article-title":"Lumpy skin disease virus","volume":"3","author":"Weiss","year":"1968","journal-title":"Virol. Monogr."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4102\/jsava.v72i2.619","article-title":"Lumpy skin disease in southern Africa: A review of the disease and aspects of control","volume":"72","author":"Hunter","year":"2001","journal-title":"J. S. Afr Vet. Assoc."},{"key":"ref_25","unstructured":"OIE (2019). Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2019, World Organization for Animal Health, OIE."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/vr.i2800","article-title":"Lumpy skin disease: A direct threat to Europe","volume":"178","author":"Beard","year":"2016","journal-title":"Vet. Rec"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2014.06.009","article-title":"Characterization of sheep pox virus vaccine for cattle against lumpy skin disease virus","volume":"109","author":"Tuppurainen","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_28","unstructured":"Klement, E., Broglia, A., Antoniou, S.E., Tsiamadis, V., Plevraki, E., Petrovic, T., Polacek, V., Debeljak, Z., Miteva, A., and Alexandrov, T. (2018). Neethling vaccine proved highly effective in controlling lumpy skin disease epidemics in the Balkans. Prev. Vet. Med."},{"key":"ref_29","first-page":"5","article-title":"A survey of vaccines produced for OIE list A diseases in OIE member countries","volume":"114","author":"Roth","year":"2003","journal-title":"Dev. Biol."},{"key":"ref_30","first-page":"161","article-title":"Vaccines for lumpy skin disease, sheep pox and goat pox","volume":"114","author":"Kitching","year":"2003","journal-title":"Dev. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/0021-9975(85)90026-X","article-title":"The alterations in pathogenicity and immunogenicity of a Kenya sheep and goat pox virus on serial passage in bovine foetal muscle cell cultures","volume":"95","author":"Davies","year":"1985","journal-title":"J. Comp. Pathol."},{"key":"ref_32","first-page":"165","article-title":"The optimal conditions for the multiplication of Neethling-type lumpy skin disease virus in embryonated eggs","volume":"36","author":"Munz","year":"1969","journal-title":"Onderstepoort J. Vet. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1111\/tbed.12257","article-title":"Adverse Reactions to Field Vaccination Against Lumpy Skin Disease in Jordan","volume":"63","author":"Abutarbush","year":"2016","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21859\/isv.10.4.1","article-title":"Evaluation of Humoral and Cell-mediated Immunity of Two Capripoxvirus Vaccine Strains against Lumpy Skin Disease Virus","volume":"10","author":"Norian","year":"2016","journal-title":"Iran. J. Virol."},{"key":"ref_35","first-page":"33","article-title":"Immune response characteristic of Capri pox virus vaccines following emergency vaccination of cattle against lumpy skin disease virus","volume":"9","author":"Varshovi","year":"2018","journal-title":"Iran. J. Vet. Sci Tech."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1016\/j.vaccine.2015.07.071","article-title":"Comparison of the efficacy of Neethling lumpy skin disease virus and x10RM65 sheep-pox live attenuated vaccines for the prevention of lumpy skin disease\u2013The results of a randomized controlled field study","volume":"33","author":"Klement","year":"2015","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.vaccine.2015.01.035","article-title":"Evaluation of the safety, immunogenicity and efficacy of three capripoxvirus vaccine strains against lumpy skin disease virus","volume":"33","author":"Gari","year":"2015","journal-title":"Vaccine"},{"key":"ref_38","unstructured":"Abdelwahab, M., Khafagy, H., Moustafa, A., and Saad, M. (2016). Evaluation of Humoral and Cell-mediated Immunity of Lumpy Skin Disease Vaccine Prepared from Local strainin calves and Its Related to Maternal Immunity Evaluation of Humoral and Cell-mediated Immunity of Lumpy Skin Disease Vaccine Prepared from Local in calves and Its. J. Am. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/tbed.12646","article-title":"Investigation on the incidence of adverse reactions, viraemia and haematological changes following field immunization of cattle using a live attenuated vaccine against lumpy skin disease","volume":"65","author":"Katsoulos","year":"2018","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/tbed.12730","article-title":"Detection of lumpy skin disease virus in skin lesions, blood, nasal swabs and milk following preventive vaccination","volume":"65","author":"Bedekovic","year":"2018","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/vr.135.14.330","article-title":"Adverse reactions in cattle to a capripox vaccine","volume":"135","author":"Yeruham","year":"1994","journal-title":"Vet. Rec."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Morgenstern, M., and Klement, E. (2020). The Effect of Vaccination with Live Attenuated Neethling Lumpy Skin Disease Vaccine on Milk Production and Mortality-An Analysis of 77 Dairy Farms in Israel. Vaccines, 8.","DOI":"10.3390\/vaccines8020324"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.vaccine.2009.01.020","article-title":"Appearance of skin lesions in cattle populations vaccinated against lumpy skin disease: Statutory challenge","volume":"27","author":"Brenner","year":"2009","journal-title":"Vaccine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s00705-019-04229-6","article-title":"Detection of vaccine-like strains of lumpy skin disease virus in outbreaks in Russia in 2017","volume":"164","author":"Kononov","year":"2019","journal-title":"Arch. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Boumart, Z., Daouam, S., Belkourati, I., Rafi, L., Tuppurainen, E., Tadlaoui, K.O., and El Harrak, M. (2016). Comparative innocuity and efficacy of live and inactivated sheeppox vaccines. BMC Vet. Res., 12.","DOI":"10.1186\/s12917-016-0754-0"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"108689","DOI":"10.1016\/j.vetmic.2020.108689","article-title":"Development and Evaluation of an Inactivated Lumpy Skin Disease Vaccine for Cattle","volume":"245","author":"Hamdi","year":"2020","journal-title":"Vet. Microbiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/0264-410X(83)90004-X","article-title":"Progress towards sheep and goat pox vaccines","volume":"1","author":"Kitching","year":"1983","journal-title":"Vaccine"},{"key":"ref_48","first-page":"69","article-title":"Sheep-pox vaccine prepared from formaldehyde inactivated virus adsorbed to aluminium hydroxide gel","volume":"29","author":"Solyom","year":"1982","journal-title":"Acta Microbiol. Acad. Sci. Hung."},{"key":"ref_49","first-page":"67","article-title":"Trials for preparation of inactivated sheep pox vaccine using binary ethyleneimine","volume":"10","author":"Awad","year":"2003","journal-title":"Egypt. J. Immunol."},{"key":"ref_50","first-page":"207","article-title":"Studies on inactivated goat pox vaccine","volume":"2","author":"Yadav","year":"1986","journal-title":"Indian J. Virol."},{"key":"ref_51","first-page":"1018","article-title":"Efficacy of inactivated and live attenuated goatpox vaccines","volume":"79","author":"Kavitha","year":"2009","journal-title":"Indian J. Anim. Sci."},{"key":"ref_52","first-page":"86","article-title":"Further trials on the inactivated goat pox vaccine","volume":"8","author":"Pal","year":"1992","journal-title":"Indian J. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.biologicals.2004.09.001","article-title":"Validation of binary ethyleneimine (BEI) used as an inactivant for foot and mouth disease tissue culture vaccine","volume":"32","author":"Aarthi","year":"2004","journal-title":"Biologicals"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1128\/jcm.3.2.209-210.1976","article-title":"Inactivation of viruses in serum with binary ethyleneimine","volume":"3","author":"Bahnemann","year":"1976","journal-title":"J. Clin. Microbiol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Wolff, J., Krstevski, K., Beer, M., and Hoffmann, B. (2020). Minimum Infective Dose of a Lumpy Skin Disease Virus Field Strain from North Macedonia. Viruses, 12.","DOI":"10.3390\/v12070768"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jviromet.2006.05.020","article-title":"A universal heterologous internal control system for duplex real-time RT-PCR assays used in a detection system for pestiviruses","volume":"136","author":"Hoffmann","year":"2006","journal-title":"J. Virol. Methods"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.virol.2007.10.002","article-title":"Capripoxvirus tissue tropism and shedding: A quantitative study in experimentally infected sheep and goats","volume":"371","author":"Bowden","year":"2008","journal-title":"Virology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.vetmic.2018.05.022","article-title":"Suitability of group-level oral fluid sampling in ruminant populations for lumpy skin disease virus detection","volume":"221","author":"Dietze","year":"2018","journal-title":"Vet. Microbiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01863914","article-title":"Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche","volume":"162","year":"1931","journal-title":"Naunyn-Schmiedebergs Archiv. Exp. Pathol. Pharmakol."},{"key":"ref_60","first-page":"227","article-title":"The method of \u2018right and wrong cases\u2019 (\u2018constant stimuli\u2019) without gauss\u2019s formulae","volume":"2","author":"Spearman","year":"1908","journal-title":"Br. J. Psychol."},{"key":"ref_61","unstructured":"Zoetis (2020, December 09). Herbivac LS. Available online: https:\/\/www.zoetis.co.za\/products\/beef-and-feedlot\/herbivac-ls.aspx."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1007\/s00705-019-04411-w","article-title":"Experimental lumpy skin disease virus infection of cattle: Comparison of a field strain and a vaccine strain","volume":"164","author":"Moritz","year":"2019","journal-title":"Arch. Virol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1016\/j.vaccine.2011.05.012","article-title":"Bovine Neonatal Pancytopenia: Is this alloimmune syndrome caused by vaccine-induced alloreactive antibodies?","volume":"29","author":"Bastian","year":"2011","journal-title":"Vaccine"},{"key":"ref_64","unstructured":"MVP-Adjuvants (2020, June 26). Information about Polygen. Available online: https:\/\/mvpadjuvants.com\/wp-content\/uploads\/2017\/10\/PHIB-17018-Adjuvants-Bulletin_Polygen.pdf."},{"key":"ref_65","first-page":"861","article-title":"A study on the role of cellular and humoral factors in immunity to sheep-pox","volume":"50","author":"Srivastava","year":"1980","journal-title":"Indian J. Anim. Sci."},{"key":"ref_66","first-page":"263","article-title":"Observations on cellular response in experimentally sheep-pox-infected lambs","volume":"67","author":"Bachh","year":"1997","journal-title":"Indian J. Anim. Sci."}],"container-title":["Vaccines"],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/1\/4\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T18:58:08Z","timestamp":1720292288000},"score":17.102282,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/1\/4"}},"issued":{"date-parts":[[2020,12,23]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["vaccines9010004"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9010004","ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"published":{"date-parts":[[2020,12,23]]}},{"indexed":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T11:54:35Z","timestamp":1714737275914},"reference-count":20,"publisher":"Elsevier","isbn-type":[{"value":"9780080361499","type":"print"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[1989]]},"DOI":"10.1016\/b978-0-08-036149-9.50020-8","type":"book-chapter","created":{"date-parts":[[2013,10,22]],"date-time":"2013-10-22T21:55:54Z","timestamp":1382478954000},"page":"143-147","source":"Crossref","is-referenced-by-count":0,"title":["Current Status of Malaria Vaccines: The Need for Safe and Effective Adjuvants"],"prefix":"10.1016","author":[{"given":"W.A.","family":"SIDDIQUI","sequence":"first","affiliation":[]},{"given":"L.Q.","family":"TAM","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/B978-0-08-036149-9.50020-8_bib1","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(87)90540-X","volume":"i","author":"Ballou","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/B978-0-08-036149-9.50020-8_bib2","doi-asserted-by":"crossref","first-page":"8328","DOI":"10.1073\/pnas.83.21.8328","volume":"83","author":"Cheung","year":"1986","journal-title":"Proc. Natl. Acad. Sci., USA"},{"key":"10.1016\/B978-0-08-036149-9.50020-8_bib3","first-page":"166","volume":"226","author":"Clyde","year":"1973","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/B978-0-08-036149-9.50020-8_bib4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/323259a0","volume":"323","author":"Collins","year":"1986","journal-title":"Nature"},{"key":"10.1016\/B978-0-08-036149-9.50020-8_bib5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/310789a0","volume":"310","author":"Coppel","year":"1984","journal-title":"Nature"},{"key":"10.1016\/B978-0-08-036149-9.50020-8_bib6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/311379a0","volume":"311","author":"Hall","year":"1984","journal-title":"Nature"},{"key":"10.1016\/B978-0-08-036149-9.50020-8_bib7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/328257a0","volume":"328","author":"Herrington","year":"1987","journal-title":"Nature"},{"key":"10.1016\/B978-0-08-036149-9.50020-8_bib8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/294361a0","article-title":"Immunization against blood-stage rodent malaria using purified parasite antigens","volume":"294","author":"Holder","year":"1981","journal-title":"Nature"},{"key":"10.1016\/B978-0-08-036149-9.50020-8_bib9","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1126\/science.2452484","volume":"240","author":"Lowell","year":"1988","journal-title":"Science"},{"key":"10.1016\/B978-0-08-036149-9.50020-8_bib10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/216160a0","volume":"216","author":"Nussenzweig","year":"1967","journal-title":"Nature"},{"key":"10.1016\/B978-0-08-036149-9.50020-8_bib11","unstructured":"Patarroyo, M. E., P. Romero, M. L. Torres, P. Clavijo, D. Andreu, D. Lozada, L. Sanchez, P. del Portillo, C. Pinilla, A. Moreno, A. Alegria and R. Houghten (1987a). In: F. Brown, R. Channock and R. Lerner (eds) Vaccines 87, _pp. 117\u2013124."},{"key":"10.1016\/B978-0-08-036149-9.50020-8_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/328629a0","volume":"328","author":"Patarroyo","year":"1987","journal-title":"Nature"},{"key":"10.1016\/B978-0-08-036149-9.50020-8_bib13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/332158a0","volume":"332","author":"Patarroyo","year":"1988","journal-title":"Nature"},{"key":"10.1016\/B978-0-08-036149-9.50020-8_bib14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1084\/jem.160.2.441","volume":"160","author":"Perrin","year":"1984","journal-title":"J. Exp. Med."},{"key":"10.1016\/B978-0-08-036149-9.50020-8_bib15","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1172\/JCI111881","volume":"75","author":"Perrin","year":"1985","journal-title":"J. Clin. Invest"},{"key":"10.1016\/B978-0-08-036149-9.50020-8_bib16","first-page":"9","volume":"1986","author":"Ribi","year":"1986","journal-title":"Microbiology"},{"key":"10.1016\/B978-0-08-036149-9.50020-8_bib17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1128\/IAI.56.3.682-686.1988","volume":"56","author":"Richards","year":"1988","journal-title":"Infect. Immun."},{"key":"10.1016\/B978-0-08-036149-9.50020-8_bib18","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1126\/science.406671","volume":"197","author":"Siddiqui","year":"1977","journal-title":"Science"},{"key":"10.1016\/B978-0-08-036149-9.50020-8_bib19","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1128\/IAI.52.1.314-318.1986","volume":"52","author":"Siddiqui","year":"1986","journal-title":"Infect. Immun."},{"key":"10.1016\/B978-0-08-036149-9.50020-8_bib20","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1073\/pnas.84.9.3014","volume":"84","author":"Siddiqui","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Advances in Immunopharmacology"],"language":"en","deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T10:55:53Z","timestamp":1596711353000},"score":17.094992,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780080361499500208"}},"issued":{"date-parts":[[1989]]},"ISBN":["9780080361499"],"references-count":20,"URL":"https:\/\/doi.org\/10.1016\/b978-0-08-036149-9.50020-8","published":{"date-parts":[[1989]]}},{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T17:21:01Z","timestamp":1648747261672},"reference-count":0,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Family Practice News"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/s0300-7073(07)71193-3","type":"journal-article","created":{"date-parts":[[2009,1,10]],"date-time":"2009-01-10T05:27:02Z","timestamp":1231565222000},"page":"22","source":"Crossref","is-referenced-by-count":0,"title":["Three Vaccines at Once Found Safe And Effective"],"prefix":"10.1016","volume":"37","author":[{"given":"Diana","family":"Mahoney","sequence":"first","affiliation":[]}],"member":"78","container-title":["Family Practice News"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300707307711933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300707307711933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T11:50:38Z","timestamp":1545479438000},"score":17.089554,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300707307711933"}},"issued":{"date-parts":[[2007,10]]},"references-count":0,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0300707307711933"],"URL":"https:\/\/doi.org\/10.1016\/s0300-7073(07)71193-3","ISSN":["0300-7073"],"issn-type":[{"value":"0300-7073","type":"print"}],"published":{"date-parts":[[2007,10]]}},{"indexed":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T14:41:28Z","timestamp":1655822488519},"reference-count":1,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reactions Weekly"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40278-022-09004-3","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T10:03:06Z","timestamp":1642759386000},"page":"7-7","source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 vaccines safe in people living with HIV"],"prefix":"10.1007","volume":"1890","member":"297","published-online":{"date-parts":[[2022,1,22]]},"reference":[{"key":"9004_CR1","doi-asserted-by":"crossref","unstructured":"Aledo MG, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 and BNT162b2 vaccines in people living with HIV. AIDS : 6 Jan 2022. Available from: URL: \nhttp:\/\/doi.org\/10.1097\/QAD.0000000000003161","DOI":"10.1097\/QAD.0000000000003161"}],"container-title":["Reactions Weekly"],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40278-022-09004-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40278-022-09004-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40278-022-09004-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T14:09:47Z","timestamp":1655820587000},"score":17.089554,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40278-022-09004-3"}},"issued":{"date-parts":[[2022,1]]},"references-count":1,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["9004"],"URL":"https:\/\/doi.org\/10.1007\/s40278-022-09004-3","ISSN":["0114-9954","1179-2051"],"issn-type":[{"value":"0114-9954","type":"print"},{"value":"1179-2051","type":"electronic"}],"published":{"date-parts":[[2022,1]]}},{"indexed":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T05:21:48Z","timestamp":1733548908219,"version":"3.30.1"},"reference-count":8,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Global Health"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/s2214-109x(24)00226-2","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T22:38:22Z","timestamp":1721255902000},"page":"e1229-e1230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Delivering safe dengue vaccines"],"prefix":"10.1016","volume":"12","author":[{"given":"Scott B","family":"Halstead","sequence":"first","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S2214-109X(24)00226-2_bib1","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1473-3099(10)70166-3","article-title":"Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes","volume":"10","author":"Halstead","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/S2214-109X(24)00226-2_bib2","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1128\/CVI.00316-10","article-title":"How innate immune mechanisms contribute to antibody-enhanced viral infections","volume":"17","author":"Ubol","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/S2214-109X(24)00226-2_bib3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-virology-101416-041848","article-title":"The good, the bad, and the shocking: the multiple roles of dengue virus nonstructural protein 1 in protection and pathogenesis","volume":"5","author":"Glasner","year":"2018","journal-title":"Annu Rev Virol"},{"key":"10.1016\/S2214-109X(24)00226-2_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02125","article-title":"Human T cell response to dengue virus infection","volume":"10","author":"Tian","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/S2214-109X(24)00226-2_bib5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/S2214-109X(24)00226-2_bib6","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","article-title":"Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4\u00b75-year results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Tricou","year":"2024","journal-title":"Lancet Glob Health"},{"key":"10.1016\/S2214-109X(24)00226-2_bib7","first-page":"203","article-title":"WHO position paper on dengue vaccines\u2014May 2024","volume":"99","year":"2024","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/S2214-109X(24)00226-2_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21384-0","article-title":"A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans","volume":"12","author":"Nivarthi","year":"2021","journal-title":"Nat Commun"}],"container-title":["The Lancet Global Health"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214109X24002262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214109X24002262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T22:12:44Z","timestamp":1733523164000},"score":17.081753,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214109X24002262"}},"issued":{"date-parts":[[2024,8]]},"references-count":8,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2214109X24002262"],"URL":"https:\/\/doi.org\/10.1016\/s2214-109x(24)00226-2","ISSN":["2214-109X"],"issn-type":[{"type":"print","value":"2214-109X"}],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delivering safe dengue vaccines","name":"articletitle","label":"Article Title"},{"value":"The Lancet Global Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S2214-109X(24)00226-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]},{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T02:32:46Z","timestamp":1648866766869},"reference-count":1,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reactions Weekly"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40278-020-87197-2","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T02:05:17Z","timestamp":1607652317000},"page":"5-5","source":"Crossref","is-referenced-by-count":0,"title":["Vaccines in Australia's national programme are considered \"very safe\""],"prefix":"10.1007","volume":"1834","member":"297","published-online":{"date-parts":[[2020,12,12]]},"reference":[{"key":"87197_CR1","unstructured":"Australian Government Department of Health. Vaccine safety in Australia - AusVaxSafety summary report 2019. Internet Document : [19 pages], 2 Dec 2020. Available from: URL: \nhttps:\/\/www.health.gov.au\/sites\/default\/files\/documents\/2020\/11\/vaccine-safety-in-australia-ausvaxsafety-summary-report-2019.pdf"}],"container-title":["Reactions Weekly"],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40278-020-87197-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40278-020-87197-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40278-020-87197-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T02:06:33Z","timestamp":1607652393000},"score":17.078735,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40278-020-87197-2"}},"issued":{"date-parts":[[2020,12]]},"references-count":1,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["87197"],"URL":"https:\/\/doi.org\/10.1007\/s40278-020-87197-2","ISSN":["0114-9954","1179-2051"],"issn-type":[{"value":"0114-9954","type":"print"},{"value":"1179-2051","type":"electronic"}],"published":{"date-parts":[[2020,12]]}},{"indexed":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T06:11:19Z","timestamp":1672985479990},"reference-count":21,"publisher":"Solen s.r.o.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Prakt. L\u00e9k\u00e1ren.","Prakticke lekarenstvi"],"published-print":{"date-parts":[[2021,1,5]]},"DOI":"10.36290\/lek.2020.031","type":"journal-article","created":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T07:45:13Z","timestamp":1609832713000},"page":"204-207","source":"Crossref","is-referenced-by-count":1,"title":["Are vaccines safe?"],"prefix":"10.36290","volume":"16","author":[{"given":"Ale\u0161","family":"Franc","sequence":"first","affiliation":[]}],"member":"21073","reference":[{"key":"ref0","first-page":"151","article-title":"Vakc\u00edny z pohledu farmaceuta. \u010ces. slov","volume":"69","author":"Franc","year":"2020","journal-title":"Farm"},{"key":"ref1","article-title":"Acronyms for Vaccines. CDC","volume-title":"\u2011recs\/vac&#x","author":"ACIP","year":"2011"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/9781118870914"},{"key":"ref3","volume-title":"Vaccine safety basics learning","author":"Morth","year":"2018"},{"key":"ref4","volume-title":"Vaccine knowledge project, authoritative information for all. Oxford Vaccine Grop. University of Oxford","author":"Loving","year":"2016"},{"key":"ref5","first-page":"27","article-title":"\u00da\u010dinnost ch\u0159ipkov\u00fdch vakc\u00edn","volume":"6","author":"Petr\u00e1\u0161","year":"2008","journal-title":"Prakt l\u00e9k\u00e1ren"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10588"},{"key":"ref7","article-title":"Jak vznikaj\u00ed vakc\u00edny: prvn\u00ed je bezpe\u010dnost, a\u017e t\u0159et\u00ed f\u00e1ze \u0159e\u0161\u00ed \u00fa\u010dinnost. Vitalia.cz (2019) -","volume-title":"\u2011vznikaji\u2011vakciny\u2011prvni\u2011je\u2011bezpecnost\u2011az\u2011ve\u2011treti\u2011fazi\u2011ucinnost","author":"Krbcov\u00e1","year":"2019"},{"key":"ref8","first-page":"1000167","article-title":"An overview of immunologic adjuvants","volume":"4","author":"Aiyer&#x","year":"2013","journal-title":"J Vaccines Vacci"},{"key":"ref9","article-title":"Vakc\u00edny o\u010dami chemika: \u010co sa dost\u00e1va do detsk\u00e9ho organizmu pri o\u010dkovan\u00ed? Sloboda v o\u010dkovan\u00ed (2013) -","volume-title":"\u2011ocami\u2011chemika\u2011co\u2011sa\u2011dostava\u2011do\u2011detskeho\u2011organizmu\u2011pri\u2011ockovani","author":"Krausov\u00e1","year":"2013"},{"key":"ref10","volume-title":"Hlinit\u00e1 s\u016fl jako adjuvans ve vakc\u00edn\u00e1ch. Vakciny.Net","author":"Petr\u00e1\u0161","year":"2017"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2478\/intox-2019-0007"},{"key":"ref12","first-page":"7","article-title":"General biological products standards","volume":"21","author":"","year":"","journal-title":"CFR"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.14293\/S2199-1006.1.SOR-UNCAT.AM2TNP.v1.RUKTYY"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2015.02.030"},{"key":"ref17","article-title":"Childrens Hospital of Philadelphia -","volume-title":"\u2011programs\/vaccine\u2011education\u2011center\/vaccine&#x","author":"Vaccine Ingredients","year":"2011"},{"key":"ref18","first-page":"240","article-title":"Kontraindikace p\u0159i o\u010dkov\u00e1n\u00ed","volume":"9","author":"Dra\u017ean","year":"2008","journal-title":"Pediatr pro Praxi"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3205"},{"key":"ref20","article-title":"Konflikt z\u00e1jm\u016f \u0159editele Prymuly? Hor\u0161\u00ed, ne\u017e se na prvn\u00ed pohled zd\u00e1lo. Zdravotnick\u00fd den\u00edk (2016) -","volume-title":"\u2011zajmu\u2011reditele\u2011prymuly\u2011horsi\u2011nez\u2011se\u2011na\u2011prvni\u2011pohled\u2011zdalo","author":"Cikrt","year":"2016"},{"key":"ref21","first-page":"4","article-title":"Pr\u016fmyslov\u00e9 vyu\u017eit\u00ed t\u011bl\u00ed\u010dek potracen\u00fdch d\u011bt\u00ed","volume":"4","author":"Dudov\u00e1","year":"2015","journal-title":"Informa\u010dn\u00ed ob\u011b\u017en\u00edk Hnut\u00ed pro \u017eivot \u010cR"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-013-9878-5"}],"container-title":["Praktick\u00e9 l\u00e9k\u00e1renstv\u00ed"],"original-title":["Jsou vakc\u00edny bezpe\u010dn\u00e9?"],"link":[{"URL":"http:\/\/www.praktickelekarenstvi.cz\/doi\/10.36290\/lek.2020.031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T11:15:36Z","timestamp":1672917336000},"score":17.067497,"resource":{"primary":{"URL":"http:\/\/www.praktickelekarenstvi.cz\/doi\/10.36290\/lek.2020.031.html"}},"issued":{"date-parts":[[2021,1,5]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,1,5]]}},"URL":"https:\/\/doi.org\/10.36290\/lek.2020.031","ISSN":["1801-2434","1803-5329"],"issn-type":[{"value":"1801-2434","type":"print"},{"value":"1803-5329","type":"electronic"}],"published":{"date-parts":[[2021,1,5]]}},{"indexed":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T08:12:55Z","timestamp":1713341575318},"reference-count":0,"publisher":"RCN Publishing Ltd.","issue":"25","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nursing Standard"],"published-print":{"date-parts":[[2014,2,19]]},"DOI":"10.7748\/ns2014.02.28.25.45.e8486","type":"journal-article","created":{"date-parts":[[2014,2,19]],"date-time":"2014-02-19T10:36:36Z","timestamp":1392806196000},"page":"45-52","source":"Crossref","is-referenced-by-count":12,"title":["Safe storage and handling of vaccines"],"prefix":"10.7748","volume":"28","author":[{"given":"Jane","family":"Chiodini","sequence":"first","affiliation":[]}],"member":"4499","container-title":["Nursing Standard"],"language":"en","deposited":{"date-parts":[[2014,2,19]],"date-time":"2014-02-19T10:36:47Z","timestamp":1392806207000},"score":16.905682,"resource":{"primary":{"URL":"http:\/\/rcnpublishing.com\/doi\/abs\/10.7748\/ns2014.02.28.25.45.e8486"}},"issued":{"date-parts":[[2014,2,19]]},"references-count":0,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2014,2,19]]}},"alternative-id":["10.7748\/ns2014.02.28.25.45.e8486"],"URL":"https:\/\/doi.org\/10.7748\/ns2014.02.28.25.45.e8486","ISSN":["0029-6570","2047-9018"],"issn-type":[{"value":"0029-6570","type":"print"},{"value":"2047-9018","type":"electronic"}],"published":{"date-parts":[[2014,2,19]]}},{"indexed":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T01:25:15Z","timestamp":1711070715022},"reference-count":0,"publisher":"Rowman & Littlefield Publishers","isbn-type":[{"value":"9781442215801","type":"print"}],"content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2012]]},"DOI":"10.5771\/9781442215801-213","type":"book-chapter","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T08:16:05Z","timestamp":1711008965000},"page":"213-214","source":"Crossref","is-referenced-by-count":0,"title":["About the Authors"],"prefix":"10.5771","author":[{"given":"Stacy  Mintzer","family":"Herlihy","sequence":"first","affiliation":[]},{"given":"E. Allison","family":"Hagood","sequence":"additional","affiliation":[]}],"member":"3821","container-title":["Your Baby's Best Shot"],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T08:38:04Z","timestamp":1711010284000},"score":16.905682,"resource":{"primary":{"URL":"https:\/\/www.nomos-elibrary.de\/index.php?doi=10.5771\/9781442215801-213"}},"issued":{"date-parts":[[2012]]},"ISBN":["9781442215801"],"references-count":0,"URL":"https:\/\/doi.org\/10.5771\/9781442215801-213","published":{"date-parts":[[2012]]}},{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T19:07:18Z","timestamp":1648840038850},"reference-count":0,"publisher":"Springer Science and Business Media LLC","issue":"1648","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Inpharma Weekly"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.2165\/00128413-200816480-00019","type":"journal-article","created":{"date-parts":[[2008,7,28]],"date-time":"2008-07-28T03:07:22Z","timestamp":1217214442000},"page":"7","source":"Crossref","is-referenced-by-count":0,"title":["Plant-grown cancer vaccines are safe and can be produced quickly and inexpensively,"],"prefix":"10.1007","volume":"&NA;","author":[{"family":"&NA;","sequence":"first","affiliation":[]}],"member":"297","container-title":["Inpharma Weekly"],"language":"en","deposited":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T09:03:21Z","timestamp":1362128601000},"score":16.870575,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2165\/00128413-200816480-00019"}},"subtitle":[""],"issued":{"date-parts":[[2008,7]]},"references-count":0,"journal-issue":{"issue":"1648"},"URL":"https:\/\/doi.org\/10.2165\/00128413-200816480-00019","ISSN":["1173-8324"],"issn-type":[{"value":"1173-8324","type":"print"}],"published":{"date-parts":[[2008,7]]}},{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T03:05:26Z","timestamp":1648782326641},"reference-count":17,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.vaccine.2010.09.105","type":"journal-article","created":{"date-parts":[[2010,10,7]],"date-time":"2010-10-07T04:26:18Z","timestamp":1286425578000},"page":"7577-7578","source":"Crossref","is-referenced-by-count":3,"title":["World Pneumonia Day: Fighting pneumonia with safe and affordable vaccines"],"prefix":"10.1016","volume":"28","author":[{"given":"Ron","family":"Dagan","sequence":"first","affiliation":[]},{"given":"Gregory","family":"Poland","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"May (19)","key":"10.1016\/j.vaccine.2010.09.105_bib0005","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1056\/NEJM200005113421904","article-title":"Mortality from pneumonia in children in the United States, 1939 through 1996","volume":"342","author":"Dowell","year":"2000","journal-title":"N Engl J Med"},{"issue":"September (9693)","key":"10.1016\/j.vaccine.2010.09.105_bib0010","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","article-title":"Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates","volume":"374","author":"O\u2019Brien","year":"2009","journal-title":"Lancet"},{"issue":"October (8)","key":"10.1016\/j.vaccine.2010.09.105_bib0015","first-page":"1105","article-title":"Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid?","volume":"149","author":"Scheifele","year":"1993","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2010.09.105_bib0020","unstructured":"World Pneumonia Day. World Pneumonia Day Facts. World Pneumonia Day; 09-08-2010."},{"key":"10.1016\/j.vaccine.2010.09.105_bib0025","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJM199106203242503","article-title":"The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex","volume":"324","author":"Santosham","year":"1991","journal-title":"N Engl J Med"},{"issue":"April (9060)","key":"10.1016\/j.vaccine.2010.09.105_bib0030","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(96)09267-7","article-title":"Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants","volume":"349","author":"Mulholland","year":"1997","journal-title":"Lancet"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2010.09.105_bib0035","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-3156.2008.02027.x","article-title":"Haemophilus influenzae type b conjugate vaccine is highly effective in the Ugandan routine immunization program: a case\u2013control study","volume":"13","author":"Lee","year":"2008","journal-title":"Trop Med Int Health"},{"issue":"September (9 Suppl.)","key":"10.1016\/j.vaccine.2010.09.105_bib0040","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1097\/00006454-199809001-00005","article-title":"Haemophilus influenzae type b conjugate vaccines: a review of efficacy data","volume":"17","author":"Heath","year":"1998","journal-title":"Pediatr Infect Dis J"},{"issue":"May (18)","key":"10.1016\/j.vaccine.2010.09.105_bib0045","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease after the introduction of protein\u2013polysaccharide conjugate vaccine","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2010.09.105_bib0050","first-page":"1","article-title":"Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine\u2014United States, 1997\u20132006","volume":"58","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"March (13)","key":"10.1016\/j.vaccine.2010.09.105_bib0055","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.vaccine.2006.09.008","article-title":"The preventable burden of pneumococcal disease in the developing world","volume":"25","author":"Scott","year":"2007","journal-title":"Vaccine"},{"issue":"October (14)","key":"10.1016\/j.vaccine.2010.09.105_bib0060","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMoa035060","article-title":"A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection","volume":"349","author":"Klugman","year":"2003","journal-title":"N Engl J Med"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2010.09.105_bib0065","first-page":"463","article-title":"Pneumococcal conjugate vaccine\u2014a health priority","volume":"98","author":"Zar","year":"2008","journal-title":"S Afr Med J"},{"issue":"March (9465)","key":"10.1016\/j.vaccine.2010.09.105_bib0070","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S0140-6736(05)71876-6","article-title":"Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial","volume":"365","author":"Cutts","year":"2005","journal-title":"Lancet"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2010.09.105_bib0075","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nm1077","article-title":"A role for Streptococcus pneumoniae in virus-associated pneumonia","volume":"10","author":"Madhi","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2010.09.105_bib0080","unstructured":"World Health Organization. WHO\/UNICEF estimates of national immunization coverage. World Health Organization; 02-24-2010."},{"key":"10.1016\/j.vaccine.2010.09.105_bib0085","unstructured":"Bill & Melinda Gates Foundation. Decade-of-vaccines. 09-08-2010."}],"container-title":["Vaccine"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10014477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10014477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T10:54:37Z","timestamp":1544180077000},"score":16.870575,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10014477"}},"issued":{"date-parts":[[2010,11]]},"references-count":17,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0264410X10014477"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.09.105","ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"published":{"date-parts":[[2010,11]]}},{"indexed":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T06:10:33Z","timestamp":1738044633066,"version":"3.33.0"},"posted":{"date-parts":[[2025,1,28]]},"group-title":"Public Health and Healthcare","reference-count":0,"publisher":"MDPI AG","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"accepted":{"date-parts":[[2025,1,26]]},"abstract":"<jats:p>Objective: This study introduces the Denominator-Adjusted Rate Estimates of Substance Adverse Events Frequency Evaluation (DARE-SAFE) method to analyze pharmacovigilance reporting rates for vaccines and common pharmaceuticals. Methods: We calculated reporting rates for the top 250 most prescribed drugs in the US FDA Adverse Event Reporting System (FAERS) and common vaccines in the Vaccine Adverse Events Reporting System (VAERS). For vaccines, we used CDC dose data and OpenVAERS reports. For pharmaceuticals, we utilized prescription data from ClinCalc and FAERS reports for 2022. Results: VAERS reporting rates varied significantly across vaccine types. COVID-19 vaccines showed a 63.0&amp;plusmn;0.6 times higher rate of VAERS deaths per dose and an 18.95&amp;plusmn;0.02 times higher rate of total adverse event reports compared to influenza vaccines. The ratio of total VAERS reports to deaths for vaccines was approximately 70:1 (R&amp;sup2;=0.966). For pharmaceuticals, the ratio of total adverse event reports to deaths was about 43:1 (R&amp;sup2;=0.697), with a strong correlation between serious adverse events and deaths (ratio 11:1, R&amp;sup2;=0.768). Conclusion: DARE-SAFE provides a standardized method for comparing reporting rates across different medical products. The observed differences between vaccines and pharmaceuticals, as well as among different vaccine types, warrant further investigation into reporting practices, actual safety profiles, and potential biases in surveillance systems.<\/jats:p>","DOI":"10.20944\/preprints202501.2023.v1","type":"posted-content","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T03:44:10Z","timestamp":1738035850000},"source":"Crossref","is-referenced-by-count":0,"title":["DARE-SAFE: Denominator-Adjusted Rate Estimates of Substance Adverse Events Frequency Evaluation in Pharmaceuticals and Vaccines"],"prefix":"10.20944","author":[{"given":"Matthew","family":"Halma","sequence":"first","affiliation":[]},{"given":"Joseph","family":"Varon","sequence":"additional","affiliation":[]}],"member":"1968","deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T03:46:34Z","timestamp":1738035994000},"score":16.864975,"resource":{"primary":{"URL":"https:\/\/www.preprints.org\/manuscript\/202501.2023\/v1"}},"issued":{"date-parts":[[2025,1,28]]},"references-count":0,"URL":"https:\/\/doi.org\/10.20944\/preprints202501.2023.v1","published":{"date-parts":[[2025,1,28]]},"subtype":"preprint"},{"indexed":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T05:22:06Z","timestamp":1736918526936,"version":"3.33.0"},"reference-count":0,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,1,14]]},"DOI":"10.1001\/jama.2024.24891","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T16:31:06Z","timestamp":1734107466000},"page":"111","source":"Crossref","is-referenced-by-count":0,"title":["Trial Shows It\u2019s Safe to Get COVID-19, Flu Vaccines at the Same Time"],"prefix":"10.1001","volume":"333","author":[{"given":"Samantha","family":"Anderer","sequence":"first","affiliation":[]}],"member":"10","container-title":["JAMA"],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2828298\/jama_anderer_2024_ib_240363_1735855297.47925.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T16:04:01Z","timestamp":1736870641000},"score":16.864975,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2828298"}},"issued":{"date-parts":[[2025,1,14]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1,14]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.24891","ISSN":["0098-7484"],"issn-type":[{"type":"print","value":"0098-7484"}],"published":{"date-parts":[[2025,1,14]]}},{"indexed":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T06:11:17Z","timestamp":1657519877617},"reference-count":0,"publisher":"Indonesian Society of Obstetrics and Gynecology","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indones J Obstet Gynecol"],"DOI":"10.32771\/inajog.v10i2.1744","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T05:12:56Z","timestamp":1657516376000},"page":"63-64","source":"Crossref","is-referenced-by-count":0,"title":["Are Vaccines Safe during Pregnancy ?"],"prefix":"10.32771","author":[{"given":"Johanes C","family":"Mose","sequence":"first","affiliation":[]}],"member":"17998","published-online":{"date-parts":[[2022,4,28]]},"container-title":["Indonesian Journal of Obstetrics and Gynecology"],"link":[{"URL":"https:\/\/inajog.com\/index.php\/journal\/article\/download\/1744\/765","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/inajog.com\/index.php\/journal\/article\/download\/1744\/765","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T05:31:13Z","timestamp":1657517473000},"score":16.854153,"resource":{"primary":{"URL":"https:\/\/inajog.com\/index.php\/journal\/article\/view\/1744"}},"issued":{"date-parts":[[2022,4,28]]},"references-count":0,"URL":"https:\/\/doi.org\/10.32771\/inajog.v10i2.1744","ISSN":["2338-7335","2338-6401"],"issn-type":[{"value":"2338-7335","type":"electronic"},{"value":"2338-6401","type":"print"}],"published":{"date-parts":[[2022,4,28]]}},{"indexed":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T05:30:02Z","timestamp":1736314202740,"version":"3.32.0"},"reference-count":76,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sciensano","award":["-"]},{"name":"EURL for Diseases Caused by Capripox Viruses","award":["-"]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Vaccination is an effective approach to prevent, control and eradicate diseases, including lumpy skin disease (LSD). One of the measures to address farmer hesitation to vaccinate is guaranteeing the quality of vaccine batches. The purpose of this study was to demonstrate the importance of a quality procedure via the evaluation of the LSD vaccine, Lumpivax (Kevevapi). The initial PCR screening revealed the presence of wild type LSD virus (LSDV) and goatpox virus (GTPV), in addition to vaccine LSDV. New phylogenetic PCRs were developed to characterize in detail the genomic content and a vaccination\/challenge trial was conducted to evaluate the impact on efficacy and diagnostics. The characterization confirmed the presence of LSDV wild-, vaccine- and GTPV-like sequences in the vaccine vial and also in samples taken from the vaccinated animals. The analysis was also suggestive for the presence of GTPV-LSDV (vaccine\/wild) recombinants. In addition, the LSDV status of some of the animal samples was greatly influenced by the differentiating real-PCR used and could result in misinterpretation. Although the vaccine was clinically protective, the viral genomic content of the vaccine (being it multiple Capripox viruses and\/or recombinants) and the impact on the diagnostics casts serious doubts of its use in the field.<\/jats:p>","DOI":"10.3390\/vaccines9091019","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T07:46:14Z","timestamp":1631605574000},"page":"1019","source":"Crossref","is-referenced-by-count":21,"title":["The Importance of Quality Control of LSDV Live Attenuated Vaccines for Its Safe Application in the Field"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4056-214X","authenticated-orcid":false,"given":"Andy","family":"Haegeman","sequence":"first","affiliation":[{"name":"Unit of Exotic and Particular Diseases, Scientific Directorate Infectious Diseases in Animals, Sciensano, Groeselenberg 99, B-1180 Brussels, Belgium"}]},{"given":"Ilse","family":"De Leeuw","sequence":"additional","affiliation":[{"name":"Unit of Exotic and Particular Diseases, Scientific Directorate Infectious Diseases in Animals, Sciensano, Groeselenberg 99, B-1180 Brussels, Belgium"}]},{"given":"Meruyert","family":"Saduakassova","sequence":"additional","affiliation":[{"name":"Kazakh Scientific Research Veterinary Institute (KazSRVI\/\/KazNIVI), Raiymbek ave. 223, Almaty 050016, Kazakhstan"}]},{"given":"Willem","family":"Van Campe","sequence":"additional","affiliation":[{"name":"Experimental Center Machelen, Scientific Directorate Infectious Diseases in Animals, Sciensano, Kerklaan 68, B-1830 Machelen, Belgium"}]},{"given":"Laetitia","family":"Aerts","sequence":"additional","affiliation":[{"name":"EURL for Diseases Caused by Capripox Viruses, Scientific Directorate Infectious Diseases in Animals, Sciensano, Groeselenberg 99, B-1180 Brussels, Belgium"}]},{"given":"Wannes","family":"Philips","sequence":"additional","affiliation":[{"name":"EURL for Diseases Caused by Capripox Viruses, Scientific Directorate Infectious Diseases in Animals, Sciensano, Groeselenberg 99, B-1180 Brussels, Belgium"}]},{"given":"Akhmetzhan","family":"Sultanov","sequence":"additional","affiliation":[{"name":"Kazakh Scientific Research Veterinary Institute (KazSRVI\/\/KazNIVI), Raiymbek ave. 223, Almaty 050016, Kazakhstan"}]},{"given":"Laurent","family":"Mostin","sequence":"additional","affiliation":[{"name":"Experimental Center Machelen, Scientific Directorate Infectious Diseases in Animals, Sciensano, Kerklaan 68, B-1830 Machelen, Belgium"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2928-3521","authenticated-orcid":false,"given":"Kris","family":"De Clercq","sequence":"additional","affiliation":[{"name":"Unit of Exotic and Particular Diseases, Scientific Directorate Infectious Diseases in Animals, Sciensano, Groeselenberg 99, B-1180 Brussels, Belgium"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6054","DOI":"10.1128\/JVI.76.12.6054-6061.2002","article-title":"The genomes of sheeppox and goatpox viruses","volume":"76","author":"Tulman","year":"2002","journal-title":"J. Virol."},{"key":"ref_2","unstructured":"Tuppurainen, E., Alexandrov, T., and Beltr\u00e1n-Alcrudo, D. (2017). Lumpy Skin Disease Field Manual\u2014A Manual for Veterinarians, Food and Agriculture Organization of the United Nations (FAO). FAO Animal Production and Health Manual No. 20."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11259-020-09780-1","article-title":"A review: Lumpy skin disease and its emergence in India","volume":"44","author":"Gupta","year":"2020","journal-title":"Vet. Res. Commun."},{"key":"ref_4","unstructured":"FAO (2020). Introduction and Spread of Lumpy Skin Disease in South, East and Southeast Asia\u2014Qualitative Risk Assessment and Management, FAO Animal Production and Health."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s11250-012-0340-9","article-title":"Risk assessments of lumpy skin diseases in Borena bull market chain and its implication for livelihoods and international trade","volume":"45","author":"Alemayehu","year":"2013","journal-title":"Trop. Anim. Health Prod."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.prevetmed.2011.07.003","article-title":"Epidemiological aspects and financial impact of lumpy skin disease in Ethiopia","volume":"15","author":"Gari","year":"2011","journal-title":"Prev. Vet. Med."},{"key":"ref_7","first-page":"63","article-title":"Lumpy Skin Disease: Its Effect on Hides and Leather and a Comparison on this Respect with some other Skin Diseases","volume":"7","author":"Green","year":"1959","journal-title":"Bull. Epizoot. Dis. Afr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1865-1682.2008.01043.x","article-title":"Capripoxviruses: An emerging worldwide threat to sheep, goats and cattle","volume":"55","author":"Babiuk","year":"2008","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11250-013-0483-3","article-title":"Lumpy skin disease of cattle: An emerging problem in the Sultanate of Oman","volume":"46","author":"Tageldin","year":"2014","journal-title":"Trop. Anim. Health Prod."},{"key":"ref_10","first-page":"8","article-title":"Review on Epidemiology and Economic Importance of Lumpy Skin Disease","volume":"4","author":"Abera","year":"2015","journal-title":"Int. J. Basic Appl. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.20506\/rst.13.1.758","article-title":"Draught Animals and Welfare","volume":"13","author":"Ramaswamy","year":"1994","journal-title":"Rev. Sci. Technol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.prevetmed.2017.09.003","article-title":"Economic Impact of Lumpy Skin Disease and Cost Effectiveness of Vaccination for the Control of Outbreaks in Ethiopia","volume":"147","author":"Molla","year":"2017","journal-title":"Prev. Vet. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1016\/j.vaccine.2015.07.071","article-title":"Comparison of the Efficacy of Neethling Lumpy Skin Disease Virus and x10RM65 Sheep-Pox Live Attenuated Vaccines for the Prevention of Lumpy Skin Disease\u2014The Results of a Randomized Controlled Field Study","volume":"33","author":"Klement","year":"2015","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/tbed.12444","article-title":"Review: Capripoxvirus Diseases: Current Status and Opportunities for Control","volume":"64","author":"Tuppurainen","year":"2017","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"104595","DOI":"10.1016\/j.prevetmed.2018.12.001","article-title":"Neethling Vaccine Proved Highly Effective in Controlling Lumpy Skin Disease Epidemics in the Balkans","volume":"181","author":"Klement","year":"2020","journal-title":"Prev. Vet. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Haegeman, A., De Leeuw, I., Mostin, L., Campe, W.V., Aerts, L., Venter, E., Tuppurainen, E., Saegerman, C., and De Clercq, K. (2021). Comparative Evaluation of Lumpy Skin Disease Virus-Based Live Attenuated Vaccines. Vaccines, 8.","DOI":"10.3390\/vaccines9050473"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1111\/tbed.12257","article-title":"Adverse Reactions to Field Vaccination Against Lumpy Skin Disease in Jordan","volume":"63","author":"Abutarbush","year":"2016","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"108689","DOI":"10.1016\/j.vetmic.2020.108689","article-title":"Development and Evaluation of an Inactivated Lumpy Skin Disease Vaccine for Cattle","volume":"245","author":"Hamdi","year":"2020","journal-title":"Vet. Microbiol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wolff, J., Moritz, T., Schlottau, K., Hoffmann, D., Beer, M., and Hoffmann, B. (2020). Development of a Safe and Highly Efficient Inactivated Vaccine Candidate against Lumpy Skin Disease Virus. Vaccines, 23.","DOI":"10.3390\/vaccines9010004"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s11626-017-0203-9","article-title":"Best practices for detecting and mitigating the risk of cell culture contaminants","volume":"53","author":"Nims","year":"2017","journal-title":"In Vitro Cell. Dev. Biol. Anim."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.5858\/133.9.1463","article-title":"Henrietta, Lacks, HeLa cells, and cell culture contamination","volume":"133","author":"Lucey","year":"2009","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.biologicals.2005.01.004","article-title":"Microbial contamination of cell cultures: A 2 years study","volume":"33","author":"Mirjalili","year":"2005","journal-title":"Biologicals"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41587-020-0507-2","article-title":"Viral contamination in biologic manufacture and implications for emerging therapies","volume":"38","author":"Barone","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/1040638718814583","article-title":"Bovine viral diarrhea in captive Rocky Mountain bighorn sheep associated with administration of a contaminated modified-live bluetongue virus vaccine","volume":"31","author":"Fox","year":"2019","journal-title":"J. Vet. Diagn. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3382\/ps\/pey129","article-title":"The intracorporal interaction of fowl adenovirus type 4 and LaSota strain significantly aggravates the pathogenicity of one another after using contaminated Newcastle disease virus-attenuated vaccine","volume":"1","author":"Su","year":"2019","journal-title":"Poult. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1016\/j.vaccine.2016.03.097","article-title":"Detection and isolation of Bluetongue virus from commercial vaccine batches","volume":"14","author":"Bumbarov","year":"2016","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/tbed.12004","article-title":"Bluetongue serotype 2 and 9 modified live vaccine viruses as causative agents of abortion in livestock: A retrospective analysis in Italy","volume":"61","author":"Savini","year":"2014","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1017\/S0950268810000580","article-title":"Low diversity of foot-and-mouth disease serotype C virus in Kenya: Evidence for probable vaccine strain re-introductions in the field","volume":"139","author":"Sangula","year":"2011","journal-title":"Epidemiol. Infect."},{"key":"ref_29","unstructured":"World Organization for Animal Health (OIE) (2021, July 07). Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 3.4.12: Lumpy Skin Disease. Available online: https:\/\/www.oie.int\/fileadmin\/Home\/eng\/Health_standards\/tahm\/3.04.12_LSD.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/ilar.47.4.364","article-title":"Establishing an appropriate period of acclimatization following transportation of laboratory animals","volume":"47","author":"Obernier","year":"2006","journal-title":"ILAR J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-1-60761-629-0_7","article-title":"Simultaneous detection of bluetongue virus RNA, internal control GAPDH mRNA, and external control synthetic RNA by multiplex real-time PCR","volume":"630","author":"Vandenbussche","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jviromet.2013.07.010","article-title":"Development and validation of three Capripoxvirus real-time PCRs for parallel testing","volume":"193","author":"Haegeman","year":"2013","journal-title":"J. Virol. Methods"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jviromet.2017.08.011","article-title":"Development and validation of a TaqMan probe-based real-time PCR method for the differentiation of wild type lumpy skin disease virus from vaccine virus strains","volume":"249","author":"Agianniotaki","year":"2017","journal-title":"J. Virol. Methods"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Vidanovi\u0107, D., Te\u0161ovi\u0107, B., \u0160ekler, M., Debeljak, Z., Vaskovi\u0107, N., Matovi\u0107, K., Koltsov, A., Krstevski, K., Petrovi\u0107, T., and De Leeuw, I. (2021). Validation of TaqMan-Based Assays for Specific Detection and Differentiation of Wild-Type and Neethling Vaccine Strains of LSDV. Microorganisms, 9.","DOI":"10.3390\/microorganisms9061234"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12985-018-0969-8","article-title":"A gel-based PCR method to differentiate sheeppox virus field isolates from vaccine strains","volume":"2","author":"Chibssa","year":"2018","journal-title":"Virol. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.vetmic.2010.09.038","article-title":"Use of the Capripoxvirus homologue of Vaccinia virus 30 kDa RNA polymerase subunit (RPO30) gene as a novel diagnostic and genotyping target: Development of a classical PCR method to differentiate Goat poxvirus from Sheep poxvirus","volume":"149","author":"Lamien","year":"2011","journal-title":"Vet. Microbiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1111\/tbed.12342","article-title":"Investigation of a Possible Link Between Vaccination and the 2010 Sheep Pox Epizootic in Morocco","volume":"63","author":"Haegeman","year":"2016","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_38","first-page":"365","article-title":"Primer3 on the WWW for general users and for biologist programmers","volume":"132","author":"Rozen","year":"2000","journal-title":"Methods Mol. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"113800","DOI":"10.1016\/j.jviromet.2019.113800","article-title":"An Immunoperoxidase Monolayer Assay (IPMA) for the detection of lumpy skin disease antibodies","volume":"277","author":"Haegeman","year":"2020","journal-title":"J. Virol. Methods"},{"key":"ref_40","first-page":"14","article-title":"GeneDoc: A tool for editing and annotating multiple sequence alignments","volume":"4","author":"Nicholas","year":"1997","journal-title":"Embnet. News"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"vev003","DOI":"10.1093\/ve\/vev003","article-title":"RDP4: Detection and analysis of recombination patterns in virus genomes","volume":"1","author":"Martin","year":"2015","journal-title":"Virus Evol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/bioinformatics\/16.6.562","article-title":"RDP: Detection of recombination amongst aligned sequences","volume":"16","author":"Martin","year":"2000","journal-title":"Bioinformatics"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1006\/viro.1999.0056","article-title":"Possible emergence of new geminiviruses by frequent recombination","volume":"265","author":"Padidam","year":"1999","journal-title":"Virology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1089\/aid.2005.21.98","article-title":"A modified bootscan algorithm for automated identification of recombinant sequences and recombination breakpoints","volume":"21","author":"Martin","year":"2005","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/molbev\/msx263","article-title":"Improved Algorithmic Complexity for the 3SEQ Recombination Detection Algorithm","volume":"35","author":"Lam","year":"2018","journal-title":"Mol. Biol. Evol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"13757","DOI":"10.1073\/pnas.241370698","article-title":"Evaluation of methods for detecting recombination from DNA sequences: Computer simulations","volume":"98","author":"Posada","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/bioinformatics\/16.7.573","article-title":"Sister-scanning: A Monte Carlo procedure for assessing signals in recombinant sequences","volume":"16","author":"Gibbs","year":"2000","journal-title":"Bioinformatics"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/BF00182389","article-title":"Analyzing the mosaic structure of genes","volume":"34","author":"Smith","year":"1992","journal-title":"J. Mol. Evol."},{"key":"ref_49","first-page":"e01113","article-title":"Complete Genome Sequence of the Goatpox Virus Strain Gorgan Obtained Directly from a Commercial Live Attenuated Vaccine","volume":"4","author":"Mathijs","year":"2016","journal-title":"Genome Announc."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e01255-16","DOI":"10.1128\/genomeA.01255-16","article-title":"Complete Genome Sequences of the Neethling-Like Lumpy Skin Disease Virus Strains Obtained Directly from Three Commercial Live Attenuated Vaccines","volume":"4","author":"Mathijs","year":"2016","journal-title":"Genome Announc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e00550-17","DOI":"10.1128\/genomeA.00550-17","article-title":"Complete Genome Sequence of the Lumpy Skin Disease Virus Isolated from the First Reported Case in Greece in 2015","volume":"5","author":"Agianniotaki","year":"2017","journal-title":"Genome Announc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.vaccine.2014.10.025","article-title":"Why German farmers have their animals vaccinated against Bluetongue virus serotype 8: Results of a questionnaire survey","volume":"33","author":"Gethmann","year":"2015","journal-title":"Vaccine"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3389\/fvets.2019.00488","article-title":"Willingness to Vaccinate (WTV) and Willingness to Pay (WTP) for Vaccination Against Peste des Petits Ruminants (PPR) in Mali","volume":"6","author":"Wane","year":"2020","journal-title":"Front. Vet. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2014.06.009","article-title":"Characterization of sheep pox virus vaccine for cattle against lumpy skin disease virus","volume":"109","author":"Tuppurainen","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1126\/science.2448875","article-title":"Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase","volume":"239","author":"Saiki","year":"1988","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"287430","DOI":"10.1155\/2014\/287430","article-title":"Error Rate Comparison during Polymerase Chain Reaction by DNA Polymerase","volume":"2014","author":"McInerney","year":"2014","journal-title":"Mol. Biol. Int."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1099\/0022-1317-79-12-2921","article-title":"Contribution of Taq polymerase-induced errors to the estimation of RNA virus diversity","volume":"79","author":"Bracho","year":"1998","journal-title":"J. Gen. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/tbed.12763","article-title":"Karmakar, A.P. Molecular epidemiology of goat pox viruses","volume":"65","author":"Roy","year":"2018","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e00977-20","DOI":"10.1128\/MRA.00977-20","article-title":"Complete Coding Sequence of a Lumpy Skin Disease Virus from an Outbreak in Bulgaria in 2016","volume":"9","author":"Mathijs","year":"2020","journal-title":"Microbiol. Resour. Announc."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1128\/JVI.00022-14","article-title":"Genome scale patterns of recombination between coinfecting vaccinia viruses","volume":"88","author":"Qin","year":"2014","journal-title":"J. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1017\/S0022172400039887","article-title":"Hybrids derived from the viruses of variola major and cowpox","volume":"62","author":"Bedson","year":"1964","journal-title":"J. Hyg."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4049\/jimmunol.130.1.399","article-title":"Malignant rabbit fibroma virus causes secondary immunosuppression in rabbits","volume":"130","author":"Strayer","year":"1983","journal-title":"J. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1099\/0022-1317-70-2-485","article-title":"Poxvirus genetic recombination during natural virus transmission","volume":"70","author":"Gershon","year":"1989","journal-title":"J. Gen. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Sprygin, A., Pestova, Y., Bjadovskaya, O., Prutnikov, P., Zinyakov, N., Kononova, S., Ruchnova, O., Lozovoy, D., Chvala, I., and Kononov, A. (2020). Evidence of recombination of vaccine strains of lumpy skin disease virus with field strains, causing disease. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0232584"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Sprygin, A., Babin, Y., Pestova, Y., Kononova, S., Wallace, D.B., Van Schalkwyk, A., Byadovskaya, O., Diev, V., Lozovoy, D., and Kononov, A. (2018). Analysis and insights into recombination signals in lumpy skin disease virus recovered in the field. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0207480"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1007\/s00705-020-04756-7","article-title":"Full-length genome characterization of a novel recombinant vaccine-like lumpy skin disease virus strain detected during the climatic winter in Russia, 2019","volume":"165","author":"Sprygin","year":"2020","journal-title":"Arch. Virol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/tbed.13898","article-title":"Lumpy skin disease outbreaks in China, since 3 August 2019","volume":"68","author":"Lu","year":"2021","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/tbed.12100","article-title":"Bluetongue virus RNA detection by real-time rt-PCR in post-vaccination samples from cattle","volume":"62","author":"Garigliany","year":"2015","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1099\/vir.0.004507-0","article-title":"Yemen and Vietnam capripoxviruses demonstrate a distinct host preference for goats compared with sheep","volume":"90","author":"Babiuk","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.antiviral.2015.04.008","article-title":"Capripox disease in Ethiopia: Genetic differences between field isolates and vaccine strain, and implications for vaccination failure","volume":"119","author":"Gelaye","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Byadovskaya, O., Pestova, Y., Kononov, A., Shumilova, I., Kononova, S., Nesterov, A., Babiuk, S., and Sprygin, A. (2020). Performance of the currently available DIVA real-time PCR assays in classical and recombinant lumpy skin disease viruses. Transbound. Emerg. Dis., online ahead of print.","DOI":"10.1111\/tbed.13942"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"20076","DOI":"10.1038\/s41598-019-56605-6","article-title":"Experimental evidence of mechanical lumpy skin disease virus transmission by Stomoxys calcitrans biting flies and Haematopota spp. horseflies","volume":"9","author":"Sohier","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/tbed.12897","article-title":"Detection of vaccine-like lumpy skin disease virus in cattle and Musca domestica L. flies in an outbreak of lumpy skin disease in Russia in 2017","volume":"65","author":"Sprygin","year":"2018","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Wang, Y., Zhao, L., Yang, J., Shi, M., Nie, F., Liu, S., Wang, Z., Huang, D., Wu, H., and Li, D. (2021). Analysis of vaccine-like lumpy skin disease virus from flies near the western border of China. Transbound. Emerg. Dis., online ahead of print.","DOI":"10.1111\/tbed.14159"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-662-39771-8_3","article-title":"Lumpy skin disease virus","volume":"3","author":"Weiss","year":"1968","journal-title":"Virol. Monogr."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"7436","DOI":"10.1038\/s41598-020-64029-w","article-title":"Non-vector-borne transmission of lumpy skin disease virus","volume":"10","author":"Kononov","year":"2020","journal-title":"Sci. Rep."}],"container-title":["Vaccines"],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/9\/1019\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T10:46:59Z","timestamp":1736246819000},"score":16.746002,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/9\/1019"}},"issued":{"date-parts":[[2021,9,13]]},"references-count":76,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["vaccines9091019"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9091019","ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"published":{"date-parts":[[2021,9,13]]}},{"indexed":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T07:10:35Z","timestamp":1721977835848},"reference-count":35,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2003,4]]},"DOI":"10.1586\/14760584.2.2.285","type":"journal-article","created":{"date-parts":[[2005,1,13]],"date-time":"2005-01-13T16:28:29Z","timestamp":1105633709000},"page":"285-293","source":"Crossref","is-referenced-by-count":81,"title":["Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines"],"prefix":"10.1586","volume":"2","author":[{"given":"Samuele","family":"Peppoloni","sequence":"first","affiliation":[]},{"given":"Paolo","family":"Ruggiero","sequence":"additional","affiliation":[]},{"given":"Mario","family":"Contorni","sequence":"additional","affiliation":[]},{"given":"Maurizio","family":"Morandi","sequence":"additional","affiliation":[]},{"given":"Mariagrazia","family":"Pizza","sequence":"additional","affiliation":[]},{"given":"Rino","family":"Rappuoli","sequence":"additional","affiliation":[]},{"given":"Audino","family":"Podda","sequence":"additional","affiliation":[]},{"given":"Giuseppe Del","family":"Giudice","sequence":"additional","affiliation":[]}],"member":"301","published-online":{"date-parts":[[2014,1,9]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0167-5699(99)01523-6","volume":"20","author":"Rappuoli R","year":"1999","journal-title":"Immune'. Today"},{"key":"CIT0003","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/infdis\/173.3.627","volume":"173","author":"Takahashi I","year":"1996","journal-title":"j Infect. Dis"},{"key":"CIT0005","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1128\/IAI.69.3.1528-1535.2001","volume":"69","author":"Bowman CC","year":"2001","journal-title":"Infect. Immun"},{"key":"CIT0006","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0264-410X(93)90004-H","volume":"11","author":"Wilson AD","year":"1993","journal-title":"Vaccine"},{"key":"CIT0008","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/j.1365-2958.1991.tb01925.x","volume":"5","author":"Jobling MG","year":"1991","journal-title":"Mol Mcrobiol"},{"key":"CIT0009","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2958.1994.tb01265.x","volume":"14","author":"Domenighini M","year":"1994","journal-title":"Mal Microbial"},{"key":"CIT0010","first-page":"1617","volume":"63","author":"Dickinson DL","year":"1995","journal-title":"Infect. 'minim"},{"key":"CIT0011","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1128\/IAI.65.1.331-334.1997","volume":"65","author":"Giannelli V","year":"1997","journal-title":"Infect. Immun"},{"key":"CIT0012","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1073\/pnas.92.5.1644","volume":"92","author":"Douce G","year":"1995","journal-title":"Proc. Nat! Acad. Sci USA"},{"key":"CIT0014","first-page":"2277","volume":"22","author":"Lycke N","year":"1992","journal-title":"The adjuvant effect of Vibrio cholerae and Escherichia con heat-labile enterotoxins is linked to their ADP\u2014ribosyltransferase activity. Eur. j Immunol"},{"key":"CIT0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2958.1994.tb01266.x","volume":"14","author":"Pizza M","year":"1994","journal-title":"Mal Mcrobiol"},{"key":"CIT0016","first-page":"2147","volume":"180","author":"Pizza M","year":"1994","journal-title":"co\/ienterotoxin induces neutralizing antibodies against the A subunit. j Exp. Med"},{"key":"CIT0017","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1128\/IAI.64.12.5413-5416.1996","volume":"64","author":"de Haan L","year":"1996","journal-title":"Infect. Immun"},{"key":"CIT0018","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0264-410X(98)80100-X","volume":"16","author":"Douce G","year":"1998","journal-title":"Vaccine"},{"key":"CIT0019","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1574-6968.1997.tb10431.x","volume":"152","author":"Kato M","year":"1997","journal-title":"FEMS Mcrobiol Lett"},{"key":"CIT0020","first-page":"4400","volume":"67","author":"Douce G","year":"1999","journal-title":"Genetically detoxified mutants of heat-labile toxin from Escherichia cob are able to act as oral adjuvants. Infect. Immun"},{"key":"CIT0022","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0165-2478(99)00013-9","volume":"67","author":"Partidos CD","year":"1999","journal-title":"Immunol Lett"},{"key":"CIT0024","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.4049\/jimmunol.155.10.4621","volume":"155","author":"Marinaro M","year":"1995","journal-title":"I Immunol"},{"key":"CIT0025","first-page":"5750","volume":"1165","author":"Ryan EJ","year":"2000","journal-title":"I Immuno"},{"key":"CIT0027","first-page":"523","volume":"19","author":"Del Giudice G","year":"2001","journal-title":"The design of vaccines against Helicobacter pylori and their development. Ann. Rev Immunol"},{"key":"CIT0029","first-page":"5306","volume":"68","author":"Scharton-Kersten T","year":"2000","journal-title":"Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits and unrelated adjuvants. Infect. Immun"},{"key":"CIT0031","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.1128\/JVI.74.19.8843-8853.2000","volume":"74","author":"Yuan L","year":"2000","journal-title":"Virol"},{"key":"CIT0032","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0264-410X(00)00312-1","volume":"19","author":"Greer CE","year":"2000","journal-title":"Vaccine"},{"key":"CIT0033","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.4049\/jimmunol.166.2.1106","volume":"166","author":"Simmons CP","year":"2001","journal-title":"j Immunol"},{"key":"CIT0036","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0264-410X(00)00414-X","volume":"19","author":"Hagiwar Y","year":"2001","journal-title":"Vaccine"},{"key":"CIT0039","first-page":"1605","volume":"69","author":"Bonenfant C","year":"2001","journal-title":"Immun"},{"key":"CIT0040","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0168-3659(00)00330-8","volume":"70","author":"Singh M","year":"2001","journal-title":"Control. Release"},{"key":"CIT0043","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nri936","volume":"2","author":"Ricciardi-Castagnoli P","year":"2002","journal-title":"Nat. Rev Immunol"},{"key":"CIT0044","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/S0264-410X(00)00553-3","volume":"21","author":"Pizza M","year":"2001","journal-title":"Vaccine"},{"key":"CIT0046","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1086\/315337","volume":"181","author":"Clack R","year":"2000","journal-title":"j Infect. Dis"},{"key":"CIT0047","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0016-5085(99)70063-6","volume":"116","author":"Michetti P","year":"1999","journal-title":"Gastroenterology"},{"key":"CIT0048","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.4049\/jimmunol.165.9.4778","volume":"165","author":"van Ginkel FVV","year":"2000","journal-title":"J Immunol"},{"key":"CIT0049","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0264-410X(99)00168-1","volume":"18","author":"Cheng E","year":"1999","journal-title":"Vaccine"},{"key":"CIT0051","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/IAI.68.2.672-679.2000","volume":"68","author":"Simecka RV","year":"2000","journal-title":"Infect. Immun"},{"key":"CIT0052","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1128\/IAI.69.6.3581-3590.2001","volume":"69","author":"Kotloff K","year":"2001","journal-title":"Infect. Immun"}],"container-title":["Expert Review of Vaccines"],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/14760584.2.2.285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T15:14:52Z","timestamp":1682954092000},"score":16.711712,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1586\/14760584.2.2.285"}},"issued":{"date-parts":[[2003,4]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,1,9]]},"published-print":{"date-parts":[[2003,4]]}},"alternative-id":["10.1586\/14760584.2.2.285"],"URL":"https:\/\/doi.org\/10.1586\/14760584.2.2.285","ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"published":{"date-parts":[[2003,4]]}},{"indexed":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T05:27:03Z","timestamp":1737437223615,"version":"3.33.0"},"reference-count":61,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bill &amp; Melinda Gates Foundation","award":["#00053344"]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Brucellosis is a zoonotic disease that causes significant negative impacts on the animal industry and affects over half a million people worldwide every year. The limited safety and efficacy of current animal brucellosis vaccines, combined with the lack of a licensed human brucellosis vaccine, have led researchers to search for new vaccine strategies to combat the disease. To this end, the present research aimed to evaluate the safety and efficacy of a green vaccine candidate that combines Brucella abortus S19 smooth lipopolysaccharide (sLPS) with Quillaja saponin (QS) or QS-Xyloglucan mix (QS-X) against mucosal brucellosis in BALB\/C mice. The results of the study indicate that administering two doses of either sLPS-QS or sLPS-QS-X was safe for the animals, triggered a robust immune response, and enhanced protection following intranasal challenge with S19. Specifically, the vaccine combinations led to the secretion of IgA and IgG1 in the BALF of the immunized mice. We also found a mixed IgG1\/IgG2a systemic response indicating evidence of both Th1 and Th2 activation, with a predominance of the IgG1 over the IgG2a. These candidates resulted in significant reductions in the bioburden of lung, liver, and spleen tissue compared to the PBS control group. The sLPS-QS vaccination had conferred the greatest protection, with a 130-fold reduction in Brucella burdens in lung and a 55.74-fold reduction in the spleen compared to PBS controls. Vaccination with sLPS-QS-X resulted in the highest reduction in splenic Brucella loads, with a 364.6-fold decrease in bacterial titer compared to non-vaccinated animals. The study suggests that the tested vaccine candidates are safe and effective in increasing the animals\u2019 ability to respond to brucellosis via mucosal challenge. It also supports the use of the S19 challenge strain as a safe and cost-effective method for testing Brucella vaccine candidates under BSL-2 containment conditions.<\/jats:p>","DOI":"10.3390\/vaccines11030546","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T08:52:21Z","timestamp":1677487941000},"page":"546","source":"Crossref","is-referenced-by-count":4,"title":["Safe Subunit Green Vaccines Confer Robust Immunity and Protection against Mucosal Brucella Infection in Mice"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3616-3800","authenticated-orcid":false,"given":"Mostafa F.","family":"Abushahba","sequence":"first","affiliation":[{"name":"Department of Veterinary Pathobiology, University of Missouri, Columbia, MO 65211, USA"},{"name":"Department of Zoonotic Diseases, Faculty of Veterinary Medicine, Assiut University,  Assiut 71515, Egypt"}]},{"given":"Alexis S.","family":"Dadelahi","sequence":"additional","affiliation":[{"name":"Department of Veterinary Pathobiology, University of Missouri, Columbia, MO 65211, USA"}]},{"given":"Emily L.","family":"Lemoine","sequence":"additional","affiliation":[{"name":"Department of Veterinary Pathobiology, University of Missouri, Columbia, MO 65211, USA"}]},{"given":"Jerod A.","family":"Skyberg","sequence":"additional","affiliation":[{"name":"Department of Veterinary Pathobiology, University of Missouri, Columbia, MO 65211, USA"}]},{"given":"Swati","family":"Vyas","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, N.P. Marg, Matunga (E), Mumbai 400019, Maharashtra, India"}]},{"given":"Sagar","family":"Dhoble","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, N.P. Marg, Matunga (E), Mumbai 400019, Maharashtra, India"}]},{"given":"Vinod","family":"Ghodake","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, N.P. Marg, Matunga (E), Mumbai 400019, Maharashtra, India"}]},{"given":"Vandana B.","family":"Patravale","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, N.P. Marg, Matunga (E), Mumbai 400019, Maharashtra, India"}]},{"given":"Jeffrey J.","family":"Adamovicz","sequence":"additional","affiliation":[{"name":"Department of Veterinary Pathobiology, University of Missouri, Columbia, MO 65211, USA"},{"name":"Laboratory for Infectious Disease Research, University of Missouri, Columbia, MO 65211, USA"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1473-3099(06)70382-6","article-title":"The New Global Map of Human Brucellosis","volume":"6","author":"Pappas","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","unstructured":"(2020, November 14). Signs and Symptoms | Brucellosis | CDC, Available online: https:\/\/www.cdc.gov\/brucellosis\/symptoms\/index.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e00073-19","DOI":"10.1128\/CMR.00073-19","article-title":"Laboratory Diagnosis of Human Brucellosis","volume":"33","author":"Yagupsky","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.ijvsm.2018.01.007","article-title":"Sero-Diagnosis of Brucellosis in Sheep and Humans in Assiut and El-Minya Governorates, Egypt","volume":"6","author":"Abdelbaset","year":"2018","journal-title":"Int. J. Vet. Sci. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/vms3.1048","article-title":"Identification of Potential Antigenic Peptides of Brucella through Proteome and Peptidome","volume":"9","author":"Pei","year":"2023","journal-title":"Vet. Med. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.ijantimicag.2010.06.015","article-title":"Update on Brucellosis: Therapeutic Challenges","volume":"36","author":"Solera","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5539\/gjhs.v8n7p77","article-title":"Risk Factors for Relapse of Human Brucellosis","volume":"8","author":"Moulana","year":"2015","journal-title":"Glob. J. Health Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.vetmic.2009.06.021","article-title":"Brucellosis: A Re-Emerging Zoonosis","volume":"140","author":"Seleem","year":"2010","journal-title":"Vet. Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.20506\/rst.32.1.2197","article-title":"Economics of Brucellosis Impact and Control in Low-Income Countries","volume":"32","author":"McDermott","year":"2013","journal-title":"Rev. Sci. Tech."},{"key":"ref_10","unstructured":"Constable, P., Hinchcliff, K., Done, S., and Gr\u00fcnberg, W. (2017). Veterinary Medicine, Elsevier."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13567-015-0199-7","article-title":"Recent Advances in Brucella Abortus Vaccines","volume":"46","author":"Dorneles","year":"2015","journal-title":"Vet. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.15585\/mmwr.mm6807a6","article-title":"Notes from the Field: Human Brucella Abortus RB51 Infections Caused by Consumption of Unpasteurized Domestic Dairy Products United States, 2017\u20132019","volume":"68","author":"Kharod","year":"2019","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1177\/030098589603300607","article-title":"Experimental Infection of Pregnant Cattle with the Vaccine Candidate Brucella Abortus Strain RB51: Pathologic, Bacteriologic, and Serologic Findings","volume":"33","author":"Palmer","year":"1996","journal-title":"Vet. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1177\/1040638713499570","article-title":"Abortion and Premature Birth in Cattle Following Vaccination with Brucella Abortus Strain RB51","volume":"25","author":"Dougherty","year":"2013","journal-title":"J. Vet. Diagnostic Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0167-5877(96)01110-5","article-title":"A Review of the Use of B. Melitensis Rev 1 Vaccine in Adult Sheep and Goats","volume":"31","author":"Blasco","year":"1997","journal-title":"Prev. Vet. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nri1777","article-title":"Mucosal Vaccines: The Promise and the Challenge","volume":"6","author":"Neutra","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.3389\/fimmu.2019.01759","article-title":"Immune Response to Mucosal Brucella Infection","volume":"10","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_18","first-page":"1","article-title":"The Immunogenicity of OMP31 Peptides and Its Protection Against Brucella Melitensis Infection in Mice","volume":"9","author":"Zhang","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3389\/fimmu.2019.01589","article-title":"Route of Infection Strongly Impacts the Host-Pathogen Relationship","volume":"10","author":"Demars","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nri3251","article-title":"Recent Progress in Mucosal Vaccine Development: Potential and Limitations","volume":"12","author":"Lycke","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Pasquevich, K.A., Iba\u00f1ez, A.E., Coria, L.M., Samartino, C.G., Estein, S.M., Zwerdling, A., Barrionuevo, P., Oliveira, F.S., Seither, C., and Warzecha, H. (2011). An Oral Vaccine Based on U-Omp19 Induces Protection against B. Abortus Mucosal Challenge by Inducing an Adaptive IL-17 Immune Response in Mice. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0016203"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Cid, R., and Bol\u00edvar, J. (2021). Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies. Biomolecules, 11.","DOI":"10.3390\/biom11081072"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"925773","DOI":"10.3389\/fvets.2022.925773","article-title":"Evaluation of Brucellosis Vaccines: A Comprehensive Review","volume":"9","author":"Heidary","year":"2022","journal-title":"Front. Vet. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1128\/iai.60.4.1385-1389.1992","article-title":"Lipopolysaccharide (LPS) from Brucella Abortus Is Less Toxic than That from Escherichia Coli, Suggesting the Possible Use of B. Abortus or LPS from B. Abortus as a Carrier in Vaccines","volume":"60","author":"Goldstein","year":"1992","journal-title":"Infect. Immun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e24853","DOI":"10.5812\/jjm.24853","article-title":"Comparison of Biological and Immunological Characterization of Lipopolysaccharides from Brucella Abortus RB51 and S19","volume":"8","author":"Kianmehr","year":"2015","journal-title":"Jundishapur J. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1128\/IAI.70.7.3324-3329.2002","article-title":"Protection of Mice against Brucellosis by Intranasal Immunization with Brucella Melitensis Lipopolysaccharide as a Noncovalent Complex with Neisseria Meningitidis Group B Outer Membrane Protein","volume":"70","author":"Bhattacharjee","year":"2002","journal-title":"Infect. Immun."},{"key":"ref_27","first-page":"100053","article-title":"Xyloglucan Based Mucosal Nanovaccine for Immunological Protection against Brucellosis Developed by Supercritical Fluid Technology","volume":"2","author":"Vyas","year":"2020","journal-title":"Int. J. Pharm. X"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e14055","DOI":"10.1111\/jfpp.14055","article-title":"Production of Xyloglucan Component Extracted from Tamarind (Tamarindus Indica) Seeds Using Microwave Treatment for Seed Decortication","volume":"43","author":"Nguyen","year":"2019","journal-title":"J. Food Process. Preserv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cbi.2010.09.024","article-title":"Storage Xyloglucans: Potent Macrophages Activators","volume":"189","author":"Noleto","year":"2011","journal-title":"Chem. Biol. Interact."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jff.2018.05.035","article-title":"Mucoadhesive Role of Tamarind Xyloglucan on Inflammation Attenuates Ulcerative Colitis","volume":"47","author":"Periasamy","year":"2018","journal-title":"J. Funct. Foods"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.tips.2018.03.005","article-title":"Elucidating the Mechanisms of Action of Saponin-Derived Adjuvants","volume":"39","author":"Marciani","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cimid.2016.01.004","article-title":"Quillaja Brasiliensis Saponins Induce Robust Humoral and Cellular Responses in a Bovine Viral Diarrhea Virus Vaccine in Mice","volume":"45","author":"Cibulski","year":"2016","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1631\/jzus.2007.B0153","article-title":"Adjuvant Effects of Saponins on Animal Immune Responses","volume":"8","author":"Rajput","year":"2007","journal-title":"J. Zhejiang Univ. Sci. B."},{"key":"ref_34","first-page":"67","article-title":"Adjuvant and Haemolytic Activities of 47 Saponins Derived from Medicinal and Food Plants","volume":"381","author":"Kenji","year":"2000","journal-title":"Biol. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/icb.2016.5","article-title":"Nasal Vaccination Stimulates CD8(+) T Cells for Potent Protection against Mucosal Brucella Melitensis Challenge","volume":"94","author":"Clapp","year":"2016","journal-title":"Immunol. Cell Biol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Wang, H., Hoffman, C., Yang, X., Clapp, B., and Pascual, D.W. (2020). Targeting Resident Memory T Cell Immunity Culminates in Pulmonary and Systemic Protection against Brucella Infection. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008176"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"995327","DOI":"10.3389\/fimmu.2022.995327","article-title":"Live Mucosal Vaccination Stimulates Potent Protection via Varied CD4+ and CD8+ T Cell Subsets against Wild-Type Brucella Melitensis 16M Challenge","volume":"13","author":"Goodwin","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1128\/IAI.05080-11","article-title":"pascual Protective Live Oral Brucellosis Vaccines Stimulate Th1 and Th17 Cell Responses","volume":"79","author":"Clapp","year":"2011","journal-title":"Infect. Immun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/01971529808005484","article-title":"Standardization of Smooth Lipopolysaccharide Preparations for Use in Diagnostic Serological Tests for Bovine Antibody Brucella Abortus","volume":"19","author":"Nielsen","year":"1998","journal-title":"J. Immunoassay"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1128\/jcm.28.12.2627-2631.1990","article-title":"Modification of the Silver Staining Technique to Detect Lipopolysaccharide in Polyacrylamide Gels","volume":"28","author":"Fomsgaard","year":"1990","journal-title":"J. Clin. Microbiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.vaccine.2016.01.029","article-title":"Novel ISCOMs from Quillaja Brasiliensis Saponins Induce Mucosal and Systemic Antibody Production, T-Cell Responses and Improved Antigen Uptake","volume":"34","author":"Cibulski","year":"2016","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/286216","article-title":"Effects of Saponins against Clinical E. Coli Strains and Eukaryotic Cell Line","volume":"2012","author":"Arabski","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3762\/bjoc.8.87","article-title":"Triterpenoid Saponins from the Roots of Acanthophyllum Gypsophiloides Regel","volume":"8","author":"Khatuntseva","year":"2012","journal-title":"Beilstein J. Org. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4103\/0976-500X.119726","article-title":"How to Calculate Sample Size in Animal Studies?","volume":"4","author":"Charan","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"104809","DOI":"10.1016\/j.micinf.2021.104809","article-title":"Characterization of Brucella Abortus S19 as a Challenge Strain for Use in a Mouse Model of Brucellosis","volume":"23","author":"Jacob","year":"2021","journal-title":"Microbes Infect."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/laban1005-39","article-title":"A Rapid, Simple, and Humane Method for Submandibular Bleeding of Mice Using a Lancet","volume":"34","author":"Golde","year":"2005","journal-title":"Lab Anim. (N. Y.)"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1128\/jcm.25.4.600-604.1987","article-title":"Detection of Antibody to Murine Cytomegalovirus by Enzyme-Linked Immunosorbent and Indirect Immunofluorescence Assays","volume":"25","author":"Classen","year":"1987","journal-title":"J. Clin. Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e00075-20","DOI":"10.1128\/IAI.00075-20","article-title":"B Cells Inhibit CD4+ T Cell-Mediated Immunity to Brucella Infection in a Major Histocompatibility Complex Class II-Dependent Manner","volume":"88","author":"Dadelahi","year":"2020","journal-title":"Infect. Immun."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Lowry, J.E., Isaak, D.D., Leonhardt, J.A., Vernati, G., Pate, J.C., and Andrews, G.P. (2011). Vaccination with Brucella Abortus Recombinant In Vivo-Induced Antigens Reduces Bacterial Load and Promotes Clearance in a Mouse Model for Infection. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017425"},{"key":"ref_50","first-page":"3","article-title":"Extraction, Purification and Characterization of Lipopolysaccharide from Escherichia Coli and Salmonella Typhi","volume":"3","author":"Rezania","year":"2011","journal-title":"Avicenna J. Med. Biotechnol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1128\/iai.24.2.371-378.1979","article-title":"Immune and Mitogenic Responses by BALB\/c, C3H\/HeJ, and Nude Mice to Brucella Abortus Bacterin and Lipopolysaccharide","volume":"24","author":"Spellman","year":"1979","journal-title":"Infect. Immun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1128\/iai.46.1.74-80.1984","article-title":"Induction of Immune and Adjuvant Immunoglobulin G Responses in Mice by Brucella Lipopolysaccharide","volume":"46","author":"Moreno","year":"1984","journal-title":"Infect. Immun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3923\/jbs.2010.767.772","article-title":"Novel Approach of Vaccination against Brucella Abortus 544 Based on a Combination of Fusion Proteins, Human Serum Albumin and Brucella Abortus Lipopolysaccharides","volume":"10","author":"Pakzad","year":"2010","journal-title":"J. Biol. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00430-014-0356-z","article-title":"Influence of Brucella Abortus Lipopolysaccharide as an Adjuvant on the Immunogenicity of HPV-16 L1VLP Vaccine in Mice","volume":"204","author":"Kianmehr","year":"2015","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4142\/jvs.2018.19.3.416","article-title":"Effect of Immunization Routes and Protective Efficacy of Brucella Antigens Delivered via Salmonella Vector Vaccine","volume":"19","author":"Lalsiamthara","year":"2018","journal-title":"J. Vet. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biologicals.2021.06.002","article-title":"Immunization Effect of Lipopolysaccharide Antigen in Conjugation with PLGA Nanoparticles as a Nanovaccine against Brucella Melitensis Infection","volume":"72","author":"Maleki","year":"2021","journal-title":"Biologicals"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Pietrzak, B., Tomela, K., Olejnik-Schmidt, A., Mackiewicz, A., and Schmidt, M. (2020). Secretory IgA in Intestinal Mucosal Secretions as an Adaptive Barrier against Microbial Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239254"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1080\/089583798197295","article-title":"Timing of Low-Level NO2 Exposure Alters Antigen-Specific IgE, IgG, and IgG(2a) Antibody Production in Mice","volume":"10","author":"Fujimaki","year":"1998","journal-title":"Inhal. Toxicol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/01.shk.0000142249.08135.e9","article-title":"Innate Immune Response in Th1- and Th2-Dominant Mouse Strains","volume":"22","author":"Watanabe","year":"2004","journal-title":"Shock"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1128\/iai.61.5.1722-1729.1993","article-title":"Lipopolysaccharide from Brucella Abortus Behaves as a T-Cell-Independent Type 1 Carrier in Murine Antigen-Specific Antibody Responses","volume":"61","author":"Betts","year":"1993","journal-title":"Infect. Immun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1128\/CMR.16.1.65-78.2003","article-title":"Molecular Host-Pathogen Interaction in Brucellosis: Current Understanding and Future Approaches to Vaccine Development for Mice and Humans","volume":"16","author":"Ko","year":"2003","journal-title":"Clin. Microbiol. Rev."}],"container-title":["Vaccines"],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/3\/546\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T22:48:08Z","timestamp":1737413288000},"score":16.70648,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/3\/546"}},"issued":{"date-parts":[[2023,2,25]]},"references-count":61,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["vaccines11030546"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11030546","ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"published":{"date-parts":[[2023,2,25]]}},{"indexed":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T18:18:36Z","timestamp":1732040316343},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1038\/s41577-021-00525-y","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T17:03:24Z","timestamp":1614791004000},"page":"200-201","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Are COVID-19 vaccines safe in pregnancy?"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"http:\/\/orcid.org\/0000-0001-5654-5083","authenticated-orcid":false,"given":"Victoria","family":"Male","sequence":"first","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"key":"525_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines \u2014 a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"525_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2020.10.005","author":"S Cosma","year":"2020","unstructured":"Cosma, S. et al. Coronavirus disease 2019 and first-trimester spontaneous abortion: a case\u2013control study of 225 pregnant patients. Am. J. Obstet. Gynecol. https:\/\/doi.org\/10.1016\/j.ajog.2020.10.005 (2020).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"525_CR3","unstructured":"Lu-Culligan, A. & Iwasaki, A. The false rumours about vaccines that are scaring women. New York Times (26 Jan 2021)."},{"key":"525_CR4","unstructured":"United States Food & Drug Administration. Pfizer-BioNTech COVID-19 vaccine (BNT162, PF-07302048). Vaccines and related biological products advisory committee briefing document. FDA https:\/\/www.fda.gov\/media\/144246\/download (2020)."},{"key":"525_CR5","unstructured":"United States Food & Drug Administration. Vaccines and related biological products advisory committee meeting December 17, 2020. FDA briefing document: Moderna COVID-19 vaccine. FDA https:\/\/www.fda.gov\/media\/144434\/download (2020)."},{"key":"525_CR6","unstructured":"Medicines & Healthcare products Regulatory Agency. Public assessment report authorisation for temporary supply. COVID-19 vaccine AstraZeneca, solution for injection in multidose container COVID-19 vaccine (ChAdOx1-S [recombinant]). MHRA https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/949772\/UKPAR_COVID_19_Vaccine_AstraZeneca_05.01.2021.pdf (2021)."},{"key":"525_CR7","unstructured":"Nunez-Smith, M. & Fauci, A. Press briefing by White House COVID-19 response team and public health officials, 10 February 2021. The White House https:\/\/www.whitehouse.gov\/briefing-room\/press-briefings\/2021\/02\/10\/press-briefing-by-white-house-covid-19-response-team-and-public-health-officials-3\/ (2021)."},{"key":"525_CR8","unstructured":"Medicines & Healthcare products Regulatory Agency. Coronavirus vaccine - weekly summary of yellow card reporting. gov.uk https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions\/coronavirus-vaccine-summary-of-yellow-card-reporting (2021)."},{"key":"525_CR9","doi-asserted-by":"publisher","first-page":"m3320","DOI":"10.1136\/bmj.m3320","volume":"370","author":"J Allotey","year":"2020","unstructured":"Allotey, J. et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ 370, m3320 (2020).","journal-title":"BMJ"},{"key":"525_CR10","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.03.21250579","author":"P Gilbert","year":"2021","unstructured":"Gilbert, P. & Rudnick, C. Newborn antibodies to SARS-CoV-2 detected in cord blood after maternal vaccination. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2021.02.03.21250579 (2021).","journal-title":"medRxiv"}],"updated-by":[{"updated":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"DOI":"10.1038\/s41577-021-00533-y","type":"correction","source":"publisher","label":"Correction"}],"container-title":["Nature Reviews Immunology"],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41577-021-00525-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41577-021-00525-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41577-021-00525-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:00:20Z","timestamp":1684620020000},"score":16.686607,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-021-00525-y"}},"issued":{"date-parts":[[2021,3,3]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["525"],"URL":"https:\/\/doi.org\/10.1038\/s41577-021-00525-y","ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"published":{"date-parts":[[2021,3,3]]},"assertion":[{"value":"3 March 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2021","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41577-021-00533-y","URL":"https:\/\/doi.org\/10.1038\/s41577-021-00533-y","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]},{"indexed":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T01:46:34Z","timestamp":1725068794873},"reference-count":47,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"IAPorto Research Center"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Reported cases of anaphylaxis following COVID-19 vaccination raised concerns about the safety of these vaccines, namely in patients suffering from clonal mast cell (MC) disorders\u2014a heterogenous group of disorders in which patients may be prone to anaphylaxis caused by vaccination. This study aimed to assess the safety of COVID-19 vaccines in patients with clonal MC disorders. We performed an ambidirectional cohort study with 30 clonal MC disorder patients (n = 26 in the prospective arm and n = 4 in the retrospective arm), that were submitted to COVID-19 vaccination. Among these, 11 (37%) were males, and median age at vaccination date was 41 years (range: 5y to 76y). One patient had prior history of anaphylaxis following vaccination. Those in the prospective arm received a premedication protocol including H1- and H2-antihistamines and montelukast, while those in the retrospective arm did not premedicate. Overall, patients received a total of 81 doses, 73 under premedication and 8 without premedication. No MC activation symptoms were reported. COVID-19 vaccination seems to be safe in patients with clonal mast cell disorders, including those with prior anaphylaxis following vaccination. Robust premedication protocols may allow for vaccination in ambulatory settings.<\/jats:p>","DOI":"10.3390\/vaccines10050718","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T12:21:25Z","timestamp":1651666885000},"page":"718","source":"Crossref","is-referenced-by-count":9,"title":["COVID-19 Vaccination Is Safe among Mast Cell Disorder Patients, under Adequate Premedication"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"http:\/\/orcid.org\/0000-0003-0134-617X","authenticated-orcid":false,"given":"Tiago Azenha","family":"Rama","sequence":"first","affiliation":[{"name":"Servi\u00e7o de Imunoalergologia, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"},{"name":"Servi\u00e7o de Imunologia B\u00e1sica e Cl\u00ednica, Departamento de Patologia, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal"},{"name":"EPIUnit\u2014Institute of Public Health, University of Porto, 4050-600 Porto, Portugal"},{"name":"Laboratory for Integrative and Translational Research in Population Health (ITR), 4050-600 Porto, Portugal"}]},{"given":"Joana","family":"Miranda","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Imunoalergologia, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"}]},{"given":"Diana","family":"Silva","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Imunoalergologia, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"},{"name":"Servi\u00e7o de Imunologia B\u00e1sica e Cl\u00ednica, Departamento de Patologia, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal"},{"name":"EPIUnit\u2014Institute of Public Health, University of Porto, 4050-600 Porto, Portugal"},{"name":"Laboratory for Integrative and Translational Research in Population Health (ITR), 4050-600 Porto, Portugal"}]},{"given":"Lu\u00eds","family":"Amaral","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Imunoalergologia, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"}]},{"given":"Eunice","family":"Castro","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Imunoalergologia, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"}]},{"given":"Alice","family":"Coimbra","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Imunoalergologia, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"}]},{"ORCID":"http:\/\/orcid.org\/0000-0002-7294-9296","authenticated-orcid":false,"given":"Andr\u00e9","family":"Moreira","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Imunoalergologia, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"},{"name":"Servi\u00e7o de Imunologia B\u00e1sica e Cl\u00ednica, Departamento de Patologia, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal"},{"name":"EPIUnit\u2014Institute of Public Health, University of Porto, 4050-600 Porto, Portugal"},{"name":"Laboratory for Integrative and Translational Research in Population Health (ITR), 4050-600 Porto, Portugal"}]},{"given":"Jos\u00e9 Lu\u00eds","family":"Pl\u00e1cido","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Imunoalergologia, Centro Hospitalar Universit\u00e1rio S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa2117128","article-title":"Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina","volume":"386","author":"Lin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"key":"ref_3","unstructured":"(2021, November 28). European Medicines Agency\u2014COVID-19 vaccines. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/covid-19-vaccines."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Garvey, L.H., and Nasser, S. (2020). Allergic reactions to the first COVID-19 vaccine: Is polyethylene glycol (PEG) the culprit?. Br. J. Anaesth.","DOI":"10.1016\/j.bja.2020.12.020"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1016\/j.jaip.2021.06.006","article-title":"The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach","volume":"9","author":"Greenhawt","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.vaccine.2021.11.066","article-title":"Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines","volume":"40","author":"Maltezou","year":"2022","journal-title":"Vaccine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12948-022-00167-y","article-title":"The risk of anaphylaxis behind authorized COVID-19 vaccines: A meta-analysis","volume":"20","author":"Sobczak","year":"2022","journal-title":"Clin. Mol. Allergy"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Rama, T.A., Coutinho, R.M., Mota, D., Moreira, A., and Cernada, J. (2021). Hypersensitivity to the Moderna COVID-19 vaccine caused by tromethamine: PEG is not always the culprit excipient. J. Investig Allergol Clin. Immunol., 32.","DOI":"10.18176\/jiaci.0773"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1111\/all.14794","article-title":"Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation","volume":"76","author":"Klimek","year":"2021","journal-title":"Allergy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1111\/all.14725","article-title":"COVID-19 vaccine anaphylaxis: IgE, complement or what else? A reply to: \u201cCOVID-19 vaccine anaphylaxis: PEG or not?\u201d","volume":"76","author":"Cabanillas","year":"2021","journal-title":"Allergy"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1016\/j.jaip.2021.06.011","article-title":"Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review","volume":"9","author":"Gulen","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_16","unstructured":"Swerdlow, S., Campo, E., Harris, N., Jaffe, E., Pileri, S., Stein, H., and Thiele, J. (2017). Mastocytosis. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC. [Revised 4th ed.]."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: A study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/pai.12647","article-title":"Evaluation of vaccination safety in children with mastocytosis","volume":"28","author":"Parente","year":"2017","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/cea.12882","article-title":"Vaccination management in children and adults with mastocytosis","volume":"47","author":"Zanoni","year":"2017","journal-title":"Clin. Exp. Allergy"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4274\/jpr.galenos.2019.96720","article-title":"Occurrence of Unexpected Adverse Reactions to Vaccines in Children with Mastocytosis","volume":"7","author":"Abuhay","year":"2020","journal-title":"J. Pediatric. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/pde.14492","article-title":"Assessing vaccination reactions in pediatric patients with maculopapular cutaneous mastocytosis","volume":"38","author":"Johansen","year":"2021","journal-title":"Pediatr. Derm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2021.01.004","article-title":"mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis","volume":"147","author":"Rama","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jaip.2022.01.030","article-title":"Safety of COVID-19 vaccination in patients with clonal mast cell disorders","volume":"10","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1016\/j.jaip.2021.05.010","article-title":"Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome","volume":"9","author":"Kaakati","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e650","DOI":"10.1097\/HS9.0000000000000650","article-title":"A UK Survey Examining the Experience of Adults With Mastocytosis Receiving COVID-19 Vaccination","volume":"5","author":"Sriskandarajah","year":"2021","journal-title":"Hemasphere"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jaip.2022.01.037","article-title":"COVID-19 vaccination in the setting of mastocytosis-Pfizer-BioNTech mRNA vaccine is safe and well tolerated","volume":"10","author":"Lazarinis","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0145-2126(01)00041-8","article-title":"Morphologic properties of neoplastic mast cells: Delineation of stages of maturation and implication for cytological grading of mastocytosis","volume":"25","author":"Sperr","year":"2001","journal-title":"Leuk Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0145-2126(01)00021-2","article-title":"Diagnosis of mastocytosis: General histopathological aspects, morphological criteria, and immunohistochemical findings","volume":"25","author":"Horny","year":"2001","journal-title":"Leuk Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: A consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41590-022-01130-4","article-title":"Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses","volume":"23","author":"Tomalka","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1398-9995.2012.02812.x","article-title":"Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis","volume":"67","author":"Morgado","year":"2012","journal-title":"Allergy"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/j.jaip.2021.02.023","article-title":"COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms","volume":"9","author":"Giannetti","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1111\/all.14958","article-title":"Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don\u2019t give up on the second dose!","volume":"76","author":"Krantz","year":"2021","journal-title":"Allergy"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Li, D.H., Lee, E., and Song, C. (2022). Successful mRNA COVID-19 vaccination in a patient with a history of severe polyethylene glycol anaphylaxis. Res. Sq.","DOI":"10.21203\/rs.3.rs-1263943\/v1"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Cabanillas, B., Novak, N., and Akdis, C.A. (2021). The form of PEG matters: PEG conjugated with lipids and not PEG alone could be the specific form involved in allergic reactions to COVID-19 vaccines. Allergy.","DOI":"10.1111\/all.15187"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaci.2021.04.032","article-title":"Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy","volume":"148","author":"Troelnikov","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jaip.2018.12.003","article-title":"Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized","volume":"7","author":"Stone","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/cea.12760","article-title":"Immediate-type hypersensitivity to polyethylene glycols: A review","volume":"46","author":"Wenande","year":"2016","journal-title":"Clin. Exp. Allergy"},{"key":"ref_40","first-page":"517","article-title":"Anaphylactic reactions to polyethylene glycol-containing bowel cleansing preparations after Moderna COVID-19 vaccination","volume":"54","author":"Schreiner","year":"2021","journal-title":"Endoscopy"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/978-1-0716-0696-4_27","article-title":"Identification and Immunophenotypic Characterization of Normal and Pathological Mast Cells","volume":"2163","author":"Morgado","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jaci.2018.10.063","article-title":"Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology","volume":"143","author":"Carter","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.jaip.2021.03.041","article-title":"COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)","volume":"9","author":"Bonadonna","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/annrheumdis-2021-220656","article-title":"High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases","volume":"80","author":"Ruddy","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: A multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"100541","DOI":"10.1016\/j.waojou.2021.100541","article-title":"Successful SARS-CoV-2 vaccine allergy risk-management: The experience of a large Italian University Hospital","volume":"14","author":"Paoletti","year":"2021","journal-title":"World Allergy Organ. J."},{"key":"ref_47","first-page":"388","article-title":"Drug hypersensitivity in indolent systemic mastocytosis, without skin lesions, presenting with anaphylaxis to hymenoptera venoms","volume":"76","author":"Rama","year":"2021","journal-title":"Allergy"}],"container-title":["Vaccines"],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/5\/718\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T06:06:31Z","timestamp":1722233191000},"score":16.669401,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/5\/718"}},"issued":{"date-parts":[[2022,5,4]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["vaccines10050718"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10050718","ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"published":{"date-parts":[[2022,5,4]]}},{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T21:22:43Z","timestamp":1694640163115},"reference-count":22,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1586\/erv.10.56","type":"journal-article","created":{"date-parts":[[2010,7,12]],"date-time":"2010-07-12T16:48:01Z","timestamp":1278953281000},"page":"697-701","source":"Crossref","is-referenced-by-count":4,"title":["HPV vaccine continues to be safe and effective, and its benefits continue to outweigh its risks"],"prefix":"10.1586","volume":"9","author":[{"given":"Richard M","family":"Haupt","sequence":"first","affiliation":[]},{"given":"Carlos","family":"Sattler","sequence":"additional","affiliation":[]}],"member":"301","published-online":{"date-parts":[[2014,1,9]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1586\/erv.09.123","volume":"8","author":"Harper","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"CIT0002","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1586\/erv.09.120","volume":"8","author":"Harper","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"CIT0003","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","volume":"356","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"CIT0004","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.4161\/hv.5.10.9515"},{"key":"CIT0006","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/GCO.0b013e328332c910","volume":"21","author":"Harper","year":"2009","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"CIT0007","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","volume":"356","author":"Garland","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60946-5"},{"key":"CIT0009","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","volume":"369","year":"2007","journal-title":"Lancet"},{"key":"CIT0010","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"CIT0011","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","volume":"102","author":"Munoz","year":"2010","journal-title":"J. Natl Cancer Inst."},{"key":"CIT0012","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","volume":"199","author":"Garland","year":"2009","journal-title":"J. Infect. Dis."},{"key":"CIT0013","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/01.AOG.0000245786.86267.80","volume":"108","author":"Hampl","year":"2006","journal-title":"Obstet. Gynecol."},{"key":"CIT0014","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0029-7844(95)00045-S","volume":"85","author":"Monk","year":"1995","journal-title":"Obstet. Gynecol."},{"key":"CIT0015","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/ijc.24116","volume":"124","author":"De Vuyst","year":"2009","journal-title":"Int. J. Cancer"},{"key":"CIT0016","unstructured":"Dawson B, Trapp RG.Basic and Clinical Biostatistics. Mcgraw-Hill, NY, USA (2004)."},{"key":"CIT0017","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/QCO.0b013e328334c0e1","volume":"23","author":"Stanley","year":"2010","journal-title":"Curr. Opin. Infect. Dis."},{"key":"CIT0018","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum. Vaccin."},{"key":"CIT0019","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/INF.0b013e3181b77906","volume":"29","author":"Block","year":"2010","journal-title":"Pediatr. Infect. Dis. J."},{"key":"CIT0020","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/AOG.0b013e3181c2ca21","volume":"114","author":"Garland","year":"2009","journal-title":"Obstet. Gynecol."},{"key":"CIT0021","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1097\/AOG.0b013e3181c2a122","volume":"114","author":"Dana","year":"2009","journal-title":"Obstet. Gynecol."},{"key":"CIT0022","doi-asserted-by":"crossref","first-page":"7270","DOI":"10.1016\/j.vaccine.2009.09.097","volume":"27","author":"Agorastos","year":"2009","journal-title":"Vaccine"}],"container-title":["Expert Review of Vaccines"],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/erv.10.56","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T08:46:25Z","timestamp":1635669985000},"score":16.663696,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1586\/erv.10.56"}},"issued":{"date-parts":[[2010,7]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,1,9]]},"published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1586\/erv.10.56"],"URL":"https:\/\/doi.org\/10.1586\/erv.10.56","ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"published":{"date-parts":[[2010,7]]}},{"indexed":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T07:54:52Z","timestamp":1700466892188},"reference-count":0,"publisher":"BMJ","license":[{"start":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T00:00:00Z","timestamp":1525824000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj.k2059","type":"journal-article","created":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T09:25:24Z","timestamp":1525857924000},"page":"k2059","update-policy":"http:\/\/dx.doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["HPV vaccines are effective and safe and work best in young women, review finds"],"prefix":"10.1136","author":[{"given":"Nigel","family":"Hawkes","sequence":"first","affiliation":[]}],"member":"239","published-online":{"date-parts":[[2018,5,9]]},"container-title":["BMJ"],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.k2059","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.k2059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T00:43:13Z","timestamp":1601080993000},"score":16.651974,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.k2059"}},"issued":{"date-parts":[[2018,5,9]]},"references-count":0,"alternative-id":["10.1136\/bmj.k2059"],"URL":"https:\/\/doi.org\/10.1136\/bmj.k2059","ISSN":["0959-8138","1756-1833"],"issn-type":[{"value":"0959-8138","type":"print"},{"value":"1756-1833","type":"electronic"}],"published":{"date-parts":[[2018,5,9]]}},{"indexed":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T04:02:58Z","timestamp":1705118578981},"reference-count":9,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[1988,4,1]],"date-time":"1988-04-01T00:00:00Z","timestamp":575856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[1988,4]]},"DOI":"10.1016\/s0264-410x(88)80019-7","type":"journal-article","created":{"date-parts":[[2005,3,8]],"date-time":"2005-03-08T23:31:07Z","timestamp":1110324667000},"page":"151-154","source":"Crossref","is-referenced-by-count":96,"title":["Safe, live Vibrio cholerae vaccines?"],"prefix":"10.1016","volume":"6","author":[{"given":"Ronald","family":"Taylor","sequence":"first","affiliation":[]},{"given":"Carolyn","family":"Shaw","sequence":"additional","affiliation":[]},{"given":"Kenneth","family":"Peterson","sequence":"additional","affiliation":[]},{"given":"Patricia","family":"Spears","sequence":"additional","affiliation":[]},{"given":"John","family":"Mekalanos","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0264-410X(88)80019-7_bib1","first-page":"271","article-title":"Oral immunization with killed whole Vibrio and B subunit or procholeragenoid combination cholera vaccines: immune response and protection from V. cholerae challenge","volume":"Vol. 3","author":"Black","year":"1986"},{"key":"10.1016\/S0264-410X(88)80019-7_bib2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/306551a0","article-title":"Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development","volume":"306","author":"Mekalanos","year":"1983","journal-title":"Nature"},{"key":"10.1016\/S0264-410X(88)80019-7_bib3","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/308655a0","article-title":"Recombinant nontoxinogenic Vibrio cholerae strains as attenuated cholera vaccine candidates","volume":"308","author":"Kaper","year":"1984","journal-title":"Nature"},{"key":"10.1016\/S0264-410X(88)80019-7_bib4","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1128\/IAI.46.2.564-569.1984","article-title":"Construction of a potential live oral bivalent vaccine for typhoid fever and cholera-Escherichia coli-related diarrheas","volume":"46","author":"Clements","year":"1984","journal-title":"Infect. Immun."},{"key":"10.1016\/S0264-410X(88)80019-7_bib5","first-page":"2833","article-title":"Use of phoA gene fusions to identify a pilus colonization factor coordinately regulated with cholera toxin","volume":"84","author":"Taylor","year":"1987"},{"key":"10.1016\/S0264-410X(88)80019-7_bib6","series-title":"Acute Enteric Infections of Children. New Prospects for Treatment and Prevention","first-page":"443","article-title":"Volunteer studies in the development of vaccines against cholera and enterotoxigenic Escherichia coli: A review","author":"Levine","year":"1981"},{"key":"10.1016\/S0264-410X(88)80019-7_bib7","first-page":"1800","article-title":"Adhesin to human cells by Escherichia coli lacking the major subunit of a digalactoside-specific pilus-adhesin","volume":"82","author":"Uhlin","year":"1985"},{"key":"10.1016\/S0264-410X(88)80019-7_bib8","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1126\/science.2983426","article-title":"Rapid and sensitive protein similarity searches","volume":"227","author":"Lipman","year":"1985","journal-title":"Science"},{"key":"10.1016\/S0264-410X(88)80019-7_bib9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev.mi.40.100186.003045","article-title":"Genetics of bacterial enterotoxins","volume":"40","author":"Betley","year":"1986","journal-title":"Annu. Rev. Microbiol."}],"container-title":["Vaccine"],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X88800197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X88800197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T07:39:32Z","timestamp":1586158772000},"score":16.651974,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X88800197"}},"issued":{"date-parts":[[1988,4]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1988,4]]}},"alternative-id":["S0264410X88800197"],"URL":"https:\/\/doi.org\/10.1016\/s0264-410x(88)80019-7","ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"published":{"date-parts":[[1988,4]]}},{"indexed":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:55:42Z","timestamp":1722992142309},"reference-count":28,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>This study investigates the effect of ethical leadership, commitment and healthy\/safe workplace practices toward employee COVID-19 vaccination. In addition, this study examines the perception of employees from technological intrusive vaccination of chips or quantum dot. In our research, we adopted the social exchange theory as its theoretical framework. Moreover, an online questionnaire was distributed to employees working in the banking sector in Lebanon during the COVID-19 pandemic. In total, 244 bankers completed the survey. Data was analyzed by SPSS statistical software version 26 and SmartPLS to test the relationship between the variables. The results generated showed a positive relationship between ethical leadership, commitment, and safety influencing employees to accept vaccination but not necessarily technological intrusive vaccination (chip or quantum dot). We suggest that organizations should influence leaders to enhance proper behaviors and attitudes to create a healthy, safe, and ethical culture that consequently increases employees\u2019 commitment. Finally, this study recommends future researchers to investigate the topic of COVID-19 vaccination and test other employees\u2019 perception from different industries and countries.<\/jats:p>","DOI":"10.3390\/vaccines10030416","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T01:19:10Z","timestamp":1646961550000},"page":"416","source":"Crossref","is-referenced-by-count":9,"title":["The Impact of Ethical Leadership, Commitment and Healthy\/Safe Workplace Practices toward Employee Attitude to COVID-19 Vaccination\/Implantation in the Banking Sector in Lebanon"],"prefix":"10.3390","volume":"10","author":[{"given":"Samira","family":"Kabbani","sequence":"first","affiliation":[{"name":"Adnan Kassar School of Business, Lebanese American University, Beirut 1102-2801, Lebanon"}]},{"given":"Silva","family":"Karkoulian","sequence":"additional","affiliation":[{"name":"Adnan Kassar School of Business, Lebanese American University, Beirut 1102-2801, Lebanon"}]},{"ORCID":"http:\/\/orcid.org\/0000-0002-8410-1188","authenticated-orcid":false,"given":"Puzant","family":"Balozian","sequence":"additional","affiliation":[{"name":"Adnan Kassar School of Business, Lebanese American University, Beirut 1102-2801, Lebanon"}]},{"ORCID":"http:\/\/orcid.org\/0000-0002-4405-5703","authenticated-orcid":false,"given":"Sandra","family":"Rizk","sequence":"additional","affiliation":[{"name":"Department of Natural Sciences, Lebanese American University, Beirut 1102-2801, Lebanon"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09669582.2020.1758708","article-title":"Pandemics, tourism and global change: A rapid assessment of COVID-19","volume":"29","author":"Scott","year":"2021","journal-title":"J. Sustain. Tour."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s12630-020-01651-2","article-title":"Social distancing: Implications for the operating room in the face of COVID-19","volume":"67","author":"Prin","year":"2020","journal-title":"Can. J. Anaesth."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1108\/IJCHM-08-2020-0814","article-title":"How do hotels in developing countries manage the impact of COVID-19? The case of Lebanese hotels","volume":"33","author":"Yacoub","year":"2021","journal-title":"Int. J. Contemp. Hosp. Manag."},{"key":"ref_4","unstructured":"(2022, January 21). Coronavirus Worldometers [Internet]. Available online: https:\/\/www.worldometers.info\/coronavirus\/."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Al Halabi, C.K., Obeid, S., Sacre, H., Akel, M., Hallit, R., Salameh, P., and Hallit, S. (2021). Attitudes of Lebanese adults regarding COVID-19 vaccination. BMC Public Health, 21.","DOI":"10.1186\/s12889-021-10902-w"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Sallam, M., Dababseh, D., Eid, H., Al-Mahzoum, K., Al-Haidar, A., Taim, D., Yaseen, A., Ababneh, N.A., Bakri, F.G., and Mahafzah, A. (2021). High Rates of COVID-19 Vaccine Hesitancy and Its Association with Conspiracy Beliefs: A Study in Jordan and Kuwait among Other Arab Countries. Vaccines, 9.","DOI":"10.3390\/vaccines9010042"},{"key":"ref_7","unstructured":"(2022, January 21). Why the COVID Vaccines Can\u2019t Contain a Tracking Microchip or Make You Magnetic. Available online: https:\/\/www.cnbc.com\/video\/2021\/10\/01\/why-theres-no-5g-tracking-microchip-in-the-covid-vaccine.html."},{"key":"ref_8","unstructured":"(2022, January 21). Coronavirus: Bill Gates \u2018Microchip\u2019 Conspiracy Theory and Other Vaccine Claims Fact-Checked. Available online: https:\/\/www.bbc.com\/news\/52847648."},{"key":"ref_9","unstructured":"(2022, February 25). How to Talk to Conspiracy Theorists\u2014And Still Be Kind. MIT Technology Review. Available online: https:\/\/www.technologyreview.com\/2020\/07\/15\/1004950\/how-to-talk-to-conspiracy-theorists-and-still-be-kind\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"eaay7162","DOI":"10.1126\/scitranslmed.aay7162","article-title":"Biocompatible near-infrared quantum dots delivered to the skin by microneedle patches record vaccination","volume":"11","author":"McHugh","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_11","unstructured":"(2022, February 25). Storing Medical Information below the Skin\u2019s Surface. MIT News. Massachusetts Institute of Technology. Available online: https:\/\/news.mit.edu\/2019\/storing-vaccine-history-skin-1218."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2478\/orga-2018-0010","article-title":"Factors Affecting the Intentions to Use RFID Subcutaneous Microchip Implants for Healthcare Purposes","volume":"51","author":"Werber","year":"2018","journal-title":"Organizacija"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.obhdp.2005.03.002","article-title":"Ethical leadership: A social learning perspective for construct development and testing","volume":"97","author":"Brown","year":"2005","journal-title":"Organ. Behav. Hum. Decis. Process."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1108\/JEA-10-2012-0110","article-title":"Development and validity of the Ethical Leadership Questionnaire","volume":"52","author":"Langlois","year":"2014","journal-title":"J. Educ. Adm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.2044-8325.1990.tb00506.x","article-title":"The measurement and antecedents of affective, continuance and normative commitment to the organization","volume":"63","author":"Allen","year":"1990","journal-title":"J. Occup. Psychol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1037\/0021-9010.78.4.538","article-title":"Commitment to organizations and occupations: Extension and test of a three-component conceptualization","volume":"78","author":"Meyer","year":"1993","journal-title":"J. Appl. Psychol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/10803548.2013.11077020","article-title":"Developing a Questionnaire for Measuring Safety Climate in the Workplace in Serbia","volume":"19","author":"Strbac","year":"2013","journal-title":"Int. J. Occup. Saf. Ergon."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0022-4375(98)00011-5","article-title":"Measuring Perceptions of Workplace Safety: Development and Validation of the Work Safety Scale","volume":"29","author":"Hayes","year":"1998","journal-title":"J. Saf. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1016\/j.vaccine.2014.06.001","article-title":"Healthcare workers under a mandated H1N1 vaccination policy with employment termination penalty: A survey to assess employee perception","volume":"32","author":"Winston","year":"2014","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3201\/eid1405.071437","article-title":"Public Response to Community Mitigation Measures for Pandemic Influenza","volume":"14","author":"Blendon","year":"2008","journal-title":"Emerg. Infect. Dis."},{"key":"ref_21","unstructured":"Hair, J.F. (2010). Multivariate Data Analysis, Prentice Hall. [7th ed.]."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/002224378101800104","article-title":"Evaluating Structural Equation Models with Unobservable Variables and Measurement Error","volume":"18","author":"Fornell","year":"1981","journal-title":"J. Mark. Res."},{"key":"ref_23","first-page":"295","article-title":"The Partial Least Squares Approach to Structural Equation Modeling","volume":"295","author":"Chin","year":"1998","journal-title":"Mod. Methods Bus. Res."},{"key":"ref_24","first-page":"285","article-title":"The Partial Least Squares (PLS) Approach to Causal Modelling: Personal Computer Adoption and Use as an Illustration","volume":"2","author":"Barclay","year":"1995","journal-title":"Technol. Stud."},{"key":"ref_25","unstructured":"(2022, January 21). Trend That Worries Health Experts: As U.S. Gets Closer to COVID-19 Vaccine, Fewer People Say They\u2019d Get One. Available online: https:\/\/morningconsult.com\/2020\/09\/11\/vaccine-acceptance-public-poll\/."},{"key":"ref_26","unstructured":"McKie, R. (2022, January 21). COVID-19: Only Half of Britons Would Definitely Have Vaccination. Available online: https:\/\/www.theguardian.com\/world\/2020\/aug\/09\/only-half-of-britons-would-definitely-have-covid-19-vaccination."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"575950","DOI":"10.3389\/fpsyg.2020.575950","article-title":"A Proactive Approach for Managing COVID-19: The Importance of Understanding the Motivational Roots of Vaccination Hesitancy for SARS-CoV2","volume":"11","author":"Taylor","year":"2020","journal-title":"Front. Psychol."},{"key":"ref_28","unstructured":"(2022, February 20). The Annual Report. Available online: https:\/\/www.abl.org.lb\/english\/the-annual-report."}],"container-title":["Vaccines"],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/3\/416\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T07:01:12Z","timestamp":1722063672000},"score":16.648214,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/3\/416"}},"issued":{"date-parts":[[2022,3,10]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["vaccines10030416"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10030416","ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"published":{"date-parts":[[2022,3,10]]}}],"items-per-page":100,"query":{"start-index":0,"search-terms":"Vaccines are safe"}}}